



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :

C12Q 1/68

A2

(11) International Publication Number:

WO 00/58510

(43) International Publication Date:

5 October 2000 (05.10.00)

(21) International Application Number: PCT/IB00/00435

(22) International Filing Date: 30 March 2000 (30.03.00)

(30) Priority Data:

60/126,903	30 March 1999 (30.03.99)	US
60/131,971	30 April 1999 (30.04.99)	US
60/132,065	30 April 1999 (30.04.99)	US
60/143,928	14 July 1999 (14.07.99)	US
60/145,915	27 July 1999 (27.07.99)	US
60/146,453	29 July 1999 (29.07.99)	US
60/146,452	29 July 1999 (29.07.99)	US
60/162,288	28 October 1999 (28.10.99)	US

(71) Applicant (for all designated States except US): GENSET [FR/FR]; Intellectual Property Department, 24, rue Royale, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COHEN, Daniel [FR/FR]; 1, Bd Richard Wallace, F-92200 Neuilly-sur-Seine (FR). BLUMENFELD, Marta [FR/FR]; 5, rue Tagore, F-75013 Paris (FR). CHUMAKOV, Ilya [FR/FR]; 196, rue des Chevreteuilles, F-77000 Vaux-le-Penil (FR). BOUGUEL-ERET, Lydie [FR/FR]; 108, avenue Victor Hugo, F-92170 Vanves (FR). BIHAIN, Bernard [BE/US]; 238 Pacific

View Lane, Encinitas, CA 92024 (US). ESSIUX, Laurent [FR/FR]; 107, rue de Reuilly, F-75012 Paris (FR).

(74) Common Representative: GENSET; Intellectual Property Department, 24, rue Royale, F-75008 Paris (FR).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: SCHIZOPHRENIA ASSOCIATED GENES, PROTEINS AND BIALLELIC MARKERS

(57) Abstract

The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SCHIZOPHRENIA ASSOCIATED GENES, PROTEINS AND BIALLELIC MARKERS

5

FIELD OF THE INVENTION

The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

15

BACKGROUND OF THE INVENTION

Advances in the technological armamentarium available to basic and clinical investigators have enabled increasingly sophisticated studies of brain and nervous system function in health and disease. Numerous hypotheses both neurobiological and pharmacological have been advanced with respect to the neurochemical and genetic mechanisms involved in central nervous system (CNS) disorders, including psychiatric disorders and neurodegenerative diseases. However, CNS disorders have complex and poorly understood etiologies, as well as symptoms that are overlapping, poorly characterized, and difficult to measure. As a result future treatment regimes and drug development efforts will be required to be more sophisticated and focused on multigenic causes, and will need new assays to segment disease populations, and provide more accurate diagnostic and prognostic information on patients suffering from CNS disorders.

20

25

Neurological Basis of CNS Disorders

Neurotransmitters serve as signal transmitters throughout the body. Diseases that affect neurotransmission can therefore have serious consequences. For example, for over 30 years the leading theory to explain the biological basis of many psychiatric disorders such as depression has been the monoamine hypothesis. This theory proposes that depression is partially due to a deficiency in one of the three main biogenic monoamines, namely dopamine, norepinephrine and/or serotonin.

30

35

In addition to the monoamine hypothesis, numerous arguments tend to show the value

in taking into account the overall function of the brain and no longer only considering a single neuronal system. In this context, the value of dual specific actions on the central aminergic systems including second and third messenger systems has now emerged.

Endocrine Basis of CNS Disorders

5 It is furthermore apparent that the main monoamine systems, namely dopamine, norepinephrine and serotonin, do not completely explain the pathophysiology of many CNS disorders. In particular, it is clear that CNS disorders may have an endocrine component; the hypothalamic-pituitary-adrenal (HPA) axis, including the effects of corticotrophin-releasing factor and glucocorticoids, plays an important role in the pathophysiology of CNS disorders.

10 In the hypothalamus-pituitary-adrenal (HPA) axis, the hypothalamus lies at the top of the hierarchy regulating hormone secretion. It manufactures and releases peptides (small chains of amino acids) that act on the pituitary, at the base of the brain, stimulating or inhibiting the pituitary's release of various hormones into the blood. These hormones, among them growth hormone, thyroid-stimulating hormone and adrenocorticotrophic hormone (ACTH), control the
15 release of other hormones from target glands. In addition to functioning outside the nervous system, the hormones released in response to pituitary hormones also feed back to the pituitary and hypothalamus. There they deliver inhibitory signals that serve to limit excess hormone biosynthesis.

CNS Disorders

20 Neurotransmitter and hormonal abnormalities are implicated in disorders of movement (e.g. Parkinson's disease, Huntington's disease, motor neuron disease, etc.), disorders of mood (e.g. unipolar depression, bipolar disorder, anxiety, etc.) and diseases involving the intellect (e.g. Alzheimer's disease, Lewy body dementia, schizophrenia, etc.). In addition, these systems have been implicated in many other disorders, such as coma, head injury, cerebral infarction,
25 epilepsy, alcoholism and the mental retardation states of metabolic origin seen particularly in childhood.

Genetic Analysis of Complex Traits

30 Until recently, the identification of genes linked with detectable traits has relied mainly on a statistical approach called linkage analysis. Linkage analysis is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. Linkage analysis involves the study of families with multiple affected individuals and is useful in the detection of inherited-traits, which are caused by a single gene, or possibly a very small number of genes. But, linkage studies have proven difficult when applied to complex genetic traits. Most traits of medical relevance do not follow
35 simple Mendelian monogenic inheritance. However, complex diseases often aggregate in

families, which suggests that there is a genetic component to be found. Such complex traits are often due to the combined action of multiple genes as well as environmental factors. Such complex trait, include susceptibilities to heart disease, hypertension, diabetes, cancer and inflammatory diseases. Drug efficacy, response and tolerance/toxicity can also be considered as multifactorial traits involving a genetic component in the same way as complex diseases.

Linkage analysis cannot be applied to the study of such traits for which no large informative families are available. Moreover, because of their low penetrance, such complex traits do not segregate in a clear-cut Mendelian manner as they are passed from one generation to the next. Attempts to map such diseases have been plagued by inconclusive results, demonstrating the need for more sophisticated genetic tools.

Knowledge of genetic variation in the neuronal and endocrine systems is important for understanding why some people are more susceptible to disease or respond differently to treatments. Ways to identify genetic polymorphism and to analyze how they impact and predict disease susceptibility and response to treatment are needed.

Although the genes involved in the neuronal and endocrine systems represent major drug targets and are of high relevance to pharmaceutical research, we still have scant knowledge concerning the extent and nature of, sequence variation in these genes and their regulatory elements. In the case where polymorphisms have been identified the relevance of the variation is rarely understood. While polymorphisms hold promise for use as genetic markers in determining which genes contribute to multigenic or quantitative traits, suitable markers and suitable methods for exploiting those markers have not been found and brought to bare on the genes related to disorders of the brain and nervous system.

The basis for accomplishment of these goals is to use genetic association analysis to detect markers that predict susceptibility for these traits. Recently, advances in the fields of genetics and molecular biology have allowed identification of forms, or alleles, of human genes that lead to diseases. Most of the genetic variations responsible for human diseases identified so far, belong to the class of single gene disorders. As this name implies, the development of single gene disorders is determined, or largely influenced, by the alleles of a single gene. The alleles that cause these disorders are, in general, highly deleterious (and highly penetrant) to individuals who carry them. Therefore, these alleles and their associated diseases, with some exceptions, tend to be very rare in the human population. In contrast, most common diseases and non-disease traits, such as a physiological response to a pharmaceutical agent, can be viewed as the result of many complex factors. These can include environmental exposures (toxins, allergens, infectious agents, climate, and trauma) as well as multiple genetic factors.

Association studies seek to analyze the distributions of chromosomes that have occurred

in populations of unrelated (at least not directly related) individuals. An assumption in this type of study is that genetic alleles that result in susceptibility for a common trait arose by ancient mutational events on chromosomes that have been passed down through many generations in the population. These alleles can become common throughout the population in part because the trait they influence, if deleterious, is only expressed in a fraction of those individuals who carry them. Identification of these "ancestral" chromosomes is made difficult by the fact that genetic markers are likely to have become separated from the trait susceptibility allele through the process of recombination, except in regions of DNA which immediately surround the allele. The identities of genetic markers contained within the fragments of DNA surrounding a susceptibility allele will be the same as those from the ancestral chromosome on which the allele arose. Therefore, individuals from the population who express a complex trait might be expected to carry the same set of genetic markers in the vicinity of a susceptibility allele more often than those who do not express the trait; that is these markers will show an association with the trait.

Schizophrenia

Schizophrenia is one of the most severe and debilitating of the major psychiatric diseases. It usually starts in late adolescence or early adult life and often becomes chronic and disabling. Men and women are at equal risk of developing this illness; however, most males become ill between 16 and 25 years old, while females develop symptoms between 25 and 30. People with schizophrenia often experience both "positive" symptoms (e.g., delusions, hallucinations, disorganized thinking, and agitation) and "negative" symptoms (e.g., lack of drive or initiative, social withdrawal, apathy, and emotional unresponsiveness).

Schizophrenia affects 1% of the world population. There are an estimated 45 million people with schizophrenia in the world, with more than 33 million of them in the developing countries. This disease places a heavy burden on the patient's family and relatives, both in terms of the direct and indirect costs involved and the social stigma associated with the illness, sometimes over generations. Such stigma often leads to isolation and neglect.

Moreover, schizophrenia accounts for one fourth of all mental health costs and takes up one in three psychiatric hospital beds. Most schizophrenia patients are never able to work. The cost of schizophrenia to society is enormous. In the United States, for example, the direct cost of treatment of schizophrenia has been estimated to be close to 0.5% of the gross national product. Standardized mortality ratios (SMRs) for schizophrenic patients are estimated to be two to four times higher than the general population, and their life expectancy overall is 20 % shorter than for the general population. The most common cause of death among schizophrenic patients is suicide (in 10 % of patients) which represents a 20 times higher risk than for the

general population. Deaths from heart disease and from diseases of the respiratory and digestive system are also increased among schizophrenic patients.

Bipolar Disorder

Bipolar disorders are relatively common disorders with severe and potentially disabling effects. In addition to the severe effects on patients' social development, suicide completion rates among bipolar patients are reported to be about 15%.

Bipolar disorders are characterized by phases of excitement and often including depression; the excitement phases, referred to as mania or hypomania, and depression can alternate or occur in various admixtures, and can occur to different degrees of severity and over varying time periods. Because bipolar disorders can exist in different forms and display different symptoms, the classification of bipolar disorder has been the subject of extensive studies resulting in the definition of bipolar disorder subtypes and widening of the overall concept to include patients previously thought to be suffering from different disorders. Bipolar disorders often share certain clinical signs, symptoms, treatments and neurobiological features with psychotic illnesses in general and therefore present a challenge to the psychiatrist to make an accurate diagnosis. Furthermore, because the course of bipolar disorders and various mood and psychotic disorders can differ greatly, it is critical to characterize the illness as early as possible in order to offer means to manage the illness over a long term.

Bipolar disorders appear in about 1.3% of the population and have been reported to constitute about half of the mood disorders seen in a psychiatric clinic. Bipolar disorders have been found to vary with gender depending of the type of disorder; for example, bipolar disorder I is found equally among men and women, while bipolar disorder II is reportedly more common in women. The age of onset of bipolar disorders is typically in the teenage years and diagnosis is typically made in the patient's early twenties. Bipolar disorders also occur among the elderly, generally as a result of a medical or neurological disorder.

The costs of bipolar disorders to society are enormous. The mania associated with the disease impairs performance and causes psychosis, and often results in hospitalization. This disease places a heavy burden on the patient's family and relatives, both in terms of the direct and indirect costs involved and the social stigma associated with the illness, sometimes over generations. Such stigma often leads to isolation and neglect. Furthermore, the earlier the onset, the more severe are the effects of interrupted education and social development.

The DSM-IV classification of bipolar disorder distinguishes among four types of disorders based on the degree and duration of mania or hypomania as well as two types of disorders which are evident typically with medical conditions or their treatments, or to substance abuse. Mania is recognized by elevated, expansive or irritable mood as well as by

distractability, impulsive behavior, increased activity, grandiosity, elation, racing thoughts, and pressured speech. Of the four types of bipolar disorder characterized by the particular degree and duration of mania, DSM-IV includes:

- bipolar disorder I, including patients displaying mania for at least one week;
- 5 - bipolar disorder II, including patients displaying hypomania for at least 4 days, characterized by milder symptoms of excitement than mania, who have not previously displayed mania, and have previously suffered from episodes of major depression;
- bipolar disorder not otherwise specified (NOS), including patients otherwise displaying features of bipolar disorder II but not meeting the 4 day duration for the excitement phase, or who display hypomania without an episode of major depression; and
- 10 - cyclothymia, including patients who show numerous manic and depressive symptoms that do not meet the criteria for hypomania or major depression, but which are displayed for over two years without a symptom-free interval of more than two months.

15 The remaining two types of bipolar disorder as classified in DSM-VI are disorders evident or caused by various medical disorder and their treatments, and disorders involving or related to substance abuse. Medical disorders which can cause bipolar disorders typically include endocrine disorders and cerebrovascular injuries, and medical treatments causing bipolar disorder are known to include glucocorticoids and the abuse of stimulants. The disorder associated with the use or abuse of a substance is referred to as "substance induced mood disorder with manic or mixed features".

20 Diagnosis of bipolar disorder can be very challenging. One particularly troublesome difficulty is that some patients exhibit mixed states, simultaneously manic and dysphoric or depressive, but do not fall into the DSM-IV classification because not all required criteria for mania and major depression are met daily for at least one week. Other difficulties include

25 classification of patients in the DSM-IV groups based on duration of phase since patients often cycle between excited and depressive episodes at different rates. In particular, it is reported that the use of antidepressants may alter the course of the disease for the worse by causing "rapid-cycling". Also making diagnosis more difficult is the fact that bipolar patients, particularly at what is known as Stage III mania, share symptoms of disorganized thinking and behavior with

30 bipolar disorder patients. Furthermore, psychiatrists must distinguish between agitated depression and mixed mania; it is common that patients with major depression (14 days or more) exhibit agitation, resulting in bipolar-like features. A yet further complicating factor is that bipolar patients have an exceptionally high rate of substance, particularly alcohol abuse. While the prevalence of mania in alcoholic patients is low, it is well known that substance

35 abusers can show excited symptoms. Difficulties therefore result for the diagnosis of bipolar

patients with substance abuse.

Treatment

As there are currently no cures for bipolar disorder or schizophrenia, the objective of treatment is to reduce the severity of the symptoms, if possible to the point of remission. Due to the similarities in symptoms, schizophrenia and bipolar disorder are often treated with some of the same medicaments. Both diseases are often treated with antipsychotics and neuroleptics.

For schizophrenia, for example, antipsychotic medications are the most common and most valuable treatments. There are four main classes of antipsychotic drugs which are commonly prescribed for schizophrenia. The first, neuroleptics, exemplified by chlorpromazine (Thorazine), has revolutionized the treatment of schizophrenic patients by reducing positive (psychotic) symptoms and preventing their recurrence. Patients receiving chlorpromazine have been able to leave mental hospitals and live in community programs or their own homes. But these drugs are far from ideal. Some 20% to 30% of patients do not respond to them at all, and others eventually relapse. These drugs were named neuroleptics because they produce serious neurological side effects, including rigidity and tremors in the arms and legs, muscle spasms, abnormal body movements, and akathisia (restless pacing and fidgeting). These side effects are so troublesome that many patients simply refuse to take the drugs. Besides, neuroleptics do not improve the so-called negative symptoms of schizophrenia and the side effects may even exacerbate these symptoms. Thus, despite the clear beneficial effects of neuroleptics, even some patients who have a good short-term response will ultimately deteriorate in overall functioning.

The well known deficiencies in the standard neuroleptics have stimulated a search for new treatments and have led to a new class of drugs termed atypical neuroleptics. The first atypical neuroleptic, Clozapine, is effective for about one third of patients who do not respond to standard neuroleptics. It seems to reduce negative as well as positive symptoms, or at least exacerbates negative symptoms less than standard neuroleptics do. Moreover, it has beneficial effects on overall functioning and may reduce the chance of suicide in schizophrenic patients. It does not produce the troubling neurological symptoms of the standard neuroleptics, or raise blood levels of the hormone prolactin, excess of which may cause menstrual irregularities and infertility in women, impotence or breast enlargement in men. Many patients who cannot tolerate standard neuroleptics have been able to take clozapine. However, clozapine has serious limitations. It was originally withdrawn from the market because it can cause agranulocytosis, a potentially lethal inability to produce white blood cells. Agranulocytosis remains a threat that requires careful monitoring and periodic blood tests. Clozapine can also cause seizures and other disturbing side effects (e.g., drowsiness, lowered blood pressure, drooling, bed-wetting,

and weight gain). Thus it is usually taken only by patients who do not respond to other drugs.

Researchers have developed a third class of antipsychotic drugs that have the virtues of clozapine without its defects. One of these drugs is risperidone (Risperdal). Early studies suggest that it is as effective as standard neuroleptic drugs for positive symptoms and may be somewhat more effective for negative symptoms. It produces more neurological side effects than clozapine but fewer than standard neuroleptics. However, it raises prolactin levels.

Risperidone is now prescribed for a broad range of psychotic patients, and many clinicians seem to use it before clozapine for patients who do not respond to standard drugs, because they regard it as safer. Another new drug is Olanzapine (Zyprexa) which is at least as effective as standard drugs for positive symptoms and more effective for negative symptoms. It has few neurological side effects at ordinary clinical doses, and it does not significantly raise prolactin levels.

Although it does not produce most of clozapine's most troubling side effects, including agranulocytosis, some patients taking olanzapine may become sedated or dizzy, develop dry mouth, or gain weight. In rare cases, liver function tests become transiently abnormal.

Outcome studies in schizophrenia are usually based on hospital treatment studies and may not be representative of the population of schizophrenia patients. At the extremes of outcome, 20 % of patients seem to recover completely after one episode of psychosis, whereas 14-19% of patients develop a chronic unremitting psychosis and never fully recover. In general, clinical outcome at five years seems to follow the rule of thirds: with about 35 % of patients in the poor outcome category; 36 % in the good outcome category, and the remainder with intermediate outcome. Prognosis in schizophrenia does not seem to worsen after five years.

Whatever the reasons, there is increasing evidence that leaving schizophrenia untreated for long periods early in course of the illness may negatively affect the outcome. However, the use of drugs is often delayed for patients experiencing a first episode of the illness. The patients may not realize that they are ill, or they may be afraid to seek help; family members sometimes hope the problem will simply disappear or cannot persuade the patient to seek treatment; clinicians may hesitate to prescribe antipsychotic medications when the diagnosis is uncertain because of potential side effects. Indeed, at the first manifestation of the disease, schizophrenia is difficult to distinguish from bipolar manic-depressive disorders, severe depression, drug-related disorders, and stress-related disorders. Since the optimum treatments differ among these diseases, the long term prognosis of the disorder also differs the beginning of the treatment.

For both schizophrenia and bipolar disorder, all the known molecules used for the treatment of schizophrenia have side effects and act only against the symptoms of the disease. There is a strong need for new molecules without associated side effects and directed against targets which are involved in the causal mechanisms of schizophrenia and bipolar disorder.

Therefore, tools facilitating the discovery and characterization of these targets are necessary and useful.

Schizophrenia and bipolar disorder are now considered to be brain diseases, and emphasis is placed on biological determinants in researching the conditions. In the case of schizophrenia, neuroimaging and neuropathological studies have shown evidence of brain abnormalities in schizophrenic patients. The timing of these pathological changes is unclear but are likely to be a defect in early brain development. Profound changes have also occurred in hypotheses concerning neurotransmitter abnormalities in schizophrenia. The dopamine hypothesis has been extensively revised and is no longer considered as a primary causative model.

The aggregation of schizophrenia and bipolar disorder in families, the evidence from twin and adoption studies, and the lack of variation in incidence worldwide, indicate that schizophrenia and bipolar disorder are primarily genetic conditions, although environmental risk factors are also involved at some level as necessary, sufficient, or interactive causes. For example, schizophrenia occurs in 1% of the general population. But, if there is one grandparent with schizophrenia, the risk of getting the illness increases to about 3%; one parent with Schizophrenia, to about 10%. When both parents have schizophrenia, the risk rises to approximately 40%.

Consequently, there is a strong need to identify genes involved in schizophrenia and bipolar disorder. The knowledge of these genes will allow researchers to understand the etiology of schizophrenia and bipolar disorder and could lead to drugs and medications which are directed against the cause of the diseases, not just against their symptoms.

There is also a great need for new methods for detecting a susceptibility to schizophrenia and bipolar disorder, as well as for preventing or following up the development of the disease. Diagnostic tools could also prove extremely useful. Indeed, early identification of subjects at risk of developing schizophrenia would enable early and/or prophylactic treatment to be administered. Moreover, accurate assessments of the eventual efficacy of a medicament as well as the patient's eventual tolerance to it may enable clinicians to enhance the benefit/risk ratio of schizophrenia and bipolar disorder treatment regimes.

SUMMARY OF THE INVENTION

The present invention stems from the identification of novel polymorphisms including biallelic markers located on the human chromosome 13q31-q33 locus, the identification and characterization of novel schizophrenia-related genes located on the human chromosome 13q31-q33 locus, and from the identification of genetic associations between alleles of biallelic

markers located on the human chromosome 13q31-q33 locus and disease, as confirmed and characterized in a panel of human subjects. The invention furthermore provides a fine structure map of the region which includes the schizophrenia-associated gene sequences.

5 The present invention pertains to nucleic acid molecules comprising the genomic sequences of novel human genes encoding sbg1, g34665, sbg2, g35017 and g35018 proteins, proteins encoded thereby, as well as antibodies thereto. The sbg1, g34665, sbg2, g35017 and g35018 genomic sequences may also comprise regulatory sequence located upstream (5'-end) and downstream (3'-end) of the transcribed portion of said gene, these regulatory sequences being also part of the invention. The invention also deals with the cDNA sequence encoding the
10 sbg1 and g35018 proteins.

Oligonucleotide probes or primers hybridizing specifically with a sbg1, g34665, sbg2, g35017 or g35018 genomic or cDNA sequence are also part of the present invention, as well as DNA amplification and detection methods using said primers and probes.

15 A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences described above, and in particular of recombinant vectors comprising a sbg1, g34665, sbg2, g35017 or g35018 regulatory sequence or a sequence encoding a sbg1, g34665, sbg2, g35017 or g35018 protein, as well as of cell hosts and transgenic non human animals comprising said nucleic acid sequences or recombinant vectors.

20 The invention also concerns to biallelic markers of the sbg1, g34665, sbg2, g35017 or g35018 gene and the use thereof. Included are probes and primers for use in genotyping biallelic markers of the invention.

25 An embodiment of the invention encompasses any polynucleotide of the invention attached to a solid support polynucleotide may comprise a sequence disclosed in the present specification; optionally, said polynucleotide may comprise, consist of, or consist essentially of any polynucleotide described in the present specification; optionally, said determining may be performed in a hybridization assay, sequencing assay, microsequencing assay, or an enzyme-based mismatch detection assay; optionally, said polynucleotide may be attached to a solid support, array, or addressable array; optionally, said polynucleotide may be labeled.

30 Finally, the invention is directed to drug screening assays and methods for the screening of substances for the treatment of schizophrenia, bipolar disorder or a related CNS disorder based on the role of sbg1, g34665, sbg2, g35017 and g35018 nucleotides and polynucleotides in disease. One object of the invention deals with animal models of schizophrenia, including mouse, primate, non-human primate bipolar disorder or related CNS disorder based on the role of sbg1 in disease. The invention is also directed to methods for the screening of substances or
35 molecules that inhibit the expression of sbg1, g34665, sbg2, g35017 or g35018, as well as with

methods for the screening of substances or molecules that interact with a sbg1, g34665, sbg2, g35017 or g35018 polypeptide, or that modulate the activity of a sbg1, g34665, sbg2, g35017 or g35018 polypeptide.

As noted above, certain aspects of the present invention stem from the identification of genetic associations between schizophrenia and bipolar disorder and alleles of biallelic markers located on the human chromosome 13q31-q33 region, and more particularly on a subregion thereof referred to herein as Region D. The invention provides appropriate tools for establishing further genetic associations between alleles of biallelic markers on the 13q31-13q33 locus and either side effects or benefit resulting from the administration of agents acting on schizophrenia or bipolar disorder, or schizophrenia or bipolar disorder symptoms, including agents like chlorpromazine, clozapine, risperidone, olanzapine, sertindole, quetiapine and ziprasidone.

The invention provides appropriate tools for establishing further genetic associations between alleles of biallelic markers on the 13q31-13q33 locus and a trait. Methods and products are provided for the molecular detection of a genetic susceptibility in humans to schizophrenia and bipolar disorder. They can be used for diagnosis, staging, prognosis and monitoring of this disease, which processes can be further included within treatment approaches. The invention also provides for the efficient design and evaluation of suitable therapeutic solutions including individualized strategies for optimizing drug usage, and screening of potential new medicament candidates.

Additional embodiments are set forth in the Detailed Description of the Invention and in the Examples.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a diagram showing the exon structure of the sbg1 gene.

Figure 2 is a table demonstrating the statistical significance of allelic frequencies of selected chromosome 13q31-q33 biallelic markers of the invention in sporadic and familial French Canadian schizophrenia cases and controls.

Figure 3 is a table demonstrating the results of a haplotype association analysis between total French Canadian schizophrenia cases and haplotypes which consist of chromosome 13q31-q33 biallelic markers of the invention.

Figure 4 is a table showing the involvement of selected biallelic markers of the invention in statistically significant haplotypes.

Figure 5 is a table demonstrating the results of a haplotype association analysis between French Canadian schizophrenia cases and haplotypes which consist of chromosome 13q31-q33

biallelic markers of the invention.

Figure 6 is a table demonstrating the results of a haplotype association analysis between French Canadian schizophrenia cases and haplotypes which consist of chromosome 13q31-q33 biallelic markers of the invention.

5 Figures 7A and 7B show the results of a haplotype association analysis (Omnibus LR test value distribution) between schizophrenia cases and haplotypes comprising Region D biallelic markers of the invention.

10 Figures 8A and 8B show the results of a haplotype association analysis (HaplotMaxM test value distribution) between schizophrenia cases and haplotypes comprising Region D biallelic markers of the invention.

Figures 9A and 9B show the results of a haplotype association analysis (Omnibus LR test value distribution) between bipolar disorder cases and haplotypes comprising Region D biallelic markers of the invention.

15 Figures 10A and 10B show the results of a haplotype association analysis (HaploMaxM test value distribution) between bipolar disorder cases and haplotypes comprising Region D biallelic markers of the invention.

Figures 11A and 11B show the results of a haplotype association analysis (HaploMaxS test value distribution) between bipolar disorder cases and haplotypes comprising Region D biallelic markers of the invention.

20 Figure 12 shows a comparison of the number of significant single and multipoint biallelic marker analyses in subregions D1 to D4 of Region D in French Canadian samples.

Figure 13 shows a summary of the number of significant single and multipoint biallelic marker analyses across Region D in French Canadian samples.

25 Figure 14 shows a comparison of the number of significant single and multipoint biallelic marker analyses in subregions D1 to D4 of Region D in United States schizophrenia samples.

Figure 15 shows a summary of the number of significant single and multipoint biallelic marker analyses across Region D in United States schizophrenia samples.

30 Figure 16 shows a comparison of the number of significant single and multipoint biallelic marker analyses in subregions D1 to D4 of Region D in Argentinian bipolar disorder samples.

Figure 17 shows a summary of the number of significant single and multipoint biallelic marker analyses across Region D in Argentinian bipolar disorder samples.

35 Figure 18 shows the effect of injection of an sbg1 peptide on locomotor activity and stereotypy of mice.

Figure 19 is a block diagram of an exemplary computer system.

Figure 20 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.

Figure 21 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous.

Figure 22 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence.

BRIEF DESCRIPTION OF THE SEQUENCES PROVIDED IN THE SEQUENCE LISTING

SEQ ID No. 1 contains the approximately 319kb of genomic nucleotide sequence comprising sbg1, g34665, sbg2, g35017 and g35018 nucleic acid sequences and the biallelic markers A1 to A360 and polymorphisms A361 to A489 located on the human chromosome 13q31-q33 locus.

SEQ ID Nos. 2 to 26 contain cDNA sequences of the sbg1 gene.

SEQ ID Nos. 27 to 35 contain amino acid sequences of sbg1 polypeptides, encoded by cDNAs of SEQ ID Nos. 2 to 26.

SEQ ID No. 36 to 40 contain cDNA sequences of the g35018 gene

SEQ ID No. 41 to 43 contain amino acid sequences of an g35018 polypeptides.

SEQ ID No. 44 to 53 contain primers used to isolate sbg1 cDNAs

SEQ ID No. 54 to 111 contain genomic nucleotide sequences comprising exons of the sbg1 gene from several different primates.

SEQ ID Nos. 112 to 229 respectively contain the nucleotide sequence of the amplicons which comprise the biallelic markers A243 to A360 located on the human chromosome 13q31-q33 locus.

SEQ ID No 230 contains a primer containing the additional PU 5' sequence described further in Example 2

SEQ ID No 231 contains a primer containing the additional RP 5' sequence described further in Example 2.

In accordance with the regulations relating to Sequence Listings, the following codes have been used in the Sequence Listing to indicate the locations of biallelic markers within the sequences and to identify each of the alleles present at the polymorphic base. The code "r" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other

allele is an adenine. The code "y" in the sequences indicates that one allele of the polymorphic base is a thymine, while the other allele is a cytosine. The code "m" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an cytosine. The code "k" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a thymine. The code "s" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a cytosine. The code "w" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an thymine.

DETAILED DESCRIPTION OF THE INVENTION

The identification of genes involved in a particular trait such as a specific central nervous system disorder, like schizophrenia, can be carried out through two main strategies currently used for genetic mapping: linkage analysis and association studies. Linkage analysis requires the study of families with multiple affected individuals and is now useful in the detection of mono- or oligogenic inherited traits. Conversely, association studies examine the frequency of marker alleles in unrelated trait (T+) individuals compared with trait negative (T-) controls, and are generally employed in the detection of polygenic inheritance.

Candidate region on the chromosome 13 (linkage analysis)

Genetic link or "linkage" is based on an analysis of which of two neighboring sequences on a chromosome contains the least recombinations by crossing-over during meiosis. To do this, chromosomal markers, like microsatellite markers, have been localized with precision on the genome. Genetic link analysis calculates the probabilities of recombinations on the target gene with the chromosomal markers used, according to the genealogical tree, the transmission of the disease, and the transmission of the markers. Thus, if a particular allele of a given marker is transmitted with the disease more often than chance would have it (recombination level between 0 and 0.5), it is possible to deduce that the target gene in question is found in the neighborhood of the marker.

Using this technique, it has been possible to localize several genes demonstrating a genetic predisposition of familial cancers. In order to be able to be included in a genetic link study, the families affected by a hereditary form of the disease must satisfy the "informativeness" criteria: several affected subjects (and whose constitutional DNA is available) per generation, and at best having a large number of siblings.

By linkage analysis, observations have been made, according to which a candidate region for schizophrenia is present on chromosome 13q32 locus (Blouin et al., 1998). Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance, but this method suffers from a variety of

drawbacks. First, linkage analysis is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, the resolution attainable using linkage analysis is limited, and complementary studies are required to refine the analysis of the typical 20 Mb regions initially identified through this method. In addition, linkage analysis have proven
5 difficult when applied to complex genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. In such cases, too great an effort and cost are needed to recruit the adequate number of affected families required for applying linkage analysis to these situations. Finally, linkage analysis cannot be applied to the study of traits for which no large informative families are available.

10 In the present invention alternative means for conducting association studies rather than linkage analysis between markers located on the chromosome 13q31-q33 locus and a trait, preferably schizophrenia or bipolar disorder, are disclosed.

In the present application, additional biallelic markers located on the human chromosome 13q31-q33 locus associated with schizophrenia are disclosed. The identification
15 of these biallelic markers in association with schizophrenia has allowed for the further definition of the chromosomal region suspected of containing a genetic determinant involved in a predisposition to develop schizophrenia and has resulted in the identification of novel gene sequences disclosed herein which are associated with a predisposition to develop schizophrenia. The present invention thus provides an extensive fine structure map of the 13q31-q33 locus,
20 including novel biallelic markers located on the human 13q31-q33 locus, approximately 319kb of genomic nucleotide sequence of a subregion of the human 13q31-q33 locus, and polymorphisms including biallelic markers and nucleotide deletions in said 319kb genomic sequence. The biallelic markers of the human chromosome 13q31-q33 locus and the nucleotide sequences, polymorphisms and gene sequences located in Region D subregion of the human
25 chromosome 13q31-q33 locus are useful as genetic and physical markers for further mapping studies. The approximately 319kb of genomic nucleotide sequence disclosed herein can further serve as a reference in genetic or physical analysis of deletions, substitutions, and insertions in that region. Additionally, the sequence information provides a resource for the further identification of new genes in that region. Additionally, the sequences comprising the the
30 schizophrenia-associated genes are useful, for example, for the isolation of other genes in putative gene families, the identification of homologs from other species, treatment of disease and as probes and primers for diagnostic or screening assays as described herein.

35 These identified polymorphisms are used in the design of assays for the reliable detection of genetic susceptibility to schizophrenia and bipolar disorder. They can also be used in the design of drug screening protocols to provide an accurate and efficient evaluation of the

therapeutic and side-effect potential of new or already existing medicament or treatment regime.

Definitions

As used interchangeably herein, the term "oligonucleotides", and "polynucleotides" include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form. The term "nucleotide" as used herein as an adjective to describe molecules comprising RNA, DNA, or RNA/DNA hybrid sequences of any length in single-stranded or duplex form. The term "nucleotide" is also used herein as a noun to refer to individual nucleotides or varieties of nucleotides, meaning a molecule, or individual unit in a larger nucleic acid molecule, comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or polynucleotide. Although the term "nucleotide" is also used herein to encompass "modified nucleotides" which comprise at least one modifications (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar, for examples of analogous linking groups, purine, pyrimidines, and sugars see for example PCT publication No. WO 95/04064. However, the polynucleotides of the invention are preferably comprised of greater than 50% conventional deoxyribose nucleotides, and most preferably greater than 90% conventional deoxyribose nucleotides. The polynucleotide sequences of the invention may be prepared by any known method, including synthetic, recombinant, *ex vivo* generation, or a combination thereof, as well as utilizing any purification methods known in the art.

The term "purified" is used herein to describe a polynucleotide or polynucleotide vector of the invention which has been separated from other compounds including, but not limited to other nucleic acids, carbohydrates, lipids and proteins (such as the enzymes used in the synthesis of the polynucleotide), or the separation of covalently closed polynucleotides from linear polynucleotides. A polynucleotide is substantially pure when at least about 50 %, preferably 60 to 75% of a sample exhibits a single polynucleotide sequence and conformation (linear versus covalently close). A substantially pure polynucleotide typically comprises about 50 %, preferably 60 to 90% weight/weight of a nucleic acid sample, more usually about 95%, and preferably is over about 99% pure. Polynucleotide purity or homogeneity may be indicated by a number of means well known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polynucleotide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

The term "isolated" requires that the material be removed from its original environment

(e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such
5 polynucleotide or polypeptide could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment.

The term "primer" denotes a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and used to hybridize to the target nucleotide sequence. A primer serves as an initiation point for nucleotide polymerization catalyzed by either DNA
10 polymerase, RNA polymerase or reverse transcriptase.

The term "probe" denotes a defined nucleic acid segment (or nucleotide analog segment, e.g., polynucleotide as defined herein) which can be used to identify a specific polynucleotide sequence present in samples, said nucleic acid segment comprising a nucleotide sequence complementary of the specific polynucleotide sequence to be identified.

The terms "trait" and "phenotype" are used interchangeably herein and refer to any
15 clinically distinguishable, detectable or otherwise measurable property of an organism such as symptoms of, or susceptibility to a disease for example. Typically the terms "trait" or "phenotype" are used herein to refer to symptoms of, or susceptibility to schizophrenia or bipolar disorder; or to refer to an individual's response to an agent acting on schizophrenia or
20 bipolar disorder; or to refer to symptoms of, or susceptibility to side effects to an agent acting on schizophrenia or bipolar disorder.

The term "allele" is used herein to refer to variants of a nucleotide sequence. A biallelic polymorphism has two forms. Typically the first identified allele is designated as the original allele whereas other alleles are designated as alternative alleles. Diploid organisms may be
25 homozygous or heterozygous for an allelic form.

The term "heterozygosity rate" is used herein to refer to the incidence of individuals in a population, which are heterozygous at a particular allele. In a biallelic system the heterozygosity rate is on average equal to $2P_a(1-P_a)$, where P_a is the frequency of the least common allele. In order to be useful in genetic studies a genetic marker should have an
30 adequate level of heterozygosity to allow a reasonable probability that a randomly selected person will be heterozygous.

The term "genotype" as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention a genotype preferably refers to the description of the biallelic marker alleles present in an individual or a sample. The term

“genotyping” a sample or an individual for a biallelic marker involves determining the specific allele or the specific nucleotide(s) carried by an individual at a biallelic marker.

The term “mutation” as used herein refers to a difference in DNA sequence between or among different genomes or individuals which has a frequency below 1%.

5 The term “haplotype” refers to a combination of alleles present in an individual or a sample on a single chromosome. In the context of the present invention a haplotype preferably refers to a combination of biallelic marker alleles found in a given individual and which may be associated with a phenotype.

10 The term “polymorphism” as used herein refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals. “Polymorphic” refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A “polymorphic site” is the locus at which the variation occurs. A polymorphism may comprise a substitution, deletion or insertion of one or more nucleotides. A single nucleotide polymorphism is a single base pair change. Typically a single
15 nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide, also give rise to single nucleotide polymorphisms. In the context of the present invention “single nucleotide polymorphism” preferably refers to a single nucleotide substitution. Typically, between different genomes or between different individuals, the polymorphic site may be
20 occupied by two different nucleotides.

The terms “biallelic polymorphism” and “biallelic marker” are used interchangeably herein to refer to a polymorphism having two alleles at a fairly high frequency in the population, preferably a single nucleotide polymorphism. A “biallelic marker allele” refers to the
25 nucleotide variants present at a biallelic marker site. Typically the frequency of the less common allele of the biallelic markers of the present invention has been validated to be greater than 1%, preferably the frequency is greater than 10%, more preferably the frequency is at least 20% (i.e. heterozygosity rate of at least 0.32), even more preferably the frequency is at least 30% (i.e. heterozygosity rate of at least 0.42). A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a “high quality biallelic marker.” All of the
30 genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with high quality biallelic markers.

35 The location of nucleotides in a polynucleotide with respect to the center of the polynucleotide are described herein in the following manner. When a polynucleotide has an odd number of nucleotides, the nucleotide at an equal distance from the 3' and 5' ends of the polynucleotide is considered to be “at the center” of the polynucleotide, and any nucleotide

immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be "within 1 nucleotide of the center." With an odd number of nucleotides in a polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within 2 nucleotides of the center, and so on. When a polynucleotide has an even number of nucleotides, there would be a bond and not a nucleotide at the center of the polynucleotide. Thus, either of the two central nucleotides would be considered to be "within 1 nucleotide of the center" and any of the four nucleotides in the middle of the polynucleotide would be considered to be "within 2 nucleotides of the center", and so on. For polymorphisms which involve the substitution, insertion or deletion of 1 or more nucleotides, the polymorphism, allele or biallelic marker is "at the center" of a polynucleotide if the difference between the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 3' end of the polynucleotide, and the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 5' end of the polynucleotide is zero or one nucleotide. If this difference is 0 to 3, then the polymorphism is considered to be "within 1 nucleotide of the center." If the difference is 0 to 5, the polymorphism is considered to be "within 2 nucleotides of the center." If the difference is 0 to 7, the polymorphism is considered to be "within 3 nucleotides of the center," and so on. For polymorphisms which involve the substitution, insertion or deletion of 1 or more nucleotides, the polymorphism, allele or biallelic marker is "at the center" of a polynucleotide if the difference between the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 3' end of the polynucleotide, and the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 5' end of the polynucleotide is zero or one nucleotide. If this difference is 0 to 3, then the polymorphism is considered to be "within 1 nucleotide of the center." If the difference is 0 to 5, the polymorphism is considered to be "within 2 nucleotides of the center." If the difference is 0 to 7, the polymorphism is considered to be "within 3 nucleotides of the center," and so on.

The term "upstream" is used herein to refer to a location which, is toward the 5' end of the polynucleotide from a specific reference point.

The terms "base paired" and "Watson & Crick base paired" are used interchangeably herein to refer to nucleotides which can be hydrogen bonded to one another by virtue of their sequence identities in a manner like that found in double-helical DNA with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds (See Stryer, L., *Biochemistry*, 4th edition, 1995).

The terms "complementary" or "complement thereof" are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with

another specified polynucleotide throughout the entirety of the complementary region. This term is applied to pairs of polynucleotides based solely upon their sequences and not any particular set of conditions under which the two polynucleotides would actually bind.

5 The terms "sbg1 gene", when used herein, encompasses genomic, mRNA and cDNA sequences encoding the *sbg1* protein, including the untranslated regulatory regions of the genomic DNA.

The terms "g34665 gene", when used herein, encompasses genomic, mRNA and cDNA sequences encoding the g34665 protein, including the untranslated regulatory regions of the genomic DNA.

10 The terms "sbg2 gene", when used herein, encompasses genomic, mRNA and cDNA sequences encoding the *sbg2* protein, including the untranslated regulatory regions of the genomic DNA.

The terms "g35017 gene", when used herein, encompasses genomic, mRNA and cDNA sequences encoding the g35017 protein, including the untranslated regulatory regions of the genomic DNA.

15 The terms "g35018 gene", when used herein, encompasses genomic, mRNA and cDNA sequences encoding the g35018 protein, including the untranslated regulatory regions of the genomic DNA.

20 As used herein the term "13q31-q33-related biallelic marker" relates to a set of biallelic markers residing in the human chromosome 13q31-q33 region. The term 13q31-q33-related biallelic marker encompasses all of the biallelic markers disclosed in Table 6b and any biallelic markers in linkage disequilibrium therewith, as well as any biallelic markers disclosed in Table 6c and any biallelic markers in linkage disequilibrium therewith. The preferred chromosome 13q31-q33-related biallelic marker alleles of the present invention include each one the alleles described in Tables 6b individually or in groups consisting of all the possible combinations of the alleles listed.

25 As used herein the term "Region D-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the subregion of the chromosome 13q31-q33 region referred to herein as Region D. The term Region D-related biallelic marker encompasses the biallelic markers A1 to A242, A249 to A251, A257 to A263, A269 to A270, A278, A285 to A299, A303 to A307, A324, A330, A334 to A335, A346 to 357 and A361 to A489 disclosed in Table 6b and any biallelic markers in linkage disequilibrium with markers A1 to A242, A249 to A251, A257 to A263, A269 to A270, A278, A285 to A299, A303 to A307, A324, A330, A334 to A335, A346 to 357 and A361 to A489.

35 As used herein the term "sbg1-related biallelic marker" relates to a set of biallelic

markers in linkage disequilibrium with the sbg1 gene or an sbg1 nucleotide sequence. The term sbg1-related biallelic marker encompasses the biallelic markers A85 to A219 disclosed in Table 6b and any biallelic markers in linkage disequilibrium therewith.

5 As used herein the term "g34665-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the g34665 gene or an sbg1 nucleotide sequence. The term g34665-related biallelic marker encompasses the biallelic markers A230 to A236 disclosed in Table 6b and any biallelic markers in linkage disequilibrium therewith.

10 As used herein the term "sbg2-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the sbg2 gene or an sbg2 nucleotide sequence. The term sbg2-related biallelic marker encompasses the biallelic markers A79 to A99 disclosed in Table 6b and any biallelic markers in linkage disequilibrium therewith.

15 As used herein the term "g35017-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the g35017 gene or an g35017 nucleotide sequence. The term g35017-related biallelic marker encompasses biallelic marker A41 disclosed in Table 6b and any biallelic markers in linkage disequilibrium therewith.

20 As used herein the term "g35018-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the g35018 gene or a g35018 nucleotide sequence. The term g35018-related biallelic marker encompasses the biallelic markers A1 to A39 disclosed in Table 6b and any biallelic markers in linkage disequilibrium therewith.

25 The term "polypeptide" refers to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude post-expression modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term polypeptide. Also included within the definition are polypeptides which contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

30 The term "purified" is used herein to describe a polypeptide of the invention which has been separated from other compounds including, but not limited to nucleic acids, lipids, carbohydrates and other proteins. A polypeptide is substantially pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polypeptide sequence. A substantially pure polypeptide typically comprises about 50%, preferably 60 to 90% weight/weight of a protein sample, more usually about 95%, and preferably is over about 99% pure. Polypeptide purity or

35

homogeneity is indicated by a number of means well known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

5 As used herein, the term “non-human animal” refers to any non-human vertebrate, birds and more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term “animal” is used to refer to any vertebrate, preferable a mammal. Both the terms “animal” and “mammal” expressly embrace human subjects unless preceded with the term “non-human”.

10 As used herein, the term “antibody” refers to a polypeptide or group of polypeptides which are comprised of at least one binding domain, where an antibody binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen., which allows an immunological reaction with the antigen. Antibodies include recombinant proteins comprising the binding domains, as
15 wells as fragments, including Fab, Fab', F(ab)₂, and F(ab')₂ fragments.

As used herein, an “antigenic determinant” is the portion of an antigen molecule, in this case an sbg1 polypeptide, that determines the specificity of the antigen-antibody reaction. An “epitope” refers to an antigenic determinant of a polypeptide. An epitope can comprise as few
20 as 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope comprises at least 6 such amino acids, and more usually at least 8-10 such amino acids. Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping e.g. the Pepscan method described by Geysen et al. 1984; PCT Publication No. WO 84/03564; and
25 PCT Publication No. WO 84/03506.

Variants and Fragments

The invention also relates to variants and fragments of the polynucleotides described herein, particularly of a nucleotide sequence of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229,
30 and particularly of a nucleotide sequence of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 containing one or more biallelic markers and/or other polymorphisms according to the invention.

Variants of polynucleotides, as the term is used herein, are polynucleotides that differ from a reference polynucleotide. A variant of a polynucleotide may be a naturally occurring

variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the polynucleotide may be made by mutagenesis techniques, including those applied to polynucleotides, cells or organisms.

Generally, differences are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical.

Variants of polynucleotides according to the invention include, without being limited to, nucleotide sequences which are at least 95% identical to a polynucleotide selected from the group consisting of the nucleotide sequences SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or to any polynucleotide fragment of at least 8 consecutive nucleotides of a polynucleotide selected from the group consisting of the nucleotide SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, and preferably at least 99% identical, more particularly at least 99.5% identical, and most preferably at least 99.8% identical to a polynucleotide selected from the group consisting of the nucleotide SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or to any polynucleotide fragment of at least 30, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000, to the extent that the length is consistent with the particular sequence ID, consecutive nucleotides of a polynucleotide selected from the group consisting of the nucleotide sequences of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229.

Nucleotide changes present in a variant polynucleotide may be silent, which means that they do not alter the amino acids encoded by the polynucleotide. However, nucleotide changes may also result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions.

A polynucleotide fragment is a polynucleotide having a sequence that is entirely the same as part but not all of a given nucleotide sequence, preferably the nucleotide sequence of an sbg1 polynucleotide, and variants thereof, or of a polynucleotide of any of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229, or a polynucleotide comprising one of the biallelic markers A1 to A360 or polymorphism A361 to A489, or the complements thereof. Such fragments may be "free-standing", i.e. not part of or fused to other polynucleotides, or they may be comprised within a single larger polynucleotide of which they form a part or region. Indeed, several of these fragments may be present within a single larger polynucleotide. Optionally, such fragments may comprise, consist of, or consist essentially of a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 30, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length of any of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229.

Identity Between Nucleic Acids Or Polypeptides

The terms “percentage of sequence identity” and “percentage homology” are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Homology is evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-2448; Altschul et al., 1990, J. Mol. Biol. 215(3):403-410; Thompson et al., 1994, Nucleic Acids Res. 22(2):4673-4680; Higgins et al., 1996, Methods Enzymol. 266:383-402; Altschul et al., 1990, J. Mol. Biol. 215(3):403-410; Altschul et al., 1993, Nature Genetics 3:266-272). In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool (“BLAST”) which is well known in the art (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268; Altschul et al., 1990, J. Mol. Biol. 215:403-410; Altschul et al., 1993, Nature Genetics 3:266-272; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402). In particular, five specific BLAST programs are used to perform the following task:

- (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;
- (2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;
- (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;
- (4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and
- (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as “high-scoring segment pairs,” between a query amino or nucleic

acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992, Science 256:1443-1445; Henikoff and
5 Henikoff, 1993, Proteins 17:49-61). Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical
10 Research Foundation). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical
15 significance formula of Karlin (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268).

The BLAST programs may be used with the default parameters or with modified
15 parameters provided by the user.

Stringent Hybridization Conditions

By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP,
20 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Subsequently, filter washes can be done at 37°C for 1 h in a solution containing 2 x SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1 X SSC at 50°C for 45 min.
25 Following the wash steps, the hybridized probes are detectable by autoradiography. Other conditions of high stringency which may be used are well known in the art and as cited in Sambrook et al., 1989; and Ausubel et al., 1989. These hybridization conditions are suitable for a nucleic acid molecule of about 20 nucleotides in length. There is no need to say that the hybridization conditions described above are to be adapted according to the length of the desired
30 nucleic acid, following techniques well known to the one skilled in the art. The suitable hybridization conditions may for example be adapted according to the teachings disclosed in the book of Hames and Higgins (1985) or in Sambrook et al.(1989).

Genomic Sequences of the polynucleotides of the invention

The present invention concerns genomic DNA sequences of the sbg1, g34665, sbg2, g35017 and g35018 genes, as well as DNA sequences of the human chromosome 13q31-q33 region, and more particularly, a subregion thereof referred to herein as region D.

As referred to herein, genomic sequences of sbg2, g35017 and g35018 are indicated by nucleotide position in the 5' to 3' orientation on SEQ ID No 1. sbg1 and g34665 are transcribed in the opposite direction, ie. from the nucleic acid strand complementary to SEQ ID No 1. Genomic sequences of sbg1 and g34665 are thus indicated by nucleotide position in the 3' to 5' orientation on SEQ ID No 1.

Preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of nucleotide positions 31 to 292651 and 292844 to 319608 of SEQ ID No. 1, or the complements thereof. Further nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides, to the extent that the length of said span is consistent with the length of the SEQ ID, of SEQ ID Nos. 112 to 229. Optionally, said span is at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID Nos. 112 to 114, 115 to 117, 119, 121, 125 to 145, 147 to 150, 159 to 170, and 176 to 229.

The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a nucleotide sequence of of nucleotide positions 31 to 292651 and 292844 to 319608 of SEQ ID No. 1, or a complementary sequence thereto or a fragment thereof. Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No 1 or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

Additional preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises a biallelic marker. Optionally, said contiguous span comprises a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242. Optionally allele 2 is present at the biallelic marker. It should be noted that nucleic acid fragments of any size and sequence may be comprised by the polynucleotides described in this section.

Another particularly preferred set of nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides, to the extent that such a length is consistent with the lengths of the particular nucleotide position, of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one of the following ranges of nucleotide positions, designated pos1 to pos166, of SEQ ID No. 1 listed in Table 1 below:

Table 1

Position	Position in SEQ ID No 1		Position	Position in SEQ ID No 1	
	Beginning	End		Beginning	End
pos 1	36	2000	pos 84	156001	158000
pos 2	2001	4000	pos 85	158001	160000
pos 3	4001	6000	pos 86	160001	162000
pos 4	6001	8000	pos 87	162001	164000
pos 5	8001	10000	pos 88	164001	166000
pos 6	10001	12000	pos 89	166001	168000
pos 7	12001	14000	pos 90	168001	170000
pos 8	14001	16000	pos 91	170001	172000
pos 9	16001	18000	pos 92	172001	174000
pos 10	18001	20000	pos 93	174001	176000
pos 11	20001	22000	pos 94	176001	178000
pos 12	22001	24000	pos 95	178001	180000
pos 13	24001	26000	pos 96	180001	182000
pos 14	26001	28000	pos 97	182001	184000
pos 15	28001	29966	pos 98	184001	186000
pos 16	30116	32000	pos 99	186001	188000
pos 17	32001	34000	pos 100	188001	190000
pos 18	34001	36000	pos 101	190001	192000
pos 19	36001	38000	pos 102	192001	194000
pos 20	38001	40000	pos 103	194001	196000
pos 21	40001	42000	pos 104	196001	198000
pos 22	42001	44000	pos 105	198001	200000
pos 23	44001	46000	pos 106	200001	201000

Position	Position in SEQ ID No 1		Position	Position in SEQ ID No 1	
	Beginning	End		Beginning	End
pos 24	46001	48000	pos 107	201001	202000
pos 25	48001	50000	pos 108	202001	204000
pos 26	50001	52000	pos 109	204001	206000
pos 27	52001	54000	pos 110	206001	208000
pos 28	54001	56000	pos 111	208001	210000
pos 29	56001	58000	pos 112	210001	212000
pos 30	58001	60000	pos 113	212001	214000
pos 31	60001	62000	pos 114	214001	216000
pos 32	62001	64000	pos 115	216001	218000
pos 33	64001	66000	pos 116	218001	220000
pos 34	66001	68000	pos 117	220001	222000
pos 35	68001	70000	pos 118	222001	224000
pos 36	70001	72000	pos 119	224001	226000
pos 37	72001	74000	pos 120	226001	228000
pos 38	74001	76000	pos 121	228001	230000
pos 39	76001	78000	pos 122	230001	232000
pos 40	78001	80000	pos 123	232001	234000
pos 41	80001	82000	pos 124	234001	236000
pos 42	82001	84000	pos 125	236001	238000
pos 43	84001	86000	pos 126	238001	240000
pos 44	86001	88000	pos 127	240001	242000
pos 45	88001	90000	pos 128	242001	244000
pos 46	90001	92000	pos 129	244001	246000
pos 47	92001	94000	pos 130	246001	248000
pos 48	94001	96000	pos 131	248001	250000
pos 49	96001	98000	pos 132	250001	252000
pos 50	98001	100000	pos 133	252001	254000
pos 51	10000	102000	pos 134	254001	256000
pos 52	10200	104000	pos 135	256001	258000
pos 53	10400	106000	pos 136	258001	260000
pos 54	10600	108000	pos 137	260001	262000

Position	Position in SEQ ID No 1		Position	Position in SEQ ID No 1	
	Beginning	End		Beginning	End
pos 55	10800	110000	pos 138	262001	264000
pos 56	11000	102000	pos 139	264001	266000
pos 57	10200	104000	pos 140	266001	268000
pos 58	10400	106000	pos 141	268001	270000
pos 59	10600	108000	pos 142	270001	272000
pos 60	10800	110000	pos 143	272001	274000
pos 61	11000	112000	pos 144	274001	276000
pos 62	11200	114000	pos 145	276001	278000
pos 63	11400	116000	pos 146	278001	280000
pos 64	11600	118000	pos 147	280001	282000
pos 65	11800	120000	pos 148	282001	284000
pos 66	12000	122000	pos 149	284001	286000
pos 67	12200	124000	pos 150	286001	288000
pos 68	12400	126000	pos 151	288001	290000
pos 69	12600	128000	pos 152	290001	292000
pos 70	12800	130000	pos 153	292001	294000
pos 71	13000	132000	pos 154	294001	296000
pos 72	13200	134000	pos 155	296001	298000
pos 73	13400	136000	pos 156	298001	300000
pos 74	13600	138000	pos 157	300001	302000
pos 75	13800	140000	pos 158	302001	304000
pos 76	14000	142000	pos 159	304001	306000
pos 77	14200	144000	pos 160	306001	308000
pos 78	14400	146000	pos 161	308001	310000
pos 79	14600	148000	pos 162	310001	312000
pos 80	148000	150000	pos 163	312001	314000
pos 81	150001	152000	pos 164	314001	316000
pos 82	152001	154000	pos 165	316001	318000
pos 83	154001	156000	pos 166	318001	319608

Nucleic Acid Sequences of sbg1, g34665, sbg2, g35017 and g35018

The present invention encompasses the g34665, g34673, g34667, g35017 and g35018

genes and nucleotide sequences.

g34665

5 In one aspect, the invention concerns g34665 genomic sequences consisting of, consisting essentially of, or comprising the sequence of nucleotide positions 292653 to 296047 of SEQ ID No 1, a sequence complementary thereto, as well as fragments and variants thereof. These polynucleotides may be purified, isolated, or recombinant.

10 Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides, to the extent that the length of said span is consistent with the nucleotide position range, of nucleotide positions 292653 to 292841, 295555 to 296047 or 295580 to 296047 of SEQ ID No 1. Further preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150 or 200 nucleotides, to the extent that the length of said span is consistent with the nucleotide position range, of
15 nucleotide positions 292653 to 292841, 295555 to 296047, or 295580 to 296047 of SEQ ID No 1, or the complements thereof, wherein said contiguous span comprises a g34665-related biallelic marker. Optionally, said biallelic marker is selected from the group consisting of A230 to A236. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

20 The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, 95, 97, 98 or 99% nucleotide identity with a nucleotide sequence of of nucleotide positions 290653 to 292652, 292653 to 296047, 292653 to 292841, 295555 to 296047, 295580 to 296047 and 296048 to 298048 of SEQ ID No 1 or a complementary sequence thereto or a fragment thereof. The
25 nucleotide differences as regards to nucleotide positions 290652 to 292652, 292653 to 296047, 292653 to 292841, 295555 to 296047, 295580 to 296047 and 296048 to 298048 of SEQ ID No 1 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequence of SEQ ID No 1 are predominantly located outside the coding sequences contained in
30 the exons. These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the g34665 gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the g34665 sequences.

35 Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with a g34665 nucleotide sequence of any of nucleotide positions 292653 to

296047, 292653 to 292841, 295555 to 296047, 295980 to 296047 and 296048 to 298048 SEQ ID No 1 or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

The g34665 genomic nucleic acid comprises at least 3 exons. The exon positions in SEQ ID No 1 are detailed below in Table 2.

Table 2

Exon	Position in SEQ ID No 1		Intron	Position in SEQ ID No 1	
	Beginning	End		Beginning	End
B	292653	292841	B-Ab	292842	295554
Ab	295555	296047	B-A	292842	295979
A	295980	296047			

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 3 exons of the g34665 gene, or a sequence complementary thereto. The invention also deals with purified, isolated, or recombinant nucleic acids comprising a combination of two exons of the g34665 gene.

Intron B-Ab refers to the nucleotide sequence located between Exon B and Exon Ab, and so on. The position of the introns is detailed in Table 2. Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 2 introns of the g34665 gene, or a sequence complementary thereto.

While this section is entitled "Genomic Sequences of g34665," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of g34665 on either side or between two or more such genomic sequences.

A g34665 polynucleotide or gene may further contain regulatory sequences both in the non-coding 5'-flanking region and in the non-coding 3'-flanking region that border the region containing said genes or exons.

Polynucleotides derived from 5' and 3' regulatory regions are useful in order to detect the presence of at least a copy of a nucleotide sequence comprising a g34665 nucleotide sequence of SEQ ID No. 1 or a fragment thereof in a test sample. Polynucleotides carrying the regulatory elements located at the 5' end and at the 3' end of the genes comprising the exons of the present invention may be advantageously used to control the transcriptional and translational

activity of a heterologous polynucleotide of interest.

Methods for identifying the relevant polynucleotides comprising biologically active g34665 regulatory fragments or variants of SEQ ID No 1 are further described herein. Thus, the present invention also relates to a purified or isolated nucleic acid comprising a polynucleotide which is selected from the group consisting of the 5' and 3' regulatory regions of g34665, or a sequence complementary thereto or a biologically active fragment or variant thereof.

g35017

In one aspect, the invention concerns g35017 genomic sequences consisting of, consisting essentially of, or comprising the sequence of nucleotide positions 94124 to 94964 of SEQ ID No 1, a sequence complementary thereto, as well as fragments and variants thereof. These polynucleotides may be purified, isolated, or recombinant.

The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a nucleotide sequence of of nucleotide positions 94124 to 94964 SEQ ID No 1 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards to nucleotide positions 94124 to 94964 SEQ ID No 1 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequence of SEQ ID No 1 are predominantly located outside the coding sequences contained in the exons. These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the g35017 gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the g35017 sequences.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with a g35017 nucleotide sequence of any of nucleotide positions 94124 to 94964 of SEQ ID No 1 or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or 500 nucleotides of nucleotide position 94124 to 94964 of SEQ ID No 1 or the complements thereof. Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or 500 nucleotides of nucleotide position 94124 to 94964 of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises a g35017 related biallelic marker. Optionally, said

biallelic marker is the biallelic marker designated A41 in Table 6b. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

While this section is entitled "Genomic Sequences of g35017," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of g35017 on either side or between two or more such genomic sequences.

A g35017 polynucleotide or gene may further contain regulatory sequences both in the non-coding 5'-flanking region and in the non-coding 3'-flanking region that border the region containing said genes or exons.

Polynucleotides derived from g35017 5' and 3' regulatory regions are useful in order to detect the presence of at least a copy of a nucleotide sequence comprising an g35017 nucleotide sequence of SEQ ID No. 1 or a fragment thereof in a test sample. Polynucleotides carrying the regulatory elements located at the 5' end and at the 3' end of the genes comprising the exons of the present invention may be advantageously used to control the transcriptional and translational activity of a heterologous polynucleotide of interest.

Methods for identifying the relevant polynucleotides comprising biologically active regulatory fragments or variants of a g35017 nucleic acid sequence of SEQ ID No 1 are further described herein. Thus, the present invention also relates to a purified or isolated nucleic acid comprising a polynucleotide which is selected from the group consisting of the 5' and 3' regulatory regions, or a sequence complementary thereto or a biologically active fragment or variant thereof. In one aspect, the 5' regulatory region may comprise a nucleotide sequence

g35018

In one aspect, the invention concerns g35018 genomic sequences consisting of, consisting essentially of, or comprising the sequence of nucleotide positions 1108 to 65853 of SEQ ID No 1, a sequence complementary thereto, as well as fragments and variants thereof. These polynucleotides may be purified, isolated, or recombinant.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides, to the extent that said span is consistent with the nucleotide position range, of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812 and 65505 to 65853, or the complements thereof. Further

preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of nucleotide positions 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812 or 65505 to 65853 of SEQ ID No 1, or the complements thereof, wherein said
5 contiguous span comprises a g35018 related biallelic marker. Optionally, said biallelic marker is selected from the group consisting of A1 to A39. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

10 The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a nucleotide sequence of nucleotide positions 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854 of SEQ ID No 1 or a complementary sequence
15 thereto or a fragment thereof. The nucleotide differences as regards to nucleotide positions 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854 of SEQ ID No 1 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide
20 sequence of nucleotide positions 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854 of SEQ ID No 1 are predominantly located outside the coding sequences contained in the exons. These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the
25 g35018 gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the g35018 sequences.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with a g35018 nucleotide sequence of any of nucleotide positions 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854 SEQ ID No 1, or
30 a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

Yet further nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60,
35 70, 80, 90, 100, 150, 200 or 500 nucleotides, to the extent that said span is consistent with the

nucleotide position range, of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1255 to 1289, 29967 to 30115, 30225 to 30282, or the complements thereof, as well as polynucleotides having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with said span and polynucleotides capable of hybridizing with said span.

The g35018 genomic nucleic acid comprises at least 8 exons. The exon positions in SEQ ID No 1 are detailed below in Table 3.

Table 3

Exon	Position in SEQ ID No 1		Intron	Position in SEQ ID No 1	
	Beginning	End		Beginning	End
A	1108	1289	A	1290	14876
B	14877	14920	B	14921	18777
Bbis	18778	18862	Bbis	18863	25592
C	25593	25740	C	25741	29387
D	29388	29502	D	29503	29966
E	29967	30282	E	30283	64665
F	64666	64812	F	64813	65504
G	65505	65853			

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 8 exons of the g35018 gene, or a sequence complementary thereto. The invention also deals with purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the 35018 gene, wherein the polynucleotides are arranged within the nucleic acid, from the 5'-end to the 3'-end of said nucleic acid, in the same order as in SEQ ID No 1.

Intron 1 refers to the nucleotide sequence located between Exon 1 and Exon 2, and so on. The position of the introns is detailed in Table 3. Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 7 introns of the g35018 gene, or a sequence complementary thereto.

While this section is entitled "Genomic Sequences of g35018," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of g35018 on either side or between two or more such genomic sequences.

A g35018 polynucleotide or gene may further contain regulatory sequences both in the

non-coding 5'-flanking region and in the non-coding 3'-flanking region that border the region containing said genes or exons.

Polynucleotides derived from 5' and 3' regulatory regions are useful in order to detect the presence of at least a copy of a nucleotide sequence comprising an g35018 nucleotide sequence of SEQ ID No. 1 or a fragment thereof in a test sample. Polynucleotides carrying the regulatory elements located at the 5' end and at the 3' end of the genes comprising the exons of the present invention may be advantageously used to control the transcriptional and translational activity of a heterologous polynucleotide of interest.

Methods for identifying the relevant polynucleotides comprising biologically active regulatory fragments or variants of SEQ ID No 1 are further described herein. Thus, the present invention also relates to a purified or isolated nucleic acid comprising a polynucleotide which is selected from the group consisting of the 5' and 3' regulatory regions, or a sequence complementary thereto or a biologically active fragment or variant thereof.

In one embodiment, a 5' regulatory region may comprise an isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of nucleotide positions 31 to 1107 of SEQ ID No 1, or the complements thereof. In one embodiment, a 3' regulatory region may comprise an isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of nucleotide positions 65854 to 67854 of SEQ ID No 1, or the complements thereof.

Genomic Sequences of sbg1 polynucleotides

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising, consisting essentially of, or consisting of a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of nucleotide positions 213818 to 243685 of SEQ ID No 1, or the complements thereof. Also encompassed are purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with nucleotide positions 213818 to 243685 of SEQ ID No 1, or a complementary sequence thereto or a fragment thereof. Nucleic acids of the invention encompass an sbg1 nucleic acid from any source, including primate, non-human primate, mammalian and human sbg1 nucleic acids.

Further preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the

complements thereof, wherein said contiguous span comprises an sbg1 related biallelic marker. Optimally, said biallelic marker is selected from the group consisting of A85 to A219.

Optimally, said biallelic marker is selected from the group consisting of A85 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197 and A199 to A219.

5 It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

The human sbg1 gene comprises exons selected from at least 22 different exons or exon forms, referred to herein as exons MS1, M1, M692, M862, MS2, M1069, M1090, M1117, N, N2, Nbis, O, O1, O2, Obis, P, X, Q1, Q, Qbis, Rbis and R. Of these, the following exon sets
10 contain sequence overlap and do not occur together in an mRNA: exons M1, M692, M862, MS2, M1090 M1069 and M1117; exons MS1, M1, M692 and M862; exons N and N2; exons O1 and O2; exons Q and Qbis; exons R and R bis; and exons Q and Q1.

The nucleotide positions of sbg1 exons in SEQ ID No. 1 are detailed below in Table 4. The exon structure of the sbg1 gene is further shown in Figure 1.

Table 4

Exon	Position in SEQ ID No 1	
	Beginning	End
R	215819	215941
Rbis	215819	215975
Qbis	216661	216952
Q	216661	217061
Q1	217027	217061
X	229647	229742
P	230408	230721
Obis	231272	231412
O2	231787	231880
O1	231870	231879
O	234174	234321
Nbis	237406	237428
N2	239719	239807
N	239719	239853
M117	240528	240569
M1090	240528	240596

M1069	240528	240617
MS2	240528	240644
M862	240528	240824
M692	240528	240994
M1	240528	241685
MS1	240800	240993

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the exons of the *sbgl* gene, or a sequence complementary thereto. Preferred are purified, isolated, or recombinant polynucleotides comprising at least one exon having the nucleotide position ranges listed in Table 4 selected from the group consisting of the exons MS1, M1, M692, M862, MS2, M1069, M1090, M1117, N, N2, Nbis, O, O1, O2, Obis, P, X, Q1, Q, Qbis, R and Rbis of the *sbgl* gene, or a complementary sequence thereto or a fragment or a variant thereof. Also encompassed by the invention are purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the *sbgl* gene selected from the group consisting of exons MS1, M1, M692, M862, MS2, M1069, M1090, M1117, N, N2, Nbis, O, O1, O2, Obis, P, X, Q1, Q, Qbis, R and Rbis, wherein the polynucleotides are arranged within the nucleic acid in the same relative order as in SEQ ID No. 1.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685, or the complements thereof.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with an *sbgl* nucleotide sequence of nucleotide positions 213818 to 243685, 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853,

240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 or 241686 to 243685 of SEQ ID No 1, or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

5 The present invention further embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the introns of the *sbgl* gene, or a sequence complementary thereto.

10 In other embodiments, the present invention encompasses the *sbgl* gene as well as *sbgl* genomic sequences consisting of, consisting essentially of, or comprising the sequence of nucleotide positions 215819 to 241685 of SEQ ID No 1, a sequence complementary thereto, as well as fragments and variants thereof.

15 The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence of *sbgl* having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a sequence selected from the group consisting of nucleotide positions 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685 of SEQ ID No. 1 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards the nucleotide positions 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685 of SEQ ID No. 1 may generally be distributed throughout the nucleic acid.

20 These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of a gene comprising an *sbgl* nucleic acid sequence in a test sample, or alternatively in order to amplify a target nucleotide sequence within an *sbgl* nucleic acid sequence or adjoining region.

30 Additional preferred nucleic acids of the invention include isolated, purified, or recombinant *sbgl* polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides of nucleotide positions 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880,

35

231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993, 215819 to 241685 and 241686 to 243685 of SEQ ID No 1, or the complements thereof, wherein said contiguous span comprises at least one biallelic marker. Optionally, said contiguous span comprises an *sbgl*-related biallelic marker. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section. Either the original or the alternative allele may be present at said biallelic marker.

Yet further nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or 500 nucleotides, to the extent that said span is consistent with the nucleotide position range, of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 215820 to 215941, 216661 to 217009, 230409 to 290721, 231272 to 231411, 234202 to 234321, 240528 to 240567, 240528 to 240827 and 240528 to 240996, or the complements thereof, as well as polynucleotides having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with said span, and polynucleotides capable of hybridizing with said span.

The present invention also comprises a purified or isolated nucleic acid encoding an *sbgl* protein having the amino acid sequence of any one of SEQ ID Nos 27 to 35 or a peptide fragment or variant thereof.

While this section is entitled "Genomic Sequences of *sbgl*," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences *sbgl* on either side or between two or more such genomic sequences.

***SbgI* cDNA Sequences**

The expression of the *sbgl* gene has been shown to lead to the production of several mRNA species. Several cDNA sequences corresponding to these mRNA are set forth in SEQ ID Nos 2 to 26.

The invention encompasses a purified, isolated, or recombinant nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 26, complementary sequences thereto, splice variants thereof, as well as allelic variants, and fragments thereof. Moreover, preferred polynucleotides of the invention include purified, isolated, or recombinant *sbgl* cDNAs consisting of, consisting essentially of, or comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 26. Particularly

preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 75, 80, 100, 200 or 500 nucleotides, to the extent that the length of said contiguous span is consistent with the length of the SEQ ID, of a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 26, or the complements thereof.

It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 70, 80, 85, 90 or 95% nucleotide identity with a polynucleotide selected from the group consisting of SEQ ID Nos 2 to 26, advantageously 99% nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide selected from the group consisting of SEQ ID Nos 2 to 26, or a sequence complementary thereto or a biologically active fragment thereof.

Another object of the invention relates to purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of SEQ ID Nos 2 to 26, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

The sbg1 cDNA forms of SEQ ID Nos 2 to 26 are further described in Table 5a below. Shown on the Table 5a are the positions of the 5' UTR, the open reading frame (ORF), the 3' UTR and the polyA signal on the respective SEQ ID No. Also shown are the sbg1 exons comprising the cDNA form of a particular SEQ ID No.

Table 5a

SEQ ID No	cDNA	Pos range of 5UTR		Pos range of ORF		Pos range of 3UTR		Pos range of polyA signal	
2	M862NOQbisR	1	253	254	304	305	995	971	976
3	M862NOObisP	1	253	254	304	305	1035	1020	1025
4	M1	1	187	188	520	521	1158	-	-
5	M862NOP	1	253	254	304	305	894	879	884
6	M1090NOXQbisR	1	25	26	76	77	863	839	844
7	M1117N2OO1P	-	-	2	310	311	603	588	593
8	M1117N2OP	-	-	2	358	359	593	578	583
9	M1117NOO1P	-	-	2	49	50	649	634	639
10	M1117NOO2P	-	-	2	49	50	733	718	723
11	MS1MS2NOQbisR	1	267	268	318	319	1009	985	990

12	M1069NOQR	1	46	47	97	98	897	873	878
13	M1069N2OQ1QbisR	1	46	47	343	344	777	753	758
14	M1069NOQ1QbisR	1	46	47	97	98	823	799	804
15	M1069N2OO2QbisR	1	46	47	427	428	836	812	817
16	M1069NOO2QbisR	1	46	47	97	98	882	858	863
17	M1069N2NbisoO2X QbisR	1	46	47	235	236	955	931	936
18	M1069N2OQR	1	46	47	343	344	851	827	832
19	M1069N2OQbisR	1	46	47	508	509	742	718	723
20	M1069NNbisOQR	1	46	47	97	98	920	896	901
21	M1069NNbisOQbisR	1	46	47	97	98	811	787	792
22	M1069NOO2XQbisR	1	46	47	97	98	978	954	959
23	M1069NOXQR	1	46	47	97	98	993	969	974
24	M1069NOQbisRbis	1	46	47	97	98	822	-	-
25	M1069N2OQbisRbis	1	46	47	508	509	776	-	-
26	M1069N2OXQR	1	46	47	367	368	947	923	928

Primers used to isolate the particular sbg1 cDNAs listed above from RNA from various tissues are provided below in Table 5b. Primers designed to hybridize to nucleic acid sequences of exons MS1, M862, M1090, M1117 and MS2, and exons P and R resulted in the cloning of multiple cDNA forms for several sets of primers. The primers used are listed in SEQ ID Nos 44 to 53.

mRNA forms of sbg1 were found to differ among tissues; Table 5c lists cDNA forms cloned from various tissues and the relative percentages and numbers of clones found per tissue for each listed sbg1 mRNA form.

The present inventors have also identified further variations in cDNA sequence as obtained from various tissues and compared with the consensus sbg1 genomic nucleotide sequence. The tissues from which cDNA was cloned were obtained from pooled individuals numbering from 11 to 60. Table 5d below describes the identities of variants, the nucleotide position of the variation in nucleotide sequence of SEQ ID No 2, and the number of samples having the specified sequence for each respective nucleotide position on the sbg1 cDNA sequence of SEQ ID No. 2. Also indicated in Table 5d are amino acid changes in the corresponding sbg1 polypeptide sequence (described herein), if any, resulting from the nucleotide sequence variations in the cDNA of SEQ ID No 2.

These variants may represent rare polymorphisms or may be the result of tissue-specific RNA editing. Alternatively, some variations may be the result of the presence in the human genome of one or more sbg1-related genes or a small family of sbg1-related genes with strict tissue specificity of expression and small variation in gene structure. The latter hypothesis was tested by applicants for the case where the exon-intron structure of these genes are identical, demonstrating that variations in at least exons M and N are not the result of the presence of related genes.

The present invention thus further encompasses variant sbg1 polynucleotides having at least one nucleotide substitution as described in Table 5d below. The nucleotide and amino acid variations as shown in Table 5d are shown in terms of the nucleotide sequence of SEQ ID No. 2, and specify variations as found in exons M862, N, O, Qbis and R. The invention encompasses purified, isolated, or recombinant polynucleotides and polypeptides encoded thereby, wherein the polynucleotides comprise a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 100, 150, or 200 nucleotides of SEQ ID No 2 or the complement thereof, and wherein said contiguous span further comprises a nucleotide sequence variation according to Table 5d.

The present invention comprises a purified or isolated sbg1 cDNA encoding an sbg1 protein or a peptide fragment or variant thereof. In one embodiment, a purified or isolated nucleic acid encoding an sbg1 protein may have the amino acid sequence of any of SEQ ID Nos 27 to 35 or a peptide fragment or variant thereof.

Preferred nucleic acids of the invention also include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 75, 80, 100, 200 or 500 nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 26, or the complements thereof, wherein said span comprises a sbg1-related biallelic marker of the invention. The positions of selected biallelic markers of the invention in sbg1 cDNA sequences and polypeptide sequences are listed below in Table 5e. Said contiguous span may comprise a biallelic marker selected from the group of biallelic markers listed in Table 5e; optionally, said biallelic marker is selected from the group consisting of the biallelic markers located in an sbg1 cDNA form, as listed in Table 5e; optionally, said biallelic marker is selected from the group consisting of the biallelic markers located in an sbg1 coding sequence, as listed in Table 5e.

Expression of sbg1 mRNA was further confirmed by Northern blotting. Using a probe corresponding to exon O of the sbg1 gene, a band corresponding to an sbg1 mRNA was detected.

While this section is entitled "sbg1 cDNA Sequences," it should be noted that nucleic

acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of *sbg1* on either side or between two or more such genomic sequences.

Table 5b

PRIMERS	cDNA Form Observed	Tissue
g34872MbisEco CCCGAATCCCCAAACTTCTTTCAATTAAGAACCA (SEQ ID No 26)	MSIMS2NOQbisR	testis
g34872LR1309nBamH1 ATCGGGATCCAGAGATTCTCCAGTCACACAGGCC (SEQ ID No 27)		
g34872genolF22nEcoRI TACTGGAATCCAGGTAGAGTGAAGCAAGTAATGTGTGTGAG M862NOQbisR (SEQ ID No 28)		testis
g34872LR1309nBamH1 ATCGGGATCCAGAGATTCTCCAGTCACACAGGC (SEQ ID No 27)		amygdala caudate nucleus cerebellum hippocampus substantia nigra thalamus
g34872MterEco CGAGAATTCGATGATTTAGCTGGGAGGACCCNA (SEQ ID No 30)		
g34872LR1305nBam TCGGGATCCAGTCACACAGGCCAGGT (SEQ ID No 31)	M1090NOQbisR M1090NOXQbisR M1090N2OQbisR	testis
g34872LF1140EcoRI GCTGGGAATTCGCTGGAAGAAGCTGATGGGTGCTGATTCTC (SEQ ID No 32)	M1117NOQbisR	testis
g34872LR1309nBamH1 ATCGGGATCCAGAGATTCTCCAGTCACACAGGC (SEQ ID No 27)	M1117N2OQbisR M1117N2O02QbisR M1117N002QbisR M1117N2OQR	amygdala caudate nucleus cerebellum corpus callosum cortex hippocampus substantia nigra
g34872LF1064Eco TCAGAATTCATCTCTGCTTCACAATGCCG (SEQ ID No 34)		
g34872LR1309nBamH1 ATCGGGATCCAGAGATTCTCCAGTCACACAGGC (SEQ ID No 27)	MS2NOQ1QbisR MS2NO02QbisR MS2N2OQ1QbisR MS2NOQR MS2NOQbisR	testis
g34872genolF22nEcoRI TACTGGAATTCAGGTAGAGTGAAGCAAGTAATGTGTGTGAG		

(SEQ ID No 28)	g34872exRBAM139	ACGGGATCCTTTTCAGTACTGAAGTTGAGAGGGAGA	M862NOObisP	testis
(SEQ ID No 35)			M862NOP	

(SEQ ID No 32)	g34872LF1140ECOR1	GCTGGGAATTCGCTGGAAAGCTGATGGGTGCTGATTCTC	M1117NOP	testis
(SEQ ID No 33)	g34872exRBAM139	ACGGGATCCTTTTCAGTACTGAAGTTGAGAGGGAGA	M1117N2OP	
			M1117N2001P	
			M1117N002P	

Table 5c

Primers for Cloning (exons)	Tissue	Percentage cDNA Form cloned

M688 and R	testicle	100% MS1MS2NOQBisR (95 clones)

M862 and R	testicle	100% M862NOQBisR (188 clones)
	amygdala	100% M862NOQBisR (42 clones)
	caudate nucleus	100% M862NOQBisR (39 clones)
	cerebellum	100% M862NOQBisR (87 clones)
	hippocampus	100% M862NOQBisR (36 clones)
	substantia nigra	100% M862NOQBisR (96 clones)
	thalamus	100% M862NOQBisR (30 clones)

M1090 and R	testicle	45% M1090NOQBisR (5 clones)
		45% M1090NOQBisR (5 clones)
		10% M1090N2OQBisR (1 clone)

M1117 and R	testicle	26% M1117NOQBisR (23 clones)
		70% M1117N2OQBisR (62 clones)
		2% M1117N2O2OQBisR (2 clones)
		1% M1117N2O2OQBisR (1 clones)

	amygdala	100% M1117NOQBisR (90 clones)
	caudate nucleus	100% M1117NOQBisR (94 clones)
	cerebellum	100% M1117NOQBisR (88 clones)
	corpus callosum	100% M1117NOQBisR (94 clones)
	cortex	100% M1117NOQBisR (95 clones)
	hippocampus	100% M1117N2OQR (66 clones)
	substantia nigra	100% M1117N2OQR (90 clones)

MS2 and R	testicle	1% MS2N2O2OQBisR (1 clones)
		2% MS2N2OQ1OQBisR (2 clones)
		19% MS2NOO2OQBisR (18 clones)
		2% MS2NOQ1OQBisR (2 clones)
		8% MS2NOQR (8 clones)
		67% MS2NOQBisR (63 clones)

M1069 and R

Testicle

67% MNOQbisR
 16% MNOQR
 3% MN2OqbisR
 6% MNOXQR
 2% MN2OQR
 1% MNOO2XqbisR
 2% MNNbisOQbisR
 1% MNNbisOQR
 1% MN2NBisOO2XqbisR
 1% MN2OXQR

Brain

Hypothalamus cDNA
 Cerebellum
 Amygdala Cdna
 MOLT4 cells
 Spinal cord

100% MNOQbisR
 100% MN2OQbisR
 100% MNOQbisR
 100% MN2OQbisR
 100% MN2OQR
 57% MNOQbisR
 21% MN2OqbisR
 18% MNOQR
 3% MNOQbisRbis
 1% MN2OQbisRbis

M862 and P

testicle

97% M862NOObisP (88 clones)
 3% M862NOP (3 clones)

M1117 and P

hippocampus
testicle

100% M1117NOP (80 clones)
 58% M1117NOP (54 clones)
 37% M1117N2OP (35 clones)
 1% M1117N2OO1P (1 clone)
 1% M1117NOO1P (1 clone)
 2% M1117NOO2P (2 clones)

M1117 and O

Testicle

Cerebellum
 Hippocampus
 Caudate nucleus
 Corpus callosum
 Amygdala

MNO
 MNO
 MNO
 MNO
 MNO
 MNO

MNO
MNO
MNO
MNO
MNO
MN20
MN20

Lung
Fetal liver
Pancreas
Stomach
HL60 cell line
Spinal cord
trachea

Table 5d

Pos (1 to 998)	genomic	testicle	cerebellum	sbgl1 (exons M862NOQbisR) Subs nigra	amygdala	caudate nucleus
55	A	47A/1G	25A	43A/1G	40A/2G	17A/11G
122	A	48A	25A	20G/24A	40A/2G	28A
170	T	48T	25T	44T	35T/7C	19T/9C
178	G	48G	25G	24G/20A	42G	28G
209	T	47T/1C	25T	19T/25C	41T/1A	28T
226	A	48A	25G	44A	41A/1G	28A
248	G	48G	25G	44G	38G/4A	28G
258	T	48T	25C	44T	41T/1C	28T
286	T	48T	25T	44T	42T	24T/4C
301	beginning of exon N					
325	T/A:L->Q	46T/2A	25T	44T	36T/6A	21T/7A
351	A/G:R->G	48A	25A	43A/1G	35A/7G	28A
391	A/G:K->R	48G	25G	44G	42G	28G
393	A/T:S->C	48A	25A	44A	29A/13T	28A
429	T/C:S->P	48T	21T/4C	44T	42T	28T
436	beginning of exon O					
468	A/G:T->A	47A/1G	25A	1A	15G/2A	2G
497	T/C:H->H	47T/1C	25T	1T/1C	23T/2C	12T
511	T/C:L->S	48T	25T	28T	31C/9T	16C/11T/1N
529	A/G:H->R	48A	25A	39A	41A/1G	18A/10G
538	G/A:R->K	48G	25G	23G/17A	42G	28G
540	T/C:S->P	48T	25C	40T	42T	28T
571	A/G:Q->R	48A	25A	43A	37A/5G	24A/4G
584	beginning of exon Qbis					
608	T/C:V->V	48T	19T/6C	44T	42T	28T
616	T/C:V->A	48T	25T	44T	41T/1C	21T/7C
702	T/C:Y->H	48T	25T	44T	42T	17T/11C
706	A/G:N->S	48A	24G/1A	44A	42A	28A
718	A/G:D->G	48A	25A	44A	42A	18A/10G
803	A	48A	25A	44A	38A/4G	28A
829	C	48C	25C	25C/19T	41C/1N	27C/1N
856	G	42G/6A	25G	25G/19A	32G/10A	24G/4A
876	beginning of exon R					
901	C	48C	25C	25C/19T	40C/2N	27C/1N
915	A	46A/1G	25A	43A/1G	29G/13A	23G/5A
934	C	46C	25C	43C/1T	38C/4T	28C
938	C	46C	25C	44C	31C/11T	23C/5T

Table 5e

Amplicon	Biallelic Marker Name	Allele 1	Allele 2	Genomic position on SEQ ID No 1	cDNA form: position of marker on cDNA (position in polypeptide)
8-132	8-132-179	A	T	215838	M862NOQbisR:976 M1090NOXQbisR:844 MS1 MS2NOQbisR:990 M1069NOQR:878 M1069N2OQ1QbisR:758 M1069NOQ1QbisR:804 M1069N2OO2QbisR:817 M1069NOO2QbisR:863 M1069N2NbisoO2XQbisR:936 M1069N2OQR:832 M1069N2OQbisR:723 M1069NNbisOQR:901 M1069NNbisOQbisR:792 M1069NOO2XQbisR:959 M1069NOXQR:974 M1069NOQbisRbis:803 M1069N2OQbisRbis:757 M1069N2OXQR:928
8-132	8-132-164	A	G	215853	M862NOQbisR:961 M1090NOXQbisR:829 MS1 MS2NOQbisR:975 M1069NOQR:863 M1069N2OQ1QbisR:743 M1069NOQ1QbisR:789 M1069N2OO2QbisR:802 M1069NOO2QbisR:848 M1069N2NbisoO2XQbisR:921 M1069N2OQR:817 M1069N2OQbisR:708 M1069NNbisOQR:886 M1069NNbisOQbisR:777 M1069NOO2XQbisR:944 M1069NOXQR:959 M1069NOQbisRbis:788 M1069N2OQbisRbis:742

8-132	8-132-97	A	G	215920	M1069N2OXQR:913
					M862NOQbisR:894 M1090NOXQbisR:762 MS1 MS2NOQbisR:908 M1069NOQR:796 M1069N2OQ1QbisR:676 M1069NOQ1QbisR:722 M1069N2OO2QbisR:735 M1069NOO2QbisR:781 M1069N2NbisoO2XQbisR:854 M1069N2OQR:750 M1069N2OQbisR:641 M1069NNbisOQR:819 M1069NNbisOQbisR:710 M1069NOO2XQbisR:877 M1069NOXQR:892 M1069NOQbisRbis:721 M1069N2OQbisRbis:675 M1069N2OXQR:846
99-13929	99-13929-201	G	T	216028	
8-131	8-131-363	G	T	216538	
8-131	8-131-199	G	T	216702	M862NOQbisR:831 M1090NOXQbisR:699 MS1 MS2NOQbisR:845 M1069NOQR:733 M1069N2OQ1QbisR:613 M1069NOQ1QbisR:659 M1069N2OO2QbisR:672 M1069NOO2QbisR:718 M1069N2NbisoO2XQbisR:791 M1069N2OQR:687 M1069N2OQbisR:578 M1069NNbisOQR:756 M1069NNbisOQbisR:647 M1069NOO2XQbisR:814 M1069NOXQR:829 M1069NOQbisRbis:624 M1069N2OQbisRbis:578 M1069N2OXQR:783
8-130	8-130-236	C	T	216874	M862NOQbisR:659

					M1090NOXQbisR:527 MS1 MS2NOQbisR:673 M1069NOQR:561 M1069N2OQ1QbisR:441 M1069NOQ1QbisR:487 M1069N2OO2QbisR:500 M1069NOO2QbisR:546 M1069N2NbisoO2XQbisR:619 M1069N2OQR:515 M1069N2OQbisR:406 M1069NNbisOQR:584 M1069NNbisOQbisR:475 M1069NOO2XQbisR:642 M1069NOXQR:657 M1069NOQbisRbis:452 M1069N2OQbisRbis:406 M1069N2OXQR:611
8-130	8-130-220	G	T	216890	M862NOQbisR:643 M1090NOXQbisR:511 MS1 MS2NOQbisR:657 M1069NOQR:545 M1069N2OQ1QbisR:425 M1069NOQ1QbisR:471 M1069N2OO2QbisR:484 M1069NOO2QbisR:530 M1069N2NbisoO2XQbisR:603 M1069N2OQR:499 M1069N2OQbisR:390 (115) M1069NNbisOQR:568 M1069NNbisOQbisR:459 M1069NOO2XQbisR:626 M1069NOXQR:641 M1069NOQbisRbis:436 M1069N2OQbisRbis:390 (1150) M1069N2OXQR:595
8-130	8-130-144	C	T	216966	M1069NOQR:469 M1069N2OQR:423 M1069NNbisOQR:492 M1069NOXQR:565 M1069N2OXQR:519
8-130	8-130-143	A	G	216967	M1069NOQR:468

					M1069N2OQR:422 M1069NNbisOQR:491 M1069NOXQR:564 M1069N2OXQR:518
8-130	8-130-102	C	T	217008	M1069NOQR:427 M1069N2OQR:381 M1069NNbisOQR:450 M1069NOXQR:523 M1069N2OXQR:477
8-130	8-130-101	G	T	217009	M1069NOQR:426 M1069N2OQR:380 M1069NNbisOQR:449 M1069NOXQR:522 M1069N2OXQR:476
8-130	8-130-83	A	C	217027	M1069NOQR:408 M1069N2OQ1QbisR:362 M1069NOQ1QbisR:408 M1069N2OQR:362 M1069NNbisOQR:431 M1069NOXQR:504 M1069N2OXQR:458
8-143	8-143-245	G	T	229669	M1090NOXQbisR:426 M1069N2NbisOO2XQbisR:518 M1069NOO2XQbisR:541 M1069NOXQR:447 M1069N2OXQR:401
8-143	8-143-242	A	G	229672	M1090NOXQbisR:423 M1069N2NbisOO2XQbisR:515 M1069NOO2XQbisR:538 M1069NOXQR:444 M1069N2OXQR:398
8-143	8-143-239	C	T	229675	M1090NOXQbisR:420 M1069N2NbisOO2XQbisR:512 M1069NOO2XQbisR:535 M1069NOXQR:441 M1069N2OXQR:395
8-143	8-143-232	G	C	229682	M1090NOXQbisR:413 M1069N2NbisOO2XQbisR:505 M1069NOO2XQbisR:528 M1069NOXQR:434 M1069N2OXQR:388

8-119	8-119-210	A	C	230432	M862NOObisP:1011 M862NOP:870 M1117N2OO1P:579 M1117N2OP:569 M1117NOO1P:625 M1117NOO2P:709
8-119	8-119-204	A	C	230438	M862NOObisP:1005 M862NOP:864 M1117N2OO1P:573 M1117N2OP:563 M1117NOO1P:619 M1117NOO2P:703
8-119	8-119-200	A	G	230442	M862NOObisP:1001 M862NOP:860 M1117N2OO1P:569 M1117N2OP:559 M1117NOO1P:615 M1117NOO2P:699
8-119	8-119-195	A	C	230447	M862NOObisP:996 M862NOP:855 M1117N2OO1P:564 M1117N2OP:554 M1117NOO1P:610 M1117NOO2P:694
8-119	8-119-125	C	T	230517	M862NOObisP:926 M862NOP:785 M1117N2OO1P:494 M1117N2OP:484 M1117NOO1P:540 M1117NOO2P:624
8-119	8-119-120	A	G	230522	M862NOObisP:921 M862NOP:780 M1117N2OO1P:489 M1117N2OP:479 M1117NOO1P:535 M1117NOO2P:619
8-119	8-119-97	C	T	230545	M862NOObisP:898 M862NOP:757 M1117N2OO1P:466 M1117N2OP:456 M1117NOO1P:512 M1117NOO2P:596
8-119	8-119-93	G	T	230549	M862NOObisP:894

					M862NOP:753 M1117N2OO1P:462 M1117N2OP:452 M1117NOO1P:508 M1117NOO2P:592
8-119	8-119-38	A	T	230604	M862NOObisP:839 M862NOP:698 M1117N2OO1P:407 M1117N2OP:397 M1117NOO1P:453 M1117NOO2P:537
8-138	8-138-234	C	T	230684	M862NOObisP:759 M862NOP:618 M1117N2OO1P:327 M1117N2OP:317 10 M1117NOO1P:373 M1117NOO2P:457
8-138	8-138-218	A	G	230700	M862NOObisP:743 M862NOP:602 M1117N2OO1P:311 M1117N2OP:301 M1117NOO1P:357 M1117NOO2P:441
8-142	8-142-211	CAAA	-	231293	M862NOObisP:700
8-142	8-142-132	A	G	231372	M862NOObisP:621
8-145	8-145-197	C	T	231811	M1117NOO2P:395 M1069N2OO2QbisR:397 M1069NOO2QbisR:443 M1069N2NbisoO2XQbisR:420 M1069NOO2XQbisR:443
8-145	8-145-154	C	T	231854	231854 M1117NOO2P:352 M1069N2OO2QbisR:354
8-145	8-145-138	A	C	231870	M1117N2OO1P:289 (96) M1117NOO1P:335 M1117NOO2P:336 M1069N2OO2QbisR:338 (98) M1069NOO2QbisR:384 M1069N2NbisoO2XQbisR:361 M1069NOO2XQbisR:384
8-137	8-137-182	C	T	234277	M862NOQbisR:477 M862NOObisP:477

					M862NOP:477 M1090NOXQbisR:249 M1117N2OO1P:176 (59) M1117N2OP:176 (59) M1117NOO1P:222 M1117NOO2P:222 MS1 MS2NOQbisR:491 M1069NOQR:270 M1069N2OQ1QbisR:224 (60) M1069NOQ1QbisR:270 M1069N2OO2QbisR:224 (60) M1069NOO2QbisR:270 M1069N2NbisoO2XQbisR:247 M1069N2OQR:224 (60) M1069N2OQbisR:224 (60)
8-137	8-137-152	A	C	234307	M862NOQbisR:447 M862NOObisP:447 M862NOP:447 M1090NOXQbisR:219 M1117N2OO1P:146 (49) M1117N2OP:146 (49) M1117NOO1P:192 M1117NOO2P:192 MS1 MS2NOQbisR:461 M1069NOQR:240 M1069N2OQ1QbisR:194 (50) M1069NOQ1QbisR:240 M1069N2OO2QbisR:194 (50) M1069NOO2QbisR:240 M1069N2NbisoO2XQbisR:217 (57) M1069N2OQR:194 (50) M1069N2OQbisR:194 (50) M1069NNbisoQR:263 M1069NNbisoQbisR:263 M1069NOO2XQbisR:240 M1069NOXQR:240 M1069NOQbisRbis:240 M1069N2OQbisRbis:194 (50) M1069N2OXQR:194 (50)
99-16038	99-16038-118	C	T	239763	M862NOQbisR:388 M862NOObisP:388

					M862NOP:388 M1090NOXQbisR:160 M1117N2OO1P:87 (29) M1117N2OP:87 (29) M1117NOO1P:133 M1117NOO2P:133 MS1 MS2NOQbisR:402 M1069NOQR:181 M1069N2OQ1QbisR:135 (30) M1069NOQ1QbisR:181 M1069N2OO2QbisR:135 (30) M1069NOO2QbisR:181 M1069N2NbisoO2XQbisR:135 (30) M1069N2OQR:135 (30) M1069N2OQbisR:135 (30) M1069NNbisOQR:181 M1069NNbisOQbisR:181 M1069NOO2XQbisR:181 M1069NOXQR:181 M1069NOQbisRbis:181 M1069N2OQbisRbis:135 (30) M1069N2OXQR:135 (30)
8-153	8-153-313	C	T	239763	M862NOQbisR:388 M862NOObisP:388 M862NOP:388 M1090NOXQbisR:160 M1117N2OO1P:87 (29) M1117N2OP:87 (29) M1117NOO1P:133 M1117NOO2P:133 MS1 MS2NOQbisR:402 M1069NOQR:181 M1069N2OQ1QbisR:135 (30) M1069NOQ1QbisR:181 M1069N2OO2QbisR:135 (30) M1069NOO2QbisR:181 M1069N2NbisoO2XQbisR:135 (30) M1069N2OQR:135 (30) M1069N2OQbisR:135 (30) M1069NNbisOQR:181 M1069NNbisOQbisR:181

					M1069NOO2XQbisR:181 M1069NOXQR:181 M1069NOQbisRbis:181 M1069N2OQbisRbis:135 (30) M1069N2OXQR:135 (30)
8-135	8-135-166	G	T	240543	M862NOQbisR:282 (10) M862NOObisP:282 (10) M1:1143 M862NOP:282 (10) M1090NOXQbisR:54 (10) M1117N2OO1P:27 (9) M1117N2OP:27 (9) M1117NOO1P:27 (9) M1117NOO2P:27 (9) MS1 MS2NOQbisR:296 (10) M1069NOQR:75 (10) M1069N2OQ1QbisR:75 (10) M1069NOQ1QbisR:75 (10) M1069N2OO2QbisR:75 (10) M1069NOO2QbisR:75 (10) M1069N2NbisoO2XQbisR:75 (10) M1069N2OQR:75 (10) M1069N2OQbisR:75 (10) M1069NNbisOQR:75 (10) M1069NNbisOQbisR:75 (10) M1069NOO2XQbisR:75 (10) M1069NOXQR:75 (10) M1069NOQbisRbis:75 (10) M1069N2OQbisRbis:75 (10) M1069N2OXQR:75 (10)
8-135	8-135-112	A	G	240597	M862NOQbisR:228 M862NOObisP:228 M1:1089 M862NOP:228 MS1 MS2NOQbisR:242 M1069NOQR:21 M1069N2OQ1QbisR:21 M1069NOQ1QbisR:21 M1069N2OO2QbisR:21 M1069NOO2QbisR:21 M1069N2NbisoO2XQbisR:21

					M1069N2OQR:21 M1069N2OQbisR:21 M1069NNbisOQR:21 M1069NNbisOQbisR:21 M1069NOO2XQbisR:21 M1069NOXQR:21 M1069NOQbisRbis:21 M1069N2OQbisRbis:21 M1069N2OXQR:21
99-16050	99-16050-235	G	C	240772	M862NOQbisR:53 M862NOObisP:53 M1:914 M862NOP:53
8-144	8-144-378	C	T	240858	M1:828 MS1 MS2NOQbisR:136
8-144	8-144-234	C	T	241002	M1:684
8-144	8-144-196	A	T	241040	M1:646
8-144	8-144-127	TGGAT AC	-	241109	M1:577
8-141	8-141-304	C	T	241217	M1:469
8-141	8-141-260	C	T	241261	M1:425 (80)
8-141	8-141-161	G	T	241360	M1:326 (47)
8-140	8-140-286	A	G	241507	M1:179
8-140	8-140-173	A	C	241620	M1:66
8-140	8-140-108	G	C	241685	M1:1

Sbg1 Coding Regions

The *sbg1* open reading frame is contained in the corresponding mRNA of a cDNA sequence selected from the group consisting of SEQ ID Nos 2 to 26. The effective *sbg1* coding sequence (CDS) may include several forms as indicated above, in some embodiments encompassing isolated, purified, and recombinant polynucleotides which encode a polypeptide comprising a contiguous span of at least 4 amino acids, preferably 6, more preferably at least 8 or 10 amino acids, yet more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 27 to 35. The effective *sbg1* coding sequence (CDS) may comprise the region between the first nucleotide of the ATG codon and the end nucleotide of the stop codon of SEQ ID Nos 2 to 26 as indicated in Table 5a above.

The above disclosed polynucleotide that contains the coding sequence of the *sbg1* gene may be expressed in a desired host cell or a desired host organism when this polynucleotide is placed under the control of suitable expression signals. The expression signals may be either

the expression signals contained in the regulatory regions in the *sbg1* gene of the invention or in contrast the signals may be exogenous regulatory nucleic sequences. Such a polynucleotide, when placed under the suitable expression signals, may also be inserted in a vector for its expression and/or amplification.

Regulatory Sequences Of *sbg1*

As mentioned, the genomic sequence of the *sbg1* gene contains regulatory sequences both in the non-coding 5'-flanking region and in the non-coding 3'-flanking region that border the *sbg1* coding region containing the exons of the gene.

In one aspect, the 3'-regulatory sequence of the *sbg1* gene may comprise the sequence localized between the nucleotide in position 213818 and the nucleotide in position 215818 of the nucleotide sequence of SEQ ID No 1. In one aspect, the 5'-regulatory sequence of the *sbg1* gene may comprise the sequence localized between the 5' end of the particular form of exon M and nucleotide position 243685 of SEQ ID No 1.

Polynucleotides derived from the 5' and 3' regulatory regions are useful in order to detect the presence of at least a copy of an *sbg1* nucleotide sequence of SEQ ID No 1 or a fragment thereof in a test sample.

The promoter activity of the 5' regulatory regions contained in *sbg1* can be assessed as described below.

In order to identify the relevant biologically active polynucleotide fragments or variants of an *sbg1* regulatory region, one of skill in the art will refer to Sambrook et al.(1989), which describes the use of a recombinant vector carrying a marker gene (i.e. beta galactosidase, chloramphenicol acetyl transferase, etc.) the expression of which will be detected when placed under the control of a biologically active polynucleotide fragment or variant of the *sbg1* sequence of SEQ ID No 1. Genomic sequences located upstream of the first exon of the *sbg1* gene are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, p β gal-Basic, p β gal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech, or pGL2-basic or pGL3-basic promoterless luciferase reporter gene vector from Promega. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, luciferase, β galactosidase, or green fluorescent protein. The sequences upstream of the *sbg1* coding region are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert

with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for increasing transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Promoter sequence within the upstream genomic DNA may be further defined by constructing nested 5' and/or 3' deletions in the upstream DNA using conventional techniques such as Exonuclease III or appropriate restriction endonuclease digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity, such as described, for example, by Coles et al.(1998). In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into cloning sites in promoter reporter vectors. This type of assay is well-known to those skilled in the art and is described in WO 97/17359, US Patent No. 5,374,544; EP 582 796; US Patent No. 5,698,389; US 5,643,746; US Patent No. 5,502,176; and US Patent 5,266,488.

The strength and the specificity of the promoter of the *sbgl* gene can be assessed through the expression levels of a detectable polynucleotide operably linked to the *sbgl* promoter in different types of cells and tissues. The detectable polynucleotide may be either a polynucleotide that specifically hybridizes with a predefined oligonucleotide probe, or a polynucleotide encoding a detectable protein, including an *sbgl* polypeptide or a fragment or a variant thereof. This type of assay is well-known to those skilled in the art and is described in US Patent No. 5,502,176; and US Patent No. 5,266,488. Some of the methods are discussed in more detail below.

Polynucleotides carrying the regulatory elements located at the 5' end and at the 3' end of the *sbgl* coding region may be advantageously used to control the transcriptional and translational activity of an heterologous polynucleotide of interest.

Thus, the present invention also concerns a purified or isolated nucleic acid comprising a polynucleotide which is selected from the group consisting of the 5' and 3' regulatory regions of *sbgl*, or a sequence complementary thereto or a biologically active fragment or variant thereof. In one aspect, "3' regulatory region" may comprise the nucleotide sequence located between positions 213818 and 215818 of SEQ ID No 1. In one aspect, "5' regulatory region" may comprise the nucleotide sequence located between the 5' end of a particular variant of exon

M and nucleotide position 243685 of SEQ ID No 1. The 5' end of particular form of exon M may be selected from the group consisting of nucleotide positions 240569, 241596, 240617, 240644, 240824, 240994, 241685 and 240993 of SEQ ID No 1. In a preferred aspect, the 5' regulatory region comprises the nucleotides of nucleotide positions 241686 to 243685 of SEQ ID No 1.

The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 95% nucleotide identity with a polynucleotide selected from the group consisting of the 5' and 3' regulatory regions, advantageously 99 % nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide selected from the group consisting of the 5' and 3' regulatory regions, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

Another object of the invention consists of purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of the nucleotide sequences of the 5'- and 3' regulatory regions of *sbg1*, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

Preferred fragments of the 5' regulatory region have a length of about 1500 or 1000 nucleotides, preferably of about 500 nucleotides, more preferably about 400 nucleotides, even more preferably 300 nucleotides and most preferably about 200 nucleotides.

Preferred fragments of the 3' regulatory region are at least 50, 100, 150, 200, 300 or 400 bases in length.

"Biologically active" *sbg1* polynucleotide derivatives of SEQ ID No 1 are polynucleotides comprising or alternatively consisting in a fragment of said polynucleotide which is functional as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide in a recombinant cell host. It could act either as an enhancer or as a repressor.

For the purpose of the invention, a nucleic acid or polynucleotide is "functional" as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide if said regulatory polynucleotide contains nucleotide sequences which contain transcriptional and translational regulatory information, and such sequences are "operably linked" to nucleotide sequences which encode the desired polypeptide or the desired polynucleotide.

The regulatory polynucleotides of the invention may be prepared from the nucleotide sequence of SEQ ID No 1 by cleavage using suitable restriction enzymes, as described for example in Sambrook et al.(1989). The regulatory polynucleotides may also be prepared by digestion of SEQ ID No 1 by an exonuclease enzyme, such as *Bal31* (Wabiko et al., 1986).

These regulatory polynucleotides can also be prepared by nucleic acid chemical synthesis, as described elsewhere in the specification.

The sbg1 regulatory polynucleotides according to the invention may be part of a recombinant expression vector that may be used to express a coding sequence in a desired host cell or host organism. The recombinant expression vectors according to the invention are described elsewhere in the specification.

A preferred 5'-regulatory polynucleotide of the invention includes the 5'-untranslated region (5'-UTR) of the sbg1 cDNA, or a biologically active fragment or variant thereof.

A preferred 3'-regulatory polynucleotide of the invention includes the 3'-untranslated region (3'-UTR) of the sbg1 cDNA, or a biologically active fragment or variant thereof.

A further object of the invention consists of a purified or isolated nucleic acid comprising:

a) a nucleic acid comprising a regulatory nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence comprising a polynucleotide of the sbg1 5' regulatory region or a complementary sequence thereto;

(ii) a nucleotide sequence comprising a polynucleotide having at least 95% of nucleotide identity with the nucleotide sequence of the sbg1 5' regulatory region or a complementary sequence thereto;

(iii) a nucleotide sequence comprising a polynucleotide that hybridizes under stringent hybridization conditions with the nucleotide sequence of the sbg1 5' regulatory region or a complementary sequence thereto; and

(iv) a biologically active fragment or variant of the polynucleotides in (i), (ii) and (iii);

b) a polynucleotide encoding a desired polypeptide or a nucleic acid of interest, operably linked to the nucleic acid defined in (a) above; and

c) optionally, a nucleic acid comprising a 3'- regulatory polynucleotide, preferably a 3'- regulatory polynucleotide of the sbg1 gene.

In a specific embodiment of the nucleic acid defined above, said nucleic acid includes the 5'-untranslated region (5'-UTR) of the sbg1 cDNA, or a biologically active fragment or variant thereof.

In a second specific embodiment of the nucleic acid defined above, said nucleic acid includes the 3'-untranslated region (3'-UTR) of the sbg1 cDNA, or a biologically active fragment or variant thereof.

The regulatory polynucleotide of the 5' regulatory region, or its biologically active fragments or variants, is operably linked at the 5'-end of the polynucleotide encoding the

desired polypeptide or polynucleotide.

The regulatory polynucleotide of the 3' regulatory region, or its biologically active fragments or variants, is advantageously operably linked at the 3'-end of the polynucleotide encoding the desired polypeptide or polynucleotide.

The desired polypeptide encoded by the above-described nucleic acid may be of various nature or origin, encompassing proteins of prokaryotic or eukaryotic origin. Among the polypeptides expressed under the control of an *sbgl* regulatory region include bacterial, fungal or viral antigens. Also encompassed are eukaryotic proteins such as intracellular proteins, like "house keeping" proteins, membrane-bound proteins, like receptors, and secreted proteins like endogenous mediators such as cytokines. The desired polypeptide may be the *sbgl* protein, especially the protein of the amino acid sequences of SEQ ID Nos 27 to 35, or a fragment or a variant thereof.

The desired nucleic acids encoded by the above-described polynucleotide, usually an RNA molecule, may be complementary to a desired coding polynucleotide, for example to the *sbgl* coding sequence, and thus useful as an antisense polynucleotide.

Such a polynucleotide may be included in a recombinant expression vector in order to express the desired polypeptide or the desired nucleic acid in host cell or in a host organism. Suitable recombinant vectors that contain a polynucleotide such as described herein are disclosed elsewhere in the specification.

Genomic Sequences of *sbgl* polynucleotides

Particularly preferred *sbgl* nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 nucleotides, to the extent that the length of said span is consistent with said nucleotide position range, of nucleotide positions 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915 of SEQ ID No 1, or the complements thereof.

It should be noted that nucleic acid fragments of any size and sequence may be comprised by the polynucleotides described in this section.

The human *sbgl* gene comprises exons selected from at least 4 exons, referred to herein as exons S, T, U and V. The nucleotide positions of *sbgl* exons in SEQ ID No. 1 are detailed below in Table 5f.

Table 5f

Exon	Position in SEQ ID No 1		Intron	Position in SEQ ID No 1	
	Beginning	End		Beginning	End

S	201188	201234	S	201235	214675
T	214676	214793	T	214794	215701
U	215702	215746	U	215747	216835
V	216836	216915			

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the exons of the *sbg2* gene, or a sequence complementary thereto. Preferred are purified, isolated, or recombinant polynucleotides comprising at least one exon having the nucleotide position ranges listed in Table 5f selected from the group consisting of the exons S, T, U and V of the *sbg2* gene, or a complementary sequence thereto or a fragment or a variant thereof. Also encompassed by the invention are purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the *sbg2* gene selected from the group consisting of exons S, T, U and V, wherein the polynucleotides are arranged within the nucleic acid in the same relative order as in SEQ ID No. 1.

The present invention further embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the introns of the *sbg2* gene, or a sequence complementary thereto. The position of the introns is detailed in Table 5f. Intron S refers to the nucleotide sequence located between Exon S and Exon T, and so on. Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 3 introns of the *sbg2* gene, or a sequence complementary thereto.

The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence of *sbg2* having at least 70, 75, 80, 85, 90, 95, 98 or 99% nucleotide identity with a sequence selected from the group consisting of nucleotide positions 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915 of SEQ ID No. 1 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards the nucleotide positions 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915 of SEQ ID No. 1 may be generally randomly distributed throughout the entire nucleic acid.

Another object of the invention relates to purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of nucleotide positions 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915 of SEQ ID No. 1, or a sequence complementary thereto or a variant thereof or a

biologically active fragment thereof.

Additional preferred nucleic acids of the invention include isolated, purified, or recombinant *sbg2* polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides of nucleotide positions 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915 of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises an *sbg2*-related biallelic marker. Optionally, said biallelic marker is selected from the group consisting of A79 to A99. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section. Either the original or the alternative allele may be present at said biallelic marker.

An *sbg2* polynucleotide or gene may further contain regulatory sequences both in the non-coding 5'-flanking region and in the non-coding 3'-flanking region that border the region containing said genes or exons. Polynucleotides derived from 5' and 3' regulatory regions are useful in order to detect the presence of at least a copy of a nucleotide sequence comprising an *sbg2* nucleotide sequence of SEQ ID No. 1 or a fragment thereof in a test sample.

Polynucleotides carrying the regulatory elements located at the 5' end and at the 3' end of the genes comprising the exons of the present invention may be advantageously used to control the transcriptional and translational activity of a heterologous polynucleotide of interest.

While this section is entitled "*sbg2* cDNA Sequences," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of *sbg2* on either side or between two or more such genomic sequences.

Polynucleotide Constructs

The terms "polynucleotide construct" and "recombinant polynucleotide" are used interchangeably herein to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their initial natural environment. It should be noted that the present invention embodies recombinant vectors comprising any one of the polynucleotides described in the present invention.

DNA Constructs that Enables Directing Temporal and Spatial Expression of *sbg1*, *g34665*, *sbg2*, *g35017* and *g35018* Nucleic Acid Sequences in Recombinant Cell Hosts and in Transgenic Animals

In order to study the physiological and phenotypic consequences of a lack of synthesis

of a protein encoded by a nucleotide sequence comprising an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide, both at the cell level and at the multi cellular organism level, the invention also encompasses DNA constructs and recombinant vectors enabling a conditional expression of a specific allele of a nucleotide sequence comprising an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide and also of a copy of a sequence comprising a nucleotide sequence of an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide, or a fragment thereof, harboring substitutions, deletions, or additions of one or more bases. These base substitutions, deletions or additions may be located either in an exon, an intron or a regulatory sequence, in particular a 5' regulatory sequence of an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide. In a preferred embodiment, the nucleotide sequence comprising an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide further comprises a biallelic marker of the present invention.

A first preferred DNA construct is based on the tetracycline resistance operon tet from *E. coli* transposon Tn10 for controlling the expression of an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide, such as described by Gossen et al. (1992, 1995) and Furth et al. (1994). Such a DNA construct contains seven tet operator sequences from Tn10 (tetop) that are fused to either a minimal promoter or a 5'-regulatory sequence of the sbg1, g34665, sbg2, g35017 or g35018 polynucleotide, said minimal promoter or said sbg1, g34665, sbg2, g35017 or g35018 polynucleotide regulatory sequence being operably linked to a polynucleotide of interest that codes either for a sense or an antisense oligonucleotide or for a polypeptide, including an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide-encoded polypeptide or a peptide fragment thereof. This DNA construct is functional as a conditional expression system for the nucleotide sequence of interest when the same cell also comprises a nucleotide sequence coding for either the wild type (tTA) or the mutant (rTA) repressor fused to the activating domain of viral protein VP16 of herpes simplex virus, placed under the control of a promoter, such as the HCMVIE1 enhancer/promoter or the MMTV-LTR. Indeed, a preferred DNA construct of the invention comprises both the polynucleotide containing the *tet* operator sequences and the polynucleotide containing a sequence coding for the tTA or the rTA repressor.

In a specific embodiment, the conditional expression DNA construct contains the sequence encoding the mutant tetracycline repressor rTA, the expression of the polynucleotide of interest is silent in the absence of tetracycline and induced in its presence.

DNA Constructs Allowing Homologous Recombination: Replacement Vectors

A second preferred DNA construct will comprise, from 5'-end to 3'-end: (a) a first nucleotide sequence comprising an sbg1 polynucleotide; (b) a nucleotide sequence comprising a positive selection marker, such as the marker for neomycine resistance (*neo*); and (c) a second nucleotide sequence comprising a respective sbg1 polynucleotide, and is located on the

genome downstream of the first *sbg1* polynucleotide sequence (a). Also encompassed are DNA construct prepared in an analogous manner using *g34665*, *sbg2*, *g35017* or *g35018* nucleotide sequences in place of the *sbg1* sequences described above.

In a preferred embodiment, this DNA construct also comprises a negative selection marker located upstream the nucleotide sequence (a) or downstream the nucleotide sequence (c). Preferably, the negative selection marker comprises the thymidine kinase (*tk*) gene (Thomas et al., 1986), the hygromycin beta gene (Te Riele et al., 1990), the *hprt* gene (Van der Lugt et al., 1991; Reid et al., 1990) or the Diphtheria toxin A fragment (*Dt-A*) gene (Nada et al., 1993; Yagi et al. 1990). Preferably, the positive selection marker is located within and exon of an *sbg1*, *g34665*, *sbg2*, *g35017* or *g35018* polynucleotide so as to interrupt the sequence encoding the *sbg1*, *g34665*, *sbg2*, *g35017* or *g35018* protein. These replacement vectors are described, for example, by Thomas et al. (1986; 1987), Mansour et al. (1988) and Koller et al. (1992).

The first and second nucleotide sequences (a) and (c) may be indifferently located within an *sbg1*, *g34665*, *sbg2*, *g35017* or *g35018* polynucleotide regulatory sequence, an intronic sequence, an exon sequence or a sequence containing both regulatory and/or intronic and/or exon sequences. The size of the nucleotide sequence of (a) and (c) ranges from 1 to 50 kb, preferably from 1 to 10 kb, more preferably from 2 to 6 kb and most preferably from 2 to 4 kb.

DNA Constructs Allowing Homologous Recombination: Cre-LoxP System.

These new DNA constructs make use of the site specific recombination system of the P1 phage. The P1 phage possesses a recombinase called Cre which interacts specifically with a 34 base pairs *loxP* site. The *loxP* site is composed of two palindromic sequences of 13 bp separated by a 8 bp conserved sequence (Hoess et al., 1986). The recombination by the Cre enzyme between two *loxP* sites having an identical orientation leads to the deletion of the DNA fragment.

The Cre-*loxP* system used in combination with a homologous recombination technique has been first described by Gu et al. (1993, 1994). Briefly, a nucleotide sequence of interest to be inserted in a targeted location of the genome harbors at least two *loxP* sites in the same orientation and located at the respective ends of a nucleotide sequence to be excised from the recombinant genome. The excision event requires the presence of the recombinase (Cre) enzyme within the nucleus of the recombinant cell host. The recombinase enzyme may be brought at the desired time either by (a) incubating the recombinant cell hosts in a culture medium containing this enzyme, by injecting the Cre enzyme directly into the desired cell, such as described by Araki et al. (1995), or by lipofection of the enzyme into the cells, such as

described by Baubonis et al.(1993); (b) transfecting the cell host with a vector comprising the *Cre* coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter being optionally inducible, said vector being introduced in the recombinant cell host, such as described by Gu et al.(1993) and Sauer et al.(1988); (c) introducing in the genome
5 of the cell host a polynucleotide comprising the *Cre* coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter is optionally inducible, and said polynucleotide being inserted in the genome of the cell host either by a random insertion event or an homologous recombination event, such as described by Gu et al.(1994).

In a specific embodiment, the vector containing the sequence to be inserted in an *sbg1*,
10 *g34665*, *sbg2*, *g35017* or *g35018* gene sequence by homologous recombination is constructed in such a way that selectable markers are flanked by *loxP* sites of the same orientation, it is possible, by treatment by the *Cre* enzyme, to eliminate the selectable markers while leaving the *sbg1*, *g34665*, *sbg2*, *g35017* or *g35018* polynucleotide sequences of interest that have been inserted by an homologous recombination event. Again, two selectable markers are needed: a
15 positive selection marker to select for the recombination event and a negative selection marker to select for the homologous recombination event. Vectors and methods using the *Cre-loxP* system are described by Zou et al.(1994).

Thus, in one aspect, a further preferred DNA construct of the invention comprises, from 5'-end to 3'-end: (a) a first nucleotide sequence that is comprised by an *sbg1* polynucleotide; (b)
20 a nucleotide sequence comprising a polynucleotide encoding a positive selection marker, said nucleotide sequence comprising additionally two sequences defining a site recognized by a recombinase, such as a *loxP* site, the two sites being placed in the same orientation; and (c) a second nucleotide sequence comprising an *sbg1* polynucleotide, and is located on the genome downstream of the first *sbg1* polynucleotide sequence (a). Also encompassed are DNA
25 construct prepared in an analogous manner using *g34665*, *sbg2*, *g35017* or *g35018* nucleotide sequences in place of the *sbg1* sequences described above.

The sequences defining a site recognized by a recombinase, such as a *loxP* site, are preferably located within the nucleotide sequence (b) at suitable locations bordering the nucleotide sequence for which the conditional excision is sought. In one specific embodiment,
30 two *loxP* sites are located at each side of the positive selection marker sequence, in order to allow its excision at a desired time after the occurrence of the homologous recombination event.

In a preferred embodiment of a method using the third DNA construct described above, the excision of the polynucleotide fragment bordered by the two sites recognized by a recombinase, preferably two *loxP* sites, is performed at a desired time, due to the presence
35 within the genome of the recombinant host cell of a sequence encoding the *Cre* enzyme

operably linked to a promoter sequence, preferably an inducible promoter, more preferably a tissue-specific promoter sequence and most preferably a promoter sequence which is both inducible and tissue-specific, such as described by Gu et al.(1994).

The presence of the Cre enzyme within the genome of the recombinant cell host may result from the breeding of two transgenic animals, the first transgenic animal bearing the sbg1, g34665, sbg2, g35017 or g35018 polynucleotide -derived sequence of interest containing the *loxP* sites as described above and the second transgenic animal bearing the *Cre* coding sequence operably linked to a suitable promoter sequence, such as described by Gu et al.(1994).

Spatio-temporal control of the Cre enzyme expression may also be achieved with an adenovirus based vector that contains the Cre gene thus allowing infection of cells, or *in vivo* infection of organs, for delivery of the Cre enzyme, such as described by Anton and Graham (1995) and Kanegae et al.(1995).

The DNA constructs described above may be used to introduce a desired nucleotide sequence of the invention, preferably an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide, and most preferably an altered copy an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide sequence, within a predetermined location of the targeted genome, leading either to the generation of an altered copy of a targeted gene (knock-out homologous recombination) or to the replacement of a copy of the targeted gene by another copy sufficiently homologous to allow an homologous recombination event to occur (knock-in homologous recombination). In a specific embodiment, the DNA constructs described above may be used to introduce an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide.

Nuclear Antisense DNA Constructs

Other compositions containing a vector of the invention comprise an oligonucleotide fragment of the sbg1, g34665, sbg2, g35017 or g35018 polynucleotide sequences of SEQ ID No.1 respectively, as an antisense tool that inhibits the expression of the corresponding gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995) or those described in PCT Application No WO 95/24223.

Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to the 5'end of an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide mRNA. In one embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targeted gene are used.

Preferably, the antisense polynucleotides of the invention have a 3' polyadenylation signal that has been replaced with a self-cleaving ribozyme sequence, such that RNA polymerase II transcripts are produced without poly(A) at their 3' ends, these antisense

polynucleotides being incapable of export from the nucleus, such as described by Liu et al.(1994). In a preferred embodiment, these sbg1, g34665, sbg2, g35017 or g35018 antisense polynucleotides also comprise, within the ribozyme cassette, a histone stem-loop structure to stabilize cleaved transcripts against 3'-5' exonucleolytic degradation, such as the structure described by Eckner et al.(1991).

Oligonucleotide Probes And Primers

The polynucleotides of the invention are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID No. 1 or of the respective sbg1, g34665, sbg2, g35017 and g35018 polynucleotide or gene, or a fragment, complement, or variant thereof in a test sample.

Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides, to the extent that said span is consistent with the length of the nucleotide position range, of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 4, 5, 7 or 10 of the following nucleotide positions of SEQ ID No 1:

(a) nucleotide positions 31 to 292651 and 292844 to 319608;

(b) 290653 to 292652, 292653 to 296047, 292653 to 292841, 295555 to 296047, 295580 to 296047 and 296048 to 298048;

(c) 94124 to 94964;

(d) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;

(e) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685;

(f) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915; or

(g) a complementary sequence thereto or a fragment thereof.

Probes and primers of the invention also include isolated, purified, or recombinant polynucleotides having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of nucleotide positions 31 to 292651 and 292844 to 319608 of SEQ ID No. 1.

Preferred probes and primers of the invention also include isolated, purified, or recombinant polynucleotides comprising an sbg1, g34665, sbg2, g35017 or g35018 nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with at least one sequence selected from the group consisting of the following nucleotide positions of SEQ ID No. 1:

5 (a) 290653 to 292652, 292653 to 296047, 292653 to 292841, 295555 to 296047, 295580 to 296047 and 296048 to 298048;

(b) 94124 to 94964;

(c) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;

10 (d) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685;

15 (e) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915; or

(f) a complementary sequence thereto or a fragment thereof.

20 Another set of probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one of the ranges of nucleotide positions, designated pos1 to pos166, of SEQ ID No. 1 listed in Table 1 above.

25 The invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of nucleotide positions 31 to 292651 and 292844 to 319608 of SEQ ID No. 1, or a variant thereof or a sequence complementary thereto. Particularly preferred are nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a nucleic acid selected from the group consisting of nucleotide positions:

30 (a) 290653 to 292652, 292653 to 296047, 292653 to 292841, 295555 to 296047, 295580 to 296047 and 296048 to 298048;

35 (b) 94124 to 94964;

(c) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;

(d) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685;

(e) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915; or

(f) a complementary sequence thereto or a fragment thereof.

The formation of stable hybrids depends on the melting temperature (T_m) of the DNA. The T_m depends on the length of the primer or probe, the ionic strength of the solution and the G+C content. The higher the G+C content of the primer or probe, the higher is the melting temperature because G:C pairs are held by three H bonds whereas A:T pairs have only two. The GC content in the probes of the invention usually ranges between 10 and 75 %, preferably between 35 and 60 %, and more preferably between 40 and 55 %.

A probe or a primer according to the invention may be between 8 and 2000 nucleotides in length, or is specified to be at least 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500, 1000 nucleotides in length. More particularly, the length of these probes can range from 8, 10, 15, 20, or 30 to 100 nucleotides, preferably from 10 to 50, more preferably from 15 to 30 nucleotides. Shorter probes tend to lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. Longer probes are expensive to produce and can sometimes self-hybridize to form hairpin structures. The appropriate length for primers and probes under a particular set of assay conditions may be empirically determined by one of skill in the art.

The primers and probes can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang et al.(1979), the phosphodiester method of Brown et al.(1979), the diethylphosphoramidite method of Beaucage et al.(1981) and the solid support method described in EP 0 707 592.

Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444; 5,034,506 and 5,142,047. The probe may have to be rendered "non-extendable" in

that additional dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group. Alternatively, the 3' hydroxyl group simply can be cleaved, replaced or modified; U.S. Patent Application Serial No. 07/049,061 filed April 19, 1993, describes modifications which can be used to render a probe non-extendable.

Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating a label detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive substances (^{32}P , ^{35}S , ^3H , ^{125}I), fluorescent dyes (5-bromodesoxyuridin, fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at their 3' and 5' ends. Examples of non-radioactive labeling of nucleic acid fragments are described in the French patent No. FR-7810975 or by Urdea et al (1988) or Sanchez-Pescador et al (1988). In addition, the probes according to the present invention may have structural characteristics such that they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European patent No. EP 0 225 807 (Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be

notably used in Southern hybridization to genomic DNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in a sequence comprising a polynucleotide of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229, or an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide or gene or mRNA using other techniques.

5 Any of the polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be
10 selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which
15 is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the
20 capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a
25 plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes and other configurations known to those of ordinary skill in the art. The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the
30 invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

Consequently, the invention also comprises a method for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos.
35 1 to 26, 36 to 40 and 54 to 229, a fragment or a variant thereof or a complementary sequence

thereto in a sample, said method comprising the following steps of:

a) bringing into contact a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, a fragment or a variant thereof or a complementary sequence thereto and the sample to be assayed; and

b) detecting the hybrid complex formed between the probe and a nucleic acid in the sample.

The invention further concerns a kit for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, a fragment or a variant thereof or a complementary sequence thereto in a sample, said kit comprising:

a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, a fragment or a variant thereof or a complementary sequence thereto; and

b) optionally, the reagents necessary for performing the hybridization reaction.

In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate. In a third preferred embodiment, the nucleic acid probe or the plurality of nucleic acid probes comprise either a sequence which is selected from the group consisting of the nucleotide sequences of P1 to P360 and the complementary sequence thereto, B1 to B229, C1 to C229, D1 to D360, E1 to E360, or a nucleotide sequence comprising a biallelic marker selected from the group consisting of A1 to A360 or a polymorphism selected from the group consisting of A361 to A489, or the complements thereto.

Oligonucleotide Arrays

A substrate comprising a plurality of oligonucleotide primers or probes of the invention may be used either for detecting or amplifying targeted sequences in a nucleotide sequence of SEQ ID No. 1, more particularly in an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide, or in genes comprising an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide and may also be used for detecting mutations in the coding or in the non-coding sequences of an sbg1, g34665, sbg2, g35017 or g35018 nucleic acid sequence, or genes comprising an sbg1, g34665, sbg2, g35017 or g35018 nucleic acid sequence.

Any polynucleotide provided herein may be attached in overlapping areas or at random

locations on the solid support. Alternatively the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as Genechips™, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., 1991, incorporated herein by reference). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPST™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPST™ technologies are provided in US Patents 5,143,854; and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

In another embodiment of the oligonucleotide arrays of the invention, an oligonucleotide probe matrix may advantageously be used to detect mutations occurring in an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide, including in genes comprising an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide and preferably in an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide regulatory region. For this particular purpose, probes are specifically designed to have a nucleotide sequence allowing their hybridization to the genes that carry known mutations (either by deletion, insertion or substitution of one or several nucleotides). By known mutations in an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide, it is meant, mutations in an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide that have

been identified according; the technique used by Huang et al.(1996) or Samson et al.(1996), for example, may be used to identify such mutations.

Another technique that is used to detect mutations in an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide is the use of a high-density DNA array. Each oligonucleotide probe constituting a unit element of the high density DNA array is designed to match a specific subsequence of an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide. Thus, an array consisting of oligonucleotides complementary to subsequences of the target gene sequence is used to determine the identity of the target sequence with the wild-type gene sequence, measure its amount, and detect differences between the target sequence and the reference wild-type nucleic acid sequence of an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide. In one such design, termed 4L tiled array, is implemented a set of four probes (A, C, G, T), preferably 15-nucleotide oligomers. In each set of four probes, the perfect complement will hybridize more strongly than mismatched probes. Consequently, a nucleic acid target of length L is scanned for mutations with a tiled array containing 4L probes, the whole probe set containing all the possible mutations in the known wild reference sequence. The hybridization signals of the 15-mer probe set tiled array are perturbed by a single base change in the target sequence. As a consequence, there is a characteristic loss of signal or a "footprint" for the probes flanking a mutation position. This technique was described by Chee et al. in 1996.

Consequently, the invention concerns an array of nucleic acid molecules comprising at least one polynucleotide described above as probes and primers. Preferably, the invention concerns an array of nucleic acid comprising at least two polynucleotides described above as probes and primers.

Sbg1, g34665, sbg2, g35017 and g35018 Proteins and Polypeptide Fragments:

The terms "sbg1 polypeptides", "g34665 polypeptides", "sbg2 polypeptides", "g35017 polypeptides", "g35018 polypeptides" are used herein to embrace all of the proteins and polypeptides encoded by the respective sbg1, g34665, sbg2, g35017 and g35018 polypeptides of the present invention. Forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies proteins from humans, mammals, primates, non-human primates, and includes isolated or purified sbg1 proteins consisting, consisting essentially, or comprising the sequence of SEQ ID Nos 27 to 35, isolated or purified g34665, g35017 and sbg2 proteins encoded by the g34665, g35017 and sbg2 polynucleotide sequence of SEQ ID No 1, and isolated or purified g35018 proteins consisting, consisting essentially, or comprising the sequence of SEQ ID Nos 41 to 43.

It should be noted that the sbg1, g34665, sbg2, g35017 and g35018 proteins of the invention also comprise naturally-occurring variants of the amino acid sequence of the respective human sbg1, g34665, sbg2, g35017 and g35018 proteins.

The present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 4 amino acids, preferably at least 6, more preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids, to the extent that said span is consistent with the length of a particular SEQ ID, of SEQ ID Nos 27 to 35 and 41 to 43. In other preferred embodiments the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in an sbg1, g34665, sbg2, g35017 and g35018 protein sequence.

The invention also embodies isolated, purified, and recombinant sbg1 polypeptides comprising a contiguous span of at least 4 amino acids, preferably at least 6 or at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 27 to 35, wherein said contiguous span comprises an amino acid variation according to Table 5e.

The present inventors have further identified potential cleavage sites in the sbg1 polypeptides, and several specific sbg1 peptides. An sbg1 peptide has further been tested in behavioral studies by injection in mice, as further detailed in Example 7. In particular, the polypeptide of SEQ ID No 29 contains a protease cleavage site at amino acid positions 62 to 63; the polypeptide of SEQ ID No 30 contains a protease cleavage site at amino acid positions 63 to 64 and 110 to 111; the polypeptide of SEQ ID No 32 contains a protease cleavage site at amino acid positions 63 to 64; the polypeptide of SEQ ID No 33 contains a protease cleavage site at amino acid positions 54 to 55 and 57 to 58; the polypeptide of SEQ ID No 34 contains a protease cleavage site at amino acid positions 63 to 64 and 122 to 123; and the polypeptide of SEQ ID No 35 contains a protease cleavage site at amino acid positions 62 to 63 and 63 to 64. Additionally, sbg1 polypeptides of SEQ ID Nos 30, 32 and 34 contain cysteine residues predicted to be capable of forming a disulfide bridge at amino acid positions 82 and 104 of SEQ ID No 30, amino acid positions 82 and 106 and SEQ ID No 32, and amino acid positions 132 and 142 of SEQ ID No 34. In particularly preferred embodiment, the invention comprises isolated, purified, and recombinant sbg1 peptides comprising a contiguous span of at least 4 amino acids, preferably at least 6 or at least 8 to 10 amino acids, more preferably at least 12 or 15 amino acids of an amino acid position range selected from the group consisting of amino acid positions: 1 to 63 and 64 to 102 of SEQ ID No 29; 1 to 64, 65 to 111 and 112 to 119 of SEQ ID No 30; 1 to 64 and 65 to 126 of SEQ ID No 32; 1 to 64, 65 to 123 and 124 to 153 of SEQ ID No 34; and 1 to 61 and 65 to 106 of SEQ ID No 35.

The invention further embodies sbg1, g34665, sbg2, g35017 and g35018 polypeptides, including isolated and recombinant polypeptides, encoded respectively by sbg1, g34665, sbg2, g35017 and g35018 polynucleotides consisting, consisting essentially, or comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or 500 nucleotides, to the extent that the length of said span is consistent with the nucleotide position range, of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 4, 5, 7 or 10 of the following nucleotide positions of SEQ ID No 1:

(a) 290653 to 292652, 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047;

(b) 94144 to 94964

(c) 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, and 65505 to 65853;

(d) 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685 and 240800 to 240993;

(e) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915; or the complements thereof.

The present invention further embodies isolated, purified, and recombinant polypeptides encoded by an sbg1 polynucleotide or gene comprising at least one sbg1 nucleotide sequence selected from the group consisting of the following sbg1 exons: MS1, M1, M692, M862, MS2, M1069, M1090, M1117, N, N2, Nbis, O, O1, O2, Obis, P, X, Q1, Q, Qbis, R and Rbis.

The invention also encompasses a purified, isolated, or recombinant polypeptides comprising an amino acid sequence having at least 70, 75, 80, 85, 90, 95, 98 or 99% amino acid identity with the amino acid sequence of SEQ ID Nos 27 to 35 and 41 to 43 or a fragment thereof.

Sbg1, g34665, sbg2, g35017 and g35018 proteins are preferably isolated from human or mammalian tissue samples or expressed from human or mammalian genes. The sbg1, g34665, sbg2, g35017 and g35018 polypeptides of the invention can be made using routine expression methods known in the art. The polynucleotide encoding the desired polypeptide, is ligated into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems is used in forming recombinant polypeptides, and a summary of some of the more common systems. The polypeptide is then isolated from lysed cells or from the culture medium

and purified to the extent needed for its intended use. Purification is by any technique known in the art, for example, differential extraction, salt fractionation, chromatography, centrifugation, and the like. See, for example, Methods in Enzymology for a variety of methods for purifying proteins.

5 In addition, shorter protein fragments can be produced by chemical synthesis. Alternatively the proteins of the invention is extracted from cells or tissues of humans or non-human animals. Methods for purifying proteins are known in the art, and include the use of detergents or chaotropic agents to disrupt particles followed by differential extraction and separation of the polypeptides by ion exchange chromatography, affinity chromatography,
10 sedimentation according to density, and gel electrophoresis.

Any sbg1, g34665, sbg2, g35017 or g35018 cDNA or fragment thereof, including the respective cDNA sequences of SEQ ID Nos 2 to 26 and 36 to 40 is used to express sbg1, g34665, sbg2, g35017 or g35018 proteins and polypeptides. The nucleic acid encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or polypeptide to be expressed is operably linked to a promoter in
15 an expression vector using conventional cloning technology. The sbg1, g34665, sbg2, g35017 or g35018 insert in the expression vector may comprise the full coding sequence for the respective sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof. For example, the sbg1 or g35018 derived insert may encode a polypeptide comprising at least 10 consecutive amino acids of the respective sbg1 or g35018 protein of SEQ ID Nos 27 to 35 and 41 to 43.

20 The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the
25 sequence is optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Patent No. 5,082,767.

In one embodiment, the entire coding sequence of the sbg1, g34665, sbg2, g35017 or g35018 cDNA through the poly A signal of the cDNA are operably linked to a promoter in the expression vector. Alternatively, if the nucleic acid encoding a portion of the sbg1, g34665, sbg2, g35017 or g35018 protein lacks a methionine to serve as the initiation site, an initiating methionine
30 can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the insert from the sbg1, g34665, sbg2, g35017 or g35018 cDNA lacks a poly A signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglII and Sall restriction endonuclease enzymes and incorporating it
35 into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion

of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The nucleic acid encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof is obtained by PCR from a bacterial vector containing the a nucleotide sequence of an exon of an sbg1, g34665, sbg2, g35017 or g35018 gene as described herein and in SEQ ID No 1, or from an sbg1 or g35018 cDNA comprising a nucleic acid of SEQ ID No 2 to 26 and 36 to 40 using oligonucleotide primers complementary to the sbg1, g34665, sbg2, g35017 or g35018 nucleic acid or portion thereof and containing restriction endonuclease sequences for Pst I incorporated into the 5' primer and BglII at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the sequence encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof is positioned properly with respect to the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1, now containing a poly A signal and digested with BglII.

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri).

Alternatively, the nucleic acids encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof is cloned into pED6dpc2 (Genetics Institute, Cambridge, MA). The resulting pED6dpc2 constructs is transfected into a suitable host cell, such as COS 1 cells. Methotrexate resistant cells are selected and expanded.

The above procedures may also be used to express a mutant sbg1, g34665, sbg2, g35017 or g35018 protein responsible for a detectable phenotype or a portion thereof.

The expressed proteins are purified using conventional purification techniques such as ammonium sulfate precipitation or chromatographic separation based on size or charge. The protein encoded by the nucleic acid insert may also be purified using standard immunochromatography techniques. In such procedures, a solution containing the expressed sbg1, g34665, sbg2, g35017 or g35018 protein or portion thereof, such as a cell extract, is applied to a column having antibodies against the sbg1, g34665, sbg2, g35017 or g35018 protein or portion thereof is attached to the chromatography matrix. The expressed protein is allowed to bind the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound proteins. The specifically bound expressed protein is then released from the column and recovered using standard techniques.

To confirm expression of the sbg1, g34665, sbg2, g35017 or g35018 protein or a portion

thereof, the proteins expressed from host cells containing an expression vector containing an insert encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof can be compared to the proteins expressed in host cells containing the expression vector without an insert. The presence of a band in samples from cells containing the expression vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof is being expressed. Generally, the band will have the mobility expected for the sbg1, g34665, sbg2, g35017 or g35018 protein or portion thereof. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

Antibodies capable of specifically recognizing the expressed sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof are described below.

If antibody production is not possible, the nucleic acids encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof is incorporated into expression vectors designed for use in purification schemes employing chimeric polypeptides. In such strategies the nucleic acid encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or a portion thereof is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera is β -globin or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to β -globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites is engineered between the β -globin gene or the nickel binding polypeptide and the sbg1, g34665, sbg2, g35017 or g35018 protein or portion thereof. Thus, the two polypeptides of the chimera is separated from one another by protease digestion.

One useful expression vector for generating β -globin chimeric proteins is pSG5 (Stratagene), which encodes rabbit β -globin. Intron II of the rabbit β -globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al., (1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems such as the In vitro ExpressTM Translation Kit (Stratagene).

Antibodies That Bind sbg1, g34665, sbg2, g35017 or g35018 Polypeptides of the Invention

Any sbg1, g34665, sbg2, g35017 or g35018 polypeptide or whole protein may be used to generate antibodies capable of specifically binding to an expressed sbg1, g34665, sbg2, g35017 and g35018 protein or fragments thereof.

For an antibody composition to specifically bind to an sbg1, g34665, sbg2, g35017 or g35018 protein, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for full length sbg1, g34665, sbg2, g35017 or g35018 protein than for any full length protein in an ELISA, RIA, or other antibody-based binding assay. For an antibody composition to specifically bind to a variant sbg1, g34665, sbg2, g35017 or g35018 protein, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for the respective full length variant sbg1, g34665, sbg2, g35017 or g35018 protein than for the respective reference sbg1, g34665, sbg2, g35017 or g35018 full length protein in an ELISA, RIA, or other antibody-based binding assay.

One antibody composition of the invention is capable of specifically binding or specifically binds to the respective sbg1 or g35018 proteins of SEQ ID Nos 27 to 35 and 41 to 43. Other antibody compositions of the invention are capable of specifically binding or specifically bind to an sbg1, sbg2 or g35018 protein variant. Optionally said sbg1 protein variant may be a natural variant provided in Tables 5d or 5e.

In one embodiment, the invention concerns antibody compositions, either polyclonal or monoclonal, capable of selectively binding, or selectively bind to an epitope-containing a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of an sbg1, g34665, sbg2, g35017 or g35018 polypeptide.

The invention also concerns a purified or isolated antibody capable of specifically binding to a mutated sbg1, g34665, sbg2, g35017 or g35018 protein or to a fragment or variant thereof comprising an epitope of the mutated sbg1, g34665, sbg2, g35017 or g35018 protein. In another preferred embodiment, the present invention concerns an antibody capable of binding to a polypeptide comprising at least 10 consecutive amino acids of an sbg1, g34665, sbg2, g35017 or g35018 protein and including at least one of the amino acids which can be encoded by the trait causing mutations.

In a preferred embodiment, the invention concerns the use in the manufacture of antibodies of a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of any of SEQ ID Nos 27 to 35 and 41 to 43.

Non-human animals, and more particularly non-human mammals and non-human primates, whether wild-type or transgenic, which express a different species of sbg1, g34665, sbg2, g35017 or g35018 than the one to which antibody binding is desired, and animals which do not express sbg1, g34665, sbg2, g35017 or g35018 (i.e. an sbg1, g34665, sbg2, g35017 or g35018 knock out animal as described in herein) are particularly useful for preparing antibodies.

5 sbg1, g34665, sbg2, g35017 or g35018 knock out animals will recognize all or most of the exposed regions of an sbg1, g34665, sbg2, g35017 or g35018 protein as foreign antigens, and therefore produce antibodies with a wider array of sbg1, g34665, sbg2, g35017 or g35018 epitopes. Moreover, smaller polypeptides with only 10 to 30 amino acids may be useful in obtaining specific binding to any one of the sbg1, g34665, sbg2, g35017 or g35018 proteins. In addition, the humoral immune system of animals which produce a species of sbg1, g34665, sbg2, g35017 or g35018 that resembles the antigenic sequence will preferentially recognize the differences between the animal's native sbg1, g34665, sbg2, g35017 or g35018 species and the antigen sequence, and produce antibodies to these unique sites in the antigen sequence. Such a technique will be particularly useful in obtaining antibodies that specifically bind to any one of the sbg1, g34665, sbg2, g35017 or g35018 proteins.

10 Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample.

15 The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body. Thus in one embodiment, the invention comprises the use of an antibody capable of specifically recognizing sbg1, g34665, sbg2, g35017 or g35018 for the treatment of schizophrenia or bipolar disorder.

20 The antibodies of the invention may be labeled by any one of the radioactive, fluorescent or enzymatic labels known in the art.

Consequently, the invention is also directed to a method for detecting specifically the presence of an sbg1, g34665, sbg2, g35017 or g35018 polypeptide according to the invention in a biological sample, said method comprising the following steps:

25 a) bringing into contact the biological sample with a polyclonal or monoclonal antibody that specifically binds an sbg1, g34665, sbg2, g35017 or g35018 polypeptide, or to a peptide fragment or variant thereof; and

b) detecting the antigen-antibody complex formed.

30 The invention also concerns a diagnostic kit for detecting *in vitro* the presence of an sbg1, g34665, sbg2, g35017 or g35018 polypeptide according to the present invention in a biological sample, wherein said kit comprises:

a) a polyclonal or monoclonal antibody that specifically binds an sbg1, g34665, sbg2, g35017 or g35018 polypeptide, or to a peptide fragment or variant thereof, optionally labeled;

35 b) a reagent allowing the detection of the antigen-antibody complexes formed, said reagent carrying optionally a label, or being able to be recognized itself by a labeled reagent,

more particularly in the case when the above-mentioned monoclonal or polyclonal antibody is not labeled by itself.

Biallelic markers of the inventions

Advantages of the biallelic markers of the present invention

The biallelic marker of the inventions of the present invention offer a number of important advantages over other genetic markers such as RFLP (Restriction fragment length polymorphism) and VNTR (Variable Number of Tandem Repeats) markers.

The first generation of markers, were RFLPs, which are variations that modify the length of a restriction fragment. But methods used to identify and to type RFLPs are relatively wasteful of materials, effort, and time. The second generation of genetic markers were VNTRs, which can be categorized as either minisatellites or microsatellites. Minisatellites are tandemly repeated DNA sequences present in units of 5-50 repeats which are distributed along regions of the human chromosomes ranging from 0.1 to 20 kilobases in length. Since they present many possible alleles, their informative content is very high. Minisatellites are scored by performing Southern blots to identify the number of tandem repeats present in a nucleic acid sample from the individual being tested. However, there are only 10^4 potential VNTRs that can be typed by Southern blotting. Moreover, both RFLP and VNTR markers are costly and time-consuming to develop and assay in large numbers.

Single nucleotide polymorphism or biallelic markers can be used in the same manner as RFLPs and VNTRs but offer several advantages. Single nucleotide polymorphisms are densely spaced in the human genome and represent the most frequent type of variation. An estimated number of more than 10^7 sites are scattered along the 3×10^9 base pairs of the human genome. Therefore, single nucleotide polymorphism occur at a greater frequency and with greater uniformity than RFLP or VNTR markers which means that there is a greater probability that such a marker will be found in close proximity to a genetic locus of interest. Single nucleotide polymorphisms are less variable than VNTR markers but are mutationally more stable.

Also, the different forms of a characterized single nucleotide polymorphism, such as the biallelic markers of the present invention, are often easier to distinguish and can therefore be typed easily on a routine basis. Biallelic markers have single nucleotide based alleles and they have only two common alleles, which allows highly parallel detection and automated scoring. The biallelic markers of the present invention offer the possibility of rapid, high-throughput genotyping of a large number of individuals.

Biallelic markers are densely spaced in the genome, sufficiently informative and can be assayed in large numbers. The combined effects of these advantages make biallelic markers

extremely valuable in genetic studies. Biallelic markers can be used in linkage studies in families, in allele sharing methods, in linkage disequilibrium studies in populations, in association studies of case-control populations. An important aspect of the present invention is that biallelic markers allow association studies to be performed to identify genes involved in complex traits. Association studies examine the frequency of marker alleles in unrelated case- and control-populations and are generally employed in the detection of polygenic or sporadic traits. Association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families (linkage studies). Biallelic markers in different genes can be screened in parallel for direct association with disease or response to a treatment. This multiple gene approach is a powerful tool for a variety of human genetic studies as it provides the necessary statistical power to examine the synergistic effect of multiple genetic factors on a particular phenotype, drug response, sporadic trait, or disease state with a complex genetic etiology.

Polymorphisms, Biallelic Markers And Polynucleotides Comprising Them
Polynucleotides of the present invention

In one aspect, the invention concerns biallelic markers associated with schizophrenia. The invention comprises chromosome 13q31-q33-related biallelic markers, region D-related biallelic markers, sbg1-related biallelic markers, g34665-related biallelic markers, sbg2-related biallelic markers, g35017-related biallelic markers and g35018-related biallelic markers. The markers and polymorphisms are generally referred to herein as A1, A2, A3 and so on. The polymorphisms and biallelic markers of the invention comprise the biallelic markers designated A1 to A360 in Table 6b. The polymorphisms of the invention also comprise the polymorphisms designated A361 to A489 in Table 6c. Also included are biallelic markers in linkage disequilibrium with the biallelic markers of the invention.

Details of chromosome 13q31-q33-related biallelic markers on the subregions designated Region D including subregions thereof designated Regions D1, D2, D3 and D4, and adjacent regions referred to as Region E and Region G are shown below and in Tables 6B and 6c. Regions D, G and E of the chromosome 13q31-q33 locus are also shown in Figure 2. References to the corresponding SEQ ID number, to alternative marker designations, and positions of the sequence features within the SEQ ID are given in Tables 6b and 6c for biallelic markers A1 to A242 and 361 to 489 located in Region D3 and D4. Further biallelic markers from the group designated A243 to A360 in Tables 6b and 6c are located in Regions D1, D2, G and E. The relative positions of biallelic markers on Region G and E are further detailed below in Table 5g; the relative positions of biallelic markers on Region D1 and D2 are further detailed

below in Table 5h.

Table 5g

Biallelic marker	Region E biallelic markers	Position on contig
A311	99-26171-71	20778
A333	99-26173-470	22456
A308	99-26166-257	24731
A310	99-26169-211	31620
A312	99-26183-156	35869
A309	99-26167-278	43220
A78	99-20978-89	51405
A275	99-20983-48	65076
A272	99-20977-72	70519
A274	99-20981-300	94914
A327	99-6080-99	134366
A325	99-5912-49	149345
A252	99-15229-412	154582
A276	99-22310-148	161605
A254	99-15232-291	162153
A247	99-14021-108	164660
A300	99-26126-498	170445
A329	99-7337-204	198083
A243	8-94-252	206618
A253	99-15231-219	212050
A246	8-98-68	213871
A245	8-97-98	215017
A326	99-6012-220	216597
A255	99-15239-377	223699
A244	8-95-43	236882
A328	99-7308-157	239008
A248	99-14364-415	255729

Biallelic marker	Region G biallelic markers	Position on contig
A359	99-27912-272	153458
A322	99-26234-336	210058
A267	99-15672-166	266449
A283	99-25917-115	268222
A266	99-15668-139	278427
A282	99-25906-131	291272
A265	99-15665-398	306920
A264	99-15664-185	311251
A268	99-15682-318	315770
A271	99-20933-81	342868
A323	99-26238-186	347179
A302	99-26146-264	349864
A321	99-26233-275	362053
A279	99-25869-182	362236
A317	99-26222-149	391049
A301	99-26138-193	400078
A318	99-26223-225	405361
A319	99-26225-148	416529
A284	99-25924-215	421281
A320	99-26228-172	427201
A280	99-25881-275	435974
A281	99-25897-264	440452
A337	99-26769-256	471739
A338	99-26772-268	483511
A339	99-26776-209	494003
A340	99-26779-437	505947
A341	99-26781-25	514635
A342	99-26782-300	516212
A343	99-26783-81	519187
A344	99-26787-96	529412
A345	99-26789-201	540145
A316	99-26201-267	584018

A315	99-26191-58	601044
A314	99-26190-20	602591
A313	99-26189-164	603145
A277	99-25029-241	727473
A336	99-26559-315	740802

Table 5h

Biallelic marker	Region D1 biallelic markers	Position on contig
A357	99-27365/421	48742
A356	99-27361/181	54932
A257	99-15253/382	56599
A355	99-27360/142	57371
A251	99-15065/85	61002
A346	99-27297/280	61855
A262	99-15355/150	62749
A324	99-5873/159	64700
A261	99-15280/432	76977
A347	99-27306/108	92355
A249	99-15056/99	93854
A258	99-15256/392	98336
A349	99-27323/372	100260
A260	99-15261/202	101114
A250	99-15063/155	105587
A259	99-15258/337	110395
A348	99-27312/58	117521
A351	99-27345/189	134904
A352	99-27349/267	138974
A353	99-27352/197	141065
A354	99-27353/105	141494

Biallelic marker	Region D2 biallelic markers	Position on contig
A304	99-26150/276	168065
A307	99-26156/290	173255
A306	99-26154/107	175557
A305	99-26153/44	177194
A298	99-25985/194	186447
A292	99-25974/143	190018
A335	99-26284/394	193065
A303	99-26147/396	196922
A285	99-25950/121	205288
A294	99-25978/166	215025
A293	99-25977/311	216394
A291	99-25972/317	224712
A297	99-25984/312	230966
A287	99-25965/399	236799
A286	99-25961/376	244955
A288	99-25966/241	254680
A350	99-27335/191	25486
A289	99-25967/57	257662
A290	99-25969/200	261166
A296	99-25980/173	261957
A295	99-25979/93	263848
A299	99-25989/398	269515
A334	99-26267/524	275710

The polynucleotide of the invention may consist of, consist essentially of, or comprise a contiguous span of nucleotides of a sequence from any of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 as well as sequences which are complementary thereto ("complements thereof"). The "contiguous span" may be at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500,

1000 or 2000 nucleotides in length, to the extent that a contiguous span of these lengths is consistent with the lengths of the particular Sequence ID.

The present invention encompasses polynucleotides for use as primers and probes in the methods of the invention. These polynucleotides may consist of, consist essentially of, or
5 comprise a contiguous span of nucleotides of a sequence from any of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 as well as sequences which are complementary thereto ("complements thereof"). The "contiguous span" may be at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length, to the extent that a contiguous span of these lengths is consistent with the lengths of the particular Sequence ID. It should be noted that the
10 polynucleotides of the present invention are not limited to having the exact flanking sequences surrounding the polymorphic bases which, are enumerated in the Sequence Listing. Rather, it will be appreciated that the flanking sequences surrounding the biallelic markers and other polymorphisms of the invention, or any of the primers or probes of the invention which, are more distant from the markers, may be lengthened or shortened to any extent compatible with their intended use and the present invention specifically contemplates such sequences. It will be
15 appreciated that the polynucleotides of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 may be of any length compatible with their intended use. Also the flanking regions outside of the contiguous span need not be homologous to native flanking sequences which actually occur in human subjects. The addition of any nucleotide sequence, which is compatible with the
20 nucleotides intended use is specifically contemplated. The contiguous span may optionally include the biallelic markers of the invention in said sequence. Biallelic markers generally comprise a polymorphism at one single base position. Each biallelic marker therefore corresponds to two forms of a polynucleotide sequence which, when compared with one another, present a nucleotide modification at one position. Usually, the nucleotide modification
25 involves the substitution of one nucleotide for another. Optionally allele 1 or allele 2 of the biallelic markers disclosed in Table 6b may be specified as being present at the biallelic marker of the invention. The contiguous span may optionally include a nucleotide at a polymorphism position described in Table 6c, including single nucleotide substitutions, deletions as well as multiple nucleotide deletions. The polymorphisms of Table 6c have not been validated as
30 biallelic markers, but are expected to be mostly biallelic and may also be referred to as biallelic markers herein. Optionally, allele 1 or allele 2 of the polymorphisms of Table 6c may be specified as being present at the polymorphism of the invention. Preferred polynucleotides may consist of, consist essentially of, or comprise a contiguous span of nucleotides of a sequence from SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 as well as sequences which are
35 complementary thereto. The "contiguous span" may be at least 8, 10, 12, 15, 18, 20, 25, 35, 40,

50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length, to the extent that a contiguous span of these lengths is consistent with the lengths of the particular Sequence ID.

5 A preferred probe or primer comprises a nucleic acid comprising a polynucleotide selected from the group of the nucleotide sequences of P1 to P360 and the complementary sequence thereto, B1 to B229, C1 to C229, D1 to D360, E1 to E360.

10 The invention also relates to polynucleotides that hybridize, under conditions of high or intermediate stringency, to a polynucleotide of any of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 as well as sequences, which are complementary thereto. Preferably such polynucleotides are at least 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length, to the extent that a polynucleotide of these lengths is consistent with the lengths of the particular Sequence ID. Preferred polynucleotides comprise a polymorphism of the invention. Optionally either allele 1 or allele 2 of the polymorphism disclosed in Table 6c may be specified as being present at the polymorphism of the invention. Particularly preferred polynucleotides comprise a biallelic marker of the invention. Optionally either allele 1 or allele 2 of the biallelic markers disclosed in Table 6b may be specified as being present at the biallelic marker of the invention. Conditions of high stringency are further described herein.

15 The primers of the present invention may be designed from the disclosed sequences for any method known in the art. A preferred set of primers is fashioned such that the 3' end of the contiguous span of identity with the sequences of any of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 is present at the 3' end of the primer. Such a configuration allows the 3' end of the primer to hybridize to a selected nucleic acid sequence and dramatically increases the efficiency of the primer for amplification or sequencing reactions. In a preferred set of primers the contiguous span is found in one of the sequences described in Table 6a. Allele specific primers may be designed such that a biallelic marker or other polymorphism of the invention is at the 3' end of the contiguous span and the contiguous span is present at the 3' end of the primer. Such allele specific primers tend to selectively prime an amplification or sequencing reaction so long as they are used with a nucleic acid sample that contains one of the two alleles present at said marker. The 3' end of primer of the invention may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a biallelic marker of the invention in said sequence or at any other location which is appropriate for their intended use in sequencing, amplification or the location of novel sequences or markers. Primers with their 3' ends located 1 nucleotide upstream of an biallelic marker of the invention have a special utility as microsequencing assays. Preferred microsequencing primers are described in Table 6d.

25 30 35 The probes of the present invention may be designed from the disclosed sequences for any method known in the art, particularly methods which allow for testing if a particular

sequence or marker disclosed herein is present. A preferred set of probes may be designed for use in the hybridization assays of the invention in any manner known in the art such that they selectively bind to one allele of a biallelic marker or other polymorphism, but not the other under any particular set of assay conditions. Preferred hybridization probes may consist of, consist essentially of, or comprise a contiguous span which ranges in length from 8, 10, 12, 15, 18 or 20 to 25, 35, 40, 50, 60, 70, or 80 nucleotides, or be specified as being 12, 15, 18, 20, 25, 35, 40, or 50 nucleotides in length and including an biallelic marker or other polymorphism of the invention in said sequence. In a preferred embodiment, either of allele 1 or 2 disclosed in Table 6b or 6c may be specified as being present at the biallelic marker site. In another preferred embodiment, said biallelic marker may be within 6, 5, 4, 3, 2, or 1 nucleotides of the center of the hybridization probe or at the center of said probe.

In one embodiment the invention encompasses isolated, purified, and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of any one of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229 and the complement thereof, wherein said span includes a polymorphism of the invention, a chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker in said sequence; optionally, wherein said polymorphism, chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker selected from the group consisting of A1 to A489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232, A328 to 489; optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and 361 to 489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242, A250 to A251, A259, A269 to A270, A278, A285 to A299, A303 to A307, A330, A334 to A335 and A346 to 357 and 361 to 489, and

the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide; optionally, wherein said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide; optionally, wherein the 3' end of said contiguous span is present at the 3' end of said polynucleotide; and optionally, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide. In a preferred embodiment, said probes comprise, consists of, or consists essentially of a sequence selected from the following sequences: P1 to P360 and the complementary sequences thereto.

In another embodiment the invention encompasses isolated, purified and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of any one of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229, or the complement thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located within 20 nucleotides upstream of a polymorphism of the invention, chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker in said sequence; optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said a chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232, A328 to A360, and and 361 to 489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and 361 to 489; optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic

marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242, A250 to A251, A259, A269 to A270, A278, A285 to A299, A303 to A307, A330, A334 to A335, A346 to 357 and 361 to 489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker; and optionally, wherein said polynucleotide comprises, consists of, or consists essentially of a sequence selected from the following sequences: D1 to D360 and E1 to E360.

In a further embodiment, the invention encompasses isolated, purified, or recombinant polynucleotides comprising, consisting of, or consisting essentially of a sequence selected from the following sequences: B1 to B229 and C1 to C229.

In an additional embodiment, the invention encompasses polynucleotides for use in hybridization assays, sequencing assays, and enzyme-based mismatch detection assays for determining the identity of the nucleotide at a chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker in any of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the complement thereof, as well as polynucleotides for use in amplifying segments of nucleotides comprising a polymorphism of the invention, a chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker in any of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the complement thereof; optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232, A328 to A360 and 361 to 489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242, A250 to A251, A259, A269 to A270, A278, A285 to A299, A303 to A307, A330, A334 to A335 and A346 to 357 and

361 to 489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; and optionally, wherein chromosome 13q31-q33-related biallelic marker, region D-related biallelic marker, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and 361 to 489, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith.

These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods, which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., Science, 251:767-777, 1991). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPS™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPS™ technologies are provided in US Patents 5,143,854 and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis technique. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

Oligonucleotide arrays may comprise at least one of the sequences selected from the group consisting of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229; and the sequences complementary thereto or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 consecutive nucleotides, to the extent that fragments of these lengths is consistent with the lengths of the particular Sequence ID, for determining whether a sample contains one or more alleles of the biallelic markers of the present invention.

Oligonucleotide arrays may also comprise at least one of the sequences selected from the group consisting of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229; and the sequences complementary thereto or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 consecutive nucleotides, to the extent that fragments of these lengths is consistent with the lengths of the particular Sequence ID, for amplifying one or more alleles of the biallelic markers of Table 6b or polymorphisms of Table 6c. In other embodiments, arrays may also comprise at least one of the sequences selected from the group consisting of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229; and the sequences complementary thereto or a fragment

thereof of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500 , 1000 or 2000 consecutive nucleotides, to the extent that fragments of these lengths is consistent with the lengths of the particular Sequence ID, for conducting microsequencing analyses to determine whether a sample contains one or more alleles of the biallelic markers of the invention. In still
5 further embodiments, the oligonucleotide array may comprise at least one of the sequences selecting from the group consisting of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229; and the sequences complementary thereto or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500 , 1000 or 2000 nucleotides in length, to the extent that fragments of these lengths is consistent with the lengths of the particular Sequence ID, for determining
10 whether a sample contains one or more alleles of the polymorphisms and biallelic markers of the present invention.

A further object of the invention relates to an array of nucleic acid sequences comprising either at least one of the sequences selected from the group consisting of P1 to P360, B1 to B229, C1 to C229, D1 to D360 E1 to E360 or the sequences complementary thereto
15 or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 30, or 40 consecutive nucleotides thereof, or at least one sequence comprising at least 1, 2, 3, 4, 5, 10, 20 biallelic markers selected from the group consisting of A1 to A489 or the complements thereof. The invention also pertains to an array of nucleic acid sequences comprising either at least 1, 2, 3, 4, 5, 10, 20 of the sequences selected from the group consisting of P1 to P360, B1 to B229, C1 to C229, D1
20 to D360, E1 to E360 or the sequences complementary thereto or a fragment thereof of at least 8 consecutive nucleotides thereof, or at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A360 or the complements thereto.

The present invention also encompasses diagnostic kits comprising one or more polynucleotides of the invention, optionally with a portion or all of the necessary reagents and
25 instructions for genotyping a test subject by determining the identity of a nucleotide at an biallelic marker of the invention. The polynucleotides of a kit may optionally be attached to a solid support, or be part of an array or addressable array of polynucleotides. The kit may provide for the determination of the identity of the nucleotide at a marker position by any method known in the art including, but not limited to, a sequencing assay method, a
30 microsequencing assay method, a hybridization assay method, or enzyme-based mismatch detection assay. Optionally such a kit may include instructions for scoring the results of the determination with respect to the test subjects' predisposition to schizophrenia, or likely response to an agent acting on schizophrenia, or chances of suffering from side effects to an agent acting on schizophrenia.

35 Finally, in any embodiments of the present invention, a biallelic marker may may

optionally comprise:

(a) a biallelic marker selected from the group consisting of sbg1-related markers A85 to A219, or more preferably a biallelic marker selected from the group consisting of sbg1-related markers A85 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197 and A199 to A219;

(b) a biallelic marker selected from the group consisting of g34665-related markers A230 to A236;

(c) a biallelic marker selected from the group consisting of sbg2-related markers A79 to A99;

(d) the g35017-related marker A41;

(e) a biallelic marker selected from the group consisting of g35018-related markers A1 to A39;

(f) a biallelic marker selected from the group consisting of A239, A227, A198, A228, A223, A107, A218, A270, A75, A62, A65 and A70;

(g) a biallelic marker selected from the group consisting of A48, A60, A61, A62, A65, A70, A75, A76, A80, A107, A108, A198, A218, A221, A223, A227, A228, A239, A285, A286, A287, A288, A290, A292, A293, A295, A299 and A304;

(h) a biallelic marker selected from the group consisting of A304, A307, A305, A298, A292, A293, A291, A287, A286, A288, A289, A290, A295, A299, A241, A239, A228, A227, A223, A221, A218, A198, A178, 99-24649/186 A108, A107, A80, A75, A70, A65, and A62; and/or

(i) a biallelic marker selected from the group consisting of A304, A307, A305, A298, A292, A293, A291, A287, A286, A288, A289, A290, A295, A299, A241, A239, A228, A227, A223, A221, A218, A198, A178, A108, A107, A80, A76, A75, A70, A65, A62, A61, A60 A48.

Optionally, in any of the embodiments described herein, a Region D- or chromosome 13q31-q33-related biallelic marker may be selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242, A250 to A251, A259, A269 to A270, A278, A285 to A299, A303 to A307, A330, A334 to A335, A346 to 357 and 361 to 489. Optionally, in any of the embodiments described herein, a chromosome 13q31-q33-related biallelic marker may be selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489. A set of said Region D-related biallelic markers or chromosome 13q31-q33-related biallelic markers may comprise at least 1, 2, 3, 4, 5,

10, 20, 40, 50, 100 or 200 of said biallelic markers, respectively.

Optionally, any of the compositions of methods described herein may specifically exclude at least 1, 2, 3, 4, 5, 10, 20 biallelic markers, or all of the biallelic markers selected from the group consisting of: A70, A75, A95, A107, A113, A178, A198, A223, A247 to A249, A252, A254, A256 to A258, A260 to A265, A267, A324 to A328.

Furthermore, in any of the embodiments of the present invention, a set of chromosome 13q31-q33-related biallelic markers, Region D-related biallelic markers, or sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic markers may comprise at least 1, 2, 3, 4, 5, 10, 20, 40, 50, 100 or 200 of said biallelic markers.

Methods For De Novo Identification Of Biallelic Markers

Any of a variety of methods can be used to screen a genomic fragment for single nucleotide polymorphisms such as differential hybridization with oligonucleotide probes, detection of changes in the mobility measured by gel electrophoresis or direct sequencing of the amplified nucleic acid. A preferred method for identifying biallelic markers involves comparative sequencing of genomic DNA fragments from an appropriate number of unrelated individuals.

In a first embodiment, DNA samples from unrelated individuals are pooled together, following which the genomic DNA of interest is amplified and sequenced. The nucleotide sequences thus obtained are then analyzed to identify significant polymorphisms. One of the major advantages of this method resides in the fact that the pooling of the DNA samples substantially reduces the number of DNA amplification reactions and sequencing reactions, which must be carried out. Moreover, this method is sufficiently sensitive so that a biallelic marker obtained thereby usually demonstrates a sufficient frequency of its less common allele to be useful in conducting association studies. Usually, the frequency of the least common allele of a biallelic marker identified by this method is at least 10%.

In a second embodiment, the DNA samples are not pooled and are therefore amplified and sequenced individually. This method is usually preferred when biallelic markers need to be identified in order to perform association studies within candidate genes. Preferably, highly relevant gene regions such as promoter regions or exon regions may be screened for biallelic markers. A biallelic marker obtained using this method may show a lower degree of informativeness for conducting association studies, e.g. if the frequency of its less frequent allele may be less than about 10%. Such a biallelic marker will however be sufficiently informative to conduct association studies and it will further be appreciated that including less informative biallelic markers in the genetic analysis studies of the present invention, may allow

in some cases the direct identification of causal mutations, which may, depending on their penetrance, be rare mutations.

The following is a description of the various parameters of a preferred method used by the inventors for the identification of the biallelic markers of the present invention.

Genomic DNA samples

The genomic DNA samples from which the biallelic markers of the present invention are generated are preferably obtained from unrelated individuals corresponding to a heterogeneous population of known ethnic background. The number of individuals from whom DNA samples are obtained can vary substantially, preferably from about 10 to about 1000, more preferably from about 50 to about 200 individuals. Usually, DNA samples are collected from at least about 100 individuals in order to have sufficient polymorphic diversity in a given population to identify as many markers as possible and to generate statistically significant results.

As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples, which can be tested by the methods of the present invention described herein, and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the present invention is from peripheral venous blood of each donor. Techniques to prepare genomic DNA from biological samples are well known to the skilled technician. Details of a preferred embodiment are provided in Example 1. The person skilled in the art can choose to amplify pooled or unpooled DNA samples.

DNA Amplification

The identification of biallelic markers in a sample of genomic DNA may be facilitated through the use of DNA amplification methods. DNA samples can be pooled or unpooled for the amplification step. DNA amplification techniques are well known to those skilled in the art. Various methods to amplify DNA fragments carrying biallelic markers are further described hereinafter herein. The PCR technology is the preferred amplification technique used to identify new biallelic markers.

In a first embodiment, biallelic markers are identified using genomic sequence information generated by the inventors. Genomic DNA fragments, such as the inserts of the BAC clones described above, are sequenced and used to design primers for the amplification of

500 bp fragments. These 500 bp fragments are amplified from genomic DNA and are scanned for biallelic markers. Primers may be designed using the OSP software (Hillier L. and Green P., 1991). All primers may contain, upstream of the specific target bases, a common oligonucleotide tail that serves as a sequencing primer. Those skilled in the art are familiar with primer extensions, which can be used for these purposes.

In another embodiment of the invention, genomic sequences of candidate genes are available in public databases allowing direct screening for biallelic markers. Preferred primers, useful for the amplification of genomic sequences encoding the candidate genes, focus on promoters, exons and splice sites of the genes. A biallelic marker present in these functional regions of the gene have a higher probability to be a causal mutation.

Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms

The amplification products generated as described above, are then sequenced using any method known and available to the skilled technician. Methods for sequencing DNA using either the dideoxy-mediated method (Sanger method) or the Maxam-Gilbert method are widely known to those of ordinary skill in the art. Such methods are for example disclosed in Maniatis et al. (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Second Edition, 1989). Alternative approaches include hybridization to high-density DNA probe arrays as described in Chee et al. (Science 274, 610, 1996).

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. The products of the sequencing reactions are run on sequencing gels and the sequences are determined using gel image analysis. The polymorphism search is based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position. Because each dideoxy terminator is labeled with a different fluorescent molecule, the two peaks corresponding to a biallelic site present distinct colors corresponding to two different nucleotides at the same position on the sequence. However, the presence of two peaks can be an artifact due to background noise. To exclude such an artifact, the two DNA strands are sequenced and a comparison between the peaks is carried out. In order to be registered as a polymorphic sequence, the polymorphism has to be detected on both strands.

The above procedure permits those amplification products, which contain biallelic markers to be identified. The detection limit for the frequency of biallelic polymorphisms detected by sequencing pools of 100 individuals is approximately 0.1 for the minor allele, as verified by sequencing pools of known allelic frequencies. However, more than 90% of the biallelic polymorphisms detected by the pooling method have a frequency for the minor allele

higher than 0.25. Therefore, the biallelic markers selected by this method have a frequency of at least 0.1 for the minor allele and less than 0.9 for the major allele. Preferably at least 0.2 for the minor allele and less than 0.8 for the major allele, more preferably at least 0.3 for the minor allele and less than 0.7 for the major allele, thus a heterozygosity rate higher than 0.18, preferably higher than 0.32, more preferably higher than 0.42.

In another embodiment, biallelic markers are detected by sequencing individual DNA samples, the frequency of the minor allele of such a biallelic marker may be less than 0.1.

Validation of the biallelic markers of the present invention

The polymorphisms are evaluated for their usefulness as genetic markers by validating that both alleles are present in a population. Validation of the biallelic markers is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. Microsequencing is a preferred method of genotyping alleles. The validation by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group can be as small as one individual if that individual is heterozygous for the allele in question. Preferably the group contains at least three individuals, more preferably the group contains five or six individuals, so that a single validation test will be more likely to result in the validation of more of the biallelic markers that are being tested. It should be noted, however, that when the validation test is performed on a small group it may result in a false negative result if as a result of sampling error none of the individuals tested carries one of the two alleles. Thus, the validation process is less useful in demonstrating that a particular initial result is an artifact, than it is at demonstrating that there is a *bona fide* biallelic marker at a particular position in a sequence. All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with validated biallelic markers.

Evaluation of the frequency of the biallelic markers of the present invention

The validated biallelic markers are further evaluated for their usefulness as genetic markers by determining the frequency of the least common allele at the biallelic marker site. The determination of the least common allele is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. This determination of frequency by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group must be large enough to be representative of the population as a

whole. Preferably the group contains at least 20 individuals, more preferably the group contains at least 50 individuals, most preferably the group contains at least 100 individuals. Of course the larger the group the greater the accuracy of the frequency determination because of reduced sampling error. A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a "high quality biallelic marker." All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with high quality biallelic markers.

Another embodiment of the invention comprises methods of estimating the frequency of an allele in a population comprising genotyping individuals from said population for a 13q31-q33-related biallelic marker and determining the proportional representation of said biallelic marker in said population. In addition, the methods of estimating the frequency of an allele in a population encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: Optionally, said 13q31-q33-related biallelic marker may be in a sequence selected individually or in any combination from the group consisting of SEQ Nos 1 to 26, 36 to 40 and 54 to 229; and the complements thereof; optionally, said 13q31-q33-related biallelic marker may be selected from the biallelic markers described in Table 6b or 6c; optionally, determining the frequency of a biallelic marker allele in a population may be accomplished by determining the identity of the nucleotides for both copies of said biallelic marker present in the genome of each individual in said population and calculating the proportional representation of said nucleotide at said 13q31-q33-related biallelic marker for the population; optionally, determining the frequency of a biallelic marker allele in a population may be accomplished by performing a genotyping method on a pooled biological sample derived from a representative number of individuals, or each individual, in said population, and calculating the proportional amount of said nucleotide compared with the total.

Methods Of Genotyping An Individual For Biallelic Markers

Methods are provided to genotype a biological sample for one or more biallelic markers of the present invention, all of which may be performed *in vitro*. Such methods of genotyping comprise determining the identity of a nucleotide at an biallelic marker of the invention by any method known in the art. These methods find use in genotyping case-control populations in association studies as well as individuals in the context of detection of alleles of biallelic markers which, are known to be associated with a given trait, in which case both copies of the biallelic marker present in individual's genome are determined so that an individual may be classified as homozygous or heterozygous for a particular allele.

These genotyping methods can be performed nucleic acid samples derived from a single

individual or pooled DNA samples.

Genotyping can be performed using similar methods as those described above for the identification of the biallelic markers, or using other genotyping methods such as those further described below. In preferred embodiments, the comparison of sequences of amplified genomic fragments from different individuals is used to identify new biallelic markers whereas microsequencing is used for genotyping known biallelic markers in diagnostic and association study applications.

Another embodiment of the invention encompasses methods of genotyping a biological sample comprising determining the identity of a nucleotide at a 13q31-q33-related biallelic marker. In addition, the genotyping methods of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: Optionally, said 13q31-q33-related biallelic marker may be in a sequence selected individually or in any combination from the group consisting of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229, and the complements thereof; optionally, said 13q31-q33-related biallelic marker may be selected individually or in any combination from the biallelic markers described in Table 6b and 6c; optionally, said method further comprises determining the identity of a second nucleotide at said biallelic marker, wherein said first nucleotide and second nucleotide are not base paired (by Watson & Crick base pairing) to one another; optionally, said biological sample is derived from a single individual or subject; optionally, said method is performed *in vitro*; optionally, said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome; optionally, said biological sample is derived from multiple subjects or individuals; optionally, said method further comprises amplifying a portion of said sequence comprising the biallelic marker prior to said determining step; optionally, wherein said amplifying is performed by PCR, LCR, or replication of a recombinant vector comprising an origin of replication and said portion in a host cell; optionally, wherein said determining is performed by a hybridization assay, sequencing assay, microsequencing assay, or an enzyme-based mismatch detection assay.

Source of DNA for genotyping

Any source of nucleic acids, in purified or non-purified form, can be utilized as the starting nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired. DNA or RNA may be extracted from cells, tissues, body fluids and the like as described herein. While nucleic acids for use in the genotyping methods of the invention can be derived from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

Amplification Of DNA Fragments Comprising Biallelic Markers

Methods and polynucleotides are provided to amplify a segment of nucleotides comprising one or more biallelic marker of the present invention. It will be appreciated that amplification of DNA fragments comprising biallelic markers may be used in various methods and for various purposes and is not restricted to genotyping. Nevertheless, many genotyping methods, although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest. Such methods specifically increase the concentration or total number of sequences that span the biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely on amplification of DNA segments carrying a biallelic marker of the present invention.

Amplification of DNA may be achieved by any method known in the art. The established PCR (polymerase chain reaction) method or by developments thereof or alternatives. Amplification methods which can be utilized herein include but are not limited to Ligase Chain Reaction (LCR) as described in EP A 320 308 and EP A 439 182, Gap LCR (Wolcott, M.J.), the so-called "NASBA" or "3SR" technique described in Guatelli J.C. et al. (1990) and in Compton J. (1991), Q-beta amplification as described in EP A 4544 610, strand displacement amplification as described in Walker et al. (1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461.

LCR and Gap LCR are exponential amplification techniques, both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-3'hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent but are separated by 2 to 3 bases.

For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Patent No. 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall R.L. et al. (1994). AGLCR is a modification of GLCR that allows the amplification of RNA.

Some of these amplification methods are particularly suited for the detection of single nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as it is further described herein.

The PCR technology is the preferred amplification technique used in the present invention. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see Molecular Cloning to Genetic Engineering White, B.A. Ed. (1997) and the publication entitled "PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites. PCR has further been described in several patents including US Patents 4,683,195, 4,683,202 and 4,965,188.

Primers can be prepared by any suitable method. As for example, direct chemical synthesis by a method such as the phosphodiester method of Narang S.A. et al. (1979), the phosphodiester method of Brown E.L. et al. (1979), the diethylphosphoramidite method of Beaucage et al. (1981) and the solid support method described in EP 0 707 592.

In some embodiments the present invention provides primers for amplifying a DNA fragment containing one or more biallelic markers of the present invention. It will be appreciated that the primers listed are merely exemplary and that any other set of primers which produce amplification products containing one or more biallelic markers of the present invention.

The spacing of the primers determines the length of the segment to be amplified. In the context of the present invention amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical, fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers may be any sequence

which allow the specific amplification of any DNA fragment carrying the markers. Amplification primers may be labeled or immobilized on a solid support as described in the section titled "Oligonucleotide Probes and Primers".

Methods of Genotyping DNA samples for Biallelic Markers

5 Any method known in the art can be used to identify the nucleotide present at a biallelic marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove simple for one of ordinary skill in the art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the DNA region carrying the biallelic marker of interest. While the
10 amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al. (1989), denaturing
15 gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield, V.C. et al. (1991), White et al. (1992), Grompe, M. et al. (1989) and Grompe, M. (1993). Another method for determining the identity of the nucleotide present at a particular polymorphic site employs a specialized exonuclease-resistant nucleotide derivative as described in US patent 4,656,127.

20 Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, enzyme-based mismatch detection assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the microsequencing technique. The term "sequencing assay" is used herein to refer to polymerase extension of duplex primer/template complexes and includes both
25 traditional sequencing and microsequencing.

1) Sequencing assays

The nucleotide present at a polymorphic site can be determined by sequencing methods. In a preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as described above. DNA sequencing methods are described in herein. Preferably,
30 the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Sequence analysis allows the identification of the base present at the biallelic marker site.

2) Microsequencing assays

In microsequencing methods, a nucleotide at the polymorphic site that is unique to one
35 of the alleles in a target DNA is detected by a single nucleotide primer extension reaction. This

method involves appropriate microsequencing primers which, hybridize just upstream of a polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3' end of the primer with one single ddNTP (chain terminator) complementary to the selected nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing machines to determine the identity of the incorporated nucleotide as described in EP 412 883. Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously. An example of a typical microsequencing procedure that can be used in the context of the present invention is provided in example 4.

Different approaches can be used to detect the nucleotide added to the microsequencing primer. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al. (1997). In this method amplified genomic DNA fragments containing polymorphic sites are incubated with a 5'-fluorescein-labeled primer in the presence of allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time. Alternatively, the extended primer may be analyzed by MALDI-TOF Mass Spectrometry. The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff L.A. and Smirnov I.P., 1997).

Microsequencing may be achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase microsequencing techniques. The basic microsequencing protocol is the same as described previously, except that the method is conducted as a heterogenous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase extension. The 5' ends and internal nucleotides of synthetic oligonucleotides can be modified in a number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator reagent. This eliminates the need of physical or size separation.

More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if more than one affinity group is used. This permits the analysis of several nucleic acid species or more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner oligonucleotides or templates may be attached to a solid support in a high-density format. In such solid phase microsequencing reactions, incorporated ddNTPs can be radiolabeled (Syvänen, 1994) or linked to fluorescein (Livak and Hainer, 1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be based on the binding of anti fluorescein antibody conjugated with alkaline phosphatase, followed by incubation with a chromogenic substrate (such as *p*-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Harju et al., 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated streptavidin with *o*-phenylenediamine as a substrate (WO 92/15712). As yet another alternative solid-phase microsequencing procedure, Nyren et al. (1993) described a method relying on the detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA).

Pastinen et al. (1997), describe a method for multiplex detection of single nucleotide polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide array format. High-density arrays of DNA probes attached to a solid support (DNA chips) are further described in herein.

In one aspect the present invention provides polynucleotides and methods to genotype one or more biallelic markers of the present invention by performing a microsequencing assay. Preferred microsequencing primers include those being featured Table 6d. It will be appreciated that the microsequencing primers listed in Table 6d are merely exemplary and that, any primer having a 3' end immediately adjacent to a polymorphic nucleotide may be used. Similarly, it will be appreciated that microsequencing analysis may be performed for any biallelic marker or any combination of biallelic markers of the present invention. One aspect of the present invention is a solid support which includes one or more microsequencing primers listed in Table 6d, or fragments comprising at least 8, at least 12, at least 15, or at least 20 consecutive nucleotides thereof and having a 3' terminus immediately upstream of the corresponding biallelic marker, for determining the identity of a nucleotide at biallelic marker site.

3) Mismatch detection assays based on polymerases and ligases

In one aspect the present invention provides polynucleotides and methods to determine the allele of one or more biallelic markers of the present invention in a biological sample, by mismatch detection assays based on polymerases and/or ligases. These assays are based on the specificity of polymerases and ligases. Polymerization reactions places particularly stringent requirements on correct base pairing of the 3' end of the amplification primer and the joining of two oligonucleotides hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site, especially at the 3' end. The terms "enzyme based mismatch detection assay" are used herein to refer to any method of determining the allele of a biallelic marker based on the specificity of ligases and polymerases. Preferred methods are described below. Methods, primers and various parameters to amplify DNA fragments comprising biallelic markers of the present invention are further described herein.

Allele specific amplification

Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy, whereby one of the alleles is amplified without amplification of the other allele. This is accomplished by placing a polymorphic base at the 3' end of one of the amplification primers. Because the extension forms from the 3' end of the primer, a mismatch at or near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary allele. Designing the appropriate allele-specific primer and the corresponding assay conditions are well with the ordinary skill in the art.

Ligation/amplification based methods

The "Oligonucleotide Ligation Assay" (OLA) uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target molecules. One of the oligonucleotides is biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable of detecting biallelic markers and may be advantageously combined with PCR as described by Nickerson D.A. et al. (1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Other methods which are particularly suited for the detection of biallelic markers include LCR (ligase chain reaction), Gap LCR (GLCR) which are described herein. As mentioned above LCR uses two pairs of probes to exponentially amplify a specific target. The sequences of each pair of oligonucleotides, is selected to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-

dependant ligase. In accordance with the present invention, LCR can be performed with oligonucleotides having the proximal and distal sequences of the same strand of a biallelic marker site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site. In such an embodiment, the reaction conditions are selected such that the oligonucleotides can be ligated together only if the target molecule either contains or lacks the specific nucleotide(s) that is complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the oligonucleotides will not include the biallelic marker, such that when they hybridize to the target molecule, a "gap" is created as described in WO 90/01069. This gap is then "filled" with complementary dNTPs (as mediated by DNA polymerase), or by an additional pair of oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of serving as a target during the next cycle and exponential allele-specific amplification of the desired sequence is obtained.

Ligase/Polymerase-mediated Genetic Bit AnalysisTM is another method for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.

4) Hybridization assay methods

A preferred method of determining the identity of the nucleotide present at a biallelic marker site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in such reactions, preferably include the probes defined herein. Any hybridization assay may be used including Southern hybridization, Northern hybridization, dot blot hybridization and solid-phase hybridization (see Sambrook et al., Molecular Cloning – A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., 1989).

Hybridization refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch. Specific probes can be designed that hybridize to one form of a biallelic marker and not to the other and therefore are able to discriminate between different allelic forms. Allele-specific probes are often used in pairs, one member of a pair showing perfect match to a target sequence containing the original allele and the other showing a perfect match to the target sequence containing the alternative allele. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles.

Stringent, sequence specific hybridization conditions, under which a probe will hybridize only to the exactly complementary target sequence are well known in the art (Sambrook et al., Molecular Cloning – A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., 1989). Stringent conditions are sequence dependent and will be different in different

5 circumstances. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in

10 buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe.

Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be

15 done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1X SSC at 50°C for 45 min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS, or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68°C for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. By way of example and not limitation, procedures

20 using conditions of intermediate stringency are as follows: Filters containing DNA are prehybridized, and then hybridized at a temperature of 60°C in the presence of a 5 x SSC buffer and labeled probe. Subsequently, filters washes are performed in a solution containing 2x SSC at 50°C and the hybridized probes are detectable by autoradiography. Other conditions of high and intermediate stringency which may be used are well known in the art and as cited in

25 Sambrook et al. (Molecular Cloning - A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., 1989) and Ausubel et al. (Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., 1989).

Although such hybridizations can be performed in solution, it is preferred to employ a solid-phase hybridization assay. The target DNA comprising a biallelic marker of the present

30 invention may be amplified prior to the hybridization reaction. The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a number of methods. Various detection assay formats are well known which utilize detectable labels bound to either the target or the probe to enable detection of the hybrid

35 duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and

the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps may be employed to wash away excess target DNA or probe. Standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the primers and probes.

Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., 1998). The TaqMan assay takes advantage of the 5' nuclease activity of Taq DNA polymerase to digest a DNA probe annealed specifically to the accumulating amplification product. TaqMan probes are labeled with a donor-acceptor dye pair that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al, 1995). In an alternative homogeneous hybridization-based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally quenched fluorophore (Tyagi et al., 1998).

By assaying the hybridization to an allele specific probe, one can detect the presence or absence of a biallelic marker allele in a given sample.

High-Throughput parallel hybridizations in array format are specifically encompassed within "hybridization assays" and are described below.

Hybridization to addressable arrays of oligonucleotides

Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target sequence variants. Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (the chip) at selected positions. Each DNA chip can contain thousands to millions of individual synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

The chip technology has already been applied with success in numerous cases. For example, the screening of mutations has been undertaken in the BRCA1 gene, in *S. cerevisiae* mutant strains, and in the protease gene of HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996 ; Kozal et al., 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (HyChip and HyGnostics), and Protogene Laboratories.

In general, these methods employ arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP785280, describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be "tilled" for a large number of specific polymorphisms. By "tiling" is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of monomers, i.e. nucleotides. Tiling strategies are further described in PCT application No. WO 95/11995. In a particular aspect, arrays are tiled for a number of specific, identified biallelic marker sequences. In particular the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of biallelic markers. For example, a detection block may be tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To ensure probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection block. These monosubstituted probes have bases at and up to a certain number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization from artefactual cross-hybridization. Upon completion of hybridization with the target sequence and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning may be carried out as described in PCT application No. WO 92/10092 and WO 95/11995 and US patent No. 5,424,186.

Thus, in some embodiments, the chips may comprise an array of nucleic acid sequences of fragments of about 15 nucleotides in length. In further embodiments, the chip may comprise an array including at least one of the sequences selected from the group consisting of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 and the sequences complementary thereto, or a fragment thereof at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides. In some embodiments, the chip may comprise an array of at least 2, 3, 4, 5, 6, 7, 8 or more of these polynucleotides of the invention. Solid supports and polynucleotides of the present invention attached to solid supports are further described in the

section titled "Oligonucleotide probes and Primers".

5) Integrated Systems

Another technique, which may be used to analyze polymorphisms, includes multicomponent integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions in a single functional device. An example of such technique is disclosed in US patent 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in chips.

Integrated systems can be envisaged mainly when microfluidic systems are used. These systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples are controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip. For genotyping biallelic markers, the microfluidic system may integrate nucleic acid amplification, microsequencing, capillary electrophoresis and a detection method such as laser-induced fluorescence detection.

Methods Of Genetic Analysis Using The Biallelic Markers Of The Present

Invention

Different methods are available for the genetic analysis of complex traits (see Lander and Schork, 1994). The search for disease-susceptibility genes is conducted using two main methods: the linkage approach in which evidence is sought for cosegregation between a locus and a putative trait locus using family studies, and the association approach in which evidence is sought for a statistically significant association between an allele and a trait or a trait causing allele (Khoury J. et al, 1993). In general, the biallelic markers of the present invention find use in any method known in the art to demonstrate a statistically significant correlation between a genotype and a phenotype. The biallelic markers may be used in parametric and non-parametric linkage analysis methods. Preferably, the biallelic markers of the present invention are used to identify genes associated with detectable traits using association studies, an approach which does not require the use of affected families and which permits the identification of genes associated with complex and sporadic traits.

The genetic analysis using the biallelic markers of the present invention may be conducted on any scale. The whole set of biallelic markers of the present invention or any subset of biallelic markers of the present invention may be used. In some embodiments a subset of biallelic markers corresponding to one or several candidate genes of the present invention may be used. Alternatively, a subset of biallelic markers of the present invention localised on a specific chromosome segment may be used. Further, any set of genetic markers including a

biallelic marker of the present invention may be used. As mentioned above, it should be noted that the biallelic markers of the present invention may be included in any complete or partial genetic map of the human genome. These different uses are specifically contemplated in the present invention and claims.

Linkage analysis

Linkage analysis is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. Thus, the aim of linkage analysis is to detect marker loci that show cosegregation with a trait of interest in pedigrees.

Parametric methods

When data are available from successive generations there is the opportunity to study the degree of linkage between pairs of loci. Estimates of the recombination fraction enable loci to be ordered and placed onto a genetic map. With loci that are genetic markers, a genetic map can be established, and then the strength of linkage between markers and traits can be calculated and used to indicate the relative positions of markers and genes affecting those traits (Weir, B.S., 1996). The classical method for linkage analysis is the logarithm of odds (lod) score method (see Morton N.E., 1955; Ott J, 1991). Calculation of lod scores requires specification of the mode of inheritance for the disease (parametric method). Generally, the length of the candidate region identified using linkage analysis is between 2 and 20Mb. Once a candidate region is identified as described above, analysis of recombinant individuals using additional markers allows further delineation of the candidate region. Linkage analysis studies have generally relied on the use of a maximum of 5,000 microsatellite markers, thus limiting the maximum theoretical attainable resolution of linkage analysis to about 600 kb on average.

Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance (i.e., the ratio between the number of trait positive carriers of allele a and the total number of a carriers in the population). However, parametric linkage analysis suffers from a variety of drawbacks. First, it is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, as already mentioned, the resolution attainable using linkage analysis is limited, and complementary studies are required to refine the analysis of the typical 2Mb to 20Mb regions initially identified through linkage analysis. In addition, parametric linkage analysis approaches have proven difficult when applied to complex genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. It is very difficult to model these factors adequately in a lod score analysis. In such cases, too large an effort and

cost are needed to recruit the adequate number of affected families required for applying linkage analysis to these situations, as recently discussed by Risch, N. and Merikangas, K. (1996).

Non-parametric methods

The advantage of the so-called non-parametric methods for linkage analysis is that they do not require specification of the mode of inheritance for the disease, they tend to be more useful for the analysis of complex traits. In non-parametric methods, one tries to prove that the inheritance pattern of a chromosomal region is not consistent with random Mendelian segregation by showing that affected relatives inherit identical copies of the region more often than expected by chance. Affected relatives should show excess "allele sharing" even in the presence of incomplete penetrance and polygenic inheritance. In non-parametric linkage analysis the degree of agreement at a marker locus in two individuals can be measured either by the number of alleles identical by state (IBS) or by the number of alleles identical by descent (IBD). Affected sib pair analysis is a well-known special case and is the simplest form of these methods.

The biallelic markers of the present invention may be used in both parametric and non-parametric linkage analysis. Preferably biallelic markers may be used in non-parametric methods which allow the mapping of genes involved in complex traits. The biallelic markers of the present invention may be used in both IBD- and IBS- methods to map genes affecting a complex trait. In such studies, taking advantage of the high density of biallelic markers, several adjacent biallelic marker loci may be pooled to achieve the efficiency attained by multi-allelic markers (Zhao et al., 1998).

However, both parametric and non-parametric linkage analysis methods analyse affected relatives, they tend to be of limited value in the genetic analysis of drug responses or in the analysis of side effects to treatments. This type of analysis is impractical in such cases due to the lack of availability of familial cases. In fact, the likelihood of having more than one individual in a family being exposed to the same drug at the same time is extremely low.

Population Association Studies

The present invention comprises methods for identifying one or several genes among a set of candidate genes that are associated with a detectable trait using the biallelic markers of the present invention. In one embodiment the present invention comprises methods to detect an association between a biallelic marker allele or a biallelic marker haplotype and a trait. Further, the invention comprises methods to identify a trait causing allele in linkage disequilibrium with any biallelic marker allele of the present invention.

As described above, alternative approaches can be employed to perform association studies: genome-wide association studies, candidate region association studies and candidate

gene association studies. The candidate region analysis clearly provides a short-cut approach to the identification of genes and gene polymorphisms related to a particular trait when some information concerning the biology of the trait is available. Further, the biallelic markers of the present invention may be incorporated in any map of genetic markers of the human genome in order to perform genome-wide association studies. Methods to generate a high-density map of biallelic markers has been described in US Provisional Patent application serial number 60/082,614. The biallelic markers of the present invention may further be incorporated in any map of a specific candidate region of the genome (a specific chromosome or a specific chromosomal segment for example).

As mentioned above, association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families. Association studies are extremely valuable as they permit the analysis of sporadic or multifactor traits. Moreover, association studies represent a powerful method for fine-scale mapping enabling much finer mapping of trait causing alleles than linkage studies. Studies based on pedigrees often only narrow the location of the trait causing allele. Association studies using the biallelic markers of the present invention can therefore be used to refine the location of a trait causing allele in a candidate region identified by Linkage Analysis methods. Biallelic markers of the present invention can be used to identify the involved gene; such uses are specifically contemplated in the present invention and claims.

1) Determining the frequency of a biallelic marker allele or of a biallelic marker haplotype in a population

Another embodiment of the present invention encompasses methods of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising the steps of: a) genotyping each individual in said population for at least one 13q31-q33-related biallelic marker, b) genotyping each individual in said population for a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome; and c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency. In addition, the methods of estimating the frequency of a haplotype of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: optionally said haplotype determination method is selected from the group consisting of asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark method, or an expectation maximization algorithm; optionally, said second biallelic marker is a 13q31-q33-related biallelic marker in a sequence selected from the group consisting of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229, and the

complements thereof; optionally, said 13q31-q33-related biallelic marker may be selected individually or in any combination from the biallelic markers described in Tables 6b and 6c; optionally, the identity of the nucleotides at the biallelic markers in everyone of the sequences of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229 is determined in steps a) and b).

5 **Association studies explore the relationships among frequencies for sets of alleles between loci.**

Determining the frequency of an allele in a population

Allelic frequencies of the biallelic markers in a population can be determined using one of the methods described above under the heading "Methods for genotyping an individual for biallelic markers", or any genotyping procedure suitable for this intended purpose. Genotyping 10 pooled samples or individual samples can determine the frequency of a biallelic marker allele in a population. One way to reduce the number of genotypings required is to use pooled samples. A major obstacle in using pooled samples is in terms of accuracy and reproducibility for determining accurate DNA concentrations in setting up the pools. Genotyping individual 15 samples provides higher sensitivity, reproducibility and accuracy and; is the preferred method used in the present invention. Preferably, each individual is genotyped separately and simple gene counting is applied to determine the frequency of an allele of a biallelic marker or of a genotype in a given population.

Determining the frequency of a haplotype in a population

20 The gametic phase of haplotypes is unknown when diploid individuals are heterozygous at more than one locus. Using genealogical information in families gametic phase can sometimes be inferred (Perlin et al., 1994). When no genealogical information is available, different strategies may be used. One possibility is that the multiple-site heterozygous diploids can be eliminated from the analysis, keeping only the homozygotes and the single-site 25 heterozygote individuals, but this approach might lead to a possible bias in the sample composition and the underestimation of low-frequency haplotypes. Another possibility is that single chromosomes can be studied independently, for example, by asymmetric PCR amplification (see Newton et al., 1989; Wu et al., 1989) or by isolation of single chromosome by limit dilution followed by PCR amplification (see Ruano et al., 1990). Further, a sample may 30 be haplotyped for sufficiently close biallelic markers by double PCR amplification of specific alleles (Sarkar, G. and Sommer S.S., 1991). These approaches are not entirely satisfying either because of their technical complexity, the additional cost they entail, their lack of generalisation at a large scale, or the possible biases they introduce. To overcome these difficulties, an algorithm to infer the phase of PCR-amplified DNA genotypes introduced by Clark A.G. (1990) 35 may be used. Briefly, the principle is to start filling a preliminary list of haplotypes present in

the sample by examining unambiguous individuals, that is, the complete homozygotes and the single-site heterozygotes. Then other individuals in the same sample are screened for the possible occurrence of previously recognised haplotypes. For each positive identification, the complementary haplotype is added to the list of recognised haplotypes, until the phase information for all individuals is either resolved or identified as unresolved. This method assigns a single haplotype to each multiheterozygous individual, whereas several haplotypes are possible when there are more than one heterozygous site. Alternatively, one can use methods estimating haplotype frequencies in a population without assigning haplotypes to each individual. Preferably, a method based on an expectation-maximization (EM) algorithm (Dempster et al., *J. R.* 1977) leading to maximum-likelihood estimates of haplotype frequencies under the assumption of Hardy-Weinberg proportions (random mating) is used (see Excoffier L. and Slatkin M., 1995). The EM algorithm is a generalised iterative maximum-likelihood approach to estimation that is useful when data are ambiguous and/or incomplete. The EM algorithm is used to resolve heterozygotes into haplotypes. Haplotype estimations are further described below under the heading "Statistical methods". Any other method known in the art to determine or to estimate the frequency of a haplotype in a population may also be used.

2) Linkage Disequilibrium analysis

Linkage disequilibrium is the non-random association of alleles at two or more loci and represents a powerful tool for mapping genes involved in disease traits (see Ajioka R.S. et al., 1997). Biallelic markers, because they are densely spaced in the human genome and can be genotyped in more numerous numbers than other types of genetic markers (such as RFLP or VNTR markers), are particularly useful in genetic analysis based on linkage disequilibrium. The biallelic markers of the present invention may be used in any linkage disequilibrium analysis method known in the art.

Briefly, when a disease mutation is first introduced into a population (by a new mutation or the immigration of a mutation carrier), it necessarily resides on a single chromosome and thus on a single "background" or "ancestral" haplotype of linked markers. Consequently, there is complete disequilibrium between these markers and the disease mutation: one finds the disease mutation only in the presence of a specific set of marker alleles. Through subsequent generations recombinations occur between the disease mutation and these marker polymorphisms, and the disequilibrium gradually dissipates. The pace of this dissipation is a function of the recombination frequency, so the markers closest to the disease gene will manifest higher levels of disequilibrium than those that are further away. When not broken up by recombination, "ancestral" haplotypes and linkage disequilibrium between marker alleles at different loci can be tracked not only through pedigrees but also through populations.

Linkage disequilibrium is usually seen as an association between one specific allele at one locus and another specific allele at a second locus.

The pattern or curve of disequilibrium between disease and marker loci is expected to exhibit a maximum that occurs at the disease locus. Consequently, the amount of linkage disequilibrium between a disease allele and closely linked genetic markers may yield valuable information regarding the location of the disease gene. For fine-scale mapping of a disease locus, it is useful to have some knowledge of the patterns of linkage disequilibrium that exist between markers in the studied region. As mentioned above the mapping resolution achieved through the analysis of linkage disequilibrium is much higher than that of linkage studies. The high density of biallelic markers combined with linkage disequilibrium analysis provides powerful tools for fine-scale mapping. Different methods to calculate linkage disequilibrium are described below under the heading "Statistical Methods".

3) Population-based case-control studies of trait-marker associations

As mentioned above, the occurrence of pairs of specific alleles at different loci on the same chromosome is not random and the deviation from random is called linkage disequilibrium. Association studies focus on population frequencies and rely on the phenomenon of linkage disequilibrium. If a specific allele in a given gene is directly involved in causing a particular trait, its frequency will be statistically increased in an affected (trait positive) population, when compared to the frequency in a trait negative population or in a random control population. As a consequence of the existence of linkage disequilibrium, the frequency of all other alleles present in the haplotype carrying the trait-causing allele will also be increased in trait positive individuals compared to trait negative individuals or random controls. Therefore, association between the trait and any allele (specifically a biallelic marker allele) in linkage disequilibrium with the trait-causing allele will suffice to suggest the presence of a trait-related gene in that particular region. Case-control populations can be genotyped for biallelic markers to identify associations that narrowly locate a trait causing allele. As any marker in linkage disequilibrium with one given marker associated with a trait will be associated with the trait. Linkage disequilibrium allows the relative frequencies in case-control populations of a limited number of genetic polymorphisms (specifically biallelic markers) to be analysed as an alternative to screening all possible functional polymorphisms in order to find trait-causing alleles. Association studies compare the frequency of marker alleles in unrelated case-control populations, and represent powerful tools for the dissection of complex traits.

Case-control populations (inclusion criteria)

Population-based association studies do not concern familial inheritance but compare the prevalence of a particular genetic marker, or a set of markers, in case-control populations.

They are case-control studies based on comparison of unrelated case (affected or trait positive) individuals and unrelated control (unaffected or trait negative or random) individuals.

Preferably the control group is composed of unaffected or trait negative individuals. Further, the control group is ethnically matched to the case population. Moreover, the control group is preferably matched to the case-population for the main known confusion factor for the trait under study (for example age-matched for an age-dependent trait). Ideally, individuals in the two samples are paired in such a way that they are expected to differ only in their disease status. In the following "trait positive population", "case population" and "affected population" are used interchangeably.

An important step in the dissection of complex traits using association studies is the choice of case-control populations (see Lander and Schork, 1994). A major step in the choice of case-control populations is the clinical definition of a given trait or phenotype. Any genetic trait may be analysed by the association method proposed here by carefully selecting the individuals to be included in the trait positive and trait negative phenotypic groups. Four criteria are often useful: clinical phenotype, age at onset, family history and severity. The selection procedure for continuous or quantitative traits (such as blood pressure for example) involves selecting individuals at opposite ends of the phenotype distribution of the trait under study, so as to include in these trait positive and trait negative populations individuals with non-overlapping phenotypes. Preferably, case-control populations comprise phenotypically homogeneous populations. Trait positive and trait negative populations comprise phenotypically uniform populations of individuals representing each between 1 and 98%, preferably between 1 and 80%, more preferably between 1 and 50%, and more preferably between 1 and 30%, most preferably between 1 and 20% of the total population under study, and selected among individuals exhibiting non-overlapping phenotypes. The clearer the difference between the two trait phenotypes, the greater the probability of detecting an association with biallelic markers. The selection of those drastically different but relatively uniform phenotypes enables efficient comparisons in association studies and the possible detection of marked differences at the genetic level, provided that the sample sizes of the populations under study are significant enough.

In preferred embodiments, a first group of between 50 and 300 trait positive individuals, preferably about 100 individuals, are recruited according to their phenotypes. A similar number of trait negative individuals are included in such studies.

In the present invention, typical examples of inclusion criteria include affection by schizophrenia.

Association analysis

The general strategy to perform association studies using biallelic markers derived from a region carrying a candidate gene is to scan two groups of individuals (case-control populations) in order to measure and statistically compare the allele frequencies of the biallelic markers of the present invention in both groups.

5 If a statistically significant association with a trait is identified for at least one or more of the analysed biallelic markers, one can assume that: either the associated allele is directly responsible for causing the trait (the associated allele is the trait causing allele), or more likely the associated allele is in linkage disequilibrium with the trait causing allele. The specific characteristics of the associated allele with respect to the gene function usually gives further
10 insight into the relationship between the associated allele and the trait (causal or in linkage disequilibrium). If the evidence indicates that the associated allele within the gene is most probably not the trait causing allele but is in linkage disequilibrium with the real trait causing allele, then the trait causing allele can be found by sequencing the vicinity of the associated marker.

15 Another embodiment of the present invention encompasses methods of detecting an association between a haplotype and a phenotype, comprising the steps of: a) estimating the frequency of at least one haplotype in a trait positive population according to a method of estimating the frequency of a haplotype of the invention; b) estimating the frequency of said haplotype in a control population according to the method of estimating the frequency of a
20 haplotype of the invention; and c) determining whether a statistically significant association exists between said haplotype and said phenotype. In addition, the methods of detecting an association between a haplotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: Optionally, said 13q31-q33-related biallelic marker may be in a sequence
25 selected individually or in any combination from the group consisting of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229, and the complements thereof; optionally, said 13q31-q33-related biallelic marker may be selected individually or in any combination from the biallelic markers described in Tables 6b and 6c; optionally, said control population may be a trait negative population, or a random population; optionally, said phenotype is a disease involving
30 schizophrenia, a response to an agent acting on schizophrenia, or a side effects to an agent acting on schizophrenia.

Haplotype analysis

As described above, when a chromosome carrying a disease allele first appears in a population as a result of either mutation or migration, the mutant allele necessarily resides on a
35 chromosome having a set of linked markers: the ancestral haplotype. This haplotype can be

tracked through populations and its statistical association with a given trait can be analysed. Complementing single point (allelic) association studies with multi-point association studies also called haplotype studies increases the statistical power of association studies. Thus, a haplotype association study allows one to define the frequency and the type of the ancestral carrier haplotype. A haplotype analysis is important in that it increases the statistical power of an analysis involving individual markers.

In a first stage of a haplotype frequency analysis, the frequency of the possible haplotypes based on various combinations of the identified biallelic markers of the invention is determined. The haplotype frequency is then compared for distinct populations of trait positive and control individuals. The number of trait positive individuals, which should be, subjected to this analysis to obtain statistically significant results usually ranges between 30 and 300, with a preferred number of individuals ranging between 50 and 150. The same considerations apply to the number of unaffected individuals (or random control) used in the study. The results of this first analysis provide haplotype frequencies in case-control populations, for each evaluated haplotype frequency a p-value and an odd ratio are calculated. If a statistically significant association is found the relative risk for an individual carrying the given haplotype of being affected with the trait under study can be approximated.

Interaction Analysis

The biallelic markers of the present invention may also be used to identify patterns of biallelic markers associated with detectable traits resulting from polygenic interactions. The analysis of genetic interaction between alleles at unlinked loci requires individual genotyping using the techniques described herein. The analysis of allelic interaction among a selected set of biallelic markers with appropriate level of statistical significance can be considered as a haplotype analysis. Interaction analysis comprises stratifying the case-control populations with respect to a given haplotype for the first loci and performing a haplotype analysis with the second loci with each subpopulation.

Statistical methods used in association studies are further described herein.

4) Testing for linkage in the presence of association

The biallelic markers of the present invention may further be used in TDT (transmission/disequilibrium test). TDT tests for both linkage and association and is not affected by population stratification. TDT requires data for affected individuals and their parents or data from unaffected sibs instead of from parents (see Spielmann S. et al., 1993; Schaid D.J. et al., 1996, Spielmann S. and Ewens W.J., 1998). Such combined tests generally reduce the false – positive errors produced by separate analyses.

Statistical methods

In general, any method known in the art to test whether a trait and a genotype show a statistically significant correlation may be used.

1) Methods in linkage analysis

Statistical methods and computer programs useful for linkage analysis are well-known to those skilled in the art (see Terwilliger J.D. and Ott J., 1994; Ott J., 1991).

2) Methods to estimate haplotype frequencies in a population

As described above, when genotypes are scored, it is often not possible to distinguish heterozygotes so that haplotype frequencies cannot be easily inferred. When the gametic phase is not known, haplotype frequencies can be estimated from the multilocus genotypic data. Any method known to person skilled in the art can be used to estimate haplotype frequencies (see Lange K., 1997; Weir, B.S., 1996) Preferably, maximum-likelihood haplotype frequencies are computed using an Expectation- Maximization (EM) algorithm (see Dempster et al., 1977; Excoffier L. and Slatkin M., 1995). This procedure is an iterative process aiming at obtaining maximum-likelihood estimates of haplotype frequencies from multi-locus genotype data when the gametic phase is unknown. Haplotype estimations are usually performed by applying the EM algorithm using for example the EM-HAPLO program (Hawley M.E. et al., 1994) or the Arlequin program (Schneider et al., 1997). The EM algorithm is a generalised iterative maximum likelihood approach to estimation and is briefly described below.

In the following part of this text, phenotypes will refer to multi-locus genotypes with unknown phase. Genotypes will refer to known-phase multi-locus genotypes. Suppose a sample of N unrelated individuals typed for K markers. The data observed are the unknown-phase K-locus phenotypes that can be categorised in F different phenotypes. Suppose that we have H underlying possible haplotypes (in case of K biallelic markers, $H=2^K$).

For phenotype j, suppose that c_j genotypes are possible. We thus have the following equation

$$P_j = \sum_{i=1}^{c_j} pr(genotype_i) = \sum_{i=1}^{c_j} pr(h_k, h_l) \quad \text{Equation 1}$$

where P_j is the probability of the phenotype j, h_k and h_l are the two haplotypes constituent the genotype i. Under the Hardy-Weinberg equilibrium, $pr(h_k, h_l)$ becomes :

$$pr(h_k, h_l) = pr(h_k)^2 \text{ if } h_k = h_l, pr(h_k, h_l) = 2 pr(h_k).pr(h_l) \text{ if } h_k \neq h_l. \quad \text{Equation 2}$$

The successive steps of the E-M algorithm can be described as follows:

Starting with initial values of the of haplotypes frequencies, noted $p_1^{(0)}, p_2^{(0)}, \dots, p_H^{(0)}$, these initial values serve to estimate the genotype frequencies (Expectation step) and then

estimate another set of haplotype frequencies (Maximisation step), noted $p_1^{(1)}, p_2^{(1)}, \dots, p_H^{(1)}$, these two steps are iterated until changes in the sets of haplotypes frequency are very small.

A stop criterion can be that the maximum difference between haplotype frequencies between two iterations is less than 10^{-7} . These values can be adjusted according to the desired precision of estimations. In details, at a given iteration s , the Expectation step comprises calculating the genotypes frequencies by the following equation:

$$\begin{aligned} pr(genotype_i)^{(s)} &= pr(phenotype_j) \cdot pr(genotype_i | phenotype_j)^{(s)} \\ &= \frac{n_j}{N} \cdot \frac{pr(h_k, h_l)^{(s)}}{P_j^{(s)}} \end{aligned} \quad \text{Equation 3}$$

where genotype i occurs in phenotype j , and where h_k and h_l constitute genotype i . Each probability is derived according to eq.1, and eq.2 described above.

Then the Maximisation step simply estimates another set of haplotype frequencies given the genotypes frequencies. This approach is also known as gene-counting method (Smith, 1957).

$$p_i^{(s+1)} = \frac{1}{2} \sum_{j=1}^F \sum_{i=1}^{c_j} \delta_{it} \cdot pr(genotype_i)^{(s)} \quad \text{Equation 4}$$

Where δ_{it} is an indicator variable which count the number of time haplotype t in genotype i . It takes the values of 0, 1 or 2.

To ensure that the estimation finally obtained is the maximum-likelihood estimation several values of departures are required. The estimations obtained are compared and if they are different the estimations leading to the best likelihood are kept.

3) Methods to calculate linkage disequilibrium between markers

A number of methods can be used to calculate linkage disequilibrium between any two genetic positions, in practice linkage disequilibrium is measured by applying a statistical association test to haplotype data taken from a population. Linkage disequilibrium between any pair of biallelic markers comprising at least one of the biallelic markers of the present invention (M_i, M_j) having alleles (a_i/b_i) at marker M_i and alleles (a_j/b_j) at marker M_j can be calculated for every allele combination ($a_i, a_j; a_i, b_j; b_i, a_j$ and b_i, b_j), according to the Piazza formula :

$$\Delta_{aiaj} = \sqrt{\theta_4} - \sqrt{(\theta_4 + \theta_3)(\theta_4 + \theta_2)}, \text{ where :}$$

$\theta_4 = - -$ = frequency of genotypes not having allele a_i at M_i and not having allele a_j at M_j

$\theta_3 = - +$ = frequency of genotypes not having allele a_i at M_i and having allele a_j at M_j

$\theta_2 = + -$ = frequency of genotypes having allele a_i at M_i and not having allele a_j at M_j

Linkage disequilibrium (LD) between pairs of biallelic markers (M_i, M_j) can also be calculated for every allele combination ($a_i, a_j, a_i, b_j, b_i, a_j$ and b_i, b_j), according to the maximum-likelihood estimate (MLE) for delta (the composite genotypic disequilibrium coefficient), as described by Weir (Weir B.S., 1996). The MLE for the composite linkage disequilibrium is:

$$D_{aiaj} = (2n_1 + n_2 + n_3 + n_4/2)/N - 2(\text{pr}(a_i).\text{pr}(a_j))$$

where $n_1 = \Sigma \text{phenotype } (a_i/a_i, a_j/a_j)$, $n_2 = \Sigma \text{phenotype } (a_i/a_i, a_j/b_j)$, $n_3 = \Sigma \text{phenotype } (a_i/b_i, a_j/a_j)$, $n_4 = \Sigma \text{phenotype } (a_i/b_i, a_j/b_j)$ and N is the number of individuals in the sample. This formula allows linkage disequilibrium between alleles to be estimated when only genotype, and not haplotype, data are available.

Another means of calculating the linkage disequilibrium between markers is as follows. For a couple of biallelic markers, $M_i (a/b_i)$ and $M_j (a/b_j)$, fitting the Hardy-Weinberg equilibrium, one can estimate the four possible haplotype frequencies in a given population according to the approach described above.

The estimation of gametic disequilibrium between a_i and a_j is simply:

$$D_{aiaj} = \text{pr}(\text{haplotype}(a_i, a_j)) - \text{pr}(a_i).\text{pr}(a_j).$$

Where $\text{pr}(a_i)$ is the probability of allele a_i and $\text{pr}(a_j)$ is the probability of allele a_j and where $\text{pr}(\text{haplotype}(a_i, a_j))$ is estimated as in Equation 3 above.

For a couple of biallelic marker only one measure of disequilibrium is necessary to describe the association between M_i and M_j .

Then a normalised value of the above is calculated as follows:

$$D'_{aiaj} = D_{aiaj} / \max (-\text{pr}(a_i).\text{pr}(a_j), -\text{pr}(b_i).\text{pr}(b_j)) \text{ with } D_{aiaj} < 0$$

$$D'_{aiaj} = D_{aiaj} / \max (\text{pr}(b_i).\text{pr}(a_j), \text{pr}(a_i).\text{pr}(b_j)) \text{ with } D_{aiaj} > 0$$

The skilled person will readily appreciate that other LD calculation methods can be used without undue experimentation.

Linkage disequilibrium among a set of biallelic markers having an adequate heterozygosity rate can be determined by genotyping between 50 and 1000 unrelated individuals, preferably between 75 and 200, more preferably around 100.

4) Testing for association

Methods for determining the statistical significance of a correlation between a phenotype and a genotype, in this case an allele at a biallelic marker or a haplotype made up of such alleles, may be determined by any statistical test known in the art and with any accepted threshold of statistical significance being required. The application of particular methods and thresholds of significance are well within the skill of the ordinary practitioner of the art.

Testing for association is performed by determining the frequency of a biallelic marker allele in case and control populations and comparing these frequencies with a statistical test to

determine if there is a statistically significant difference in frequency which would indicate a correlation between the trait and the biallelic marker allele under study. Similarly, a haplotype analysis is performed by estimating the frequencies of all possible haplotypes for a given set of biallelic markers in case and control populations, and comparing these frequencies with a statistical test to determine if there is a statistically significant correlation between the haplotype and the phenotype (trait) under study. Any statistical tool useful to test for a statistically significant association between a genotype and a phenotype may be used. Preferably the statistical test employed is a chi-square test with one degree of freedom. A P-value is calculated (the P-value is the probability that a statistic as large or larger than the observed one would occur by chance).

Statistical significance

In preferred embodiments, significance for diagnosis purposes, either as a positive basis for further diagnostic tests or as a preliminary starting point for early preventive therapy, the p value related to a biallelic marker association is preferably about 1×10^{-2} or less, more preferably about 1×10^{-4} or less, for a single biallelic marker analysis and about 1×10^{-3} or less, still more preferably 1×10^{-6} or less and most preferably of about 1×10^{-8} or less, for a haplotype analysis involving several markers. These values are believed to be applicable to any association studies involving single or multiple marker combinations.

The skilled person can use the range of values set forth above as a starting point in order to carry out association studies with biallelic markers of the present invention. In doing so, significant associations between the biallelic markers of the present invention and diseases involving schizophrenia can be revealed and used for diagnosis and drug screening purposes.

Phenotypic permutation

In order to confirm the statistical significance of the first stage haplotype analysis described above, it might be suitable to perform further analyses in which genotyping data from case-control individuals are pooled and randomised with respect to the trait phenotype. Each individual genotyping data is randomly allocated to two groups, which contain the same number of individuals as the case-control populations used to compile the data obtained in the first stage. A second stage haplotype analysis is preferably run on these artificial groups, preferably for the markers included in the haplotype of the first stage analysis showing the highest relative risk coefficient. This experiment is reiterated preferably at least between 100 and 10000 times. The repeated iterations allow the determination of the percentage of obtained haplotypes with a significant p-value level.

Assessment of statistical association

To address the problem of false positives similar analysis may be performed with the same case-control populations in random genomic regions. Results in random regions and the candidate region are compared as described in US Provisional Patent Application entitled "Methods, software and apparatus for identifying genomic regions harbouring a gene associated with a detectable trait".

5) Evaluation of risk factors

The association between a risk factor (in genetic epidemiology the risk factor is the presence or the absence of a certain allele or haplotype at marker loci) and a disease is measured by the odds ratio (OR) and by the relative risk (RR). If $P(R^+)$ is the probability of developing the disease for individuals with R and $P(R^-)$ is the probability for individuals without the risk factor, then the relative risk is simply the ratio of the two probabilities, that is:

$$RR = P(R^+)/P(R^-)$$

In case-control studies, direct measures of the relative risk cannot be obtained because of the sampling design. However, the odds ratio allows a good approximation of the relative risk for low-incidence diseases and can be calculated:

$$OR = \left[\frac{F^+}{1 - F^+} \right] / \left[\frac{F^-}{(1 - F^-)} \right]$$

F^+ is the frequency of the exposure to the risk factor in cases and F^- is the frequency of the exposure to the risk factor in controls. F^+ and F^- are calculated using the allelic or haplotype frequencies of the study and further depend on the underlying genetic model (dominant, recessive, additive...).

One can further estimate the attributable risk (AR) which describes the proportion of individuals in a population exhibiting a trait due to a given risk factor. This measure is important in quantitating the role of a specific factor in disease etiology and in terms of the public health impact of a risk factor. The public health relevance of this measure lies in estimating the proportion of cases of disease in the population that could be prevented if the exposure of interest were absent. AR is determined as follows:

$$AR = P_E (RR-1) / (P_E (RR-1)+1)$$

AR is the risk attributable to a biallelic marker allele or a biallelic marker haplotype. P_E is the frequency of exposure to an allele or a haplotype within the population at large; and RR is the relative risk which, is approximated with the odds ratio when the trait under study has a relatively low incidence in the general population.

AR is the risk attributable to a biallelic marker allele or a biallelic marker haplotype. P_E is the frequency of exposure to an allele or a haplotype within the population at large; and

RR is the relative risk which, is approximated with the odds ratio when the trait under study has a relatively low incidence in the general population.

Association of Biallelic Markers of the Invention with Schizophrenia

5 In the context of the present invention, an association between chromosome 13q31-q33-related biallelic markers, including Region D biallelic markers, and schizophrenia and bipolar disorder were established. Several association studies using different populations and screening samples thereof, and with different sets of biallelic markers distributed on the chromosome 13q31-q33 region and Region D thereof were carried out. Further details concerning these
10 association studies and the results are provided herein in Examples 5a to 5e.

This information is extremely valuable. The knowledge of a potential genetic predisposition to schizophrenia, even if this predisposition is not absolute, might contribute in a very significant manner to treatment efficacy of schizophrenia and to the development of new
15 therapeutic and diagnostic tools.

Identification Of Biallelic Markers In Linkage Disequilibrium With The Biallelic Markers of the Invention

Once a first biallelic marker has been identified in a genomic region of interest, the practitioner of ordinary skill in the art, using the teachings of the present invention, can easily
20 identify additional biallelic markers in linkage disequilibrium with this first marker. As mentioned before, any marker in linkage disequilibrium with a first marker associated with a trait will be associated with the trait. Therefore, once an association has been demonstrated between a given biallelic marker and a trait, the discovery of additional biallelic markers associated with this trait is of great interest in order to increase the density of biallelic markers
25 in this particular region. The causal gene or mutation will be found in the vicinity of the marker or set of markers showing the highest correlation with the trait.

Identification of additional markers in linkage disequilibrium with a given marker involves: (a) amplifying a genomic fragment comprising a first biallelic marker from a plurality of individuals; (b) identifying of second biallelic markers in the genomic region harboring said
30 first biallelic marker; (c) conducting a linkage disequilibrium analysis between said first biallelic marker and second biallelic markers; and (d) selecting said second biallelic markers as being in linkage disequilibrium with said first marker. Subcombinations comprising steps (b) and (c) are also contemplated.

35 Methods to identify biallelic markers and to conduct linkage disequilibrium analysis are described herein and can be carried out by the skilled person without undue experimentation.

The present invention then also concerns biallelic markers and other polymorphisms which are in linkage disequilibrium with the specific biallelic markers of the invention and which are expected to present similar characteristics in terms of their respective association with a given trait. In a preferred embodiment, the invention concerns biallelic markers which are in linkage disequilibrium with the specific biallelic markers.

Identification Of Functional Mutations

Once a positive association is confirmed with a biallelic marker of the present invention, the associated candidate gene sequence can be scanned for mutations by comparing the sequences of a selected number of trait positive and trait negative individuals. In a preferred embodiment, functional regions such as exons and splice sites, promoters and other regulatory regions of the gene are scanned for mutations. Preferably, trait positive individuals carry the haplotype shown to be associated with the trait and trait negative individuals do not carry the haplotype or allele associated with the trait. The mutation detection procedure is essentially similar to that used for biallelic site identification.

The method used to detect such mutations generally comprises the following steps: (a) amplification of a region of the candidate DNA sequence comprising a biallelic marker or a group of biallelic markers associated with the trait from DNA samples of trait positive patients and trait negative controls; (b) sequencing of the amplified region; (c) comparison of DNA sequences from trait-positive patients and trait-negative controls; and (d) determination of mutations specific to trait-positive patients. Subcombinations which comprise steps (b) and (c) are specifically contemplated.

It is preferred that candidate polymorphisms be then verified by screening a larger population of cases and controls by means of any genotyping procedure such as those described herein, preferably using a microsequencing technique in an individual test format. Polymorphisms are considered as candidate mutations when present in cases and controls at frequencies compatible with the expected association results.

Candidate polymorphisms and mutations of the sbg1 nucleic acid sequences suspected of being involved in a predisposition to schizophrenia can be confirmed by screening a larger population of affected and unaffected individuals using any of the genotyping procedures described herein. Preferably the microsequencing technique is used. Such polymorphisms are considered as candidate "trait-causing" mutations when they exhibit a statistically significant correlation with the detectable phenotype.

Biallelic Markers Of The Invention In Methods Of Genetic Diagnostics

The biallelic markers and other polymorphisms of the present invention can also be used to develop diagnostics tests capable of identifying individuals who express a detectable trait as the result of a specific genotype or individuals whose genotype places them at risk of developing a detectable trait at a subsequent time. The trait analyzed using the present
5 diagnostics may be any detectable trait, including predisposition to schizophrenia, age of onset of detectable symptoms, a beneficial response to or side effects related to treatment against schizophrenia. Such a diagnosis can be useful in the monitoring, prognosis and/or prophylactic or curative therapy for schizophrenia.

The diagnostic techniques of the present invention may employ a variety of
10 methodologies to determine whether a test subject has a genotype associated with an increased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular mutation, including methods which enable the analysis of individual chromosomes for haplotyping, such as family studies, single sperm DNA analysis or somatic hybrids.

The diagnostic techniques concern the detection of specific alleles present within the
15 human chromosome 13q31-q33 region; optionally within the Region D subregion; and optionally within an sbg1, g34665, sbg2, g35017 or g35018 nucleic acid sequence. More particularly, the invention concerns the detection of a nucleic acid comprising at least one of the nucleotide sequences of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or a fragment thereof or a
20 complementary sequence thereto including the polymorphic base.

These methods involve obtaining a nucleic acid sample from the individual and, determining, whether the nucleic acid sample contains at least one allele or at least one biallelic marker haplotype, indicative of a risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular the human chromosome 13q31-q33
25 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related polymorphism or mutation (trait-causing allele).

Preferably, in such diagnostic methods, a nucleic acid sample is obtained from the individual and this sample is genotyped using methods described above in "Methods Of Genotyping DNA Samples For Biallelic markers." The diagnostics may be based on a single
30 biallelic marker or a on group of biallelic markers.

In each of these methods, a nucleic acid sample is obtained from the test subject and the biallelic marker pattern of one or more of the biallelic markers of the invention is determined.

In one embodiment, a PCR amplification is conducted on the nucleic acid sample to amplify regions in which polymorphisms associated with a detectable phenotype have been
35 identified. The amplification products are sequenced to determine whether the individual

possesses one or more human chromosome 13q31-q33 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related polymorphisms associated with a detectable phenotype. The primers used to generate amplification products may comprise the primers listed in Table 6a.

Alternatively, the nucleic acid sample is subjected to microsequencing reactions as described
5 above to determine whether the individual possesses one or more human chromosome 13q31-q33 region-related polymorphisms associated with a detectable phenotype resulting from a mutation or a polymorphism in the human chromosome 13q31-q33 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related biallelic marker. The primers used in the microsequencing reactions may include the primers listed in 6d. In another embodiment, the
10 nucleic acid sample is contacted with one or more allele specific oligonucleotide probes which, specifically hybridize to one or more human chromosome 13q31-q33 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related alleles associated with a detectable phenotype. The probes used in the hybridization assay may include the probes listed in Table 6c. In another embodiment, the nucleic acid sample is contacted with a second oligonucleotide capable of
15 producing an amplification product when used with the allele specific oligonucleotide in an amplification reaction. The presence of an amplification product in the amplification reaction indicates that the individual possesses one or more human chromosome 13q31-q33 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related alleles associated with a detectable phenotype.

20 In a preferred embodiment the identity of the nucleotide present at, at least one, biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232, A328 to A360 and A361 to A489 and the complements thereof, is determined and the detectable trait is schizophrenia. Diagnostic kits
25 comprise any of the polynucleotides of the present invention.

These diagnostic methods are extremely valuable as they can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms.

Diagnostics, which analyze and predict response to a drug or side effects to a drug, may
30 be used to determine whether an individual should be treated with a particular drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug may be administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may
35 be defined as either the absence of an efficacious response or the presence of toxic side effects.

Clinical drug trials represent another application for the markers of the present invention. One or more markers indicative of response to an agent acting against schizophrenia or to side effects to an agent acting against schizophrenia may be identified using the methods described above. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

PREVENTION, DIAGNOSIS AND TREATMENT OF PSYCHIATRIC DISEASE

An aspect of the present invention relates to the preparation of a medicament for the treatment of psychiatric disease, in particular schizophrenia and bipolar disorder. The present invention embodies medicaments acting on sbg1, g34665, sbg2, g35017 or g35018.

In preferred embodiments, medicaments of the invention act on sbg1, either directly or indirectly, by acting on the sbg1 pathways. For example, the medicaments may modulate, and more preferably decrease the level of sbg1 activity which occurs in a cell or particular tissue, or increase or decrease the activity of the sbg1 protein. In certain embodiments, the invention thus comprises use of a compound capable of increasing or decreasing sbg1 expression or sbg1 protein activity in the preparation or manufacture of a medicament. Preferably, said compound is used for the treatment of a psychiatric disease, preferably for the treatment of schizophrenia or bipolar disorder. Preferably, said compound acts directly by binding to sbg1 or an sbg1 receptor.

Such medicaments may also increase or decrease the activity of a compound analogous to sbg1, a compound comprising an amino acid sequence having at least 25% homology to a sequence selected from the group consisting of SEQ ID NOs. 27 to 35, a compound comprising an amino acid sequence having at least 50% homology to a sequence selected from the group consisting of SEQ ID NOs. 27 to 35, and a compound comprising an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of SEQ ID NOs. 27 to 35.

Medicaments which increase or decrease the activity of these compounds in an individual may be used to ameliorate or prevent symptoms in individuals suffering from or predisposed to a psychiatric disease, as discussed above in the section entitled "indications".

Alternatively, sbg1 activity may be increased or decreasing by the expression of the genes encoding the identified sbg1-modulating compounds using gene therapy. Examples of vectors and promoters suitable for use in gene therapy are described above. Sbg1 activity may also be

increased or decreased by preparing an antibody which binds to an sbg1 peptide, an sbg1 receptor or a protein related thereto, as well as fragments of these proteins. Such antibodies may modulate the interaction between sbg1 and an sbg1 receptor or a protein related thereto. Antibodies and methods of obtaining them are further described herein.

5 As described above, the present invention provides cellular assays for identifying compounds for the treatment of psychiatric disease. The assays are based on detection of sbg1 expression, measurement of sbg1 protein activity, or based on the determination of other suitable schizophrenia, bipolar disorder or related psychiatric disease endpoints. Compounds for the treatment of psychiatric disease include derivative proteins or peptides which are capable of
10 inhibiting the activity of a wild type sbg1 protein, which may be identified by determining their ability to bind a wild type sbg1 protein. Compounds also include antibodies, and small molecules and drugs which may be obtained using a variety of synthetic approaches familiar to those skilled in the art, including combinatorial chemistry based techniques.

The invention further encompasses said methods for the prevention, treatment, and
15 diagnosis of disease using any of the g34665, sbg2, g35017 or g35018 nucleic acids of proteins of the invention in analogous methods.

Sbg1 in Methods of Diagnosis or Detecting Predisposition

Individuals affected by or predisposed to schizophrenia and bipolar disorder may express abnormal levels of sbg1, g34665, sbg2, g35017 or g35018. Individuals having increased or
20 decreased sbg1, g34665, sbg2, g35017 or g35018 activity in their plasma, body fluids, or body tissues may be at risk of developing schizophrenia, bipolar disorder or a variety of potentially related psychiatric conditions. In one aspect of the present invention is a method for determining whether an individual is at risk of suffering from or is currently suffering from schizophrenia, bipolar disorder or other psychotic disorders, mood disorders, autism, substance dependence or
25 alcoholism, mental retardation, or other psychiatric diseases including cognitive, anxiety, eating, impulse-control, and personality disorders, as defined with the Diagnosis and Statistical Manual of Mental Disorders fourth edition (DSM-IV) classification, comprising determining whether the individual has an abnormal level of sbg1 activity in plasma, body fluids, or body tissues. The level of sbg1 or analogous compounds in plasma, body fluids, or body tissues may be determined using
30 a variety approaches. In particular, the level may be determined using ELISA, Western Blots, or protein electrophoresis.

Biallelic Markers Of The Invention In Methods Of Genetic Diagnostics

The biallelic markers and other polymorphisms of the present invention can also be used to develop diagnostics tests capable of identifying individuals who express a detectable
35 trait as the result of a specific genotype or individuals whose genotype places them at risk of

developing a detectable trait at a subsequent time. The trait analyzed using the present diagnostics may be used to diagnose any detectable trait, including predisposition to schizophrenia or bipolar disorder, age of onset of detectable symptoms, a beneficial response to or side effects related to treatment against schizophrenia or bipolar disorder. Such a diagnosis
5 can be useful in the monitoring, prognosis and/or prophylactic or curative therapy for schizophrenia or bipolar disorder.

The diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a genotype associated with an increased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a
10 result of a particular mutation, including methods which enable the analysis of individual chromosomes for haplotyping, such as family studies, single sperm DNA analysis or somatic hybrids.

The diagnostic techniques concern the detection of specific alleles present within the human chromosome 13q31-q33 region; optionally within the Region D subregion; and
15 optionally within an sbg1, g34665, sbg2, g35017 or g35018 nucleic acid sequence. More particularly, the invention concerns the detection of a nucleic acid comprising at least one of the nucleotide sequences of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or a fragment thereof or a complementary sequence thereto including the polymorphic base.

These methods involve obtaining a nucleic acid sample from the individual and,
20 determining, whether the nucleic acid sample contains at least one allele or at least one biallelic marker haplotype, indicative of a risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular the human chromosome 13q31-q33 region-related polymorphism or mutation (trait-causing allele).

Preferably, in such diagnostic methods, a nucleic acid sample is obtained from the
25 individual and this sample is genotyped using methods described above in "Methods Of Genotyping DNA Samples For Biallelic markers." The diagnostics may be based on a single biallelic marker or a on group of biallelic markers.

In each of these methods, a nucleic acid sample is obtained from the test subject and the biallelic marker pattern of one or more of a biallelic marker of the invention is determined.

30 In one embodiment, a PCR amplification is conducted on the nucleic acid sample to amplify regions in which polymorphisms associated with a detectable phenotype have been identified. The amplification products are sequenced to determine whether the individual possesses one or more human chromosome 13q31-q33 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related polymorphisms associated with a detectable phenotype. The primers
35 used to generate amplification products may comprise the primers listed in Table 6a.

Alternatively, the nucleic acid sample is subjected to microsequencing reactions as described above to determine whether the individual possesses one or more human chromosome 13q31-q33 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related polymorphisms associated with a detectable phenotype resulting from a mutation or a polymorphism in the human chromosome 13q31-q33 region. The primers used in the microsequencing reactions may include the primers listed in Table 6d. In another embodiment, the nucleic acid sample is contacted with one or more allele specific oligonucleotide probes which, specifically hybridize to one or more human chromosome 13q31-q33 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related alleles associated with a detectable phenotype. The probes used in the hybridization assay may include the probes listed in 6b. In another embodiment, the nucleic acid sample is contacted with a second oligonucleotide capable of producing an amplification product when used with the allele specific oligonucleotide in an amplification reaction. The presence of an amplification product in the amplification reaction indicates that the individual possesses one or more human chromosome 13q31-q33 region, Region D, sbg1, g34665, sbg2, g35017 or g35018-related alleles associated with a detectable phenotype. In a preferred embodiment, the detectable trait is schizophrenia or bipolar disorder. Diagnostic kits comprise any of the polynucleotides of the present invention.

These diagnostic methods are extremely valuable as they can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms.

Diagnostics, which analyze and predict response to a drug or side effects to a drug, may be used to determine whether an individual should be treated with a particular drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug may be administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects.

Clinical drug trials represent another application for the markers of the present invention. One or more markers indicative of response to an agent acting against schizophrenia or to side effects to an agent acting against schizophrenia may be identified using the methods described above. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and

without risking undesirable safety problems.

Prevention And Treatment Of Disease Using Biallelic Markers

In large part because of the risk of suicide, the detection of susceptibility to schizophrenia, bipolar disorder as well as other psychiatric disease in individuals is very important. Consequently, the invention concerns a method for the treatment of schizophrenia or bipolar disorder, or a related disorder comprising the following steps:

- selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, preferably Region D-related markers, and more preferably sbg1, g34665, sbg2, g35017 or g35018-related markers associated with schizophrenia or bipolar disorder;
- following up said individual for the appearance (and optionally the development) of the symptoms related to schizophrenia or bipolar disorder; and
- administering a treatment acting against schizophrenia or bipolar disorder or against symptoms thereof to said individual at an appropriate stage of the disease.

Another embodiment of the present invention comprises a method for the treatment of schizophrenia or bipolar disorder comprising the following steps:

- selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers, of the human chromosome 13q31-q33 region, preferably Region D-related markers, and more preferably sbg1, g34665, sbg2, g35017 or g35018-related markers associated with schizophrenia or bipolar disorder;
- administering a preventive treatment of schizophrenia or bipolar disorder to said individual.

In a further embodiment, the present invention concerns a method for the treatment of schizophrenia or bipolar disorder comprising the following steps:

- selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33, preferably Region D-related markers, and more preferably sbg1, g34665, sbg2, g35017 or g35018-related markers associated with schizophrenia or bipolar disorder;

- administering a preventive treatment of schizophrenia or bipolar disorder to said individual;

- following up said individual for the appearance and the development of schizophrenia or bipolar disorder symptoms; and optionally

- administering a treatment acting against schizophrenia or bipolar disorder or against symptoms thereof to said individual at the appropriate stage of the disease.

For use in the determination of the course of treatment of an individual suffering from disease, the present invention also concerns a method for the treatment of schizophrenia or

bipolar disorder comprising the following steps:

- selecting an individual suffering from schizophrenia or bipolar disorder whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, preferably Region D-related markers, and preferably sbg1, g34665, sbg2, g35017 or g35018-related markers, associated with the gravity of schizophrenia or bipolar disorder or of the symptoms thereof; and
- administering a treatment acting against schizophrenia or bipolar disorder or symptoms thereof to said individual.

The invention also concerns a method for the treatment of schizophrenia or bipolar disorder in a selected population of individuals. The method comprises:

- selecting an individual suffering from schizophrenia or bipolar disorder and whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, preferably Region D-related markers, and more preferably sbg1, g34665, sbg2, g35017 or g35018-related markers associated with a positive response to treatment with an effective amount of a medicament acting against schizophrenia or bipolar disorder or symptoms thereof,
- and/or whose DNA does not comprise alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, preferably Region D-related markers, and more preferably sbg1, g34665, sbg2, g35017 or g35018-related markers associated with a negative response to treatment with said medicament; and
- administering at suitable intervals an effective amount of said medicament to said selected individual.

In the context of the present invention, a "positive response" to a medicament can be defined as comprising a reduction of the symptoms related to the disease. In the context of the present invention, a "negative response" to a medicament can be defined as comprising either a lack of positive response to the medicament which does not lead to a symptom reduction or which leads to a side-effect observed following administration of the medicament.

The invention also relates to a method of determining whether a subject is likely to respond positively to treatment with a medicament. The method comprises identifying a first population of individuals who respond positively to said medicament and a second population of individuals who respond negatively to said medicament. One or more biallelic markers is identified in the first population which is associated with a positive response to said medicament or one or more biallelic markers is identified in the second population which is associated with a negative response to said medicament. The biallelic markers may be identified using the techniques described herein.

A DNA sample is then obtained from the subject to be tested. The DNA sample is analyzed to determine whether it comprises alleles of one or more biallelic markers associated with a positive response to treatment with the medicament and/or alleles of one or more biallelic markers associated with a negative response to treatment with the medicament.

5 In some embodiments, the medicament may be administered to the subject in a clinical trial if the DNA sample contains alleles of one or more biallelic markers associated with a positive response to treatment with the medicament and/or if the DNA sample lacks alleles of one or more biallelic markers associated with a negative response to treatment with the medicament. In preferred embodiments, the medicament is a drug acting against schizophrenia or bipolar disorder.

10 Using the method of the present invention, the evaluation of drug efficacy may be conducted in a population of individuals likely to respond favorably to the medicament.

Another aspect of the invention is a method of using a medicament comprising obtaining a DNA sample from a subject, determining whether the DNA sample contains alleles of one or more biallelic markers associated with a positive response to the medicament and/or whether the DNA sample contains alleles of one or more biallelic markers associated with a negative response to the medicament, and administering the medicament to the subject if the DNA sample contains alleles of one or more biallelic markers associated with a positive response to the medicament and/or if the DNA sample lacks alleles of one or more biallelic markers associated with a negative response to the medicament.

20 The invention also concerns a method for the clinical testing of a medicament, preferably a medicament acting against schizophrenia or or bipolar disorder or symptoms thereof. The method comprises the following steps:

25 - administering a medicament, preferably a medicament susceptible of acting against schizophrenia or or bipolar disorder or symptoms thereof to a heterogeneous population of individuals,

- identifying a first population of individuals who respond positively to said medicament and a second population of individuals who respond negatively to said medicament,

30 - identifying biallelic markers in said first population which are associated with a positive response to said medicament,

- selecting individuals whose DNA comprises biallelic markers associated with a positive response to said medicament, and

- administering said medicament to said individuals.

35 In any of the methods for the prevention, diagnosis and treatment of schizophrenia and

bipolar disorder, including methods of using a medicament, clinical testing of a medicament, determining whether a subject is likely to respond positively to treatment with a medicament, said biallelic marker may optionally comprise:

(a) a biallelic marker selected from the group consisting of biallelic markers A1 to A489;

(b) a biallelic marker selected from the group consisting of biallelic markers A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242, A250 to A251, A259, A269 to A270, A278, A285 to A295, A303 to A307, A330, A334 to A335 and A346 to 357;

(c) a biallelic marker selected from the group consisting of biallelic markers A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489;

(d) a biallelic marker selected from the group consisting of sbg1-related markers A85 to A219, or more preferably a biallelic marker selected from the group consisting of sbg1-related markers A85 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197 and A199 to A219;

(e) a biallelic marker selected from the group consisting of g34665-related markers A230 to A236;

(f) a biallelic marker selected from the group consisting of sbg2-related markers A79 to A99;

(g) the g35017-related biallelic marker A41;

(h) a biallelic marker selected from the group consisting of g35018-related markers A1 to A39;

(i) a biallelic marker selected from the group consisting of A239, A227, A198, A228, A223, A107, A218, A270, A75, A62, A65 and A70;

(j) a biallelic marker selected from the group consisting of A48, A60, A61, A62, A65, A70, A75, A76, A80, A107, A108, A198, A218, A221, A223, A227, A228, A239, A285, A286, A287, A288, A290, A292, A293, A295, A299 and A304;

(k) a biallelic marker selected from the group consisting of A304, A307, A305, A298, A292, A293, A291, A287, A286, A288, A289, A290, 99- A295 A299. A241, A239, A228, A227, A223, A221, A218, A198, A178, 99-24649/186 A108, A107, A80, A75, A70, A65, and A62; and/or

(l) a biallelic marker selected from the group consisting of A304, A307, A305, A298, A292, A293, A291, A287, A286, A288, A289, A290, A295 A299, A241, A239, A228, A227,

A223, A221, A218, A198, A178, A108, A107, A80, A76, A75, A70, A65, A62, A61, A60 A48.

5 Such methods are deemed to be extremely useful to increase the benefit/risk ratio resulting from the administration of medicaments which may cause undesirable side effects and/or be inefficacious to a portion of the patient population to which it is normally administered.

10 Once an individual has been diagnosed as suffering from schizophrenia or bipolar disorder, selection tests are carried out to determine whether the DNA of this individual comprises alleles of a biallelic marker or of a group of biallelic markers associated with a positive response to treatment or with a negative response to treatment which may include either side effects or unresponsiveness.

15 The selection of the patient to be treated using the method of the present invention can be carried out through the detection methods described above. The individuals which are to be selected are preferably those whose DNA does not comprise alleles of a biallelic marker or of a group of biallelic markers associated with a negative response to treatment. The knowledge of an individual's genetic predisposition to unresponsiveness or side effects to particular medicaments allows the clinician to direct treatment toward appropriate drugs against schizophrenia or bipolar disorder or symptoms thereof.

20 Once the patient's genetic predispositions have been determined, the clinician can select appropriate treatment for which negative response, particularly side effects, has not been reported or has been reported only marginally for the patient.

25 The biallelic markers of the invention have demonstrated an association with schizophrenia and bipolar disorders. However, the present invention also comprises any of the prevention, diagnostic, prognosis and treatment methods described herein using the biallelic markers of the invention in methods of preventing, diagnosing, managing and treating related disorders, particularly related CNS disorders. By way of example, related disorders may comprise psychotic disorders, mood disorders, autism, substance dependence and alcoholism, mental retardation, and other psychiatric diseases including cognitive, anxiety, eating, impulse-control, and personality disorders, as defined with the Diagnosis and Statistical Manual of Mental Disorders fourth edition (DSM-IV) classification".

30 Recombinant Vectors

35 The term "vector" is used herein to designate either a circular or a linear DNA or RNA molecule, which is either double-stranded or single-stranded, and which comprise at least one polynucleotide of interest that is sought to be transferred in a cell host or in a unicellular or multicellular host organism.

The present invention encompasses a family of recombinant vectors that comprise a polynucleotide derived from an sbg1, g34665, sbg2, g35017 or g35018 nucleic acid sequence. Consequently, the present invention further comprises recombinant vectors comprising:

(a) sbg1 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide
5 positions 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027
to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880,
231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to
239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528
to 240824, 240528 to 240994, 240528 to 241685 and 240800 to 240993 of SEQ ID No. 1, SEQ
10 ID Nos 2 to 26 and primate sbg1 DNAs of SEQ ID Nos 54 to 111, and the complements
thereof;

(b) g34665 genomic DNA or cDNAs comprised in the nucleic acids of any of
nucleotide positions 292653 to 292841, 295555 to 296047 and 295580 to 296047 of SEQ ID
No. 1, and the complements thereof;

(c) sbg2 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide
15 positions 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915 of
SEQ ID No. 1, and the complements thereof;

(d) g35017 genomic DNA or cDNAs comprised in the nucleic acids of any of
nucleotide positions 94124 to 94964 of SEQ ID No. 1, and the complements thereof;

(e) g35018 genomic DNA or cDNAs comprised in the nucleic acids of any of
20 nucleotide positions 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to
29502, 29967 to 30282, 64666 to 64812, and 65505 to 65853 of SEQ ID No. 1, and the
complements thereof.

Generally, a recombinant vector of the invention may comprise any of the
25 polynucleotides described herein, as well as any sbg1, g34665, sbg2, g35017 or g35018 primer
or probe as defined above.

In a first preferred embodiment, a recombinant vector of the invention is used to
amplify the inserted polynucleotide derived from an sbg1, g34665, sbg2, g35017 or g35018
genomic sequence or cDNA of the invention in a suitable cell host, this polynucleotide being
30 amplified at every time that the recombinant vector replicates.

A second preferred embodiment of the recombinant vectors according to the invention
comprises expression vectors comprising either a regulatory polynucleotide or a coding nucleic
acid of the invention, or both. Within certain embodiments, expression vectors are employed to
express an sbg1, g34665, sbg2, g35017 or g35018 polypeptide which can be then purified and,
35 for example be used in ligand screening assays or as an immunogen in order to raise specific

antibodies directed against an sbg1, g34665, sbg2, g35017 or g35018 protein. In other embodiments, the expression vectors are used for constructing transgenic animals and also for gene therapy. Expression requires that appropriate signals are provided in the vectors, said signals including various regulatory elements, such as enhancers/promoters from both viral and mammalian sources that drive expression of the genes of interest in host cells. Dominant drug selection markers for establishing permanent, stable cell clones expressing the products are generally included in the expression vectors of the invention, as they are elements that link expression of the drug selection markers to expression of the polypeptide.

More particularly, the present invention relates to expression vectors which include nucleic acids encoding an sbg1, g34665, sbg2, g35017 or g35018 protein or variants or fragments thereof, under the control of a regulatory sequence of the respective sbg1, g34665, sbg2, g35017 or g35018 regulatory polynucleotides, or alternatively under the control of an exogenous regulatory sequence.

The invention also pertains to a recombinant expression vector useful for the expression of a sbg1, g34665, sbg2, g35017 or g35018 cDNA sequence.

Recombinant vectors comprising a nucleic acid containing a human chromosome 13q31-33-related biallelic marker, preferably a Region D-related biallelic marker or more preferably an sbg1-, g34665-, sbg2-, g35017- or g35018-related biallelic marker is also part of the invention. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1 to A489, and the complements thereof.

Some of the elements which can be found in the vectors of the present invention are described in further detail in the following sections.

1. General features of the expression vectors of the invention

A recombinant vector according to the invention comprises, but is not limited to, a YAC (Yeast Artificial Chromosome), a BAC (Bacterial Artificial Chromosome), a phage, a phagemid, a cosmid, a plasmid or even a linear DNA molecule which may comprise a chromosomal, non-chromosomal, semi-synthetic and synthetic DNA. Such a recombinant vector can comprise a transcriptional unit comprising an assembly of:

(1) a genetic element or elements having a regulatory role in gene expression, for example promoters or enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to 300 bp in length that act on the promoter to increase the transcription.

(2) a structural or coding sequence which is transcribed into mRNA and eventually translated into a polypeptide, said structural or coding sequence being operably linked to the regulatory elements described in (1); and

(3) appropriate transcription initiation and termination sequences. Structural units

intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, when a recombinant protein is expressed without a leader or transport sequence, it may include a N-terminal residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

Generally, recombinant expression vectors will include origins of replication, selectable markers permitting transformation of the host cell, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably a leader sequence capable of directing secretion of the translated protein into the periplasmic space or the extracellular medium. In a specific embodiment wherein the vector is adapted for transfecting and expressing desired sequences in mammalian host cells, preferred vectors will comprise an origin of replication in the desired host, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5'-flanking non-transcribed sequences. DNA sequences derived from the SV40 viral genome, for example SV40 origin, early promoter, enhancer, splice and polyadenylation sites may be used to provide the required non-transcribed genetic elements.

The *in vivo* expression of an sbg1, g34665, sbg2, g35017 or g35018 polypeptide or fragments or variants thereof may be useful in order to correct a genetic defect related to the expression of the native gene in a host organism or to the production of a biologically inactive sbg1, g34665, sbg2, g35017 or g35018 protein.

Consequently, the present invention also comprises recombinant expression vectors mainly designed for the *in vivo* production of the sbg1, g34665, sbg2, g35017 or g35018 polypeptide by the introduction of the appropriate genetic material in the organism of the patient to be treated. In preferred embodiments, said genetic material comprises at least one nucleotide sequence selected from the group of nucleotide position ranges consisting of:

(a) sbg1 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685 and 240800 to 240993 of SEQ ID No. 1, SEQ ID Nos 2 to 26 and primate sbg1 DNAs of SEQ ID Nos. 54 to 111, and the complements thereof;

(b) g34665 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 292653 to 292841, 295555 to 296047 and 295580 to 296047 of SEQ ID No. 1, and the complements thereof;

5 (c) sbg2 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915 of SEQ ID No. 1, and the complements thereof;

(d) g35017 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 94124 to 94964 of SEQ ID No. 1, and the complements thereof; and

10 (e) g35018 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, and 65505 to 65853 of SEQ ID No. 1, and the complements thereof.

This genetic material may be introduced *in vitro* in a cell that has been previously extracted from the organism, the modified cell being subsequently reintroduced in the said
15 organism, directly *in vivo* into the appropriate tissue.

2. Regulatory Elements

Promoters

The suitable promoter regions used in the expression vectors according to the present invention are chosen taking into account the cell host in which the heterologous gene has to be
20 expressed. The particular promoter employed to control the expression of a nucleic acid sequence of interest is not believed to be important, so long as it is capable of directing the expression of the nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell, such as, for example, a human or a
25 viral promoter.

A suitable promoter may be heterologous with respect to the nucleic acid for which it controls the expression or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct
30 promoter/coding sequence has been inserted.

Promoter regions can be selected from any desired gene using, for example, CAT (chloramphenicol transferase) vectors and more preferably pKK232-8 and pCM7 vectors.

Preferred bacterial promoters are the LacI, LacZ, the T3 or T7 bacteriophage RNA polymerase promoters, the gpt, lambda PR, PL and trp promoters (EP 0036776), the polyhedrin
35 promoter, or the p10 protein promoter from baculovirus (Kit Novagen) (Smith et al., 1983;

O'Reilly et al., 1992), the lambda PR promoter or also the trc promoter.

Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-L. Selection of a convenient vector and promoter is well within the level of ordinary skill in the art.

5 The choice of a promoter is well within the ability of a person skilled in the field of genetic engineering. For example, one may refer to the book of Sambrook et al.(1989) or also to the procedures described by Fuller et al.(1996).

Other regulatory elements

10 One will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed such as human growth hormone and SV40 polyadenylation signals. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

15 The vector containing the appropriate DNA sequence as described above, more preferably an sbg1 gene regulatory polynucleotide, a polynucleotide encoding an sbg1, g34665, sbg2, g35017 or g35018 polypeptide comprising at least one nucleotide sequence selected from the group of nucleotide sequence ranges consisting of:

20 (a) sbg1 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685 and 240800 to 240993 of SEQ ID No. 1, SEQ
25 ID Nos 2 to 26 and primate sbg1 DNAs or SEQ ID Nos. 54 to 111, and the complements thereof;

(b) g34665 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 292653 to 292841, 295555 to 296047 and 295580 to 296047 of SEQ ID No. 1, and the complements thereof;

30 (c) sbg2 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915 of SEQ ID No. 1, and the complements thereof;

(d) g35017 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 94124 to 94964 of SEQ ID No. 1, and the complements thereof;

35 (e) g35018 genomic DNA or cDNAs comprised in the nucleic acids of any of

nucleotide positions 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, and 65505 to 65853 of SEQ ID No. 1, and the complements thereof.

3. Selectable Markers

Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression construct. The selectable marker genes for selection of transformed host cells are preferably dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for *S. cerevisiae* or tetracycline, rifampicin or ampicillin resistance in *E. coli*, or levan saccharase for mycobacteria, this latter marker being a negative selection marker.

4. Preferred Vectors.

Bacterial vectors

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and a bacterial origin of replication derived from commercially available plasmids comprising genetic elements of pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia, Uppsala, Sweden), and GEM1 (Promega Biotec, Madison, WI, USA).

Large numbers of other suitable vectors are known to those of skill in the art, and commercially available, such as the following bacterial vectors: pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); pQE-30 (QIAexpress).

Bacteriophage vectors

The P1 bacteriophage vector may contain large inserts ranging from about 80 to about 100 kb.

The construction of P1 bacteriophage vectors such as p158 or p158/neo8 are notably described by Sternberg.(1992, 1994). Recombinant P1 clones comprising sbg1 polynucleotide sequences may be designed for inserting large polynucleotides of more than 40 kb (Linton et al., 1993). To generate P1 DNA for transgenic experiments, a preferred protocol is the protocol described by McCormick et al.(1994). Briefly, *E. coli* (preferably strain NS3529) harboring the P1 plasmid are grown overnight in a suitable broth medium containing 25 µg/ml of kanamycin. The P1 DNA is prepared from the *E. coli* by alkaline lysis using the Qiagen Plasmid Maxi kit (Qiagen, Chatsworth, CA, USA), according to the manufacturer's instructions. The P1 DNA is purified from the bacterial lysate on two Qiagen-tip 500 columns, using the washing and elution

buffers contained in the kit. A phenol/chloroform extraction is then performed before precipitating the DNA with 70% ethanol. After solubilizing the DNA in TE (10 mM Tris-HCl, pH 7.4, 1 mM EDTA), the concentration of the DNA is assessed by spectrophotometry.

When the goal is to express a P1 clone comprising an sbg1 polynucleotide sequence in a transgenic animal, typically in transgenic mice, it is desirable to remove vector sequences from the P1 DNA fragment, for example by cleaving the P1 DNA at rare-cutting sites within the P1 polylinker (*SfiI*, *NotI* or *SaII*). The P1 insert is then purified from vector sequences on a pulsed-field agarose gel, using methods similar to those originally reported for the isolation of DNA from YACs (Schedl et al., 1993a; Peterson et al., 1993,). At this stage, the resulting purified insert DNA can be concentrated, if necessary, on a Millipore Ultrafree-MC Filter Unit (Millipore, Bedford, MA, USA – 30,000 molecular weight limit) and then dialyzed against microinjection buffer (10 mM Tris-HCl, pH 7.4; 250 μ M EDTA) containing 100 mM NaCl, 30 μ M spermine, 70 μ M spermidine on a microdialysis membrane (type VS, 0.025 μ M from Millipore). The intactness of the purified P1 DNA insert is assessed by electrophoresis on 1% agarose (Sea Kem GTG; FMC Bio-products) pulse-field gel and staining with ethidium bromide.

Baculovirus vectors

A suitable vector for the expression of an sbg1 polypeptide encoded by polynucleotides of SEQ ID No. 1 or fragments or variants thereof is a baculovirus vector that can be propagated in insect cells and in insect cell lines. A specific suitable host vector system is the pVL1392/1393 baculovirus transfer vector (Pharmingen) that is used to transfect the SF9 cell line (ATCC N^oCRL 1711) which is derived from *Spodoptera frugiperda*.

Other suitable vectors for the expression of the sbg1 polypeptide encoded by the SEQ ID No. 1 or fragments or variants thereof in a baculovirus expression system include those described by Chai et al.(1993), Vlasak et al.(1983) and Lenhard et al.(1996).

Viral vectors

In one specific embodiment, the vector is derived from an adenovirus. Preferred adenovirus vectors according to the invention are those described by Feldman and Steg (1996) or Ohno et al.(1994). Another preferred recombinant adenovirus according to this specific embodiment of the present invention is the human adenovirus type 2 or 5 (Ad 2 or Ad 5) or an adenovirus of animal origin (French patent application N^o FR-93.05954).

Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery systems of choice for the transfer of exogenous polynucleotides *in vivo*, particularly to mammals, including humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal

DNA of the host.

Particularly preferred retroviruses for the preparation or construction of retroviral *in vitro* or *in vitro* gene delivery vehicles of the present invention include retroviruses selected from the group consisting of Mink-Cell Focus Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus and Rous Sarcoma virus. Particularly preferred Murine Leukemia Viruses include the 4070A and the 1504A viruses, Abelson (ATCC No VR-999), Friend (ATCC No VR-245), Gross (ATCC No VR-590), Rauscher (ATCC No VR-998) and Moloney Murine Leukemia Virus (ATCC No VR-190; PCT Application No WO 94/24298). Particularly preferred Rous Sarcoma Viruses include Bryan high titer (ATCC Nos VR-334, VR-657, VR-726, VR-659 and VR-728). Other preferred retroviral vectors are those described in Roth et al.(1996), PCT Application No WO 93/25234, PCT Application No WO 94/ 06920, Roux et al., 1989, Julan et al., 1992 and Neda et al., 1991.

Yet another viral vector system that is contemplated by the invention comprises the adeno-associated virus (AAV). The adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al., 1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (Flotte et al., 1992; Samulski et al., 1989; McLaughlin et al., 1989). One advantageous feature of AAV derives from its reduced efficacy for transducing primary cells relative to transformed cells.

BAC vectors

The bacterial artificial chromosome (BAC) cloning system (Shizuya et al., 1992) has been developed to stably maintain large fragments of genomic DNA (100-300 kb) in *E. coli*. A preferred BAC vector comprises pBeloBAC11 vector that has been described by Kim et al.(1996). BAC libraries are prepared with this vector using size-selected genomic DNA that has been partially digested using enzymes that permit ligation into either the *Bam* HI or *Hind*III sites in the vector. Flanking these cloning sites are T7 and SP6 RNA polymerase transcription initiation sites that can be used to generate end probes by either RNA transcription or PCR methods. After the construction of a BAC library in *E. coli*, BAC DNA is purified from the host cell as a supercoiled circle. Converting these circular molecules into a linear form precedes both size determination and introduction of the BACs into recipient cells. The cloning site is flanked by two *Not* I sites, permitting cloned segments to be excised from the vector by *Not* I digestion. Alternatively, the DNA insert contained in the pBeloBAC11 vector may be linearized by treatment of the BAC vector with the commercially available enzyme lambda terminase that leads to the cleavage at the unique *cos*N site, but this cleavage method results in a

full length BAC clone containing both the insert DNA and the BAC sequences.

5. Delivery Of The Recombinant Vectors

In order to effect expression of the polynucleotides and polynucleotide constructs of the invention, these constructs must be delivered into a cell. This delivery may be accomplished *in vitro*, as in laboratory procedures for transforming cell lines, or *in vivo* or *ex vivo*, as in the treatment of certain diseases states.

One mechanism is viral infection where the expression construct is encapsulated in an infectious viral particle.

Several non-viral methods for the transfer of polynucleotides into cultured mammalian cells are also contemplated by the present invention, and include, without being limited to, calcium phosphate precipitation (Graham et al., 1973; Chen et al., 1987), DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa et al., 1986; Potter et al., 1984), direct microinjection (Harland et al., 1985), DNA-loaded liposomes (Nicolau et al., 1982; Fraley et al., 1979), and receptor-mediate transfection (Wu and Wu, 1987; 1988). Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use.

Once the expression polynucleotide has been delivered into the cell, it may be stably integrated into the genome of the recipient cell. This integration may be in the cognate location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non specific location (gene augmentation). In yet further embodiments, the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle.

One specific embodiment for a method for delivering a protein or peptide to the interior of a cell of a vertebrate *in vivo* comprises the step of introducing a preparation comprising a physiologically acceptable carrier and a naked polynucleotide operatively coding for the polypeptide of interest into the interstitial space of a tissue comprising the cell, whereby the naked polynucleotide is taken up into the interior of the cell and has a physiological effect. This is particularly applicable for transfer *in vitro* but it may be applied to *in vivo* as well.

Compositions for use *in vitro* and *in vivo* comprising a "naked" polynucleotide are described in PCT application N° WO 90/11092 (Vical Inc.) and also in PCT application No. WO 95/11307 (Institut Pasteur, INSERM, Université d'Ottawa) as well as in the articles of Tacson et al.(1996) and of Huygen et al.(1996).

In still another embodiment of the invention, the transfer of a naked polynucleotide of the invention, including a polynucleotide construct of the invention, into cells may be proceeded with a particle bombardment (biolistic), said particles being DNA-coated microprojectiles

accelerated to a high velocity allowing them to pierce cell membranes and enter cells without killing them, such as described by Klein et al.(1987).

In a further embodiment, the polynucleotide of the invention may be entrapped in a liposome (Ghosh and Bacchawat, 1991; Wong et al., 1980; Nicolau et al., 1987).

5 In a specific embodiment, the invention provides a composition for the *in vivo* production of the sbg1, g34665, sbg2, g35017 and g35018 protein or polypeptide described herein. It comprises a naked polynucleotide operatively coding for this polypeptide, in solution in a physiologically acceptable carrier, and suitable for introduction into a tissue to cause cells of the tissue to express the said protein or polypeptide.

10 The amount of vector to be injected to the desired host organism varies according to the site of injection. As an indicative dose, it will be injected between 0,1 and 100 µg of the vector in an animal body, preferably a mammal body, for example a mouse body.

In another embodiment of the vector according to the invention, it may be introduced *in vitro* in a host cell, preferably in a host cell previously harvested from the animal to be treated and more preferably a somatic cell such as a muscle cell. In a subsequent step, the cell that has
15 been transformed with the vector coding for the desired sbg1 polypeptide or the desired fragment thereof is reintroduced into the animal body in order to deliver the recombinant protein within the body either locally or systemically.

Cell Hosts

20 Another object of the invention comprises a host cell that have been transformed or transfected with one of the polynucleotides described herein, and more precisely a polynucleotide comprising an sbg1 polynucleotide selected from the group consisting of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, or a fragment or a variant thereof. Are included host cells that are transformed (prokaryotic cells) or that are transfected (eukaryotic cells) with a
25 recombinant vector such as one of those described above.

Generally, a recombinant host cell of the invention comprises any one of the polynucleotides or the recombinant vectors described therein.

Preferred host cells used as recipients for the expression vectors of the invention are the following:

30 a) Prokaryotic host cells: *Escherichia coli* strains (I.E.DH5-α strain), *Bacillus subtilis*, *Salmonella typhimurium*, and strains from species like *Pseudomonas*, *Streptomyces* and *Staphylococcus*.

b) Eukaryotic host cells: HeLa cells (ATCC N°CCL2; N°CCL2.1; N°CCL2.2), Cv 1 cells (ATCC N°CCL70), COS cells (ATCC N°CRL1650; N°CRL1651), Sf-9 cells (ATCC
35 N°CRL1711), C127 cells (ATCC N° CRL-1804), 3T3 (ATCC N° CRL-6361), CHO (ATCC N°

CCL-61), human kidney 293. (ATCC N° 45504; N° CRL-1573) and BHK (ECACC N° 84100501; N° 84111301).

c) Other mammalian host cells.

Sbg1, g34665, sbg2, g35017 and g35018 gene expression in mammalian, and typically
5 human, cells may be rendered defective with the replacement of an sbg1 nucleic acid counterpart in the genome of an animal cell by an sbg1 polynucleotide according to the invention. These genetic alterations may be generated by homologous recombination events using specific DNA constructs that have been previously described.

One kind of cell hosts that may be used are mammal zygotes, such as murine zygotes.
10 For example, murine zygotes may undergo microinjection with a purified DNA molecule of interest, for example a purified DNA molecule that has previously been adjusted to a concentration range from 1 ng/ml –for BAC inserts- 3 ng/μl –for P1 bacteriophage inserts- in 10 mM Tris-HCl, pH 7.4, 250 μM EDTA containing 100 mM NaCl, 30 μM spermine, and 70 μM spermidine. When the DNA to be microinjected has a large size, polyamines and high salt
15 concentrations can be used in order to avoid mechanical breakage of this DNA, as described by Schedl et al (1993b).

Any of the polynucleotides of the invention, including the DNA constructs described herein, may be introduced in an embryonic stem (ES) cell line, preferably a mouse ES cell line. ES cell lines are derived from pluripotent, uncommitted cells of the inner cell mass of pre-
20 implantation blastocysts. Preferred ES cell lines are the following: ES-E14TG2a (ATCC n° CRL-1821), ES-D3 (ATCC n° CRL1934 and n° CRL-11632), YS001 (ATCC n° CRL-11776), 36.5 (ATCC n° CRL-11116). To maintain ES cells in an uncommitted state, they are cultured in the presence of growth inhibited feeder cells which provide the appropriate signals to preserve this embryonic phenotype and serve as a matrix for ES cell adherence. Preferred
25 feeder cells are primary embryonic fibroblasts that are established from tissue of day 13- day 14 embryos of virtually any mouse strain, that are maintained in culture, such as described by Abbondanzo et al.(1993) and are inhibited in growth by irradiation, such as described by Robertson (1987), or by the presence of an inhibitory concentration of LIF, such as described by Pease and Williams (1990).

30 The constructs in the host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

Following transformation of a suitable host and growth of the host to an appropriate cell density, the selected promoter is induced by appropriate means, such as temperature shift or chemical induction, and cells are cultivated for an additional period.

35 Cells are typically harvested by centrifugation, disrupted by physical or chemical

means, and the resulting crude extract retained for further purification.

Microbial cells employed in the expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known by the skill artisan.

5 **Transgenic Animals**

10 The terms "transgenic animals" or "host animals" are used herein designate animals that have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from *Mus* (e.g. mice), *Rattus* (e.g. rats) and *Oryctogalus* (e.g. rabbits) which have their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention. In one embodiment, the invention encompasses non-human host mammals and animals comprising a recombinant vector of the invention or an sbg1, g34665, sbg2, g35017 or g35018 gene disrupted by homologous recombination with a knock out vector. The invention also encompasses non-human primates comprising a recombinant vector of the invention or an sbg1, g34665, sbg2, g35017 or g35018 gene disrupted by homologous recombination with a knock out vector.

15 The transgenic animals of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

20 Generally, a transgenic animal according the present invention comprises any one of the polynucleotides, the recombinant vectors and the cell hosts described in the present invention.

25 In a first preferred embodiment, these transgenic animals may be good experimental models in order to study the diverse pathologies related to cell differentiation, in particular concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native sbg1, g34665, sbg2, g35017 or g35018 protein, or alternatively a mutant sbg1, g34665, sbg2, g35017 or g35018 protein.

30 In a second preferred embodiment, these transgenic animals may express a desired polypeptide of interest under the control of regulatory polynucleotides which lead to good yields in the synthesis of this protein of interest, and optionally a tissue specific expression of this protein of interest.

35 The design of the transgenic animals of the invention may be made according to the conventional techniques well known from the one skilled in the art. For more details regarding the production of transgenic animals, and specifically transgenic mice, it may be referred to US

Patents Nos 4,873,191, issued Oct. 10, 1989; 5,464,764 issued Nov 7, 1995; and 5,789,215, issued Aug 4, 1998.

Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that has incorporated exogenous genetic material. The procedure involves obtaining the genetic material, or a portion thereof, which encodes either an sbg1, g34665, sbg2, g35017 or g35018 polynucleotide or antisense polynucleotide such as described in the present specification.

A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is preferably made using electroporation, such as described by Thomas et al.(1987). The cells subjected to electroporation are screened (e.g. by selection via selectable markers, by PCR or by Southern blot analysis) to find positive cells which have integrated the exogenous recombinant polynucleotide into their genome, preferably via an homologous recombination event. An illustrative positive-negative selection procedure that may be used according to the invention is described by Mansour et al.(1988).

Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from mice, such as described by Bradley (1987). The blastocysts are then inserted into a female host animal and allowed to grow to term.

Alternatively, the positive ES cells are brought into contact with embryos at the 2.5 days old 8-16 cell stage (morulae) such as described by Wood et al.(1993) or by Nagy et al.(1993), the ES cells being internalized to colonize extensively the blastocyst including the cells which will give rise to the germ line.

The offspring of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

Thus, the present invention also concerns a transgenic animal containing a nucleic acid, a recombinant expression vector or a recombinant host cell according to the invention.

Recombinant Cell Lines Derived From The Transgenic Animals Of The Invention.

A further object of the invention comprises recombinant host cells obtained from a transgenic animal described herein. In one embodiment the invention encompasses cells derived from non-human host mammals and animals comprising a recombinant vector of the invention or a gene comprising an sbg1, g34665, sbg2, g35017 or g35018 nucleic acid sequence disrupted by homologous recombination with a knock out vector.

Recombinant cell lines may be established *in vitro* from cells obtained from any tissue of a transgenic animal according to the invention, for example by transfection of primary cell cultures with vectors expressing *onc*-genes such as SV40 large T antigen, as described by Chou (1989) and Shay et al.(1991).

Assays For Identification Of Compounds For Treatment Of Schizophrenia And Bipolar Disorder

5 The present invention provides assays which may be used to test compounds for their ability to treat CNS disorders, and in particular, to ameliorate symptoms of a CNS disorder mediated by sbg1, g34665, sbg2, g35017 or g35018. In preferred embodiments, compounds tested for their ability to ameliorate symptoms of schizophrenia or bipolar disorder mediated by sbg1, g34665, sbg2, g35017 or g35018. Compounds may also be tested for their ability to treat related disorders, including among others psychotic disorders, mood disorders, autism, substance
10 dependence and alcoholism, mental retardation, and other psychiatric diseases including cognitive, anxiety, eating, impulse-control, and personality disorders, as defined with the Diagnosis and Statistical Manual of Mental Disorders fourth edition (DSM-IV) classification.

The present invention also provides cell and animal, including primate and mouse, models of schizophrenia, bipolar disorder and related disorders.

15 In one aspect, provided are non-cell based, cell based and animal based assays for the identification of such compounds that affect sbg1 activity. Sbg1 activity may be affected by any mechanism; in certain embodiments, sbg1 activity is affected by modulating sbg1 gene expression or the activity of the sbg1 gene product.

The present methods allow the identification of compounds that affect sbg1 activity directly or indirectly. Thus, the non-cell based, cell based and animal assays of the present
20 invention may also be used to identify compounds that act on an element of a sbg1 pathway other than sbg1 itself. These compounds can then be used as a therapeutic treatment to modulate sbg1 and other gene products involved in schizophrenia, bipolar disorder and related disorders.

25 *Cell and non-cell based assays*

In one aspect, cell based assays using recombinant or non-recombinant cells may be used to identify compounds which modulate sbg1 activity.

In one aspect, a cell based assay of the invention encompasses a method for identifying a test compound for the treatment of schizophrenia or bipolar disorder comprising (a) exposing
30 a cell to a test compound at a concentration and time sufficient to ameliorate an endpoint related to schizophrenia or bipolar disorder, and (b) determining the level of sbg1 activity in a cell. Sbg1 activity can be measured, for example, by assaying a cell for mRNA transcript level, sbg1 peptide expression, localization or protein activity. Preferably the test compound is a compound capable of or suspected to be capable of ameliorating a symptom of schizophrenia,
35 bipolar disorder or a related disorder. Test compounds capable of modulating sbg1 activity may

be selected for use in developing medicaments. Such cell based assays are further described herein in the section titled "Method For Screening Ligands That Modulate The Expression Of The sbg1, g34665, sbg2, g35017 and g35018 Gene."

5 In another aspect, a cell based assay of the invention encompasses a method for identifying a compound for the treatment of schizophrenia or bipolar disorder comprising (a) exposing a cell to a level of sbg1 activity sufficient to cause a schizophrenia-related or bipolar disorder-related endpoint, and (b) exposing said cell to a test compound. A test compound can then be selected according to its ability to ameliorate said schizophrenia-related or bipolar disorder-related endpoints. sbg1 activity may be provided by any suitable method, including 10 but not limited to providing a vector containing an sbg1 nucleotide sequence, treating said cell with a compound capable of increasing sbg1 expression and treating said cell with an sbg1 peptide. Preferably said cell is treated with an sbg1 peptide comprising a contiguous span of at least 4 amino acids of SEQ ID Nos. 27 to 35; most preferably said sbg1 peptide comprises amino acid positions 124 to 153 of SEQ ID No 34, as described in Example 7. Preferably the 15 test compound is a compound capable of or suspected to be capable of ameliorating a symptom of schizophrenia, bipolar disorder or a related disorder; alternatively, the test compound is suspected of exacerbating an endpoint schizophrenia, bipolar disorder or a related disorder. A test compound capable of ameliorating any detectable symptom or endpoint of a schizophrenia, bipolar disorder or a related disorder may be selected for use in developing medicaments.

20 In another embodiment, the invention provides cell and non-cell based assays to sbg1 to determine whether sbg peptides bind to the cell surface, and to identify compounds for the treatment of schizophrenia, bipolar disorder and related disorders that interact with an sbg1 receptor. In one such embodiment, an sbg1 polynucleotide, or fragments thereof, is cloned into expression vectors such as those described herein. The proteins are purified by size, charge, 25 immunochromatography or other techniques familiar to those skilled in the art. Following purification, the proteins are labeled using techniques known to those skilled in the art. The labeled proteins are incubated with cells or cell lines derived from a variety of organs or tissues to allow the proteins to bind to any receptor present on the cell surface. Following the incubation, the cells are washed to remove non-specifically bound protein. The labeled proteins 30 are detected by autoradiography. Alternatively, unlabeled proteins may be incubated with the cells and detected with antibodies having a detectable label, such as a fluorescent molecule, attached thereto. Specificity of cell surface binding may be analyzed by conducting a competition analysis in which various amounts of unlabeled protein are incubated along with the labeled protein. The amount of labeled protein bound to the cell surface decreases as the 35 amount of competitive unlabeled protein increases. As a control, various amounts of an

unlabeled protein unrelated to the labeled protein is included in some binding reactions. The amount of labeled protein bound to the cell surface does not decrease in binding reactions containing increasing amounts of unrelated unlabeled protein, indicating that the protein encoded by the nucleic acid binds specifically to the cell surface.

5 In another embodiment, the present invention comprises non-cell based binding assays, wherein an sbg1 polypeptide is prepared and purified as in cell based binding assays described above. Following purification, the proteins are labeled and incubated with a cell membrane
10 extract or isolate derived from any desired cells from any organs, tissue or combination of organs or tissues of interest to allow the sbg1 polypeptide to bind to any receptor present on a membrane. Following the incubation, the membranes are washed to remove non-specifically bound protein. The labeled proteins may be detected by autoradiography. Specificity of membrane binding of sbg1 may be analyzed by conducting a competition analysis in which various amounts of a test compound are incubated along with the labeled protein. Any desired
15 test compound, including test polypeptides, can be incubated with the cells. The test compounds may be detected with antibodies having a detectable label, such as a fluorescent molecule, attached thereto. The amount of labeled sbg1 polypeptide bound to the cell surface decreases as the amount of competitive test compound increases. As a control, various amounts of an unlabeled protein or a compound unrelated to the test compound is included in some binding reactions. Test compounds capable of reducing the amount of sbg1 bound to cell
20 membranes may be selected as a candidate therapeutic compound.

In preferred embodiments of the cell and non-cell based assays, said sbg1 peptide comprising a contiguous span of at least 4 amino acids of SEQ ID Nos. 27 to 35; most preferably said sbg1 peptide comprises amino acid positions 124 to 153 of SEQ ID No 34.

25 Said cell based assays may comprise cells of any suitable origin; particularly preferred cells are human cells, primate cells, non-human primate cells and mouse cells. If non-human primate cells are used, the sbg1 may comprise a nucleotide sequence or be encoded by a nucleotide sequence according to the primate nucleic acid sequences of SEQ ID No. 54 to 111, or a sequence complementary thereto or a fragment thereof.

Animal model based assay

30 Non-human animal based assays may also be used to identify compounds which modulate sbg1 activity. The invention encompasses animal models and animal based assays suitable, including non-transgenic or transgenic animals, including animals containing a human or altered form of the sbg1 gene.

35 Thus, the present invention comprises treating an animal affected by schizophrenia or bipolar disorder or symptoms thereof with a test compound capable of directly or indirectly

modulating sbg1 activity.

In one aspect, an animal based assay of the invention encompasses a method for identifying a test compound for the treatment of schizophrenia or bipolar disorder comprising (a) exposing an animal to a test compound at a concentration and time sufficient to ameliorate an endpoint related to schizophrenia or bipolar disorder, and (b) determining the level of sbg1 activity at a site in said animal. Sbg1 activity can be measured in any suitable cell, tissue or site. Preferably the test compound is a compound capable of or suspected to be capable of ameliorating a symptom of schizophrenia, bipolar disorder or a related disorder. Optionally said test compound is capable or suspected to be capable of modulating sbg1 activity. Test compounds capable of modulating sbg1 activity may be selected for use in developing medicaments.

In another aspect, a animal based assay of the invention encompasses a method for identifying a compound for the treatment of schizophrenia or bipolar disorder comprising (a) exposing an animal to a level of sbg1 activity sufficient to cause a schizophrenia-related or bipolar disorder-related symptom or endpoint, and (b) exposing said animal to a test compound. A test compound can then be selected according to its ability to ameliorate said schizophrenia-related or bipolar disorder-related endpoints. sbg1 activity may be provided by any suitable method, including but not limited to providing a vector containing an sbg1 nucleotide sequence, treating said animal with a compound capable of increasing sbg1 expression and treating said cell with an sbg1 peptide. Preferably, said animal is treated with an sbg1 peptide comprising a contiguous span of at least 4 amino acids of SEQ ID Nos. 27 to 35; most preferably said sbg1 peptide comprises amino acid positions 124 to 153 of SEQ ID No 34, as described in Example 7. Preferably the test compound is a compound capable of or suspected to be capable of ameliorating a symptom of schizophrenia, bipolar disorder or a related disorder; alternatively, the test compound is suspected of exacerbating a symptom of schizophrenia, bipolar disorder or a related disorder. A test compound capable of ameliorating any detectable symptom or endpoint of a schizophrenia, bipolar disorder or a related disorder may be selected for use in developing medicaments.

Any suitable animal may be used. Preferably, said animal is a primate, a non-human primate, a mammal, or a mouse.

In one embodiment, a mouse is treated with an sbg1 peptide, exposed to a test compound, and symptoms indicative of schizophrenia, bipolar disorder or a related disorder are assessed by observing stereotypy. In other embodiments, said symptoms are assessed by performing at least one test from the group consisting of home cage observation, neurological evaluation, stress-induced hypothermia, forced swim, PTZ seizure, locomotor activity, tail

suspension, elevated plus maze, novel object recognition, prepulse inhibition, thermal pain, Y-maze, and metabolic chamber tests (Psychoscreen™ tests available from Psychogenics Inc.). Other tests are known in Crawley et al, Horm. Behav. 31(3):197-211 (1997); Crawley, Brain Res 835(1):18-26 (1999) for example.

5 In one example, the present inventors have tested sbg1 peptides by injection into mice. An sbg1 peptide comprising amino acid positions 124 to 153 of SEQ ID No 34 was injected peritoneally into adult mice as described herein in Example 7. Upon observation, mice injected with the sbg1 peptide exhibited a decrease in the frequency of their movements over the time course of the experiment. Figure 18 demonstrates (left top panel of the figure) a comparison of
10 the average number of movements in 3 separate time points (5, 10, and 15 min) with the average movements per min in the last period of observations (30, 35, 40, and 45 min). The sbg1 peptide also increased stereotypy - this effect was most prominent during the last period of observations. Because the onset of stereotypy was variable, data are presented as the average of stereotypy for observations over the entire time period.

15 The present inventors have also determined that the sbg1 gene exists in several non-human primates. In a preferred embodiment of the animal models and drug screening assays of the invention, a non-human primate is treated with an sbg1 peptide and exposed to a test compound, wherein said sbg1 peptide is encoded by a nucleotide sequence according to the primate nucleic acid sequences of SEQ ID No. 54 to 111, or a sequence complementary thereto
20 or a fragment thereof.

Any suitable test compound may be used with the screening methods of the invention. Examples of compounds that may be screened by the methods of the present invention include small organic or inorganic molecules, nucleic acids, including polynucleotides from random and directed polynucleotide libraries, peptides, including peptides derived from random and directed
25 peptide libraries, soluble peptides, fusion peptides, and phosphopeptides, antibodies including polyclonal, monoclonal, chimeric, humanized, and anti-idiotypic antibodies, and single chain antibodies, FAb, F(ab')₂ and FAb expression library fragments, and epitope-binding fragments thereof. In certain aspects, a compound capable of ameliorating or exacerbating a symptom or endpoint of schizophrenia, bipolar disorder or a related disorder may include, by way of
30 example, antipsychotic drugs in general, neuroleptics, atypical neuroleptics, antidepressants, anti-anxiety drugs, noradrenergic agonists and antagonists, dopaminergic agonists and antagonists, serotonin reuptake inhibitors, benzodiazepines.

Methods for screening substances interacting with an sbg1, g34665, sbg2, g35017 or g35018 polypeptides

For the purpose of the present invention, a ligand means a molecule, such as a protein, a peptide, an antibody or any synthetic chemical compound capable of binding to the sbg1, g34665, sbg2, g35017 or g35018 protein or one of its fragments or variants or to modulate the expression of the polynucleotide coding for the sbg1, g34665, sbg2, g35017 or g35018 or a fragment or variant thereof.

In the ligand screening method according to the present invention, a biological sample or a defined molecule to be tested as a putative ligand of the sbg1, g34665, sbg2, g35017 or g35018 protein is brought into contact with the corresponding purified sbg1, g34665, sbg2, g35017 or g35018 protein, for example the corresponding purified recombinant sbg1, g34665, sbg2, g35017 or g35018 protein produced by a recombinant cell host as described hereinbefore, in order to form a complex between this protein and the putative ligand molecule to be tested.

As an illustrative example, to study the interaction of the sbg1, g34665, sbg2, g35017 and g35018 protein, or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6, or preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 27 to 35 and 41 to 43, with drugs or small molecules, such as molecules generated through combinatorial chemistry approaches, the microdialysis coupled to HPLC method described by Wang et al. (1997) or the affinity capillary electrophoresis method described by Bush et al. (1997), can be used.

In further methods, peptides, drugs, fatty acids, lipoproteins, or small molecules which interact with the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6, or preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 27 to 35 and 41 to 43, may be identified using assays such as the following. The molecule to be tested for binding is labeled with a detectable label, such as a fluorescent, radioactive, or enzymatic tag and placed in contact with immobilized sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof under conditions which permit specific binding to occur. After removal of non-specifically bound molecules, bound molecules are detected using appropriate means.

Another object of the present invention comprises methods and kits for the screening of candidate substances that interact with an sbg1, g34665, sbg2, g35017 or g35018 polypeptide.

The present invention pertains to methods for screening substances of interest that interact with an sbg1, g34665, sbg2, g35017 or g35018 protein or one fragment or variant thereof. By their capacity to bind covalently or non-covalently to an sbg1, g34665, sbg2,

g35017 or g35018 protein or to a fragment or variant thereof, these substances or molecules may be advantageously used both *in vitro* and *in vivo*.

In vitro, said interacting molecules may be used as detection means in order to identify the presence of an sbg1, g34665, sbg2, g35017 or g35018 protein in a sample, preferably a biological sample.

A method for the screening of a candidate substance comprises the following steps :

a) providing a polypeptide comprising, consisting essentially of, or consisting of an sbg1, g34665, sbg2, g35017 or g35018 protein or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 27 to 35 and 41 to 43;

b) obtaining a candidate substance;

c) bringing into contact said polypeptide with said candidate substance; and

d) detecting the complexes formed between said polypeptide and said candidate substance.

The invention further concerns a kit for the screening of a candidate substance interacting with the sbg1, g34665, sbg2, g35017 or g35018 polypeptide, wherein said kit comprises:

a) an sbg1, g34665, sbg2, g35017 or g35018 protein having an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID Nos. 27 to 35 and 41 to 43 or a peptide fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 27 to 35 and 41 to 43; and

b) optionally means useful to detect the complex formed between the sbg1, g34665, sbg2, g35017 or g35018 protein or a peptide fragment or a variant thereof and the candidate substance.

In a preferred embodiment of the kit described above, the detection means comprise monoclonal or polyclonal antibodies directed against the sbg1, g34665, sbg2, g35017 or g35018 protein or a peptide fragment or a variant thereof.

Various candidate substances or molecules can be assayed for interaction with an sbg1, g34665, sbg2, g35017 or g35018 polypeptide. These substances or molecules include, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides. When the candidate substance or molecule comprise a polypeptide, this polypeptide may be the resulting expression product of a phage clone belonging to a phage-based random peptide library, or alternatively the polypeptide may be the resulting expression

product of a cDNA library cloned in a vector suitable for performing a two-hybrid screening assay.

The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise an sbg1, g34665, sbg2, g35017 or g35018 polypeptide or a fragment or a variant thereof, and optionally means useful to detect the complex formed between the sbg1, g34665, sbg2, g35017 or g35018 polypeptide or its fragment or variant and the candidate substance. In a preferred embodiment the detection means comprise monoclonal or polyclonal antibodies directed against the corresponding sbg1, g34665, sbg2, g35017 or g35018 polypeptide or a fragment or a variant thereof.

A. Candidate ligands obtained from random peptide libraries

In a particular embodiment of the screening method, the putative ligand is the expression product of a DNA insert contained in a phage vector (Parmley and Smith, 1988). Specifically, random peptide phages libraries are used. The random DNA inserts encode for peptides of 8 to 20 amino acids in length (Oldenburg K.R. et al., 1992; Valadon P., et al., 1996; Lucas A.H., 1994; Westerink M.A.J., 1995; Felici F. et al., 1991). According to this particular embodiment, the recombinant phages expressing a protein that binds to the immobilized sbg1, g34665, sbg2, g35017 or g35018 protein is retained and the complex formed between the sbg1, g34665, sbg2, g35017 or g35018 protein and the recombinant phage may be subsequently immunoprecipitated by a polyclonal or a monoclonal antibody directed against the sbg1, g34665, sbg2, g35017 or g35018 protein.

Once the ligand library in recombinant phages has been constructed, the phage population is brought into contact with the immobilized sbg1, g34665, sbg2, g35017 or g35018 protein. Then the preparation of complexes is washed in order to remove the non-specifically bound recombinant phages. The phages that bind specifically to the sbg1, g34665, sbg2, g35017 or g35018 protein are then eluted by a buffer (acid pH) or immunoprecipitated by the monoclonal antibody produced by the hybridoma anti- sbg1, g34665, sbg2, g35017 or g35018, and this phage population is subsequently amplified by an over-infection of bacteria (for example E. coli). The selection step may be repeated several times, preferably 2-4 times, in order to select the more specific recombinant phage clones. The last step comprises characterizing the peptide produced by the selected recombinant phage clones either by expression in infected bacteria and isolation, expressing the phage insert in another host-vector system, or sequencing the insert contained in the selected recombinant phages.

B. Candidate ligands obtained by competition experiments.

Alternatively, peptides, drugs or small molecules which bind to the sbg1, g34665, sbg2,

g35017 or g35018 protein, or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 27 to 35 and 41 to 43, may be identified in competition experiments. In such assays, the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, is immobilized to a surface, such as a plastic plate. Increasing amounts of the peptides, drugs or small molecules are placed in contact with the immobilized sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, in the presence of a detectable labeled known sbg1, g34665, sbg2, g35017 or g35018 protein ligand. For example, the sbg1, g34665, sbg2, g35017 or g35018 ligand may be detectably labeled with a fluorescent, radioactive, or enzymatic tag. The ability of the test molecule to bind the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, is determined by measuring the amount of detectably labeled known ligand bound in the presence of the test molecule. A decrease in the amount of known ligand bound to the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, when the test molecule is present indicated that the test molecule is able to bind to the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof.

C. Candidate ligands obtained by affinity chromatography.

Proteins or other molecules interacting with the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment comprising a contiguous span of at 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 27 to 35 and 41 to 43, can also be found using affinity columns which contain the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof. The sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, may be attached to the column using conventional techniques including chemical coupling to a suitable column matrix such as agarose, Affi Gel®, or other matrices familiar to those of skill in art. In some embodiments of this method, the affinity column contains chimeric proteins in which the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, is fused to glutathion S transferase (GST). A mixture of cellular proteins or pool of expressed proteins as described above is applied to the affinity column. Proteins or other molecules interacting with the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, attached to the column can then be isolated and analyzed on 2-D electrophoresis gel as described in Ramunsen et al. (1997). Alternatively, the proteins retained on the affinity column can be purified by electrophoresis based methods and sequenced. The same method can be used to isolate antibodies, to screen phage display products, or to screen phage display human antibodies.

D. Candidate ligands obtained by optical biosensor methods

Proteins interacting with the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 27 to 35 and 41 to 43, can also be screened by using an Optical Biosensor as described in Edwards and Leatherbarrow (1997) and also in Szabo et al. (1995). This technique permits the detection of interactions between molecules in real time, without the need of labeled molecules. This technique is based on the surface plasmon resonance (SPR) phenomenon. Briefly, the candidate ligand molecule to be tested is attached to a surface (such as a carboxymethyl dextran matrix). A light beam is directed towards the side of the surface that does not contain the sample to be tested and is reflected by said surface. The SPR phenomenon causes a decrease in the intensity of the reflected light with a specific association of angle and wavelength. The binding of candidate ligand molecules cause a change in the refraction index on the surface, which change is detected as a change in the SPR signal. For screening of candidate ligand molecules or substances that are able to interact with the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, is immobilized onto a surface. This surface comprises one side of a cell through which flows the candidate molecule to be assayed. The binding of the candidate molecule on the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, is detected as a change of the SPR signal. The candidate molecules tested may be proteins, peptides, carbohydrates, lipids, or small molecules generated by combinatorial chemistry. This technique may also be performed by immobilizing eukaryotic or prokaryotic cells or lipid vesicles exhibiting an endogenous or a recombinantly expressed sbg1, g34665, sbg2, g35017 or g35018 protein at their surface.

The main advantage of the method is that it allows the determination of the association rate between the sbg1, g34665, sbg2, g35017 or g35018 protein and molecules interacting with the sbg1, g34665, sbg2, g35017 or g35018 protein. It is thus possible to select specifically ligand molecules interacting with the sbg1, g34665, sbg2, g35017 or g35018 protein, or a fragment thereof, through strong or conversely weak association constants.

E. Candidate ligands obtained through a two-hybrid screening assay.

The yeast two-hybrid system is designed to study protein-protein interactions *in vivo* (Fields and Song, 1989), and relies upon the fusion of a bait protein to the DNA binding domain of the yeast Gal4 protein. This technique is also described in the US Patent N° US 5,667,973 and the US Patent N° 5,283,173 (Fields et al.).

The general procedure of library screening by the two-hybrid assay may be performed as described by Harper et al. (1993) or as described by Cho et al. (1998) or also Fromont-Racine et al. (1997).

The bait protein or polypeptide comprises, consists essentially of, or consists of an sbg1, g34665, sbg2, g35017 or g35018 polypeptide or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 27 to 35 and 41 to 43.

More precisely, the nucleotide sequence encoding the sbg1, g34665, sbg2, g35017 or g35018 polypeptide or a fragment or variant thereof is fused to a polynucleotide encoding the DNA binding domain of the GAL4 protein, the fused nucleotide sequence being inserted in a suitable expression vector, for example pAS2 or pM3.

Then, a human cDNA library is constructed in a specially designed vector, such that the human cDNA insert is fused to a nucleotide sequence in the vector that encodes the transcriptional domain of the GAL4 protein. Preferably, the vector used is the pACT vector. The polypeptides encoded by the nucleotide inserts of the human cDNA library are termed "pray" polypeptides.

A third vector contains a detectable marker gene, such as beta galactosidase gene or CAT gene that is placed under the control of a regulation sequence that is responsive to the binding of a complete Gal4 protein containing both the transcriptional activation domain and the DNA binding domain. For example, the vector pG5EC may be used.

Two different yeast strains are also used. As an illustrative but non limiting example the two different yeast strains may be the followings :

- Y190, the phenotype of which is (*MATa, Leu2-3, 112 ura3-12, trp1-901, his3-D200, ade2-101, gal4Dgal180D URA3 GAL-LacZ, LYS GAL-HIS3, cyh^r*);
- Y187, the phenotype of which is (*MATa gal4 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3, -112 URA3 GAL-lacZmet^r*), which is the opposite mating type of Y190.

Briefly, 20 µg of pAS2/ sbg1, g34665, sbg2, g35017 or g35018 and 20 µg of pACT-cDNA library are co-transformed into yeast strain Y190. The transformants are selected for growth on minimal media lacking histidine, leucine and tryptophan, but containing the histidine synthesis inhibitor 3-AT (50 mM). Positive colonies are screened for beta galactosidase by filter lift assay. The double positive colonies (*His⁺, beta-gal⁺*) are then grown on plates lacking histidine, leucine, but containing tryptophan and cycloheximide (10 mg/ml) to select for loss of pAS2/ sbg1, g34665, sbg2, g35017 and g35018 plasmids but retention of pACT-cDNA library plasmids. The resulting Y190 strains are mated with Y187 strains expressing sbg1, g34665,

sbg2, g35017 and g35018 or non-related control proteins; such as cyclophilin B, lamin, or SNF1, as *Gal4* fusions as described by Harper et al. (1993) and by Bram et al. (Bram RJ et al., 1993), and screened for beta galactosidase by filter lift assay. Yeast clones that are *beta gal*- after mating with the control *Gal4* fusions are considered false positives.

5 In another embodiment of the two-hybrid method according to the invention, interaction between the sbg1, g34665, sbg2, g35017 or g35018 or a fragment or variant thereof with cellular proteins may be assessed using the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech). As described in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech), nucleic acids encoding the sbg1, g34665, sbg2,
10 g35017 and g35018 protein or a portion thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. A desired cDNA, preferably human cDNA, is inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which
15 selects for expression of selectable markers on each of the expression vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain interaction between sbg1, g34665, sbg2, g35017 or g35018 and the protein or peptide encoded by the initially selected cDNA insert.

20 **Method For Screening Substances Interacting With The Regulatory Sequences Of An sbg1, g34665, sbg2, g35017 or g35018 Gene.**

The present invention also concerns a method for screening substances or molecules that are able to interact with the regulatory sequences of the sbg1, g34665, sbg2, g35017 or g35018 gene, such as for example promoter or enhancer sequences.

25 Nucleic acids encoding proteins which are able to interact with the regulatory sequences of the sbg1, g34665, sbg2, g35017 or g35018 gene, more particularly a nucleotide sequence selected from the group consisting of the polynucleotides of the 5' and 3' regulatory region or a fragment or variant thereof, and preferably a variant comprising one of the biallelic markers of the invention, may be identified by using a one-hybrid system, such as that described in the
30 booklet enclosed in the Matchmaker One-Hybrid System kit from Clontech (Catalog Ref. n° K1603-1). Briefly, the target nucleotide sequence is cloned upstream of a selectable reporter sequence and the resulting DNA construct is integrated in the yeast genome (*Saccharomyces cerevisiae*). The yeast cells containing the reporter sequence in their genome are then transformed with a library comprising fusion molecules between cDNAs encoding candidate

proteins for binding onto the regulatory sequences of the sbg1, g34665, sbg2, g35017 or g35018 gene and sequences encoding the activator domain of a yeast transcription factor such as GAL4. The recombinant yeast cells are plated in a culture broth for selecting cells expressing the reporter sequence. The recombinant yeast cells thus selected contain a fusion protein that is able to bind onto the target regulatory sequence of the sbg1, g34665, sbg2, g35017 or g35018 gene. Then, the cDNAs encoding the fusion proteins are sequenced and may be cloned into expression or transcription vectors *in vitro*. The binding of the encoded polypeptides to the target regulatory sequences of the sbg1, g34665, sbg2, g35017 or g35018 gene may be confirmed by techniques familiar to the one skilled in the art, such as gel retardation assays or DNase protection assays.

Gel retardation assays may also be performed independently in order to screen candidate molecules that are able to interact with the regulatory sequences of the sbg1, g34665, sbg2, g35017 or g35018 gene, such as described by Fried and Crothers (1981), Garner and Revzin (1981) and Dent and Latchman (1993). These techniques are based on the principle according to which a DNA fragment which is bound to a protein migrates slower than the same unbound DNA fragment. Briefly, the target nucleotide sequence is labeled. Then the labeled target nucleotide sequence is brought into contact with either a total nuclear extract from cells containing transcription factors, or with different candidate molecules to be tested. The interaction between the target regulatory sequence of the sbg1, g34665, sbg2, g35017 or g35018 gene and the candidate molecule or the transcription factor is detected after gel or capillary electrophoresis through a retardation in the migration.

Method For Screening Ligands That Modulate The Expression Of The sbg1, g34665, sbg2, g35017 or g35018 Gene

Another subject of the present invention is a method for screening molecules that modulate the expression of the sbg1, g34665, sbg2, g35017 or g35018 protein. Such a screening method comprises the steps of:

- a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or a variant or a fragment thereof, placed under the control of its own promoter;
- b) bringing into contact the cultivated cell with a molecule to be tested;
- c) quantifying the expression of the sbg1, g34665, sbg2, g35017 or g35018 protein or a variant or a fragment thereof.

In an embodiment, the nucleotide sequence encoding the sbg1, g34665, sbg2, g35017 or g35018 protein or a variant or a fragment thereof comprises an allele of at least one sbg1,

g34665, sbg2, g35017 or g35018 related biallelic marker.

Using DNA recombination techniques well known by the one skill in the art, the sbg1, g34665, sbg2, g35017 or g35018 protein encoding DNA sequence is inserted into an expression vector, downstream from its promoter sequence. As an illustrative example, the promoter
5 sequence of the sbg1, g34665, sbg2, g35017 or g35018 gene is contained in the nucleic acid of the 5' regulatory region.

The quantification of the expression of the sbg1, g34665, sbg2, g35017 or g35018 protein may be realized either at the mRNA level or at the protein level. In the latter case, polyclonal or monoclonal antibodies may be used to quantify the amounts of the sbg1, g34665,
10 sbg2, g35017 or g35018 protein that have been produced, for example in an ELISA or a RIA assay.

In a preferred embodiment, the quantification of the sbg1, g34665, sbg2, g35017 or g35018 mRNA is realized by a quantitative PCR amplification of the cDNA obtained by a reverse transcription of the total mRNA of the cultivated sbg1, g34665, sbg2, g35017 or g35018
15 -transfected host cell, using a pair of primers specific for sbg1, g34665, sbg2, g35017 or g35018.

The present invention also concerns a method for screening substances or molecules that are able to increase, or in contrast to decrease, the level of expression of the sbg1, g34665, sbg2, g35017 or g35018 gene. Such a method may allow the one skilled in the art to select
20 substances exerting a regulating effect on the expression level of the sbg1, g34665, sbg2, g35017 or g35018 gene and which may be useful as active ingredients included in pharmaceutical compositions for treating patients suffering from diseases.

Thus, is also part of the present invention a method for screening of a candidate substance or molecule that modulated the expression of the sbg1, g34665, sbg2, g35017 or
25 g35018 gene, this method comprises the following steps:

- providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises a nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof located upstream a polynucleotide encoding a detectable protein;
- obtaining a candidate substance; and
- 30 - determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a further embodiment, the nucleic acid comprising the nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof also includes a 5'UTR region of the sbg1 cDNA of SEQ ID No 2 to 26 or the g35018 cDNA of SEQ ID No 36 to 40,
35 or one of its biologically active fragments or variants thereof.

Among the preferred polynucleotides encoding a detectable protein, there may be cited polynucleotides encoding beta galactosidase, green fluorescent protein (GFP) and chloramphenicol acetyl transferase (CAT).

5 The invention also pertains to kits useful for performing the herein described screening method. Preferably, such kits comprise a recombinant vector that allows the expression of a nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof located upstream and operably linked to a polynucleotide encoding a detectable protein or the sbg1, g34665, sbg2, g35017 or g35018 protein or a fragment or a variant thereof.

10 In another embodiment of a method for the screening of a candidate substance or molecule that modulates the expression of the sbg1, g34665, sbg2, g35017 or g35018 gene, wherein said method comprises the following steps:

a) providing a recombinant host cell containing a nucleic acid, wherein said nucleic acid comprises a 5'UTR sequence of an sbg1, g34665, sbg2, g35017 or g35018 cDNA, preferably of an sbg1 or g35018 cDNA of SEQ ID Nos 2 to 26 or 36 to 40, or one of its biologically active
15 fragments or variants, the 5'UTR sequence or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein;

b) obtaining a candidate substance; and

c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

20 In a specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5'UTR sequence of an sbg1, g34665, sbg2, g35017 or g35018 cDNA, preferably of an sbg1 or g35018 cDNA of SEQ ID Nos 2 to 26 or 36 to 40 or one of its biologically active fragments or variants, includes a promoter sequence which is endogenous with respect to the sbg1, g34665, sbg2, g35017 or
25 g35018 5'UTR sequence.

In another specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5'UTR sequence of an sbg1, g34665, sbg2, g35017 or g35018 cDNA or one of its biologically active fragments or variants, includes a promoter sequence which is exogenous with respect to the sbg1, g34665, sbg2, g35017 or g35018 5'UTR sequence defined therein.

30 In a further preferred embodiment, the nucleic acid comprising the 5'-UTR sequence of an sbg1, g34665, sbg2, g35017 or g35018 cDNA or the biologically active fragments thereof includes an sbg1-related biallelic marker.

35 The invention further comprises a kit for the screening of a candidate substance modulating the expression of the sbg1, g34665, sbg2, g35017 or g35018 gene, wherein said kit

comprises a recombinant vector that comprises a nucleic acid including a 5'UTR sequence of the sbg1, g34665, sbg2, g35017 or g35018 cDNA of SEQ ID Nos 2 to 26 or 36 to 40, or one of their biologically active fragments or variants, the 5'UTR sequence or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein.

5 For the design of suitable recombinant vectors useful for performing the screening methods described above, it will be referred to the section of the present specification wherein the preferred recombinant vectors of the invention are detailed.

Expression levels and patterns of sbg1, g34665, sbg2, g35017 or g35018 may be analyzed by solution hybridization with long probes as described in International Patent
10 Application No. WO 97/05277. Briefly, the sbg1, g34665, sbg2, g35017 or g35018 cDNA or the sbg1, g34665, sbg2, g35017 and g35018 genomic DNA described above, or fragments thereof, is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the sbg1, g34665, sbg2, g35017 and g35018 insert comprises at least 100 or more consecutive nucleotides of the
15 genomic DNA sequence or the cDNA sequences. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridization is performed under standard stringent conditions (40-50°C for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The
20 unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

25 Quantitative analysis of sbg1, g34665, sbg2, g35017 or g35018 gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of a plurality of nucleic acids of sufficient length to permit specific detection of expression of mRNAs capable of hybridizing thereto. For example, the arrays may contain a plurality of nucleic acids derived from genes whose
30 expression levels are to be assessed. The arrays may include the sbg1, g34665, sbg2, g35017 and g35018 genomic DNA, the sbg1, g34665, sbg2, g35017 or g35018 cDNA sequences or the sequences complementary thereto or fragments thereof, particularly those comprising at least one of the biallelic markers according to the present invention. Preferably, the fragments are at least 15 nucleotides in length. In other embodiments, the fragments are at least 25 nucleotides
35 in length. In some embodiments, the fragments are at least 50 nucleotides in length. More

preferably, the fragments are at least 100 nucleotides in length. In another preferred embodiment, the fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

For example, quantitative analysis of sbg1, g34665, sbg2, g35017 or g35018 gene
5 expression may be performed with a complementary DNA microarray as described by Schena
et al.(1995 and 1996). Full length sbg1, g34665, sbg2, g35017 or g35018 cDNAs or fragments
thereof are amplified by PCR and arrayed from a 96-well microtiter plate onto silylated
microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber
to allow rehydration of the array elements and rinsed, once in 0. 2% SDS for 1 min, twice in
10 water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged
in water for 2 min at 95°C, transferred into 0. 2% SDS for 1 min, rinsed twice with water, air
dried and stored in the dark at 25°C.

Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a
single round of reverse transcription. Probes are hybridized to 1 cm² microarrays under a 14 x
15 14 mm glass coverslip for 6-12 hours at 60°C. Arrays are washed for 5 min at 25°C in low
stringency wash buffer (1 x SSC/0. 2% SDS), then for 10 min at room temperature in high
stringency wash buffer (0. 1 x SSC/0. 2% SDS). Arrays are scanned in 0. 1 x SSC using a
fluorescence laser scanning device fitted with a custom filter set. Accurate differential
expression measurements are obtained by taking the average of the ratios of two independent
20 hybridizations.

Quantitative analysis of sbg1, g34665, sbg2, g35017 or g35018 gene expression may
also be performed with full length sbg1, g34665, sbg2, g35017 or g35018 cDNAs or fragments
thereof in complementary DNA arrays as described by Pietu et al.(1996). The full length sbg1,
g34665, sbg2, g35017 or g35018 cDNA or fragments thereof is PCR amplified and spotted on
25 membranes. Then, mRNAs originating from various tissues or cells are labeled with
radioactive nucleotides. After hybridization and washing in controlled conditions, the
hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate
experiments are performed and a quantitative analysis of differentially expressed mRNAs is
then performed.

Alternatively, expression analysis using the sbg1, g34665, sbg2, g35017 or g35018
30 genomic DNA, the sbg1, g34665, sbg2, g35017 or g35018 cDNA, or fragments thereof can be
done through high density nucleotide arrays as described by Lockhart et al.(1996) and
Sosnowsky et al.(1997). Oligonucleotides of 15-50 nucleotides from the sequences of the sbg1,
g34665, sbg2, g35017 or g35018 genomic DNA, the sbg1, g34665, sbg2, g35017 or g35018
35 cDNA sequences particularly those comprising at least one of biallelic markers according the

present invention, or the sequences complementary thereto, are synthesized directly on the chip (Lockhart et al., supra) or synthesized and then addressed to the chip (Sosnowski et al., supra). Preferably, the oligonucleotides are about 20 nucleotides in length.

5 sbg1, g34665, sbg2, g35017 or g35018 cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., supra and application of different electric fields (Sosnowsky et al., 1997), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative
10 analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of sbg1, g34665, sbg2, g35017 or g35018 mRNA.

Methods For Inhibiting The Expression Of An sbg1, g34665, sbg2, g35017 or g35018 Gene

15 Other therapeutic compositions according to the present invention comprise advantageously an oligonucleotide fragment of the nucleic sequence of sbg1, g34665, sbg2, g35017 or g35018 as an antisense tool or a triple helix tool that inhibits the expression of the corresponding sbg1, g34665, sbg2, g35017 or g35018 gene. A preferred fragment of the nucleic sequence of sbg1, g34665, sbg2, g35017 or g35018 comprises an allele of at least one of
20 the biallelic markers of the invention.

Antisense Approach

Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995).

25 Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to the 5'end of the sbg1, g34665, sbg2, g35017 or g35018 mRNA. In another embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targeted gene are used.

Preferred antisense polynucleotides according to the present invention are complementary to a sequence of the mRNAs of sbg1, g34665, sbg2, g35017 or g35018 that
30 contains either the translation initiation codon ATG or a splicing donor or acceptor site.

The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the sbg1, g34665, sbg2, g35017 or g35018 mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., (1986) and

Izant and Weintraub, (1984).

In some strategies, antisense molecules are obtained by reversing the orientation of the sbg1, g34665, sbg2, g35017 or g35018 coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of sbg1, g34665, sbg2, g35017 or g35018 antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in a suitable expression vector.

Alternatively, suitable antisense strategies are those described by Rossi et al.(1991), in the International Applications Nos. WO 94/23026, WO 95/04141, WO 92/18522 and in the European Patent Application No. EP 0 572 287 A2

An alternative to the antisense technology that is used according to the present invention comprises using ribozymes that will bind to a target sequence via their complementary polynucleotide tail and that will cleave the corresponding RNA by hydrolyzing its target site (namely "hammerhead ribozymes"). Briefly, the simplified cycle of a hammerhead ribozyme comprises (1) sequence specific binding to the target RNA via complementary antisense sequences; (2) site-specific hydrolysis of the cleavable motif of the target strand; and (3) release of cleavage products, which gives rise to another catalytic cycle. Indeed, the use of long-chain antisense polynucleotide (at least 30 bases long) or ribozymes with long antisense arms are advantageous. A preferred delivery system for antisense ribozyme is achieved by covalently linking these antisense ribozymes to lipophilic groups or to use liposomes as a convenient vector. Preferred antisense ribozymes according to the present invention are prepared as described by Sczakiel et al.(1995).

Triple Helix Approach

The sbg1, g34665, sbg2, g35017 or g35018 genomic DNA may also be used to inhibit the expression of the sbg1, g34665, sbg2, g35017 or g35018 gene based on intracellular triple helix formation.

Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity when it is associated with a particular gene.

Similarly, a portion of the sbg1, g34665, sbg2, g35017 or g35018 genomic DNA can be used to study the effect of inhibiting sbg1, g34665, sbg2, g35017 or g35018 transcription within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such

homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from the sbg1, g34665, sbg2, g35017 or g35018 genomic DNA are contemplated within the scope of this invention.

To carry out gene therapy strategies using the triple helix approach, the sequences of the sbg1, g34665, sbg2, g35017 or g35018 genomic DNA are first scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting sbg1, g34665, sbg2, g35017 or g35018 expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting sbg1, g34665, sbg2, g35017 or g35018 expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which express the sbg1, g34665, sbg2, g35017 or g35018 gene.

The oligonucleotides can be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

Treated cells are monitored for altered cell function or reduced sbg1, g34665, sbg2, g35017 or g35018 expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to monitor the transcription levels of the sbg1, g34665, sbg2, g35017 or g35018 gene in cells which have been treated with the oligonucleotide.

The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced in vivo using the techniques described above in the antisense approach at a dosage calculated based on the in vitro results, as described in antisense approach.

In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al.(1989).

Pharmaceutical Compositions And Formulations

Sbg1-modulating Compounds

Using the methods disclosed herein, compounds that selectively modulate sbg1 activity *in vitro* and *in vivo* may be identified. The compounds identified by the process of the invention include, for example, antibodies having binding specificity for the sbg1 peptide. It is also expected that homologues of sbg1 may be useful for modulating sbg1-mediated activity and the related physiological condition associated with schizophrenia or bipolar disorder. Generally, it is further expected that assay methods of the present invention based on the role of sbg1 in central

nervous system disorder may be used to identify compounds capable of intervening in the assay cascade of the invention.

Indications

While sbg1 has demonstrated an association with schizophrenia and bipolar disorder, indications involving sbg1 may include various central nervous system disorders. Nervous system disorders are expected to have complex genetic bases and often share certain symptoms. In particular, as described herein, indications may include schizophrenia and other psychotic disorders, mood disorders, autism, substance dependence and alcoholism, mental retardation, and other psychiatric diseases including cognitive, anxiety, eating, impulse-control, and personality disorders, as defined with the Diagnosis and Statistical Manual of Mental Disorders fourth edition (DSM-IV) classification.

Pharmaceutical Formulations and Routes of Administration

The compounds identified using the methods of the present invention can be administered to a mammal, including a human patient, alone or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at therapeutically effective doses to treat or ameliorate schizophrenia or bipolar disorder related disorders. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms as determined by the methods described herein. Preferably, a therapeutically effective dosage is suitable for continued periodic use or administration. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

Routes of Administration

Suitable routes of administration include oral, rectal, transmucosal, or intestinal administration, parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal or intraocular injections. A particularly useful method of administering compounds for treating central nervous system disease involves surgical implantation of a device for delivering the compound over an extended period of time. Sustained release formulations of the invented medicaments particularly are contemplated.

Composition/Formulation

Pharmaceutical compositions and medicaments for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries. Proper formulation is dependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueous solutions,

preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer such as a phosphate or bicarbonate buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

5 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in
10 suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

 For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

15 For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable gaseous propellant, *e.g.*, carbon dioxide. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin, for use in an inhaler or insufflator, may
20 be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

 The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The
25 compositions may take such forms as suspensions, solutions or emulsions in aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

 Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Aqueous suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or
30 dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

 Alternatively, the active ingredient may be in powder or lyophilized form for constitution with a suitable vehicle, such as sterile pyrogen-free water, before use.

 In addition to the formulations described previously, the compounds may also be
35 formulated as a depot preparation. Such long acting formulations may be administered by

implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

5 Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.

10 Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

 The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and
15 polymers such as polyethylene glycols.

Effective Dosage.

 Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve their intended purpose. More specifically, a therapeutically effective amount means an amount
20 effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

 For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays, and a dose can be formulated in animal models.
25 Such information can be used to more accurately determine useful doses in humans.

 A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50, (the dose lethal to 50% of the test population) and the ED50 (the
30 dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD50 and ED50. Compounds which exhibit high therapeutic indices are preferred.

 The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably
35 within a range of circulating concentrations that include the ED50, with little or no toxicity. The

dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g., Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1).

Computer-Related Embodiments

As used herein the term "nucleic acid codes of the invention" encompass the nucleotide sequences comprising, consisting essentially of, or consisting of any one of the following:

a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 31 to 292651 and 292844 to 319608.

b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 54 to 229, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID.

c) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 2 to 26, 36 to 40 or the complements thereof.

d) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1:

(i) 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047;

(ii) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;

(iii) 94124 to 94964;

(iv) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and

(v) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915;

e) a contiguous span according to a), b), c) or d), wherein said span includes a biallelic marker selected from the group consisting of A1 to A489.

f) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one the ranges of nucleotide positions designated pos1 to pos166 of SEQ ID No. 1 listed in Table 1 above;

g) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 42, 44 to 48 and 52 to 269, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker;

h) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos 2 to 26, 36 to 40 and 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018 -related biallelic marker with the alternative allele present at said biallelic marker.

i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and 361 to A489.

The "nucleic acid codes of the invention" further encompass nucleotide sequences homologous to a contiguous span of at least 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides, to the extent that such a length is consistent with the particular sequence of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, and the complements thereof. The "nucleic acid codes of the invention" also encompass nucleotide sequences homologous to a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No. 1:

(i) 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047;

(ii) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;

(iii) 94124 to 94964;

(iv) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952,

216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and

(v) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915.

Homologous sequences refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, or 75% homology to these contiguous spans. Homology may be determined using any method described herein, including BLAST2N with the default parameters or with any modified parameters. Homologous sequences also may include RNA sequences in which uridines replace the thymines in the nucleic acid codes of the invention. It will be appreciated that the nucleic acid codes of the invention can be represented in the traditional single character format (See the inside back cover of Stryer, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any other format or code which records the identity of the nucleotides in a sequence.

As used herein the term "polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43" encompasses the polypeptide sequence of SEQ ID Nos 27 to 35 and 41 to 43, polypeptide sequences homologous to the polypeptides of SEQ ID Nos. 27 to 35 and 41 to 43, or fragments of any of the preceding sequences. Homologous polypeptide sequences refer to a polypeptide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75% homology to one of the polypeptide sequences of SEQ ID Nos. 27 to 35 and 41 to 43. Homology may be determined using any of the computer programs and parameters described herein, including FASTA with the default parameters or with any modified parameters. The homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error as described above. The polypeptide fragments comprise at least 4, 6, 8, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of the polypeptides of SEQ ID Nos. 27 to 35 and 41 to 43. Preferably, the fragments are novel fragments. It will be appreciated that the polypeptide codes of the SEQ ID Nos. 27 to 35 and 41 to 43 can be represented in the traditional single character format or three letter format (See the inside back cover of Starrier, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any other format which relates the identity of the polypeptides in a sequence.

It will be appreciated by those skilled in the art that the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 and polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 can be stored, recorded, and manipulated on any medium which can be read and accessed by a

computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate embodiment comprising one or more of nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, or one or more of the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 nucleic acid codes of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 polypeptide codes of SEQ ID Nos 27 to 35 and 41 to 43.

Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art.

Embodiments of the present invention include systems, particularly computer systems which store and manipulate the sequence information described herein. One example of a computer system 100 is illustrated in block diagram form in Figure 19. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to analyze the nucleotide sequences of the nucleic acid codes of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229, or the amino acid sequences of the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43. In one embodiment, the computer system 100 is a Sun Enterprise 1000 server (Sun Microsystems, Palo Alto, CA). The computer system 100 preferably includes a processor for processing, accessing and manipulating the sequence data. The processor 105 can be any well-known type of central processing unit, such as the Pentium III from Intel Corporation, or similar processor from Sun, Motorola, Compaq or International Business Machines.

Preferably, the computer system 100 is a general purpose system that comprises the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable.

In one particular embodiment, the computer system 100 includes a processor 105 connected to a bus which is connected to a main memory 115 (preferably implemented as RAM) and one or more internal data storage devices 110, such as a hard drive and/or other computer readable media having data recorded thereon. In some embodiments, the computer system 100 further includes one or more data retrieving device 118 for reading the data stored on the internal

data storage devices 110.

The data retrieving device 118 may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, etc. In some embodiments, the internal data storage device 110 is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system 100 may advantageously include or be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device.

The computer system 100 includes a display 120 which is used to display output to a computer user. It should also be noted that the computer system 100 can be linked to other computer systems 125a-c in a network or wide area network to provide centralized access to the computer system 100.

Software for accessing and processing the nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, or the amino acid sequences of the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 (such as search tools, compare tools, and modeling tools etc.) may reside in main memory 115 during execution.

In some embodiments, the computer system 100 may further comprise a sequence comparer for comparing the above-described nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 stored on a computer readable medium to reference nucleotide or polypeptide sequences stored on a computer readable medium. A "sequence comparer" refers to one or more programs which are implemented on the computer system 100 to compare a nucleotide or polypeptide sequence with other nucleotide or polypeptide sequences and/or compounds including but not limited to peptides, peptidomimetics, and chemicals stored within the data storage means. For example, the sequence comparer may compare the nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229, or the amino acid sequences of the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies, motifs implicated in biological function, or structural motifs. The various sequence comparer programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.

Figure 20 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database. The database of sequences can be a private database stored within the computer system 100, or a public database such as GENBANK, PIR OR SWISSPROT that is available through the Internet.

The process 200 begins at a start state 201 and then moves to a state 202 wherein the new

sequence to be compared is stored to a memory in a computer system 100. As discussed above, the memory could be any type of memory, including RAM or an internal storage device.

The process 200 then moves to a state 204 wherein a database of sequences is opened for analysis and comparison. The process 200 then moves to a state 206 wherein the first sequence stored in the database is read into a memory on the computer. A comparison is then performed at a state 210 to determine if the first sequence is the same as the second sequence. It is important to note that this step is not limited to performing an exact comparison between the new sequence and the first sequence in the database. Well-known methods are known to those of skill in the art for comparing two nucleotide or protein sequences, even if they are not identical. For example, gaps can be introduced into one sequence in order to raise the homology level between the two tested sequences. The parameters that control whether gaps or other features are introduced into a sequence during comparison are normally entered by the user of the computer system.

Once a comparison of the two sequences has been performed at the state 210, a determination is made at a decision state 210 whether the two sequences are the same. Of course, the term "same" is not limited to sequences that are absolutely identical. Sequences that are within the homology parameters entered by the user will be marked as "same" in the process 200.

If a determination is made that the two sequences are the same, the process 200 moves to a state 214 wherein the name of the sequence from the database is displayed to the user. This state notifies the user that the sequence with the displayed name fulfills the homology constraints that were entered. Once the name of the stored sequence is displayed to the user, the process 200 moves to a decision state 218 wherein a determination is made whether more sequences exist in the database. If no more sequences exist in the database, then the process 200 terminates at an end state 220. However, if more sequences do exist in the database, then the process 200 moves to a state 224 wherein a pointer is moved to the next sequence in the database so that it can be compared to the new sequence. In this manner, the new sequence is aligned and compared with every sequence in the database.

It should be noted that if a determination had been made at the decision state 212 that the sequences were not homologous, then the process 200 would move immediately to the decision state 218 in order to determine if any other sequences were available in the database for comparison.

Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid code of SEQ ID NOs. 1 to 26, 36 to 40 and 54 to 229 or a polypeptide code of SEQ ID Nos 27 to 35 and 41 to 43, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to the nucleic acid code of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to

229 or polypeptide code of SEQ ID Nos. 27 to 35 and 41 to 43 and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the above described nucleic acid code of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 and polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43.

Another aspect of the present invention is a method for determining the level of homology between a nucleic acid code of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 and a reference nucleotide sequence, comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code and the reference nucleotide sequence with the computer program. The computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, including BLAST2N with the default parameters or with any modified parameters. The method may be implemented using the computer systems described above. The method may also be performed by reading 2, 5, 10, 15, 20, 25, 30, or 50 of the above described nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 through use of the computer program and determining homology between the nucleic acid codes and reference nucleotide sequences.

Figure 21 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous. The process 250 begins at a start state 252 and then moves to a state 254 wherein a first sequence to be compared is stored to a memory. The second sequence to be compared is then stored to a memory at a state 256. The process 250 then moves to a state 260 wherein the first character in the first sequence is read and then to a state 262 wherein the first character of the second sequence is read. It should be understood that if the sequence is a nucleotide sequence, then the character would normally be either A, T, C, G or U. If the sequence is a protein sequence, then it should be in the single letter amino acid code so that the first and sequence sequences can be easily compared.

A determination is then made at a decision state 264 whether the two characters are the same. If they are the same, then the process 250 moves to a state 268 wherein the next characters in the first and second sequences are read. A determination is then made whether the next characters are the same. If they are, then the process 250 continues this loop until two characters are not the same. If a determination is made that the next two characters are not the

same, the process 250 moves to a decision state 274 to determine whether there are any more characters either sequence to read.

If there aren't any more characters to read, then the process 250 moves to a state 276 wherein the level of homology between the first and second sequences is displayed to the user. The level of homology is determined by calculating the proportion of characters between the sequences that were the same out of the total number of sequences in the first sequence. Thus, if every character in a first 100 nucleotide sequence aligned with a every character in a second sequence, the homology level would be 100%.

Alternatively, the computer program may be a computer program which compares the nucleotide sequences of the nucleic acid codes of the present invention, to reference nucleotide sequences in order to determine whether the nucleic acid code of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 differs from a reference nucleic acid sequence at one or more positions. Optionally such a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the nucleic acid code of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229. In one embodiment, the computer program may be a program which determines whether the nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 contain a biallelic marker or single nucleotide polymorphism (SNP) with respect to a reference nucleotide sequence. This single nucleotide polymorphism may comprise a single base substitution, insertion, or deletion, while this biallelic marker may comprise about one to ten consecutive bases substituted, inserted or deleted.

Another aspect of the present invention is a method for determining the level of homology between a polypeptide code of SEQ ID Nos. 27 to 35 and 41 to 43 and a reference polypeptide sequence, comprising the steps of reading the polypeptide code of SEQ ID Nos. 27 to 35 and 41 to 43 and the reference polypeptide sequence through use of a computer program which determines homology levels and determining homology between the polypeptide code and the reference polypeptide sequence using the computer program.

Accordingly, another aspect of the present invention is a method for determining whether a nucleic acid code of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program which identifies single nucleotide polymorphisms. The method may be implemented by the computer systems described above and the method illustrated in Figure 21. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic

acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.

5 In other embodiments the computer based system may further comprise an identifier for identifying features within the nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the amino acid sequences of the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43.

10 An "identifier" refers to one or more programs which identifies certain features within the above-described nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the amino acid sequences of the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43. In one embodiment, the identifier may comprise a program which identifies an open reading frame in the cDNAs codes of SEQ ID Nos 2 to 26 and 36 to 40.

15 Figure 22 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence. The process 300 begins at a start state 302 and then moves to a state 304 wherein a first sequence that is to be checked for features is stored to a memory 115 in the computer system 100. The process 300 then moves to a state 306 wherein a database of sequence features is opened. Such a database would include a list of each feature's attributes along with the name of the feature. For example, a feature name could be "Initiation Codon" and the attribute would be "ATG". Another example would be the feature name "TAATAA Box" and the feature attribute would be "TAATAA". An example of such a database is produced by the University of Wisconsin Genetics Computer Group (www.gcg.com).

20 Once the database of features is opened at the state 306, the process 300 moves to a state 308 wherein the first feature is read from the database. A comparison of the attribute of the first feature with the first sequence is then made at a state 310. A determination is then made at a decision state 316 whether the attribute of the feature was found in the first sequence. If the attribute was found, then the process 300 moves to a state 318 wherein the name of the found feature is displayed to the user.

30 The process 300 then moves to a decision state 320 wherein a determination is made whether more features exist in the database. If no more features do exist, then the process 300 terminates at an end state 324. However, if more features do exist in the database, then the process 300 reads the next sequence feature at a state 326 and loops back to the state 310 wherein the attribute of the next feature is compared against the first sequence.

35 It should be noted, that if the feature attribute is not found in the first sequence at the decision state 316, the process 300 moves directly to the decision state 320 in order to

determine if any more features exist in the database.

In another embodiment, the identifier may comprise a molecular modeling program which determines the 3-dimensional structure of the polypeptides codes of SEQ ID Nos. 27 to 35 and 41 to 43. In some embodiments, the molecular modeling program identifies target sequences that are most compatible with profiles representing the structural environments of the residues in known three-dimensional protein structures. (See, e.g., Eisenberg et al., U.S. Patent No. 5,436,850 issued July 25, 1995). In another technique, the known three-dimensional structures of proteins in a given family are superimposed to define the structurally conserved regions in that family. This protein modeling technique also uses the known three-dimensional structure of a homologous protein to approximate the structure of the polypeptide codes of SEQ ID Nos. 4 to 8. (See e.g., Srinivasan, et al., U.S. Patent No. 5,557,535 issued September 17, 1996). Conventional homology modeling techniques have been used routinely to build models of proteases and antibodies. (Sowdhamini et al., Protein Engineering 10:207, 215 (1997)). Comparative approaches can also be used to develop three-dimensional protein models when the protein of interest has poor sequence identity to template proteins. In some cases, proteins fold into similar three-dimensional structures despite having very weak sequence identities. For example, the three-dimensional structures of a number of helical cytokines fold in similar three-dimensional topology in spite of weak sequence homology.

The recent development of threading methods now enables the identification of likely folding patterns in a number of situations where the structural relatedness between target and template(s) is not detectable at the sequence level. Hybrid methods, in which fold recognition is performed using Multiple Sequence Threading (MST), structural equivalencies are deduced from the threading output using a distance geometry program DRAGON to construct a low resolution model, and a full-atom representation is constructed using a molecular modeling package such as QUANTA.

According to this 3-step approach, candidate templates are first identified by using the novel fold recognition algorithm MST, which is capable of performing simultaneous threading of multiple aligned sequences onto one or more 3-D structures. In a second step, the structural equivalencies obtained from the MST output are converted into interresidue distance restraints and fed into the distance geometry program DRAGON, together with auxiliary information obtained from secondary structure predictions. The program combines the restraints in an unbiased manner and rapidly generates a large number of low resolution model confirmations. In a third step, these low resolution model confirmations are converted into full-atom models and subjected to energy minimization using the molecular modeling package QUANTA. (See e.g., Aszodi et al., Proteins: Structure, Function, and Genetics, Supplement 1:38-42 (1997)).

The results of the molecular modeling analysis may then be used in rational drug design techniques to identify agents which modulate the activity of the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43.

Accordingly, another aspect of the present invention is a method of identifying a feature within the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 comprising reading the nucleic acid code(s) or the polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) or polypeptide code(s) with the computer program. In one embodiment, computer program comprises a computer program which identifies open reading frames. In a further embodiment, the computer program identifies structural motifs in a polypeptide sequence. In another embodiment, the computer program comprises a molecular modeling program. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.

The nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43 may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparers, identifiers, or sources of reference nucleotide or polypeptide sequences to be compared to the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid codes of SEQ ID Nos. 1 to 26, 36 to 40 and 54 to 229 or the polypeptide codes of SEQ ID Nos. 27 to 35 and 41 to 43. The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, *J. Mol. Biol.* 215: 403 (1990)), FASTA (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA*, 85: 2444 (1988)), FASTDB (Brutlag et al. *Comp. App. Biosci.* 6:237-245, 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.),

5 Cerius².DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II, (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMM (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwent's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database. Many other programs and data bases would be apparent to one of skill in the art given the present disclosure.

10 Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

15 Throughout this application, various publications, patents, and published patent applications are cited. The disclosures of the publications, patents, and published patent specifications referenced in this application are all hereby incorporated by reference in their entireties into the present disclosure to more fully describe the state of the art to which this invention pertains.

20 EXAMPLES

25 Several of the methods of the present invention are described in the following examples, which are offered by way of illustration and not by way of limitation. Many other modifications and variations of the invention as herein set forth can be made without departing from the spirit and scope thereof and therefore only such limitations should be imposed as are indicated by the appended claims.

30 Example 1

Identification Of Biallelic Markers - DNA Extraction

35 Donors were unrelated and healthy. They presented a sufficient diversity for being representative of a heterogeneous population. The DNA from 100 individuals was extracted and tested for the detection of the biallelic markers.

30 ml of peripheral venous blood were taken from each donor in the presence of EDTA. Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume: 10 mM Tris pH7.6; 5 mM MgCl₂; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red cells present in the supernatant, after resuspension of the pellet in the lysis solution.

The pellet of white cells was lysed overnight at 42°C with 3.7 ml of lysis solution composed of:

- 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM) / NaCl 0.4 M
- 200 µl SDS 10%
- 500 µl K-proteinase (2 mg K-proteinase in TE 10-2 / NaCl 0.4 M).

For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm. The pellet was dried at 37°C, and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD = 50 µg/ml DNA). To determine the presence of proteins in the DNA solution, the OD 260 / OD 280 ratio was determined. Only DNA preparations having a OD 260 / OD 280 ratio between 1.8 and 2 were used in the subsequent examples described below.

The pool was constituted by mixing equivalent quantities of DNA from each individual.

Example 2

Identification Of Biallelic Markers: Amplification Of Genomic DNA By PCR

The amplification of specific genomic sequences of the DNA samples of Example 1 was carried out on the pool of DNA obtained previously. In addition, 50 individual samples were similarly amplified.

PCR assays were performed using the following protocol:

Final volume	25 µl
DNA	2 ng/µl
MgCl ₂	2 mM
dNTP (each)	200 µM
primer (each)	2.9 ng/µl

Ampli Taq Gold DNA polymerase

0.05 unit/ μ l

PCR buffer (10x = 0.1 M TrisHCl pH8.3 0.5M KCl)

1x

Each pair of first primers was designed using the sequence information of genomic DNA sequences of SEQ ID Nos 1 to 26, 36 to 40 and 54 to 229 disclosed herein and the OSP software (Hillier & Green, 1991). This first pair of primers was about 20 nucleotides in length and had the sequences disclosed in Table 6a in the columns labeled "Position range of amplification primer in SEQ ID No." and "Complementary position range of amplification primer in SEQ ID No.".

Table 6a

Amplicon	SEQ ID No	Primer name	Position range of amplification primer in SEQ ID		Primer name	Complementary position range of amplification primer in SEQ ID	
99-27943	1	B1	7938	7958	C1	8446	8465
8-121	1	B2	14699	14718	C2	15100	15118
99-27935	1	B3	21365	21385	C3	21845	21864
8-122	1	B4	25409	25426	C4	25825	25844
8-123	1	B5	29349	29366	C5	29684	29701
8-147	1	B6	29900	29919	C6	30340	30356
99-34243	1	B7	49219	49239	C7	49664	49684
8-127	1	B8	64639	64657	C8	64981	64999
8-128	1	B9	65453	65471	C9	65856	65874
8-129	1	B10	65547	65566	C10	65949	65966
99-34240	1	B11	75629	75649	C11	76140	76158
99-31959	1	B12	94254	94273	C12	94683	94703
99-31960	1	B13	95034	95053	C13	95543	95563
99-31962	1	B14	96707	96727	C14	97222	97242
99-44282	1	B15	106357	106377	C15	106805	106822
99-24656	1	B16	107022	107040	C16	107495	107513
99-24636	1	B17	107132	107152	C17	107613	107630
99-31939	1	B18	108425	108444	C18	108916	108935
99-44281	1	B19	109333	109353	C19	109848	109868
99-31941	1	B20	112149	112169	C20	112720	112740
99-31942	1	B21	115144	115162	C21	115617	115637

99-24635	1	B22	155353	155373	C22	155805	155822
99-16059	1	B23	157860	157878	C23	158296	158316
99-24634	1	B24	160770	160787	C24	161240	161257
99-24639	1	B25	160279	160298	C25	160785	160802
99-7652	1	B26	168813	168830	C26	169331	169351
99-16100	1	B27	170666	170686	C27	171153	171173
99-5862	1	B28	173065	173085	C28	173495	173514
99-16083	1	B29	173830	173850	C29	174309	174327
99-16044	1	B30	175453	175470	C30	175881	175901
99-16042	1	B31	180464	180481	C31	180991	181008
99-5919	1	B32	189753	189771	C32	190187	190207
99-24658	1	B33	197116	197135	C33	197555	197572
99-30364	1	B34	198666	198684	C34	199148	199168
99-30366	1	B35	200145	200162	C35	200663	200683
99-16094	1	B36	204263	204282	C36	204643	204662
99-24644	1	B37	204741	204758	C37	205222	205240
99-16107	1	B38	206103	206120	C38	206548	206568
99-15873	1	B39	211454	211471	C39	211893	211910
8-124	1	B40	214564	214581	C40	214965	214983
8-125	1	B41	215506	215525	C41	215924	215942
8-132	1	B42	215628	215647	C42	215998	216016
99-13929	1	B43	215749	215769	C43	216210	216228
8-131	1	B44	216473	216491	C44	216883	216900
8-130	1	B45	216683	216702	C45	217091	217109
8-209	1	B46	217119	217136	C46	217521	217539
99-5897	1	B47	219408	219425	C47	219882	219899
99-24649	1	B48	220505	220522	C48	221004	221021
8-199	1	B49	221384	221402	C49	221807	221824
8-198	1	B50	221740	221759	C50	222167	222185
8-195	1	B51	222696	222713	C51	223073	223093
99-13925	1	B52	223499	223518	C52	224013	224033
8-192	1	B53	225103	225120	C53	225505	225524
99-16090	1	B54	225995	226013	C54	226510	226530
8-189	1	B55	226211	226230	C55	226615	226632

8-188	1	B56	226569	226588	C56	226988	227005
8-187	1	B57	226915	226934	C57	227319	227338
8-185	1	B58	227468	227487	C58	227888	227907
99-16051	1	B59	227768	227788	C59	228214	228231
8-184	1	B60	227832	227849	C60	228234	228252
8-183	1	B61	228209	228227	C61	228635	228654
8-181	1	B62	228898	228917	C62	229499	229517
8-180	1	B63	229443	229462	C63	229624	229642
8-179	1	B64	229442	229459	C64	229857	229874
8-143	1	B65	229487	229506	C65	229896	229913
8-178	1	B66	229739	229756	C66	230141	230159
8-177	1	B67	230097	230115	C67	230517	230536
8-119	1	B68	230210	230227	C68	230622	230641
8-138	1	B69	230517	230536	C69	230899	230917
8-175	1	B70	230705	230724	C70	231127	231144
99-15870	1	B71	231278	231298	C71	231729	231747
8-142	1	B72	231084	231103	C72	231485	231503
8-145	1	B73	231588	231605	C73	231990	232007
8-171	1	B74	232147	232166	C74	232547	232566
8-170	1	B75	232405	232423	C75	232830	232849
8-169	1	B76	232744	232762	C76	233145	233163
8-168	1	B77	233056	233074	C77	233461	233479
8-235	1	B78	233314	233334	C78	233785	233801
8-137	1	B79	234039	234058	C79	234440	234458
8-165	1	B80	234516	234533	C80	234916	234935
99-16087	1	B81	235081	235101	C81	235515	235533
8-157	1	B82	237972	237989	C82	238381	238399
8-155	1	B83	238607	238626	C83	239029	239046
99-16038	1	B84	239405	239425	C84	239862	239880
8-136	1	B85	239606	239624	C85	240012	240029
8-153	1	B86	239651	239670	C86	240058	240075
8-135	1	B87	240356	240375	C87	240691	240708
99-16050	1	B88	240518	240538	C88	240988	241006
8-144	1	B89	240810	240828	C89	241217	241235

8-141	1	B90	241094	241113	C90	241502	241520
99-15880	1	B91	241700	241717	C91	242151	242171
8-140	1	B92	241373	241392	C92	241773	241792
8-240	1	B93	242169	242188	C93	242571	242588
8-225	1	B94	244172	244191	C94	244574	244593
99-25940	1	B95	247513	247533	C95	248023	248043
99-16032	1	B96	248204	248223	C96	248588	248606
99-16055	1	B97	253315	253333	C97	253816	253834
99-16105	1	B98	255697	255715	C98	256133	256152
99-16101	1	B99	258138	258155	C99	258606	258623
99-16033	1	B100	259885	259902	C100	260324	260342
99-15875	1	B101	279626	279644	C101	280154	280173
99-13521	1	B102	287977	287995	C102	288484	288504
8-112	1	B103	292501	292519	C103	292901	292920
8-111	1	B104	295376	295395	C104	295777	295795
8-110	1	B105	295682	295701	C105	296102	296119
8-134	1	B106	295812	295830	C106	296143	296161
99-7462	1	B107	298946	298964	C107	299459	299476
99-16052	1	B108	300153	300170	C108	300660	300680
99-16047	1	B109	311615	311632	C109	312126	312144
99-25993	1	B110	315649	315668	C110	316129	316147
99-25101	1	B111	316925	316943	C111	317378	317395
Amplicon	SEQ ID No	Primer name	Position range of amplification primer in SEQ ID		Primer name	Complementary position range of amplification primer in SEQ ID	
8-94	162	B112	1250	1267	C112	1651	1669
8-95	161	B113	1125	1144	C113	1526	1543
8-97	160	B114	1249	1268	C114	1581	1598
8-98	159	B115	1135	1154	C115	1550	1568
99-14021	151	B116	1394	1411	C116	1853	1870
99-14364	152	B117	1344	1364	C117	1798	1816
99-15056	115	B118	1098	1118	C118	1582	1599
99-15063	116	B119	1347	1364	C119	1784	1804
99-15065	117	B120	1120	1140	C120	1568	1585

99-15229	157	B121	1419	1437	C121	1893	1912
99-15231	163	B122	1189	1209	C122	1701	1719
99-15232	155	B123	1211	1228	C123	1677	1695
99-15239	164	B124	1139	1156	C124	1579	1599
99-15252	118	B125	1	18	C125	434	451
99-15253	119	B126	1120	1138	C126	1578	1596
99-15256	120	B127	1110	1127	C127	1548	1565
99-15258	121	B128	1165	1183	C128	1685	1705
99-15261	122	B129	1302	1320	C129	1782	1802
99-15280	123	B130	1070	1087	C130	1590	1610
99-15355	124	B131	1352	1369	C131	1822	1840
99-15663	175	B132	1349	1369	C132	1781	1798
99-15664	176	B133	1184	1203	C133	1667	1685
99-15665	174	B134	1423	1441	C134	1879	1898
99-15668	177	B135	1363	1380	C135	1801	1821
99-15672	173	B136	1120	1138	C136	1649	1666
99-15682	178	B137	1184	1202	C137	1665	1683
99-16081	113	B138	114	131	C138	556	575
99-16082	114	B139	16	33	C139	527	547
99-20933	179	B140	1130	1149	C140	1563	1581
99-20977	147	B141	1430	1447	C141	1921	1941
99-20978	148	B142	1124	1144	C142	1571	1589
99-20981	149	B143	1202	1219	C143	1630	1650
99-20983	150	B144	1099	1119	C144	1530	1548
99-22310	154	B145	1183	1203	C145	1630	1648
99-25029	180	B146	1292	1307	C146	1722	1741
99-25224	125	B147	937	955	C147	1446	1466
99-25869	181	B148	1320	1340	C148	1849	1868
99-25881	182	B149	1227	1245	C149	1693	1713
99-25897	183	B150	1242	1262	C150	1736	1756
99-25906	184	B151	1374	1392	C151	1888	1908
99-25917	185	B152	1115	1135	C152	1595	1615
99-25924	186	B153	1287	1306	C153	1717	1736

99-25950	126	B154	1381	1399	C154	1859	1879
99-25961	127	B155	1391	1411	C155	1854	1873
99-25965	128	B156	1429	1449	C156	1879	1899
99-25966	129	B157	1219	1239	C157	1721	1741
99-25967	130	B158	1064	1084	C158	1537	1556
99-25969	131	B159	1171	1191	C159	1680	1700
99-25972	132	B160	1368	1388	C160	1795	1815
99-25974	133	B161	1100	1120	C161	1623	1643
99-25977	134	B162	1191	1211	C162	1710	1730
99-25978	135	B163	1155	1175	C163	1644	1663
99-25979	136	B164	1409	1427	C164	1924	1944
99-25980	137	B165	1332	1352	C165	1817	1837
99-25984	138	B166	1293	1310	C166	1794	1812
99-25985	139	B167	1308	1328	C167	1756	1776
99-25989	140	B168	1346	1366	C168	1880	1898
99-26126	165	B169	1004	1022	C169	1525	1545
99-26138	187	B170	1309	1327	C170	1741	1761
99-26146	188	B171	1314	1334	C171	1746	1764
99-26147	141	B172	1433	1453	C172	1879	1896
99-26150	142	B173	1323	1340	C173	1758	1776
99-26153	143	B174	1458	1476	C174	1885	1905
99-26154	144	B175	1396	1415	C175	1903	1920
99-26156	145	B176	1212	1229	C176	1702	1722
99-26166	166	B177	1237	1257	C177	1739	1757
99-26167	167	B178	1319	1339	C178	1759	1778
99-26169	168	B179	1262	1282	C179	1693	1711
99-26171	169	B180	1431	1450	C180	1860	1880
99-26183	170	B181	1348	1367	C181	1798	1818
99-26189	189	B182	1215	1235	C182	1644	1664
99-26190	190	B183	1071	1091	C183	1502	1520
99-26191	191	B184	1095	1115	C184	1539	1558
99-26201	192	B185	1304	1324	C185	1749	1767
99-26222	193	B186	1354	1373	C186	1843	1863

99-26223	194	B187	1277	1297	C187	1842	1862
99-26225	195	B188	1355	1375	C188	1805	1825
99-26228	196	B189	1330	1350	C189	1792	1812
99-26233	197	B190	1254	1274	C190	1755	1775
99-26234	198	B191	1379	1399	C191	1813	1833
99-26238	199	B192	1235	1255	C192	1668	1686
99-5873	146	B193	1176	1194	C193	1632	1649
99-5912	171	B194	1463	1483	C194	1946	1963
99-6012	158	B195	1292	1310	C195	1758	1776
99-6080	156	B196	1061	1081	C196	1572	1589
99-7308	153	B197	1345	1362	C197	1814	1834
99-7337	172	B198	1298	1318	C198	1731	1748
99-16106	200	B199	32	50	C199	518	535
99-25332	201	B200	1	18	C200	461	478
99-25516	202	B201	1	18	C201	385	404
99-26173	203	B202	1033	1052	C202	1570	1589
99-26267	204	B203	983	1002	C203	1553	1573
99-26284	205	B204	1460	1480	C204	1874	1894
99-26559	206	B205	1187	1207	C205	1650	1670
99-26769	207	B206	1249	1267	C206	1707	1727
99-26772	208	B207	1235	1254	C207	1702	1722
99-26776	209	B208	1294	1314	C208	1755	1775
99-26779	210	B209	1072	1089	C209	1548	1568
99-26781	211	B210	1477	1497	C210	1905	1925
99-26782	212	B211	1202	1221	C211	1695	1715
99-26783	213	B212	1421	1440	C212	1857	1877
99-26787	214	B213	1406	1425	C213	1872	1892
99-26789	215	B214	1301	1319	C214	1771	1791
99-27297	216	B215	1206	1224	C215	1761	1779
99-27306	217	B216	1395	1415	C216	1822	1842
99-27312	218	B217	1445	1463	C217	1940	1960
99-27323	219	B218	1132	1150	C218	1610	1628
99-27335	220	B219	1322	1342	C219	1768	1788

99-27345	221	B220	1139	1159	C220	1672	1689
99-27349	222	B221	1337	1355	C221	1748	1767
99-27352	223	B222	1250	1269	C222	1677	1697
99-27353	224	B223	1085	1105	C223	1584	1604
99-27360	225	B224	1361	1381	C224	1793	1812
99-27361	226	B225	1322	1340	C225	1815	1834
99-27365	227	B226	1081	1099	C226	1590	1609
99-27680	228	B227	1	18	C227	509	526
99-27912	229	B228	1230	1250	C228	1659	1679
99-30329	112	B229	1	18	C229	496	514

Preferably, the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification which was useful for sequencing.

Primers from the column labeled "Position range of amplification primer in SEQ ID No." contain the following additional PU 5' sequence: TGTAACGACGGCCAGT (SEQ ID No. 126); primers from the column labeled "Complementary position range of amplification primer in SEQ ID No." contain the following RP 5' sequence: CAGGAAACAGCTATGACC (SEQ ID No. 127).

The synthesis of these primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

DNA amplification was performed on a Genius II thermocycler. After heating at 95°C for 10 min, 40 cycles were performed. Each cycle comprised: 30 sec at 95°C, 54°C for 1 min, and 30 sec at 72°C. For final elongation, 10 min at 72°C ended the amplification. The quantities of the amplification products obtained were determined on 96-well microtiter plates, using a fluorometer and Picogreen as intercalant agent (Molecular Probes).

Example 3

Identification of Polymorphisms

a) Identification of Biallelic Markers from Amplified Genomic DNA of Example 2

The sequencing of the amplified DNA obtained in Example 2 was carried out on ABI 377 sequencers. The sequences of the amplification products were determined using automated dideoxy terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of the sequencing reactions were run on sequencing gels and the sequences were determined using gel image analysis (ABI Prism DNA Sequencing Analysis software (2.1.2 version)).

The sequence data were further evaluated to detect the presence of biallelic markers

within the amplified fragments. The polymorphism search was based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position as described previously.

The localization of the biallelic markers detected in the fragments of amplification are as shown below in Table 6b.

Table 6b
Biallelic Markers

Amplicon	BM	Marker Name	Polymorphism		SEQ ID No.	BM position in SEQID	Position of probes in SEQ ID No.		Probe No.
			All1	All2					
99-27943	A1	99-27943-150	G	C	1	8316	8304	8328	P1
8-121	A2	8-121-28	A	T	1	14726	14714	14738	P2
8-121	A3	8-121-36	C	T	1	14734	14722	14746	P3
8-121	A4	8-121-154	A	T	1	14852	14840	14864	P4
8-121	A5	8-121-187	A	C	1	14885	14873	14897	P5
8-121	A6	8-121-243	G	T	1	14941	14929	14953	P6
8-121	A7	8-121-281	A	C	1	14979	14967	14991	P7
8-121	A8	8-121-352	C	T	1	15050	15038	15062	P8
8-121	A9	8-121-364	C	T	1	15062	15050	15074	P9
8-121	A10	8-121-371	A	G	1	15069	15057	15081	P10
99-27935	A11	99-27935-193	G	C	1	21672	21660	21684	P11
8-122	A12	8-122-72	A	T	1	25480	25468	25492	P12
8-122	A13	8-122-100	C	T	1	25508	25496	25520	P13
8-122	A14	8-122-271	deletion of CAAA		1	25679	25667	25691	P14
8-122	A15	8-122-272	A	A	1	25680	25668	25692	P15
8-122	A16	8-122-326	A	A	1	25734	25722	25746	P16
8-122	A17	8-122-360	C	C	1	25768	25756	25780	P17
8-123	A18	8-123-55	A	A	1	29403	29391	29415	P18
8-123	A19	8-123-189	C	C	1	29537	29525	29549	P19
8-123	A20	8-123-197	C	C	1	29545	29533	29557	P20
8-123	A21	8-123-307	G	G	1	29655	29643	29667	P21
8-147	A22	8-147-270	A	A	1	30169	30157	30181	P22

99-34243	A23	99-34243-210	A	A	1	49475	49463	49487	P23
8-127	A24	8-127-28	A	A	1	64666	64654	64678	P24
8-127	A25	8-127-119	A	A	1	64757	64745	64769	P25
8-127	A26	8-127-159	A	A	1	64797	64785	64809	P26
8-127	A27	8-127-236	C	C	1	64874	64862	64886	P27
8-127	A28	8-127-240	A	A	1	64878	64866	64890	P28
8-127	A29	8-127-280	G	G	1	64918	64906	64930	P29
8-128	A30	8-128-33	C	C	1	65485	65473	65497	P30
8-128	A31	8-128-52	A	A	1	65504	65492	65516	P31
8-128	A32	8-128-61	G	G	1	65513	65501	65525	P32
8-128	A33	8-128-68	C	C	1	65520	65508	65532	P33
8-128	A34	8-128-69	A	A	1	65521	65509	65533	P34
8-128	A35	8-128-85	A	A	1	65537	65525	65549	P35
8-129	A36	8-129-50	C	C	1	65596	65584	65608	P36
8-129	A37	8-129-60	deletion of A		1	65607	65594	65618	P37
8-129	A38	8-129-311	A	G	1	65857	65845	65869	P38
8-129	A39	8-129-401	C	T	1	65947	65935	65959	P39
99-34240	A40	99-34240-492	A	T	1	75667	75655	75679	P40
99-31959	A41	99-31959-281	C	T	1	94534	94522	94546	P41
99-31960	A42	99-31960-363	A	G	1	95396	95384	95408	P42
99-31962	A43	99-31962-250	C	T	1	96956	96944	96968	P43
99-31962	A44	99-31962-450	A	G	1	97156	97144	97168	P44
99-44282	A45	99-44282-439	A	G	1	106384	106372	106396	P45
99-44282	A46	99-44282-54	C	T	1	106769	106757	106781	P46
99-24656	A47	99-24656-137	A	G	1	107158	107146	107170	P47
99-24656	A48	99-24656-260	A	G	1	107281	107269	107293	P48
99-24636	A49	99-24636-22	A	G	1	107609	107597	107621	P49
99-31939	A50	99-31939-75	A	G	1	108499	108487	108511	P50
99-31939	A51	99-31939-273	C	T	1	108697	108685	108709	P51
99-44281	A52	99-44281-418	G	T	1	109451	109439	109463	P52
99-44281	A53	99-44281-257	A	G	1	109612	109600	109624	P53
99-44281	A54	99-44281-77	A	G	1	109792	109780	109804	P54
99-31941	A55	99-31941-320	G	T	1	112468	112456	112480	P55

99-31942	A56	99-31942-325	G	T	1	115468	115456	115480	P56
99-24635	A57	99-24635-79	A	T	1	155736	155724	155748	P57
99-16059	A58	99-16059-313	A	G	1	158172	158160	158184	P58
99-24639	A59	99-24639-169	C	T	1	160634	160622	160646	P59
99-24639	A60	99-24639-163	A	C	1	160640	160628	160652	P60
99-24634	A61	99-24634-108	A	T	1	160876	160864	160888	P61
99-7652	A62	99-7652-162	A	G	1	168974	168962	168986	P62
99-7652	A63	99-7652-488	A	G	1	169300	169288	169312	P63
99-16100	A64	99-16100-83	C	T	1	170746	170734	170758	P64
99-16100	A65	99-16100-147	A	G	1	170810	170798	170822	P65
99-16100	A66	99-16100-195	G	T	1	170858	170846	170870	P66
99-16100	A67	99-16100-197	C	T	1	170860	170848	170872	P67
99-16100	A68	99-16100-244	C	T	1	170906	170894	170918	P68
99-16100	A69	99-16100-381	A	C	1	171043	171031	171055	P69
99-5862	A70	99-5862-167	A	G	1	173358	173346	173370	P70
99-16083	A71	99-16083-101	C	T	1	174227	174215	174239	P71
99-16044	A72	99-16044-351	C	T	1	175800	175788	175812	P72
99-16042	A73	99-16042-420	A	G	1	180589	180577	180601	P73
99-16042	A74	99-16042-31	G	C	1	180978	180966	180990	P74
99-5919	A75	99-5919-215	A	G	1	189957	189945	189969	P75
99-24658	A76	99-24658-410	A	G	1	197163	197151	197175	P76
99-30364	A77	99-30364-299	A	G	1	198964	198952	198976	P77
99-30366	A78	99-30366-112	G	T	1	200256	200244	200268	P78
99-16094	A79	99-16094-75	G	T	1	204588	204576	204600	P79
99-24644	A80	99-24644-194	A	G	1	204934	204922	204946	P80
99-16107	A81	99-16107-95	A	T	1	206197	206185	206209	P81
99-16107	A82	99-16107-161	A	G	1	206263	206251	206275	P82
99-16107	A83	99-16107-383	C	T	1	206485	206473	206497	P83
99-15873	A84	99-15873-303	C	T	1	211608	211596	211620	P84
8-124	A85	8-124-106	A	G	1	214669	214657	214681	P85
8-124	A86	8-124-220	A	G	1	214783	214771	214795	P86
8-124	A87	8-124-294	A	G	1	214857	214845	214869	P87
8-124	A88	8-124-316	C	T	1	214879	214867	214891	P88
8-124	A89	8-124-383	A	T	1	214946	214934	214958	P89

8-125	A90	8-125-33	C	T	1	215538	215526	215550	P90
8-132	A91	8-132-312	A	G	1	215705	215693	215717	P91
8-132	A92	8-132-179	A	T	1	215838	215826	215850	P92
8-132	A93	8-132-164	A	G	1	215853	215841	215865	P93
8-132	A94	8-132-97	A	G	1	215920	215908	215932	P94
99-13929	A95	99-13929-201	G	T	1	216028	216016	216040	P95
8-131	A96	8-131-363	G	T	1	216538	216526	216550	P96
8-131	A97	8-131-199	G	T	1	216702	216690	216714	P97
8-130	A98	8-130-236	C	T	1	216874	216862	216886	P98
8-130	A99	8-130-220	G	T	1	216890	216878	216902	P99
8-130	A100	8-130-144	C	T	1	216966	216954	216978	P100
8-130	A101	8-130-143	A	G	1	216967	216955	216979	P101
8-130	A102	8-130-102	C	T	1	217008	216996	217020	P102
8-130	A103	8-130-101	G	T	1	217009	216997	217021	P103
8-130	A104	8-130-83	A	C	1	217027	217015	217039	P104
8-209	A105	8-209-333	A	G	1	217207	217195	217219	P105
8-209	A106	8-209-290	A	C	1	217250	217238	217262	P106
99-5897	A107	99-5897-143	A	C	1	219540	219528	219552	P107
99-24649	A108	99-24649-186	A	G	1	220836	220824	220848	P108
99-24649	A109	99-24649-80	G	C	1	220942	220930	220954	P109
8-199	A110	8-199-84	G	T	1	221741	221729	221753	P110
8-198	A111	8-198-138	A	G	1	222048	222036	222060	P111
8-195	A112	8-195-348	C	T	1	222746	222734	222758	P112
99-13925	A113	99-13925-97	A	G	1	223595	223583	223607	P113
8-192	A114	8-192-82	A	G	1	225443	225431	225455	P114
99-16090	A115	99-16090-225	A	G	1	226219	226207	226231	P115
8-189	A116	8-189-340	Deletion of CTAT		1	226282	226270	226309 4	P116
8-189	A117	8-189-146	G	T	1	226487	226475	226499	P117
8-188	A118	8-188-136	C	T	1	226870	226858	226882	P118
8-187	A119	8-187-352	G	T	1	226987	226975	226999	P119
8-185	A120	8-185-319	G	T	1	227589	227577	227601	P120
8-185	A121	8-185-296	A	T	1	227612	227600	227624	P121
99-16051	A122	99-16051-226	C	T	1	228006	227994	228018	P122

99-16051	A123	99-16051-164	A	G	1	228068	228056	228080	P123
8-184	A124	8-184-119	A	T	1	228134	228122	228146	P124
8-184	A125	8-184-27	A	C	1	228226	228214	228238	P125
8-183	A126	8-183-401	C	T	1	228254	228242	228266	P126
8-181	A127	8-181-449	C	T	1	229069	229057	229081	P127
8-181	A128	8-181-350	A	T	1	229168	229156	229180	P128
8-181	A129	8-181-259	A	G	1	229259	229247	229271	P129
8-181	A130	8-181-230	A	T	1	229288	229276	229300	P130
8-181	A131	8-181-210	A	T	1	229308	229296	229320	P131
8-181	A132	8-181-165	C	T	1	229353	229341	229365	P132
8-181	A133	8-181-163	C	T	1	229355	229343	229367	P133
8-181	A134	8-181-83	C	T	1	229435	229423	229447	P134
8-180	A135	8-180-157	A	T	1	229486	229474	229498	P135
8-143	A136	8-143-332	A	C	1	229582	229570	229594	P136
8-143	A137	8-143-327	A	G	1	229587	229575	229599	P137
8-143	A138	8-143-311	A	G	1	229603	229591	229615	P138
8-143	A139	8-143-308	A	G	1	229606	229594	229618	P139
8-179	A140	8-179-268	A	C	1	229607	229595	229619	P140
8-143	A141	8-143-306	A	G	1	229608	229596	229620	P141
8-143	A142	8-143-245	G	T	1	229669	229657	229681	P142
8-143	A143	8-143-242	A	G	1	229672	229660	229684	P143
8-143	A144	8-143-239	C	T	1	229675	229663	229687	P144
8-143	A145	8-143-232	G	C	1	229682	229670	229694	P145
8-143	A146	8-143-152	G	C	1	229762	229750	229774	P146
8-178	A147	8-178-199	G	C	1	229961	229949	229973	P147
8-178	A148	8-178-123	Deletion of A		1	230037	230025	230049	P148
8-119	A149	8-119-404	C	T	1	230238	230226	230250	P149
8-177	A150	8-177-281	C	T	1	230256	230244	230268	P150
8-119	A151	8-119-377	C	T	1	230265	230253	230277	P151
8-119	A152	8-119-309	C	T	1	230333	230321	230345	P152
8-119	A153	8-119-294	G	T	1	230348	230336	230360	P153
8-119	A154	8-119-284	G	C	1	230358	230346	230370	P154
8-119	A155	8-119-272	A	T	1	230370	230358	230382	P155

8-119	A156	8-119-262	A	T	1	230380	230368	230392	P156
8-119	A157	8-119-248	C	T	1	230394	230382	230406	P157
8-119	A158	8-119-247	A	G	1	230395	230383	230407	P158
8-119	A159	8-119-210	A	C	1	230432	230420	230444	P159
8-119	A160	8-119-204	A	C	1	230438	230426	230450	P160
8-119	A161	8-119-200	A	G	1	230442	230430	230454	P161
8-119	A162	8-119-195	A	C	1	230447	230435	230459	P162
8-119	A163	8-119-125	C	T	1	230517	230505	230529	P163
8-119	A164	8-119-120	A	G	1	230522	230510	230534	P164
8-119	A165	8-119-97	C	T	1	230545	230533	230557	P165
8-119	A166	8-119-93	G	T	1	230549	230537	230561	P166
8-119	A167	8-119-38	A	T	1	230604	230592	230616	P167
8-138	A168	8-138-234	C	T	1	230684	230672	230696	P168
8-138	A169	8-138-218	A	G	1	230700	230688	230712	P169
8-138	A170	8-138-163	C	T	1	230755	230743	230767	P170
8-138	A171	8-138-54	insertion TA		1	230864	230852	230876	P171
8-175	A172	8-175-75	G	T	1	231070	231058	231082	P172
8-142	A173	8-142-386	C	T	1	231118	231106	231130	P173
8-142	A174	8-142-370	C	T	1	231134	231122	231146	P174
8-142	A175	8-142-211	deletion CAAA		1	231290	231278	231302	P175
8-142	A176	8-142-132	A	G	1	231372	231360	231384	P176
8-145	A177	8-145-339	C	T	1	231669	231657	231681	P177
99-15870	A178	99-15870-400	A	G	1	231677	231665	231689	P178
8-145	A179	8-145-231	A	T	1	231777	231765	231789	P179
8-145	A180	8-145-197	C	T	1	231811	231799	231823	P180
8-145	A181	8-145-154	C	T	1	231854	231842	231866	P181
8-145	A182	8-145-138	A	C	1	231870	231858	231882	P182
8-145	A183	8-145-78	G	C	1	231930	231918	231942	P183
8-171	A184	8-171-247	C	T	1	232320	232308	232332	P184
8-170	A185	8-170-373	C	T	1	232477	232465	232489	P185
8-169	A186	8-169-266	A	G	1	232898	232886	232910	P186
8-169	A187	8-169-166	G	T	1	232998	232986	233010	P187

8-168	A188	8-168-380	A	G	1	233100	233088	233112	P188
8-235	A189	8-235-349	C	T	1	233453	233441	233465	P189
8-235	A190	8-235-182	G	T	1	233620	233608	233632	P190
8-137	A191	8-137-340	G	C	1	234120	234108	234132	P191
8-137	A192	8-137-182	C	T	1	234277	234265	234289	P192
8-137	A193	8-137-152	A	C	1	234307	234295	234319	P193
8-165	A194	8-165-185	G	C	1	234751	234739	234763	P194
99-16087	A195	99-16087-219	G	C	1	235315	235303	235327	P195
8-157	A196	8-157-177	A	C	1	238223	238211	238235	P196
8-155	A197	8-155-258	C	T	1	238789	238777	238801	P197
99-16038	A198	99-16038-118	C	T	1	239763	239751	239775	P198
8-136	A199	8-136-166	A	G	1	239864	239852	239876	P199
8-136	A200	8-136-145	A	G	1	239885	239873	239897	P200
8-136	A201	8-136-80	C	T	1	239950	239938	239962	P201
8-153	A202	8-153-32	A	G	1	240044	240032	240056	P202
8-135	A203	8-135-212	A	G	1	240497	240485	240509	P203
8-135	A204	8-135-166	G	T	1	240543	240531	240555	P204
8-135	A205	8-135-112	A	G	1	240597	240585	240609	P205
99-16050	A206	99-16050-235	G	C	1	240772	240760	240784	P206
8-144	A207	8-144-378	C	T	1	240858	240846	240870	P207
8-144	A208	8-144-234	C	T	1	241002	240990	241014	P208
8-144	A209	8-144-196	A	T	1	241040	241028	241052	P209
8-144	A210	8-144-127	deletion TGGATA C		1	241002	240090	241014	P210
8-141	A211	8-141-304	C	T	1	241217	241205	241229	P211
8-141	A212	8-141-260	C	T	1	241261	241249	241273	P212
8-141	A213	8-141-161	G	T	1	241360	241348	241372	P213
8-140	A214	8-140-286	A	G	1	241507	241495	241519	P214
8-140	A215	8-140-173	A	C	1	241620	241608	241632	P215
8-140	A216	8-140-108	G	C	1	241685	241673	241697	P216
8-140	A217	8-140-41	A	G	1	241752	241740	241764	P217
99-15880	A218	99-15880-162	A	G	1	241861	241849	241873	P218
8-240	A219	8-240-187	G	T	1	242402	242390	242414	P219

8-225	A220	8-225-281	A	T	1	244313	244301	244325	P220
99-25940	A221	99-25940-186	A	G	1	247860	247848	247872	P221
99-25940	A222	99-25940-182	C	T	1	247864	247852	247876	P222
99-16032	A223	99-16032-292	G	T	1	248315	248303	248327	P223
99-16055	A224	99-16055-216	A	G	1	253619	253607	253631	P224
99-16105	A225	99-16105-152	A	G	1	255848	255836	255860	P225
99-16101	A226	99-16101-436	C	T	1	258573	258561	258585	P226
99-16033	A227	99-16033-244	A	G	1	260099	260087	260111	P227
99-15875	A228	99-15875-165	C	T	1	279789	279777	279801	P228
99-13521	A229	99-13521-31	A	G	1	288007	287995	288019	P229
8-112	A230	8-112-241	C	T	1	292680	292668	292692	P230
8-112	A231	8-112-155	A	C	1	292766	292754	292778	P231
8-112	A232	8-112-45	A	T	1	292876	292864	292888	P232
8-111	A233	8-111-301	deletion AGAT		1	295491	295479	295503	P233
8-110	A234	8-110-404	G	C	1	295716	295704	295728	P234
8-110	A235	8-110-89	A	G	1	296031	296019	296043	P235
8-134	A236	8-134-94	C	T	1	296068	296056	296080	P236
99-7462	A237	99-7462-508	C	T	1	298969	298957	298981	P237
99-16052	A238	99-16052-214	A	G	1	300365	300353	300377	P238
99-16047	A239	99-16047-115	A	G	1	312030	312018	312042	P239
99-25993	A240	99-25993-280	G	C	1	315928	315916	315940	P240
99-25993	A241	99-25993-367	A	G	1	316014	316002	316026	P241
99-25101	A242	99-25101-151	A	G	1	317245	317233	317257	P242
Amplicon	BM	Marker Name	Polymor- phism		SEQ ID No.	BM position	Position of probes in SEQ ID No.		Probe s
			all1	all2					
8-94	A243	8-94-252	A	G	162	1501	1489	1513	P243
8-95	A244	8-95-43	T	C	161	1501	1489	1513	P244
8-97	A245	8-97-98	G	A	160	1501	1489	1513	P245
8-98	A246	8-98-68	T	C	159	1501	1489	1513	P246
99-14021	A247	99-14021-108	A	G	151	1501	1489	1513	P247
99-14364	A248	99-14364-415	G	A	152	1501	1489	1513	P248
99-15056	A249	99-15056-99	G	A	115	1501	1489	1513	P249

99-15063	A250	99-15063-155	A	C	116	1501	1489	1513	P250
99-15065	A251	99-15065-85	C	G	117	1501	1489	1513	P251
99-15229	A252	99-15229-412	T	C	157	1501	1489	1513	P252
99-15231	A253	99-15231-219	T	G	163	1501	1489	1513	P253
99-15232	A254	99-15232-291	G	T	155	1501	1489	1513	P254
99-15239	A255	99-15239-377	G	C	164	1501	1489	1513	P255
99-15252	A256	99-15252-404	C	T	118	404	392	416	P256
99-15253	A257	99-15253-382	C	T	119	1501	1489	1513	P257
99-15256	A258	99-15256-392	C	T	120	1501	1489	1513	P258
99-15258	A259	99-15258-337	G	T	121	1501	1489	1513	P259
99-15261	A260	99-15261-202	A	G	122	1501	1489	1513	P260
99-15280	A261	99-15280-432	C	T	123	1501	1489	1513	P261
99-15355	A262	99-15355-150	C	T	124	1501	1489	1513	P262
99-15663	A263	99-15663-298	G	A	175	1501	1489	1513	P263
99-15664	A264	99-15664-185	C	A	176	1501	1489	1513	P264
99-15665	A265	99-15665-398	T	C	174	1501	1489	1513	P265
99-15668	A266	99-15668-139	C	T	177	1501	1489	1513	P266
99-15672	A267	99-15672-166	G	A	173	1501	1489	1513	P267
99-15682	A268	99-15682-318	A	T	178	1501	1489	1513	P268
99-16081	A269	99-16081-217	C	T	113	330	318	342	P269
99-16082	A270	99-16082-218	A	G	114	233	221	245	P270
99-20933	A271	99-20933-81	T	G	179	1501	1489	1513	P271
99-20977	A272	99-20977-72	A	C	147	1501	1489	1513	P272
99-20978	A273	99-20978-89	C	G	148	1501	1489	1513	P273
99-20981	A274	99-20981-300	A	G	149	1501	1489	1513	P274
99-20983	A275	99-20983-48	T	C	150	1501	1489	1513	P275
99-22310	A276	99-22310-148	G	A	154	1501	1489	1513	P276
99-25029	A277	99-25029-241	G	A	180	1501	1489	1513	P277
99-25224	A278	99-25224-189	A	G	125	1126	1114	1138	P278
99-25869	A279	99-25869-182	A	C	181	1501	1489	1513	P279
99-25881	A280	99-25881-275	G	T	182	1501	1489	1513	P280
99-25897	A281	99-25897-264	A	T	183	1501	1489	1513	P281
99-25906	A282	99-25906-131	G	T	184	1501	1489	1513	P282
99-25917	A283	99-25917-115	G	A	185	1501	1489	1513	P283

99-25924	A284	99-25924-215	G	C	186	1501	1489	1513	P284
99-25950	A285	99-25950-121	G	C	126	1501	1489	1513	P285
99-25961	A286	99-25961-376	T	G	127	1501	1489	1513	P286
99-25965	A287	99-25965-399	T	C	128	1501	1489	1513	P287
99-25966	A288	99-25966-241	T	C	129	1501	1489	1513	P288
99-25967	A289	99-25967-57	T	C	130	1501	1489	1513	P289
99-25969	A290	99-25969-200	C	A	131	1501	1489	1513	P290
99-25972	A291	99-25972-317	G	A	132	1501	1489	1513	P291
99-25974	A292	99-25974-143	T	C	133	1501	1489	1513	P292
99-25977	A293	99-25977-311	A	G	134	1501	1489	1513	P293
99-25978	A294	99-25978-166	T	C	135	1501	1489	1513	P294
99-25979	A295	99-25979-93	A	G	136	1501	1489	1513	P295
99-25980	A296	99-25980-173	A	T	137	1501	1489	1513	P296
99-25984	A297	99-25984-312	G	A	138	1501	1489	1513	P297
99-25985	A298	99-25985-194	C	T	139	1501	1489	1513	P298
99-25989	A299	99-25989-398	T	C	140	1501	1489	1513	P299
99-26126	A300	99-26126-498	A	G	165	1501	1489	1513	P300
99-26138	A301	99-26138-193	C	T	187	1501	1489	1513	P301
99-26146	A302	99-26146-264	C	A	188	1501	1489	1513	P302
99-26147	A303	99-26147-396	G	A	141	1501	1489	1513	P303
99-26150	A304	99-26150-276	T	C	142	1501	1489	1513	P304
99-26153	A305	99-26153-44	A	C	143	1501	1489	1513	P305
99-26154	A306	99-26154-107	G	T	144	1501	1489	1513	P306
99-26156	A307	99-26156-290	A	C	145	1501	1489	1513	P307
99-26166	A308	99-26166-257	G	A	166	1501	1489	1513	P308
99-26167	A309	99-26167-278	T	C	167	1501	1489	1513	P309
99-26169	A310	99-26169-211	T	C	168	1501	1489	1513	P310
99-26171	A311	99-26171-71	A	G	169	1501	1489	1513	P311
99-26183	A312	99-26183-156	C	T	170	1501	1489	1513	P312
99-26189	A313	99-26189-164	C	A	189	1501	1489	1513	P313
99-26190	A314	99-26190-20	C	A	190	1501	1489	1513	P314
99-26191	A315	99-26191-58	G	A	191	1501	1489	1513	P315
99-26201	A316	99-26201-267	C	G	192	1501	1489	1513	P316
99-26222	A317	99-26222-149	A	G	193	1501	1489	1513	P317

99-26223	A318	99-26223-225	G	T	194	1501	1489	1513	P318
99-26225	A319	99-26225-148	G	T	195	1501	1489	1513	P319
99-26228	A320	99-26228-172	G	C	196	1501	1489	1513	P320
99-26233	A321	99-26233-275	T	C	197	1501	1489	1513	P321
99-26234	A322	99-26234-336	C	G	198	1501	1489	1513	P322
99-26238	A323	99-26238-186	T	A	199	1501	1489	1513	P323
99-5873	A324	99-5873-159	G	A	146	1501	1489	1513	P324
99-5912	A325	99-5912-49	A	G	171	1501	1489	1513	P325
99-6012	A326	99-6012-220	G	T	158	1501	1489	1513	P326
99-6080	A327	99-6080-99	G	A	156	1501	1489	1513	P327
99-7308	A328	99-7308-157	C	T	153	1501	1489	1513	P328
99-7337	A329	99-7337-204	A	C	172	1501	1489	1513	P329
99-16106	A330	99-16106-48	G	T	200	79	67	91	P330
99-25332	A331	99-25332-125	A	G	201	125	113	137	P331
99-25516	A332	99-25516-307	C	T	202	306	294	318	P332
99-26173	A333	99-26173-470	C	T	203	1501	1489	1513	P333
99-26267	A334	99-26267-524	C	T	204	1501	1489	1513	P334
99-26284	A335	99-26284-394	G	A	205	1501	1489	1513	P335
99-26559	A336	99-26559-315	A	G	206	1501	1489	1513	P336
99-26769	A337	99-26769-256	A	T	207	1501	1489	1513	P337
99-26772	A338	99-26772-268	C	T	208	1501	1489	1513	P338
99-26776	A339	99-26776-209	G	T	209	1501	1489	1513	P339
99-26779	A340	99-26779-437	G	C	210	1497	1485	1509	P340
99-26781	A341	99-26781-25	G	T	211	1501	1489	1513	P341
99-26782	A342	99-26782-300	A	G	212	1501	1489	1513	P342
99-26783	A343	99-26783-81	A	T	213	1501	1489	1513	P343
99-26787	A344	99-26787-96	A	G	214	1501	1489	1513	P344
99-26789	A345	99-26789-201	C	T	215	1501	1489	1513	P345
99-27297	A346	99-27297-280	T	C	216	1501	1489	1513	P346
99-27306	A347	99-27306-108	C	T	217	1501	1489	1513	P347
99-27312	A348	99-27312-58	A	C	218	1501	1489	1513	P348
99-27323	A349	99-27323-372	G	C	219	1501	1489	1513	P349
99-27335	A350	99-27335-191	A	C	220	1501	1489	1513	P350
99-27345	A351	99-27345-189	C	G	221	1501	1489	1513	P351

99-27349	A352	99-27349-267	G	A	222	1501	1489	1513	P352
99-27352	A353	99-27352-197	C	G	223	1501	1489	1513	P353
99-27353	A354	99-27353-105	T	C	224	1501	1489	1513	P354
99-27360	A355	99-27360-142	G	T	225	1501	1489	1513	P355
99-27361	A356	99-27361-181	A	G	226	1501	1489	1513	P356
99-27365	A357	99-27365-421	C	T	227	1501	1489	1513	P357
99-27680	A358	99-27680-484	G	T	228	484	472	496	P358
99-27912	A359	99-27912-272	C	T	229	1501	1489	1513	P359
99-30329	A360	99-30329-380	C	T	112	380	368	392	P360

Certain biallelic markers of the invention are insertions or deletions, as indicated above. In particular, the deletion of the nucleotides AGAT (A223, biallelic marker 8-111-301) in Table 6b above may comprise a single deletion of the AGAT motif, or deletions of two or more AGAT motifs. This marker (A223) may thus also serve as a microsatellite marker.

BM refers to "biallelic marker". All1 and all2 refer respectively to allele 1 and allele 2 of the biallelic marker.

b) Identification of Polymorphisms by Comparison of Genomic DNA from Overlapping BACs

Genomic DNA from multiple BACs derived from the same DNA donor sample and overlapping in regions of genomic DNA of SEQ ID No. 1 was sequenced. Sequencing was carried out on ABI 377 sequencers. The sequences of the amplification products were determined using automated dideoxy terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of the sequencing reactions were run on sequencing gels and the sequences were determined using gel image analysis (ABI Prism DNA Sequencing Analysis software (2.1.2 version)).

The sequence data from the overlapping regions of SEQ ID No. 1 were evaluated to detect the presence of sequence polymorphisms. The comparison of sequences identified sequence polymorphisms including single nucleotide substitutions and deletions, and multiple nucleotide deletions. The localization of these polymorphisms within SEQ ID No. 1 is shown below in Table 6c.

Table 6c
Polymorphisms

Ref. No.	Polymorphism type	Allele 1	Allele 2	Position in SEQ ID No. 1
A361	Deletion	AAGG		61595 to 61598
A362	Deletion	ATTTT		75217 to 75221

A363	Polymorphic base	C	T	75367
A364	Deletion	CACA		88634 to 88637
A365	Polymorphic base	A	G	90113
A366	Deletion	ACAC		93698 to 93701
A367	Polymorphic base	C	T	94209
A368	Deletion	AATG		94331 to 94334
A369	Polymorphic base	A	G	95396
A370	Polymorphic base	C	T	95810
A371	Polymorphic base	C	T	96956
A372	Polymorphic base	A	G	97156
A373	Deletion	CTTTCTTTCT		98749 to 98758
A374	Deletion	TA		104314 to 104315
A375	Polymorphic base	A	C	104455
A376	Polymorphic base	A	G	104699
A377	Polymorphic base	C	T	106253
A378	Polymorphic base	A	T	106272
A379	Polymorphic base	A	C	106350
A380	Polymorphic base	A	G	106384
A381	Polymorphic base	A	G	107158
A382	Deletion	AT		107168 to 107169
A383	Polymorphic base	A	G	107609
A384	Polymorphic base	A	G	108032
A385	Deletion	ATGGAGATGGC AACACCTACAT GTGACCTTTCC AGCATGGCAGT CTCAGAGTGGG TATGGCAACAG CTGCACATGAC CTCTCCAGCAT GGCAGTCTCAG AGTGGATATGG CAACAGCTGCA CATGACCTCTC CGGCATGGCAG TCTCAG		108668 to 108816
A386	Polymorphic base	G	T	110222
A387	Polymorphic base	A	G	111978
A388	Polymorphic base	G	T	112468
A389	Deletion	ACTT		117324 to 117327
A390	Polymorphic base	C	T	118972
A391	Deletion	TT		119160 to 119161
A392	Polymorphic base	C	T	119316
A393	Polymorphic base	A	G	119321
A394	Polymorphic base	A	G	119526
A395	Polymorphic base	A	G	120573
A396	Polymorphic base	A	C	121527
A397	Polymorphic base	C	T	126105
A398	Polymorphic base	C	G	129789
A399	Polymorphic base	A	G	130777
A400	Deletion	ATT		136942 to 136944
A401	Polymorphic base	A	T	143839
A402	Polymorphic base	C	T	146668
A403	Polymorphic base	C	T	147281
A404	Polymorphic base	G	T	147505
A405	Deletion	T		148183

A406	Polymorphic base	A	C	148372
A407	Polymorphic base	A	G	149012
A408	Polymorphic base	C	T	149113
A409	Polymorphic base	A	G	151637
A410	Deletion	G		151748
A411	Polymorphic base	A	G	151769
A412	Polymorphic base	C	T	151847
A413	Polymorphic base	A	C	152691
A414	Polymorphic base	A	G	152766
A415	Polymorphic base	C	T	153046
A416	Polymorphic base	A	G	153123
A417	Polymorphic base	C	T	153925
A418	Polymorphic base	G	T	153977
A419	Polymorphic base	C	T	154502
A420	Polymorphic base	A	G	154677
A421	Polymorphic base	C	T	154879
A422	Polymorphic base	G	T	154918
A423	Polymorphic base	C	T	155802
A424	Polymorphic base	A	G	156448
A425	Polymorphic base	A	C	157238
A426	Polymorphic base	A	G	157897
A427	Polymorphic base	A	G	158172
A428	Polymorphic base	A	G	158302
A429	Deletion	TT		158510 to 158511
A430	Polymorphic base	C	T	158803
A431	Polymorphic base	C	T	160172
A432	Polymorphic base	C	T	160634
A433	Polymorphic base	C	T	161236
A434	Polymorphic base	A	G	162810
A435	Polymorphic base	A	G	163007
A436	Polymorphic base	A	G	164877
A437	Polymorphic base	C	T	166844
A438	Deletion	TCTC		166911 to 166914
A439	Polymorphic base	A	G	167754
A440	Polymorphic base	C	T	167787
A441	Polymorphic base	G	T	167894
A442	Polymorphic base	C	T	168346
A443	Polymorphic base	A	G	168414
A444	Polymorphic base	A	C	168453
A445	Polymorphic base	A	G	169300
A446	Polymorphic base	C	T	169451
A447	Polymorphic base	A	G	169627
A448	Polymorphic base	C	T	169984
A449	Polymorphic base	C	T	170199
A450	Polymorphic base	C	T	170746
A451	Polymorphic base	G	T	170858
A452	Polymorphic base	C	T	170860
A453	Polymorphic base	C	T	170906
A454	Polymorphic base	A	G	171309
A455	Polymorphic base	A	G	171413
A456	Polymorphic base	C	T	171504
A457	Polymorphic base	C	T	171539
A458	Polymorphic base	C	T	171728
A459	Polymorphic base	A	G	171898
A460	Deletion	AA		172125 to 172126

A461	Polymorphic base	A	G	172295
A462	Polymorphic base	A	G	172298
A463	Polymorphic base	A	G	172336
A464	Polymorphic base	A	G	173145
A465	Polymorphic base	C	T	173304
A466	Polymorphic base	C	T	174227
A467	Polymorphic base	A	G	174397
A468	Polymorphic base	C	T	179154
A469	Polymorphic base	C	G	180233
A470	Polymorphic base	A	G	182552
A471	Polymorphic base	C	T	182733
A472	Deletion	A		182773
A473	Polymorphic base	A	G	185759
A474	Deletion	T		186307
A475	Deletion	TATC		186976 to 186979
A476	Polymorphic base	A	T	188755
A477	Polymorphic base	A	C	188991
A478	Polymorphic base	C	T	189002
A479	Polymorphic base	A	G	189154
A480	Polymorphic base	A	G	189177
A481	Polymorphic base	A	G	189604
A482	Polymorphic base	C	T	190063
A483	Deletion	T		191164
A484	Deletion	A		193880
A485	Polymorphic base	A	G	193897
A486	Polymorphic base	A	T	194441
A487	Deletion	T		194459
A488	Polymorphic base	A	T	195306
A489	Deletion	TATC		226323 to 226326

Example 4

Validation Of The Polymorphisms Through Microsequencing

The biallelic markers identified in Example 3a were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was carried out for each individual DNA sample described in Example 1.

Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers (Table 6a).

The preferred primers used in microsequencing were about 19 nucleotides in length and hybridized just upstream of the considered polymorphic base. According to the invention, the primers used in microsequencing are detailed in Table 6d.

Table 6d

Marker Name	Biallelic Marker	SEQ ID No.	Mis. 1	Position range of microsequencing primer mis. 1 in SEQ ID No.		Mis. 2	Complementary position range of microsequencing primer mis. 2 in SEQ ID No.	
99-27943-150	A1	1	D1	8297	8315	E1	8317	8335

8-121-28	A2	1	D2	14707	14725	E2	14727	14745
8-121-36	A3	1	D3	14715	14733	E3	14735	14753
8-121-154	A4	1	D4	14833	14851	E4	14853	14871
8-121-187	A5	1	D5	14866	14884	E5	14886	14904
8-121-243	A6	1	D6	14922	14940	E6	14942	14960
8-121-281	A7	1	D7	14960	14978	E7	14980	14998
8-121-352	A8	1	D8	15031	15049	E8	15051	15069
8-121-364	A9	1	D9	15043	15061	E9	15063	15081
8-121-371	A10	1	D10	15050	15068	E10	15070	15088
99-27935-193	A11	1	D11	21653	21671	E11	21673	21691
8-122-72	A12	1	D12	25461	25479	E12	25481	25499
8-122-100	A13	1	D13	25489	25507	E13	25509	25527
8-122-271	A14	1	D14	25660	25678	E14	25680	25698
8-122-272	A15	1	D15	25661	25679	E15	25681	25699
8-122-326	A16	1	D16	25715	25733	E16	25735	25753
8-122-360	A17	1	D17	25749	25767	E17	25769	25787
8-123-55	A18	1	D18	29384	29402	E18	29404	29422
8-123-189	A19	1	D19	29518	29536	E19	29538	29556
8-123-197	A20	1	D20	29526	29544	E20	29546	29564
8-123-307	A21	1	D21	29636	29654	E21	29656	29674
8-147-270	A22	1	D22	29780	29798	E22	29800	29818
99-34243-210	A23	1	D23	49456	49474	E23	49476	49494
8-127-28	A24	1	D24	64647	64665	E24	64667	64685
8-127-119	A25	1	D25	64738	64756	E25	64758	64776
8-127-159	A26	1	D26	64778	64796	E26	64798	64816
8-127-236	A27	1	D27	64855	64873	E27	64875	64893
8-127-240	A28	1	D28	64859	64877	E28	64879	64897
8-127-280	A29	1	D29	64899	64917	E29	64919	64937
8-128-33	A30	1	D30	65466	65484	E30	65486	65504
8-128-52	A31	1	D31	65485	65503	E31	65505	65523
8-128-61	A32	1	D32	65494	65512	E32	65514	65532
8-128-68	A33	1	D33	65501	65519	E33	65521	65539
8-128-69	A34	1	D34	65502	65520	E34	65522	65540
8-128-85	A35	1	D35	65518	65536	E35	65538	65556

8-129-50	A36	1	D36	65577	65595	E36	65597	65615
8-129-60	A37	1	D37	65587	65605	E37	65607	65625
8-129-311	A38	1	D38	65838	65856	E38	65858	65876
8-129-401	A39	1	D39	65928	65946	E39	65948	65966
99-34240-492	A40	1	D40	75648	75666	E40	75668	75686
99-31959-281	A41	1	D41	94515	94533	E41	94535	94553
99-31960-363	A42	1	D42	95377	95395	E42	95397	95415
99-31962-250	A43	1	D43	96937	96955	E43	96957	96975
99-31962-450	A44	1	D44	97137	97155	E44	97157	97175
99-44282-439	A45	1	D45	106365	106383	E45	106385	106403
99-44282-54	A46	1	D46	106750	106768	E46	106770	106788
99-24656-137	A47	1	D47	107139	107157	E47	107159	107177
99-24656-260	A48	1	D48	107262	107280	E48	107282	107300
99-24636-22	A49	1	D49	107590	107608	E49	107610	107628
99-31939-75	A50	1	D50	108480	108498	E50	108500	108518
99-31939-273	A51	1	D51	108778	108796	E51	108798	108816
99-44281-418	A52	1	D52	109432	109450	E52	109452	109470
99-44281-257	A53	1	D53	109593	109611	E53	109613	109631
99-44281-77	A54	1	D54	109773	109791	E54	109793	109811
99-31941-320	A55	1	D55	112449	112467	E55	112469	112487
99-31942-325	A56	1	D56	115449	115467	E56	115469	115487
99-24635-79	A57	1	D57	155717	155735	E57	155737	155755
99-16059-313	A58	1	D58	158153	158171	E58	158173	158191
99-24639-169	A59	1	D59	160615	160633	E59	160635	160653
99-24639-163	A60	1	D60	160621	160639	E60	160641	160659
99-24634-108	A61	1	D61	160857	160875	E61	160877	160895
99-7652-162	A62	1	D62	168955	168973	E62	168975	168993
99-7652-488	A63	1	D63	169281	169299	E63	169301	169319
99-16100-83	A64	1	D64	170727	170745	E64	170747	170765
99-16100-147	A65	1	D65	170791	170809	E65	170811	170829
99-16100-195	A66	1	D66	170839	170857	E66	170859	170877
99-16100-197	A67	1	D67	170841	170859	E67	170861	170879
99-16100-244	A68	1	D68	170887	170905	E68	170907	170925
99-16100-381	A69	1	D69	171024	171042	E69	171044	171062

99-5862-167	A70	1	D70	173339	173357	E70	173359	173377
99-16083-101	A71	1	D71	174208	174226	E71	174228	174246
99-16044-351	A72	1	D72	175781	175799	E72	175801	175819
99-16042-420	A73	1	D73	180570	180588	E73	180590	180608
99-16042-31	A74	1	D74	180959	180977	E74	180979	180997
99-5919-215	A75	1	D75	189938	189956	E75	189958	189976
99-24658-410	A76	1	D76	197144	197162	E76	197164	197182
99-30364-299	A77	1	D77	198945	198963	E77	198965	198983
99-30366-112	A78	1	D78	200237	200255	E78	200257	200275
99-16094-75	A79	1	D79	204569	204587	E79	204589	204607
99-24644-194	A80	1	D80	204915	204933	E80	204935	204953
99-16107-95	A81	1	D81	206178	206196	E81	206198	206216
99-16107-161	A82	1	D82	206244	206262	E82	206264	206282
99-16107-383	A83	1	D83	206466	206484	E83	206486	206504
99-15873-303	A84	1	D84	211589	211607	E84	211609	211627
8-124-106	A85	1	D85	214650	214668	E85	214670	214688
8-124-220	A86	1	D86	214764	214782	E86	214784	214802
8-124-294	A87	1	D87	214838	214856	E87	214858	214876
8-124-316	A88	1	D88	214860	214878	E88	214880	214898
8-124-383	A89	1	D89	214927	214945	E89	214947	214965
8-125-33	A90	1	D90	215519	215537	E90	215539	215557
8-132-312	A91	1	D91	215686	215704	E91	215706	215724
8-132-179	A92	1	D92	215819	215837	E92	215839	215857
8-132-164	A93	1	D93	215834	215852	E93	215854	215872
8-132-97	A94	1	D94	215901	215919	E94	215921	215939
99-13929-201	A95	1	D95	216009	216027	E95	216029	216047
8-131-363	A96	1	D96	216519	216537	E96	216539	216557
8-131-199	A97	1	D97	216683	216701	E97	216703	216721
8-130-236	A98	1	D98	216855	216873	E98	216875	216893
8-130-220	A99	1	D99	216871	216889	E99	216891	216909
8-130-144	A100	1	D100	216947	216965	E100	216967	216985
8-130-143	A101	1	D101	216948	216966	E101	216968	216986
8-130-102	A102	1	D102	216989	217007	E102	217009	217027
8-130-101	A103	1	D103	216990	217008	E103	217010	217028

8-130-83	A104	1	D104	217008	217026	E104	217028	217046
8-209-333	A105	1	D105	217188	217206	E105	217208	217226
8-209-290	A106	1	D106	217231	217249	E106	217251	217269
99-5897-143	A107	1	D107	219521	219539	E107	219541	219559
99-24649-186	A108	1	D108	220817	220835	E108	220837	220855
99-24649-80	A109	1	D109	220923	220941	E109	220943	220961
8-199-84	A110	1	D110	221722	221740	E110	221742	221760
8-198-138	A111	1	D111	222029	222047	E111	222049	222067
8-195-348	A112	1	D112	222727	222745	E112	222747	222765
99-13925-97	A113	1	D113	223576	223594	E113	223596	223614
8-192-82	A114	1	D114	225424	225442	E114	225444	225462
99-16090-225	A115	1	D115	226200	226218	E115	226220	226238
8-189-340	A116	1	D116	226274	226292	E116	226294	226312
8-189-146	A117	1	D117	226468	226486	E117	226488	226506
8-188-136	A118	1	D118	226851	226869	E118	226871	226889
8-187-352	A119	1	D119	226968	226986	E119	226988	227006
8-185-319	A120	1	D120	227570	227588	E120	227590	227608
8-185-296	A121	1	D121	227593	227611	E121	227613	227631
99-16051-226	A122	1	D122	227987	228005	E122	228007	228025
99-16051-164	A123	1	D123	228049	228067	E123	228069	228087
8-184-119	A124	1	D124	228115	228133	E124	228135	228153
8-184-27	A125	1	D125	228207	228225	E125	228227	228245
8-183-401	A126	1	D126	228235	228253	E126	228255	228273
8-181-449	A127	1	D127	229050	229068	E127	229070	229088
8-181-350	A128	1	D128	229149	229167	E128	229169	229187
8-181-259	A129	1	D129	229240	229258	E129	229260	229278
8-181-230	A130	1	D130	229269	229287	E130	229289	229307
8-181-210	A131	1	D131	229289	229307	E131	229309	229327
8-181-165	A132	1	D132	229334	229352	E132	229354	229372
8-181-163	A133	1	D133	229336	229354	E133	229356	229374
8-181-83	A134	1	D134	229416	229434	E134	229436	229454
8-180-157	A135	1	D135	229467	229485	E135	229487	229505
8-143-332	A136	1	D136	229563	229581	E136	229583	229601
8-143-327	A137	1	D137	229568	229586	E137	229588	229606

8-143-311	A138	1	D138	229584	229602	E138	229604	229622
8-143-308	A139	1	D139	229587	229605	E139	229607	229625
8-179-268	A140	1	D140	229588	229606	E140	229608	229626
8-143-306	A141	1	D141	229589	229607	E141	229609	229627
8-143-245	A142	1	D142	229650	229668	E142	229670	229688
8-143-242	A143	1	D143	229653	229671	E143	229673	229691
8-143-239	A144	1	D144	229656	229674	E144	229676	229694
8-143-232	A145	1	D145	229663	229681	E145	229683	229701
8-143-152	A146	1	D146	229743	229761	E146	229763	229781
8-178-199	A147	1	D147	229942	229960	E147	229962	229980
8-178-123	A148	1	D148	230018	230036	E148	230038	230056
8-119-404	A149	1	D149	230219	230237	E149	230239	230257
8-177-281	A150	1	D150	230237	230255	E150	230257	230275
8-119-377	A151	1	D151	230246	230264	E151	230266	230284
8-119-309	A152	1	D152	230314	230332	E152	230334	230352
8-119-294	A153	1	D153	230329	230347	E153	230349	230367
8-119-284	A154	1	D154	230339	230357	E154	230359	230377
8-119-272	A155	1	D155	230351	230369	E155	230371	230389
8-119-262	A156	1	D156	230361	230379	E156	230381	230399
8-119-248	A157	1	D157	230375	230393	E157	230395	230413
8-119-247	A158	1	D158	230376	230394	E158	230396	230414
8-119-210	A159	1	D159	230413	230431	E159	230433	230451
8-119-204	A160	1	D160	230419	230437	E160	230439	230457
8-119-200	A161	1	D161	230423	230441	E161	230443	230461
8-119-195	A162	1	D162	230428	230446	E162	230448	230466
8-119-125	A163	1	D163	230498	230516	E163	230518	230536
8-119-120	A164	1	D164	230503	230521	E164	230523	230541
8-119-97	A165	1	D165	230526	230544	E165	230546	230564
8-119-93	A166	1	D166	230530	230548	E166	230550	230568
8-119-38	A167	1	D167	230585	230603	E167	230605	230623
8-138-234	A168	1	D168	230665	230683	E168	230685	230703
8-138-218	A169	1	D169	230681	230699	E169	230701	230719
8-138-163	A170	1	D170	230736	230754	E170	230756	230774
8-138-54	A171	1	D171	230845	230863	E171	230865	230883

8-175-75	A172	1	D172	231051	231069	E172	231071	231089
8-142-386	A173	1	D173	231099	231117	E173	231119	231137
8-142-370	A174	1	D174	231115	231133	E174	231135	231153
8-142-211	A175	1	D175	231274	231292	E175	231294	231312
8-142-132	A176	1	D176	231353	231371	E176	231373	231391
8-145-339	A177	1	D177	231650	231668	E177	231670	231688
99-15870-400	A178	1	D178	231658	231676	E178	231678	231696
8-145-231	A179	1	D179	231758	231776	E179	231778	231796
8-145-197	A180	1	D180	231792	231810	E180	231812	231830
8-145-154	A181	1	D181	231835	231853	E181	231855	231873
8-145-138	A182	1	D182	231851	231869	E182	231871	231889
8-145-78	A183	1	D183	231911	231929	E183	231931	231949
8-171-247	A184	1	D184	232301	232319	E184	232321	232339
8-170-373	A185	1	D185	232458	232476	E185	232478	232496
8-169-266	A186	1	D186	232879	232897	E186	232899	232917
8-169-166	A187	1	D187	232979	232997	E187	232999	233017
8-168-380	A188	1	D188	233081	233099	E188	233101	233119
8-235-349	A189	1	D189	233434	233452	E189	233454	233472
8-235-182	A190	1	D190	233601	233619	E190	233621	233639
8-137-340	A191	1	D191	234101	234119	E191	234121	234139
8-137-182	A192	1	D192	234258	234276	E192	234278	234296
8-137-152	A193	1	D193	234288	234306	E193	234308	234326
8-165-185	A194	1	D194	234732	234750	E194	234752	234770
99-16087-219	A195	1	D195	235296	235314	E195	235316	235334
8-157-177	A196	1	D196	238204	238222	E196	238224	238242
8-155-258	A197	1	D197	238770	238788	E197	238790	238808
99-16038-118	A198	1	D198	239744	239762	E198	239764	239782
8-136-166	A199	1	D199	239845	239863	E199	239865	239883
8-136-145	A200	1	D200	239866	239884	E200	239886	239904
8-136-80	A201	1	D201	239931	239949	E201	239951	239969
8-153-32	A202	1	D202	240025	240043	E202	240045	240063
8-135-212	A203	1	D203	240478	240496	E203	240498	240516
8-135-166	A204	1	D204	240524	240542	E204	240544	240562
8-135-112	A205	1	D205	240578	240596	E205	240598	240616

99-16050-235	A206	1	D206	240753	240771	E206	240773	240791
8-144-378	A207	1	D207	240839	240857	E207	240859	240877
8-144-234	A208	1	D208	240983	241001	E208	241003	241021
8-144-196	A209	1	D209	241021	241039	E209	241041	241059
8-144-127	A210	1	D210	241090	241108	E210	241110	241128
8-141-304	A211	1	D211	241198	241216	E211	241218	241236
8-141-260	A212	1	D212	241242	241260	E212	241262	241280
8-141-161	A213	1	D213	241341	241359	E213	241361	241379
8-140-286	A214	1	D214	241488	241506	E214	241508	241526
8-140-173	A215	1	D215	241601	241619	E215	241621	241639
8-140-108	A216	1	D216	241666	241684	E216	241686	241704
8-140-41	A217	1	D217	241733	241751	E217	241753	241771
99-15880-162	A218	1	D218	241842	241860	E218	241862	241880
8-240-187	A219	1	D219	242383	242401	E219	242403	242421
8-225-281	A220	1	D220	244294	244312	E220	244314	244332
99-25940-186	A221	1	D221	247841	247859	E221	247861	247879
99-25940-182	A222	1	D222	247845	247863	E222	247865	247883
99-16032-292	A223	1	D223	248296	248314	E223	248316	248334
99-16055-216	A224	1	D224	253600	253618	E224	253620	253638
99-16105-152	A225	1	D225	255829	255847	E225	255849	255867
99-16101-436	A226	1	D226	258554	258572	E226	258574	258592
99-16033-244	A227	1	D227	260080	260098	E227	260100	260118
99-15875-165	A228	1	D228	279770	279788	E228	279790	279808
99-13521-31	A229	1	D229	287988	288006	E229	288008	288026
8-112-241	A230	1	D230	292661	292679	E230	292681	292699
8-112-155	A231	1	D231	292747	292765	E231	292767	292785
8-112-45	A232	1	D232	292857	292875	E232	292877	292895
8-111-301	A233	1	D233	295476	295494	E233	295496	295514
8-110-404	A234	1	D234	295697	295715	E234	295717	295735
8-110-89	A235	1	D235	296012	296030	E235	296032	296050
8-134-94	A236	1	D236	296049	296067	E236	296069	296087
99-7462-508	A237	1	D237	298950	298968	E237	298970	298988
99-16052-214	A238	1	D238	300346	300364	E238	300366	300384
99-16047-115	A239	1	D239	312011	312029	E239	312031	312049

99-25993-280	A240	1	D240	315909	315927	E240	315929	315947
99-25993-367	A241	1	D241	315995	316013	E241	316015	316033
99-25101-151	A242	1	D242	317226	317244	E242	317246	317264
Marker Name	Biallelic Marker	SEQ1 ID No.	Mis. 1	Position range of microsequencing primer mis. 1 in SEQ ID No.		Mis. 2	Complementary position range of microsequencing primer mis. 2 in SEQ ID No.	
8-94-252	A243	162	D243	1482	1500*	E243	1502	1521
8-95-43	A244	161	D244	1481	1500	E244	1502	1520*
8-97-98	A245	160	D245	1482	1500*	E245	1502	1521
8-98-68	A246	159	D246	1481	1500	E246	1502	1520*
99-14021-108	A247	151	D247	1482	1500*	E247	1502	1521
99-14364-415	A248	152	D248	1482	1500*	E248	1502	1521
99-15056-99	A249	115	D249	1482	1500*	E249	1502	1521
99-15063-155	A250	116	D250	1482	1500*	E250	1502	1521
99-15065-85	A251	117	D251	1481	1500	E251	1502	1520*
99-15229-412	A252	157	D252	1481	1500	E252	1502	1520*
99-15231-219	A253	163	D253	1481	1500	E253	1502	1520*
99-15232-291	A254	155	D254	1481	1500	E254	1502	1520*
99-15239-377	A255	164	D255	1482	1500*	E255	1502	1521
99-15252-404	A256	118	D256	384	403	E256	405	423*
99-15253-382	A257	119	D257	1481	1500	E257	1502	1520*
99-15256-392	A258	120	D258	1481	1500	E258	1502	1520*
99-15258-337	A259	121	D259	1481	1500	E259	1502	1520*
99-15261-202	A260	122	D260	1482	1500*	E260	1502	1521
99-15280-432	A261	123	D261	1481	1500	E261	1502	1520*
99-15355-150	A262	124	D262	1482	1500*	E262	1502	1521
99-15663-298	A263	175	D263	1482	1500*	E263	1502	1521
99-15664-185	A264	176	D264	1482	1500*	E264	1502	1521
99-15665-398	A265	174	D265	1481	1500	E265	1502	1520*
99-15668-139	A266	177	D266	1482	1500*	E266	1502	1521
99-15672-166	A267	173	D267	1482	1500*	E267	1502	1521
99-15682-318	A268	178	D268	1482	1500*	E268	1502	1521
99-16081-217	A269	113	D269	310	329	E269	331	349*

99-16082-218	A270	114	D270	214	232*	E270	234	253
99-20933-81	A271	179	D271	1481	1500	E271	1502	1520*
99-20977-72	A272	147	D272	1482	1500*	E272	1502	1521
99-20978-89	A273	148	D273	1481	1500	E273	1502	1520*
99-20981-300	A274	149	D274	1481	1500	E274	1502	1520*
99-20983-48	A275	150	D275	1482	1500*	E275	1502	1521
99-22310-148	A276	154	D276	1481	1500	E276	1502	1520*
99-25029-241	A277	180	D277	1482	1500*	E277	1502	1521
99-25224-189	A278	125	D278	1107	1125*	E278	1127	1146
99-25869-182	A279	181	D279	1482	1500*	E279	1502	1521
99-25881-275	A280	182	D280	1481	1500	E280	1502	1520*
99-25897-264	A281	183	D281	1482	1500*	E281	1502	1521
99-25906-131	A282	184	D282	1481	1500	E282	1502	1520*
99-25917-115	A283	185	D283	1481	1500	E283	1502	1520*
99-25924-215	A284	186	D284	1482	1500*	E284	1502	1521
99-25950-121	A285	126	D285	1482	1500*	E285	1502	1521
99-25961-376	A286	127	D286	1481	1500	E286	1502	1520*
99-25965-399	A287	128	D287	1481	1500	E287	1502	1520*
99-25966-241	A288	129	D288	1481	1500	E288	1502	1520*
99-25967-57	A289	130	D289	1481	1500	E289	1502	1520*
99-25969-200	A290	131	D290	1482	1500*	E290	1502	1521
99-25972-317	A291	132	D291	1482	1500*	E291	1502	1521
99-25974-143	A292	133	D292	1481	1500	E292	1502	1520*
99-25977-311	A293	134	D293	1482	1500*	E293	1502	1521
99-25978-166	A294	135	D294	1481	1500	E294	1502	1520*
99-25979-93	A295	136	D295	1482	1500*	E295	1502	1521
99-25980-173	A296	137	D296	1482	1500*	E296	1502	1521
99-25984-312	A297	138	D297	1482	1500*	E297	1502	1521
99-25985-194	A298	139	D298	1481	1500	E298	1502	1520*
99-25989-398	A299	140	D299	1481	1500	E299	1502	1520*
99-26126-498	A300	165	D300	1482	1500*	E300	1502	1521
99-26138-193	A301	187	D301	1481	1500	E301	1502	1520*
99-26146-264	A302	188	D302	1482	1500*	E302	1502	1521
99-26147-396	A303	141	D303	1482	1500*	E303	1502	1521

99-26150-276	A304	142	D304	1481	1500	E304	1502	1520*
99-26153-44	A305	143	D305	1482	1500*	E305	1502	1521
99-26154-107	A306	144	D306	1481	1500	E306	1502	1520*
99-26156-290	A307	145	D307	1482	1500*	E307	1502	1521
99-26166-257	A308	166	D308	1481	1500	E308	1502	1520*
99-26167-278	A309	167	D309	1482	1500*	E309	1502	1521
99-26169-211	A310	168	D310	1482	1500*	E310	1502	1521
99-26171-71	A311	169	D311	1481	1500	E311	1502	1520*
99-26183-156	A312	170	D312	1482	1500*	E312	1502	1521
99-26189-164	A313	189	D313	1482	1500*	E313	1502	1521
99-26190-20	A314	190	D314	1482	1500*	E314	1502	1521
99-26191-58	A315	191	D315	1481	1500	E315	1502	1520*
99-26201-267	A316	192	D316	1481	1500	E316	1502	1520*
99-26222-149	A317	193	D317	1481	1500	E317	1502	1520*
99-26223-225	A318	194	D318	1481	1500	E318	1502	1520*
99-26225-148	A319	195	D319	1481	1500	E319	1502	1520*
99-26228-172	A320	196	D320	1482	1500*	E320	1502	1521
99-26233-275	A321	197	D321	1482	1500*	E321	1502	1521
99-26234-336	A322	198	D322	1481	1500	E322	1502	1520*
99-26238-186	A323	199	D323	1481	1500	E323	1502	1520*
99-5873-159	A324	146	D324	1481	1500	E324	1502	1520*
99-5912-49	A325	171	D325	1481	1500	E325	1502	1520*
99-6012-220	A326	158	D326	1481	1500	E326	1502	1520*
99-6080-99	A327	156	D327	1481	1500	E327	1502	1520*
99-7308-157	A328	153	D328	1482	1500*	E328	1502	1521
99-7337-204	A329	172	D329	1482	1500*	E329	1502	1521
99-16106-48	A330	200	D330	59	78	E330	80	99
99-25332-125	A331	201	D331	105	124	E331	126	145
99-25516-307	A332	202	D332	286	305	E332	307	326
99-26173-470	A333	203	D333	1481	1500	E333	1502	1521
99-26267-524	A334	204	D334	1481	1500	E334	1502	1521
99-26284-394	A335	205	D335	1481	1500	E335	1502	1521
99-26559-315	A336	206	D336	1481	1500	E336	1502	1521
99-26769-256	A337	207	D337	1481	1500	E337	1502	1521

99-26772-268	A338	208	D338	1481	1500	E338	1502	1520*
99-26776-209	A339	209	D339	1481	1500	E339	1502	1521
99-26779-437	A340	210	D340	1477	1496	E340	1498	1517
99-26781-25	A341	211	D341	1482	1500*	E341	1502	1521
99-26782-300	A342	212	D342	1482	1500*	E342	1502	1521
99-26783-81	A343	213	D343	1481	1500	E343	1502	1521
99-26787-96	A344	214	D344	1482	1500*	E344	1502	1521
99-26789-201	A345	215	D345	1482	1500*	E345	1502	1521
99-27297-280	A346	216	D346	1481	1500	E346	1502	1521
99-27306-108	A347	217	D347	1481	1500	E347	1502	1521
99-27312-58	A348	218	D348	1481	1500	E348	1502	1521
99-27323-372	A349	219	D349	1481	1500	E349	1502	1521
99-27335-191	A350	220	D350	1481	1500	E350	1502	1521
99-27345-189	A351	221	D351	1481	1500	E351	1502	1521
99-27349-267	A352	222	D352	1482	1500*	E352	1502	1521
99-27352-197	A353	223	D353	1481	1500	E353	1502	1520*
99-27353-105	A354	224	D354	1482	1500*	E354	1502	1521
99-27360-142	A355	225	D355	1482	1500*	E355	1502	1521
99-27361-181	A356	226	D356	1482	1500*	E356	1502	1521
99-27365-421	A357	227	D357	1482	1500*	E357	1502	1521
99-27680-484	A358	228	D358	464	483	E358	485	504
99-27912-272	A359	229	D359	1481	1500	E359	1502	1521
99-30329-380	A360	112	D360	361	379	E360	381	399

Mis 1 and Mis 2 respectively refer to microsequencing primers which hybridized with the coding strand or with the non-coding strand of the nucleotide sequences of the invention.

The microsequencing reaction was performed as follows :

After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20 µl final volume: 10 pmol microsequencing oligonucleotide, 1 U Thermosequenase (Amersham E79000G), 1.25 µl Thermosequenase buffer (260 mM Tris HCl pH 9.5, 65 mM MgCl₂), and the two appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94°C, 20 PCR cycles of 15 sec at 55°C, 5 sec at 72°C, and 10 sec at 94°C were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators were then

removed by ethanol precipitation. Samples were finally resuspended in formamide-EDTA loading buffer and heated for 2 min at 95°C before being loaded on a polyacrylamide sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position.. When two significant peaks are detected for the same position, each sample is categorized classification as homozygous or heterozygous type based on the height ratio.

Example 5a

Association Study Between Schizophrenia And The Biallelic Markers Of The Invention:

Collection Of DNA Samples From Affected And Non-Affected Individuals

A) Affected population

All the samples were collected from a large epidemiological study of schizophrenia undertaken in hospital centers of Quebec from October 1995 to April 1997. The population was composed of French Caucasian individuals. The study design consisted in the ascertainment of cases and two of their first degree relatives (parents or siblings).

As a whole, 956 schizophrenic cases were ascertained according to the following inclusion criteria:

- the diagnosis had been done by a psychiatrist;
- the diagnosis had been done at least 3 years before recruitment time, in order to exclude individuals suffering from transient manic-depressive psychosis or depressive disorders;

- the patient ancestors had been living in Quebec for at least 6 generations;
- it was possible to get a blood sample from 2 close relatives.

Among the 956 schizophrenic ascertained cases, 834 individuals were included in the study for the following reasons:

- for the included individual cases, the diagnosis of schizophrenia was established according to the DSM-IV (Diagnostic and Statistical Manual, Fourth edition, Revised 1994,

American Psychiatric Press);

- samples from individuals suffering from schizoaffective disorder were discarded;
- individuals suffering from catatonic schizophrenia were also excluded from the population of schizophrenic cases;

- were also excluded the individuals having a first degree relative or 2 or more second degree relatives suffering from depression or mood disorder;

- individuals having had severe head trauma, severe obstretical complications, encephalitis, or meningitis before onset of symptoms were also excluded;

- has also been excluded from the population of schizophrenic cases a patient suffering from epilepsy and treated with anticonvulsants.

The age at onset was not added as an inclusion criteria.

B) Unaffected population

Control cases were respectively ascertained based on the following cumulative criteria:

- the individual must not be affected by schizophrenia or any other psychiatric disorder;
- the individual must have 35 years old or more;
- the individual must belong to the French-Canadian population;
- the individual must have one or two first degree relative available for blood sampling.

Controls were matched with cases sex when possible.

C) Cases and Control Populations Selected for the Association Study

The unaffected population retained for the study was composed of 241 individuals. The initial sample of the clinical study was composed of 215 cases and 214 controls. The controls were composed of 116 males and 98 females while the cases were composed of 154 males and 64 females. For each control, two first degree relatives (father, mother, sisters and brothers) were available. In order to match the sex of cases and controls, the parents of female controls were substituted for the female controls where possible and where the parents were known to be unaffected by schizophrenia or other psychosis. The parents of 27 female controls were thus substituted for the respective females, resulting in a total control sample size of 241 individuals. The composition of the control sample is detailed below in Table 7.

Table 7

Description of control samples

Probands	187
Male	116
Female	71
Parents of probands	54
Fathers	27

Mothers	27
Total	241

The association data that are presented below were obtained on a population size detailed in Table 8 below, wherein the individuals have been randomly selected from the populations detailed above.

Table 8

Cases and Control Populations Selected for the Association Study			
sample type		Cases	Controls
sample size		215	241
Gender			
	Male	151	143
	Female	64	98
Familial history of psychosis (FH)*			
	positive (FH+)	82	0
	none (FH-)	133	241
* : close relatives (first or second degree)			

Both case and control populations form two groups, each group consisting of unrelated individuals that do not share a known common ancestor. Additionally, the individuals of the control population were selected among those having no family history of schizophrenia or schizophrenic disorder.

Genotyping of affected and control individuals

A) Results from the genotyping

The general strategy to perform the association studies was to individually scan the DNA samples from all individuals in each of the populations described above in order to establish the allele frequencies of biallelic markers, and among them the biallelic markers of the invention, in the diploid genome of the tested individuals belonging to each of these populations.

Allelic frequencies of every biallelic marker in each population (cases and controls) were determined by performing microsequencing reactions on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual. Genomic PCR and microsequencing were performed as detailed above in Examples 1 to 3 using the described PCR and microsequencing primers.

Single biallelic marker frequency analysis

For each allele of the biallelic markers included in this study, the difference between the allelic frequency in the unaffected population and in the population affected by schizophrenia was calculated and the absolute value of the difference was determined. The more the difference in allelic frequency for a particular biallelic marker or a particular set of biallelic markers, the more probable an association between the genomic region harboring this particular biallelic marker or set of biallelic markers and schizophrenia. Allelic frequencies were also useful to check that the markers used in the haplotype studies meet the Hardy-Weinberg proportions (random mating).

The allelic frequencies of biallelic markers in the chromosome 13q31-q33 region between the affected and the unaffected population, using the sample population described above, is set forth in Table 9.

Table 9

Allelic frequencies of markers in different sub-samples

marker	alleles	all sample			
		cases			controls
		all	HF+	HF-	
99-20978/89	C/G	0.51	0.47	0.51	0.55
99-20983/48	A/G	0.30	0.28	0.33	0.29
99-20981/300	A/G	0.54	0.51	0.55	0.56
99-20977/72	A/C	0.40	0.41	0.38	0.35
99-6080/99	C/T	0.58	0.57	0.57	0.55
99-15229/412	A/G	0.54	0.52	0.55	0.53
99-22310/148	C/T	0.46	0.48	0.44	0.47
99-15232/291	C/T	0.46	0.48	0.43	0.47
99-14021/108	A/G	0.46	0.48	0.44	0.47
8-98/68	A/G	0.20	0.18	0.23	0.19
8-97/98	C/T	0.78	0.75	0.81	0.80
99-6012/220	C/T	0.20	0.19	0.23	0.19
8-95/43	A/G	0.18	0.20	0.18	0.21
99-7308/157	C/T	0.39	0.42	0.36	0.39
99-14364/415	C/T	0.38	0.40	0.36	0.39
99-15672/166	C/T	0.51	0.47	0.54	0.54
99-15668/139	C/T	0.58	0.56	0.62	0.65
99-15665/398	A/G	0.72	0.67	0.72	0.76
99-15663/298	C/T	0.72	0.67	0.72	0.76
99-15664/185	C/T	0.69	0.62	0.72	0.72

99-15682/318	A/T	0.35	0.40	0.34	0.32
99-20933/81	A/C	0.43	0.41	0.42	0.40
99-16081/217	C/T	0.43	0.38	0.46	0.39
99-16082/218	A/G	0.33	0.31	0.35	0.32
99-5862/167	C/T	0.47	0.43	0.44	0.51
99-16100/147	A/G	0.48	0.44	0.45	0.50
99-7652/162	A/G	0.49	0.46	0.46	0.52
99-5919/215	A/G	0.66	0.71	0.69	0.60
99-5897/143	A/C	0.58	0.61	0.53	0.59
99-15870/400	A/G	0.32	0.38	0.27	0.33
99-16032/292	A/C	0.61	0.62	0.64	0.58
99-15880/162	A/G	0.62	0.63	0.65	0.58
99-16038/118	A/G	0.38	0.36	0.35	0.42
99-15875/165	C/T	0.58	0.57	0.57	0.63
99-16033/244	C/T	0.55	0.57	0.49	0.54
99-16047/115	C/T	0.73	0.75	0.68	0.73

In the association study described herein, several individual biallelic markers were shown to be significantly associated with schizophrenia. In particular, several of the chromosome 13q31-q33 region biallelic markers (99-16038/118 (A198), 99-15880/162 (A218), 99-5919/215 (A75), 99-15875/165 (A228), 99-16032/292 (A223)) showed significant association with schizophrenia in both familial and sporadic schizophrenia cases. The significance of the absolute value of the difference of allelic frequency of the individual biallelic markers in the affected and the unaffected population is set forth in Figure 2, with several biallelic marker having allelic frequency differences with p-values approaching or less than 0.05, biallelic marker 99-5919/215 (A75) having a p-value of less than 0.01. Figure 2 also shows the physical order of certain specific biallelic markers. These results show that several biallelic markers individually associated with schizophrenia are physically located in a particular region of significance, the subregion of the chromosome 13q31-q33 region referred to herein as Region D.

Haplotype frequency analysis

Analysis of markers Haplotype analysis for association of chromosome 13q31-q33-related biallelic markers and schizophrenia was performed by estimating the frequencies of all possible 2, 3 and 4 marker haplotypes in the affected and control populations described above. Haplotype estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier and Slatkin, 1995), using the EM-HAPLO program (Hawley et al., 1994)

as described above. Estimated haplotype frequencies in the affected and control population were compared by means of a chi-square statistical test (one degree of freedom).

Haplotype association results in schizophrenia cases

The results of the haplotype analysis using the chromosome 13q31-q33-related biallelic markers biallelic markers is shown in Figure 3. In particular, the figures show the most significant haplotypes using the biallelic markers: 99-16047/115 (A239), 99-16033/244 (A227), 99-16038/118 (A198), 99-15875/165 (A228), 99-16032/292 (A223), 99-5897/143 (A107), 99-15880/162 (A218), 99-16082/218 (A270), 99-5919/215 (A75), 99-7652/162 (A62), 99-16100/147 (A65), 99-5862/167 (A70).

A number of biallelic marker haplotypes were shown to be significantly associated with schizophrenia. A first preferred haplotype (HAP287 of Figure 3) consisting of four biallelic markers (99-16038/118 (A198), 99-16082/218 (A270), (99-7652/162 (A62) and 99-16100/147 (A65)) is highly significantly associated with schizophrenia in both total cases and sporadic cases. Figure 4 shows the characteristics of this haplotype. This haplotype presented a p-value of 3.1×10^{-7} and an odd-ratio of 4.01 for total cases and a p-value of 3.9×10^{-6} and an odd-ratio of 3.88 for sporadic cases. Phenotypic permutation tests confirmed the statistical significance of these results. Estimated haplotype frequencies were 13.8% in total cases, 13.5% in the sporadic cases, and 3.8 % in the controls.

Several other significant haplotypes are listed in Figure 3, including several 2-, 3- and 4-marker haplotypes. Considered to be highly significantly associated with schizophrenia are the most significant 2-marker haplotype (HAP1 consisting of biallelic markers 99-15875/165 (A228) and 99-5919/215 (A75)) and the most significant 3-marker haplotype (HAP67 consisting of biallelic markers 99-16038/118 (A198), 99-16082/218 (A270) and 99-7652/162 (A218)).

Further preferred significant haplotypes considered associated with schizophrenia are haplotypes having p-values above a desired threshold level are also; all the haplotypes listed in Figure 3 present p-values below 1.0×10^{-2} for 2-marker haplotypes, 1.0×10^{-4} for 3-marker haplotypes, and 1.0×10^{-5} for 4-marker haplotypes. All of the biallelic markers presented in Figure 4 except for 1 (99-16047/115 (A239)) are involved in haplotypes having a p-value above these threshold levels. Figure 3 shows several 2-marker haplotypes, HAP1 to HAP8, having p-values ranging from 1.0×10^{-2} to 1.2×10^{-3} , several 3-marker haplotypes, HAP67 to HAP76, having p-values ranging from 1.3×10^{-5} to 1.0×10^{-4} and several 4-marker haplotypes, HAP287 to HAP291, having p-values ranging from 8.2×10^{-7} to 3.1×10^{-7} . Figure 4 shows biallelic markers involved in significant haplotypes having significance thresholds of 1.0×10^{-2} , 1.0×10^{-4} , and 1.0×10^{-5} for 2-, 3- and 4-marker haplotypes, respectively.

Several 2-, 3- and 4-marker haplotypes, HAP 1, HAP8, HAP70, HAP71, HAP75, HAP76, HAP288, HAP290 and HAP291, often comprised the biallelic marker 99-5919/215 (A75) allele A. Furthermore, several 2-, 3- and 4-marker haplotypes, HAP7, HAP67, HAP69, HAP75, HAP287 AND HAP288, often comprised the biallelic marker 99-16038/118 (A198) allele G.

Example 5b

Association Study Between Schizophrenia And The Biallelic Markers Of The Invention

Collection Of DNA Samples From Affected And Non-Affected Individuals

Biallelic markers of the invention were further analyzed in the French Canadian population described above. For this analysis, the proband case population under study consisted of 139 individuals, the control population consisted of 141 individuals, as described in Table 10 below.

Table 10

Cases and Control Populations Selected for the Association Study			
Sample type		Cases	Controls
Sample size		139	141
Gender			
	Male	94	96
	Female	45	45
Familial history of psychosis (FH)*			
	positive (FH+)	76	0
	none (FH-)	63	141
* : close relatives (first or second degree)			

Genotyping of affected and control individuals

A) Results from the genotyping

The general strategy for performing the association studies was to individually scan the DNA samples from all individuals in each of the populations described above in order to establish the allele frequencies of biallelic markers, and among them the biallelic markers of the invention, in the diploid genome of the tested individuals belonging to each of these populations.

Allelic frequencies of every biallelic marker in each population (cases and controls) were determined by performing microsequencing reactions on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual. Genomic PCR and

microsequencing were performed as detailed above in Examples 1 to 3 using the described PCR and microsequencing primers.

Single biallelic marker frequency analysis

For each allele of the biallelic markers included in this study, the difference between the allelic frequency in the unaffected population and in the population affected by schizophrenia was calculated and the absolute value of the difference was determined. The allelic frequencies of between the affected and the unaffected population in the regions is set forth in Table 11, using the sample population described above and in Table 10. The more the difference in allelic frequency for a particular biallelic marker or a particular set of biallelic markers, the more probable an association between the genomic region harboring this particular biallelic marker or set of biallelic markers and schizophrenia. Allelic frequencies were also useful to check that the markers used in the haplotype studies meet the Hardy-Weinberg proportions (random mating).

Table 11

Allelic frequencies of markers in different sub-samples (%)

Marker	polymorphism	Cases			All controls
		All cases	HF+	HF-	
99-20978/89	C/G	50,37	47,26	54,03	55,43
99-20983/48	A/G	30,37	28,67	32,5	26,52
99-20977/72	A/C	41,01	42,11	39,68	34,4
99-20981/300	A/G	52,17	51,33	53,17	60
99-6080/99	C/T	58,82	58	59,84	54,85
99-15229/412	A/G	54,92	52,86	57,26	51,88
99-22310/148	C/T	44,2	46,71	41,13	48,57
99-15232/291	G/T	43,85	46,43	40,83	49,28
99-14021/108	A/G	44,85	47,26	42,06	48,54
8-94/252	A/G	2,22	1,97	2,54	2,52
8-98/68	A/G	19,06	17,76	20,63	19,06
8-97/98	C/T	76,26	74,34	78,57	77,3
99-6012/220	G/T	20	18,49	21,77	18,79
99-7308/157	C/T	40,31	41,89	38,18	39,36
99-14364/415	C/T	39,93	40,79	38,89	40
8-95/43	A/G	20,29	20,39	20,16	22,14
99-15672/166	C/T	49,28	47,37	51,59	56,74
99-15668/139	C/T	58,21	56,16	60,66	66,67
99-15665/398	A/G	70,5	67,76	73,81	76,79

99-15663/298	C/T	70,5	67,76	73,81	76,95
99-15664/185	G/T	66,54	62,33	71,43	72,5
99-15682/318	A/T	35,27	39,58	29,82	32,66
99-20933/81	A/C	43,12	42,76	43,55	42,45
99-26146/264	G/T	39,62	38,67	40,91	38,85
99-25922/147	G/T	44,19	39,58	50	40,94
99-16081/217	C/T	42,28	38,82	46,67	36,74
99-16082/218	A/G	34,73	31,94	38,14	33,81
99-24656/260	A/G	48,87	49,32	48,31	54,04
99-24639/163	G/T	38,52	33,33	45	40,51
99-24634/108	A/T	44,85	42,67	47,54	50
99-7652/162	A/G	45,29	44,08	46,77	50,36
99-16100/147	A/G	44,66	42,75	46,77	48,89
99-5862/167	C/T	43,53	41,45	46,03	49,29
99-5919/215	A/G	69,42	71,05	67,46	60,28
99-24658/410	C/T	64,13	69,08	58,06	61,07
99-24644/194	A/G	39,42	41,22	37,3	40,51
99-5897/143	A/C	57,61	60,67	53,97	61,07
99-24649/186	C/T	67,75	67,33	68,25	62,95
99-15870/400	A/G	33,46	36,67	29,51	30,29
99-16038/118	A/G	34,53	36,18	32,54	43,62
99-15880/162	A/G	65,11	63,16	67,46	56,43
99-25940/182	A/G	59,42	56,67	62,7	52,59
99-16032/292	A/C	64,03	61,84	66,67	55,67
99-16033/244	C/T	54,51	56,76	51,69	56,44
99-15875/165	C/T	56,88	57,89	55,65	66,3
99-16047/115	C/T	71,69	74,67	68,03	75,19
99-25993/367	A/G	44,53	40,79	49,18	40,51
99-25989/398	A/G	32,81	33,33	32,2	27,86
99-25979/93	A/G	68,12	69,08	66,94	69,32
99-25969/200	G/T	36,67	38,67	34,17	38,85
99-25966/241	A/G	66,3	67,11	65,32	63,21
99-25961/376	A/C	39,63	42,57	36,07	37,31
99-25965/399	A/G	50,36	51,97	48,39	49,64
99-25977/311	A/G	72,01	67,76	77,59	73,72
99-25950/121	C/G	31,75	36	26,61	27,54
99-25974/143	A/G	25,55	28,29	22,13	22,7
99-26150/276	A/G	46,54	51,43	40,83	47,76

99-15258/337	G/T	25,55	26,97	23,77	24,1
99-15261/202	A/G	63,06	59,46	67,5	65,15
99-15256/392	C/T	64,96	61,33	69,35	65,3
99-15056/99	C/T	32,72	36,49	28,23	31,11
99-15280/432	C/T	42,28	44	40,16	38,97
99-15355/150	C/T	72,3	70,39	74,6	68,79
99-15253/382	C/T	63,04	62,67	63,49	62,95
99-5873/159	C/T	78,1	79,05	76,98	77,34

Haplotype frequency analysis

Analysis of markers Haplotype analysis for association of chromosome 13q31-q33-related biallelic markers and schizophrenia was performed by estimating the frequencies of all possible 2, 3 and 4 marker haplotypes in the affected and control populations described above. Haplotype estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier and Slatkin, 1995), using the EM-HAPLO program (Hawley et al., 1994) as described above. Estimated haplotype frequencies in the affected and control population were compared by means of a chi-square statistical test (one degree of freedom).

Haplotype association results in schizophrenia cases

Haplotype studies yielded significant results indicating an association of the nucleotide sequences of the invention with schizophrenia. Significant results are shown in Figures 5 and 6, including descriptions of the frequency of the haplotype leading to the maximum chi square test (reference no. (1) in figures), the test of the frequency of a particular haplotype in cases vs in controls (reference no. (2) in figures) and the p- value assuming that the test has a chi-square distribution with 1 degree of freedom (ddl) (reference no. (3) in figures). The results of the haplotype analysis using 28 preferred biallelic markers of the invention, 99-24656-260 (A48), 99-24639-163 (A60), 99-24634-108 (A61), 99-7652-162 (A62), 99-16100-147 (A65), 99-5862-167 (A70), 99-5919-215 (A75), 99-24658-410 (A76), 99-24644-194 (A80), 99-5897-143 (A107), 99-24649-186 (A108), 99-16038-118 (A198), 99-15880-162 (A218), 99-25940-182 (A221), 99-16032-292 (A223), 99-16033-244 (A227), 99-15875-165 (A228), 99-16047-115 (A239), 99-25950-121 (A285), 99-25961-376 (A286), 99-25965-399 (A287), 99-25966-241 (A288), 99-25969-200 (A290), 99-25974-143 (A292), 99-25977-311 (A293), 99-25979-93 (A295), 99-25989-398 (A299), and 99-26150-276 (A304) are shown in Figures 5 and 6.

Figures 5 and 6 also show the physical order of the biallelic markers comprising the haplotypes.

Figure 5 shows the results of the haplotype analysis using the following biallelic markers located on the approximately 319kb sequence of SEQ ID No. 1: 99-24656-260 (A48), 99-24639-163 (A60), 99-24634-108 (A61), 99-7652-162 (A62), 99-16100-147 (A65), 99-5862-

167 (A70), 99-5919-215 (A75), 99-24658-410 (A76), 99-24644-194 (A80), 99-5897-143 (A107), 99-24649-186 (A108), 99-16038-118 (A198), 99-15880-162 (A218), 99-25940-182 (A221), 99-16032-292 (A223), 99-16033-244 (A227), 99-15875-165 (A228), and 99-16047-115 (A239).

5 Figure 6 shows the results of the haplotype analysis using the following biallelic markers located on the approximately 319kb of SEQ ID No. 1 as well as additional biallelic markers located on the human chromosome 13q31-q33 locus: 99-16038-118 (A198), 99-15880-162 (A218), 99-25940-182 (A221), 99-16032-292 (A223), 99-16033-244 (A227), 99-15875-165 (A228), 99-16047-115 (A239), 99-25950-121 (A285), 99-25961-376 (A286), 99-25965-399 (A287), 99-25966-241 (A288), 99-25969-200 (A290), 99-25974-143 (A292), 99-25977-311 (A293), 99-25979-93 (A295), 99-25989-398 (A299), and 99-26150-276 (A304).

A number of biallelic marker haplotypes were shown to be significantly associated with schizophrenia.

15 Several preferred haplotypes all showing highly significant association with schizophrenia and including various 2-, 3- and 4- marker haplotypes are haplotypes 817, 818 and 819, 137, 138, 1 and 2 of Figure 6, and haplotypes 970, 154 and 1 of Figure 5. The p-values, odd-ratios and estimated haplotype frequencies are further described in Figures 5 and 6. In particular, the two marker haplotype 1 of Figure 5 consisting of biallelic markers 99-5862-167 (A70) and 99-15875-165 (A228) showed a highly significant p-value of 7.8×10^{-5} and an odd-ratio of 1.61. Haplotype 818 of Figure 6 consisting of four biallelic markers (99-16032-292 (A223), 99-25969-200 (A290), 99-25977-311 (A293), and 99-25989-398 (A299)) presented a p-value of 3.1×10^{-7} and an odd-ratio of 9.08. Another example showing significance is haplotype 817 of Figure 6 consisting of four biallelic markers (99-16033-244 (A227), 99-15875-165 (A228), 99-25950-121 (A285) and 99-25979-93 (A295)), presented a p-value of 2.4×10^{-7} and an odd-ratio of 100. Phenotypic permutation tests confirmed the statistical significance of these results. Estimated haplotype frequencies were 10.5% in cases and 0 % in the controls. Haplotype 970 of Figure 5 consisting of four biallelic markers (99-5919-215 (A75), 99-24658-410 (A76), 99-15875-165 (A228), and 99-16047-115 (A239)) presented a p-value of 7.8×10^{-7} and an odd-ratio of 2.41. Phenotypic permutation tests confirmed the statistical significance of these results. Estimated haplotype frequencies were 25.7% in cases and 12.5 % in the controls.

30 Several other significant haplotypes are listed in Figures 5 and 6, including several 2-, 3- and 4-marker haplotypes. Considered to be highly significantly associated with schizophrenia are the most significant 2-marker haplotypes (for example haplotype 1 of Figure

5 noted above and the most significant 3-marker haplotypes (for example haplotype 137 of Figure 6 consisting of biallelic markers (99-15875-165 (A228), 99-16047-115 (A239) and 99-25950-121 (A285)).

Further preferred significant haplotypes considered associated with schizophrenia are haplotypes having p-values above a desired threshold level; all the haplotypes listed in Figures 5 and 6 present p-values below 1.0×10^{-2} for 2-marker haplotypes, 1.0×10^{-4} for 3-marker haplotypes, and 1.0×10^{-5} for 4-marker haplotypes. Figures 5 and 6 show several 2-marker haplotypes, haplotypes 1 to 9 and haplotypes 1 to 5 of Figures 5 and 6 respectively, having p-values ranging from 7.8×10^{-5} to 8.6×10^{-3} , several 3-marker haplotypes, haplotypes 154 to 163 and 137 to 141 of Figures 5 and 6 respectively, having p-values ranging from 3.9×10^{-6} to 1.1×10^{-4} and several 4-marker haplotypes, haplotypes 970 to 973 and 817 to 836 of Figures 5 and 6 respectively, having p-values ranging from 2.4×10^{-7} to 7.3×10^{-6} .

Additionally, a particularly large number of the significant 2-, 3- and 4-marker haplotypes often comprised the biallelic markers A223, A76, A227, A239, A286, A290, A299 and most commonly A228 (99-15875-165), allele T.

The statistical significance of the results obtained for the haplotype analysis was evaluated by a phenotypic permutation test reiterated 100 times on a computer. For this computer simulation, data from the affected and control individuals were pooled and randomly allocated to two groups which contained the same number of individuals as the case-control populations used to produce the data summarized in figures 5 and 6. A haplotype analysis was then run on these artificial groups for the markers included in the haplotypes showing strong association with schizophrenia. This experiment was reiterated 100 times and the results are shown in the columns of Figures 5 and 6 labelled "Haplotype test by permutation procedure". For a given haplotype, these results demonstrate the number of obtained (simulated) haplotypes having a p-value comparable to the one obtained for the given haplotype among 100 iterations. These results, set forth in Figures 5 and 6 validate the statistical significance of the association between the haplotypes and schizophrenia.

Example 5c

Association Study Between Schizophrenia and the Biallelic Markers of the Invention in French Canadian Samples

Collection Of DNA Samples From Affected And Non-Affected Individuals

Biallelic markers of the present invention were further genotyped in French Canadian samples as described above in order to compare the association of the 1st and the 2nd portion of Region D with schizophrenia. The population used in the study was the same as described above with the exception that 2 male FH+ cases were not included.

The biallelic markers analyzed in the study include 34 preferred biallelic markers of the invention located in Region D of the chromosome 13q31-33 region. Included in the analysis were the 14 following biallelic markers from the first of two portions of Region D: 99-26150/276 (A304), 99-26156/290 (A307), 99-26153/44 (A305), 99-25985/194 (A298), 99-25974/143 (A292), 99-25977/311 (A293), 99-25972/317 (A291), 99-25965/399 (A287), 99-25961/376 (A286), 99-25966/241 (A288), 99-25967/57 (A289), 99-25969/200 (A290), 99-25979/93 (A295) and 99-25989/398 (A299). Included in the analysis were also the 20 following biallelic markers from the second of two portions of Region D: 99-25993/367 (A241), 99-16047/115 (A239), 99-15875/165 (A228), 99-16033/244 (A227), 99-16032/292 (A223), 99-25940/182 (A221), 99-15880/162 (A218), 99-16038/118 (A198), 99-15870/400 (A178), 99-24649/186 (A108), 99-5897/143 (A107), 99-24644/194 (A80), 99-24658/410 (A76), 99-5919/215 (A75), 99-5862/167 (A70), 99-16100/147 (A65), 99-7652/162 (A62), 99-24634/108 (A61), 99-24639/163 (A60) and 99-24656/260 (A48).

Single biallelic marker association results in schizophrenia cases

Single biallelic marker studies yielded significant results, indicating an association of the nucleotide sequences of the invention with schizophrenia. Biallelic markers used in the analysis included the set of 34 biallelic markers shown in Table 11 below, 14 biallelic markers of which were located on the first of two portions of Region D, and 20 of which were located on the second portion. The distribution of markers is shown in Table 12 below. As summarized in Table 13, analyses using these biallelic markers demonstrated a significant association with schizophrenia for 5 markers on the second portion of Region D.

Table 11

REGION	CONTIG	SNPS GENOTYPED	POLYMORPHISM	FREQUENCY IN CONTROLS
D	1 st portion	99-26150/276	A/G	50
		99-26156/290	A/C	69
		99-26153/44	A/C	61
		99-25985/194	C/T	29
		99-25974/143	A/G	25
		99-25977/311	A/G	73
		99-25972/317	C/T	72
		99-25965/399	A/G	49
		99-25961/376	A/C	40
		99-25966/241	A/G	63
		99-25967/57	A/G	43
		99-25969/200	G/T	40
		99-25979/93	A/G	72
		99-25989/398	A/G	29
	2 nd portion	99-25993/367	A/G	44
		99-16047/115	C/T	73
		99-15875/165	C/T	63
		99-16033/244	C/T	54

	99-16032/292	A/C	58
	99-25940/182	A/G	53
	99-15880/162	A/G	58
	99-16038/118	A/G	42
	99-15870/400	A/G	33
	99-24649/186	C/T	65
	99-5897/143	A/C	59
	99-24644/194	A/G	39
	99-24658/410	C/T	58
	99-5919/215	A/G	60
	99-5862/167	C/T	51
	99-16100/147	A/G	50
	99-7652/162	A/G	52
	99-24634/108	A/T	53
	99-24639/163	G/T	44
	99-24656/260	A/G	54

Table 12

Region	No. of Biallelic markers (σ)	Mean frequency (σ)	Mean inter-marker distance (σ)
D 1 st half	14 (14)	0.34 (0.07)	7 (6.3)
D 2 nd half	20 (8)	0.42 (0.06)	11 (13)
D 1 st and 2 nd half	34 (22)	0.39 (0.07)	10.3 (11)

5 Haplotype frequency analysis

Analysis of markers Haplotype analysis for association of chromosome 13q31-q33-related biallelic markers and schizophrenia was performed by estimating the frequencies of all possible 2, 3 and 4 marker haplotypes in the affected and control populations described above. Haplotype estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier and Slatkin, 1995), using the EM-HAPLO program (Hawley et al., 1994) as described above.

10 Haplotype association results in schizophrenia cases

Significant results were also obtained in haplotype studies indicating an association of the nucleotide sequences of the invention with schizophrenia.

15 The present inventors having previously demonstrated highly significant association of biallelic markers located on the Region D subregion of the human chromosome 13q31-q33 locus with disease. Using the Omnibus LR test which compares the profile of haplotype frequencies, and Haplo-maxM test which is based on haplotype differences for each haplotype in two groups, Figures 7 and 8 describe the results of an analysis of the first and second portions of Region D which demonstrated an association of the second portion of Region D with

schizophrenia.

For combinations of 2 and 3 biallelic markers, one likelihood ratio test is obtained based on the haplotype frequency values calculated using the E-M algorithm. A permutation procedure was used, where data from the affected and control individuals was pooled and randomly allocated to two groups which contained the same number of individuals as the case-control populations used to produce the data. A haplotype analysis was then run on these artificial groups for the markers included in the haplotypes showing strong association with schizophrenia. This experiment was reiterated 100 times. For a given haplotype, these results demonstrate the number of obtained (simulated) haplotypes having a p-value comparable to the one obtained for the given haplotype among 100 iterations.

Figure 7 shows a comparison of the LR test value distributions of haplotype frequencies in the two portions of Region D. This association of the second portion of Region D with schizophrenia is shown using both 2-marker and 3-marker combinations. The distribution of LR test values in the different regions was analyzed using a Kruskal-Wallis rank test, a chi-square test with $r-1$ degrees of freedom, where r represents the number of value sets compared. As shown, the significance of the association is demonstrated by a chi-square value (one degree of freedom) of 74.405 and a p-value of less than 1×10^{-10} for 2 marker combinations, and a chi-square value (one degree of freedom) of 228.72 and a p-value of 1×10^{-10} for 3- marker combinations.

Another association analysis approach based on haplotype frequency differences, referred to as the Haplo-maxM test, was conducted using region D biallelic markers. For one combination of markers having h haplotypes, h differences of haplotype frequencies can be compared via a Pearson chi-square statistic (one degree of freedom). The haplo-max test selects the difference showing the maximum positive test value between cases versus controls (rejecting test values based on rare haplotype frequencies, i.e., with an estimated number of haplotypes inferior to 10); for one combination of markers there is therefore one Max-M test value. The results of the Haplo-maxM test using Region D biallelic markers are shown in Figure 8.

Figure 8 shows the distribution of haplo-maxM test values obtained for both 2-marker and 3-marker combinations in the two portions of Region D, demonstrating an association of the second portion of Region D with schizophrenia. The comparison of the distribution of Haplo-maxM test values in the two regions was analyzed using a Kruskal-Wallis rank test, a chi-square test with $r-1$ degrees of freedom, where r represents the number of value sets compared. As shown, the significance of the association is demonstrated by a chi-square value

(one degree of freedom) of 34.839 and a p-value of less than 3.58×10^{-9} for 2 marker combinations, and a chi-square value (one degree of freedom) of 13.773 and a p-value of 2.6×10^{-4} for 3- marker combinations.

The results from the haplo-maxM tests further confirms the association shown using the Omnibus LR test results.

Results of association studies discussed above using biallelic markers of the invention are further summarized in Table 13 below, showing a significant association of the biallelic markers with schizophrenia in both single biallelic marker and haplotype analysis.

Table 13

	Single-point Analysis		Multi-point analysis (Haplotype-based analysis)		
	No. of allelic freq differences > 10%	No. Significant allelic tests	Omnibus LR TEST *		
			2-mks	3-mks	4-mks
Region D, 1st portion	0	0	0,03	0,05	0,06
Region D, 2nd portion	0	5	0,30	0,30	0,31

* percentage of significant tests (5% level of significance)

Cases (N=213) / Controls (N=241)

Example 5d

Association Study Between Bipolar Disorder and the Biallelic Markers of the Invention

Description of study design

Biallelic markers of the invention were analyzed in bipolar disorder cases. As in examples above, single and multi-point analyses showed a significant association of the markers of the invention, of Region D of the chromosome 13q33 locus, and more particularly of a sub-region of Region D with bipolar disorder.

A) Description of the Affected population

All the samples were collected from a study of bipolar disorder undertaken in a hospital located south of Buenos Aires, Argentina, generally representing a population estimated at about 400,000 inhabitants. Patients were evaluated by four doctors in 1994 and 1995. The study design involved in the ascertainment of cases and their first degree relatives (parents or siblings). 514 individuals were available for the study. This group consisted of 158 subjects from 51 different families, and 356 independent subjects.

As a whole, bipolar disorder cases were ascertained according to the diagnosis of bipolar disorder established by the DSM-IV (Diagnostic and Statistical Manual, Fourth edition, Revised 1994, American Psychiatric Press);

Available for consideration for each coded case were also age, sex, nationality of parents and grand parents, ethnic origin, familial composition, marital state, socio-economic level, educational level, professional situation, employment, recreational activities, age of onset of psychiatric symptoms, age of first consultation, occurrences of obstetric or prenatal incidents, suicide attempts, other medical conditions, treatment for or occurrence of a neurological condition, familial occurrence of symptoms, previous or concurrent use of psychotropic drugs, other admissions to a hospital or medical treatments, and diagnostic reason for admission including (a) DSM-IV diagnosis and (b) symptoms first presented on admission to hospital.

Available for study were 226 bipolar disorder ascertained cases of which 203 were independent cases. This group consisted of 51 cases from 51 families, 20 cases in relatives thereof, and 155 independent cases. Upon elimination of 3 cases from the initial independent 155 cases due to discovery of a familial relation, the total number of independent cases was 203.

Cases were classified according to bipolar disorder type. The cases included 115 bipolar disorder type I individuals (including 1 rapid cycling case), 67 bipolar disorder type II individuals (including 1 rapid cycling case), 18 unclassified bipolar disorder cases, and 3 cases which remained unclassified due to lack of or inconsistent information.

The 203 independent cases were examined for a familial history of psychosis. 53 of these cases reported an occurrence of psychosis (characterized as schizophrenia or bipolar disorder) among first degree relatives (father, mother, brothers, sisters or children).

B) Description of the Unaffected population

Available for study were 201 controls which had not been affected by any psychiatric difficulties or reported any familial history of psychiatric difficulties. Available for consideration were also age, sex and ethnic origin of the unaffected population.

C) Case and Control Populations Selected for the Association Study

For the association study, the case population under study consisted of 201 individuals selected from the 226 total cases above; the control population consisted of 198 individuals selected from the 201 controls described above.

The association data that are presented in the Example 5d below were obtained on a population size detailed in Table 14 below.

Table 14

Cases and Control Populations Selected for the Association Study			
Sample type		Cases	Controls
Sample size		201	198
Gender			

	Male	68	81
	Female	124	117
	Missing	9	
Ethnic origin			
	Causasian	182	177
	Non caucasian	5	21
	Missing	14	
Familial history of psychosis (FH)*			
	positive (FH+)	54	0
	none (FH-)	147	198
* : close relatives (first degree)			

Both case and control populations form two groups, each group consisting of unrelated individuals that do not share a known common ancestor.

Genotyping of affected and control individuals

5 The general strategy was to individually scan the DNA samples from all individuals in each of the populations described above in order to establish the allele frequencies of biallelic markers, and among them the biallelic markers of the invention, in the diploid genome of the tested individuals belonging to each of these populations.

10 Allelic frequencies of every biallelic marker in each population (cases and controls) were determined by performing microsequencing reactions on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual. Genomic PCR and microsequencing were performed as detailed above in Examples 1 to 3 using the described PCR and microsequencing primers.

Association analysis

15 The association analysis included 30 preferred biallelic markers of the invention located in Region D of the chromosome 13q31-33 region. Included in the analysis were the 14 following biallelic markers from the first of two subjective portions of Region D: 99-26150/276 (A304), 99-26156/290 (A307), 99-26153/44 (A305), 99-25985/194 (A298), 99-25974/143 (A292), 99-25977/311 (A293), 99-25972/317 (A291), 99-25965/399 (A287), 99-25961/376 (A286), 99-25966/241 (A288), 25967/57 (A289), 99-25969/200 (A290), 99-25979/93 (A295) and 99-25989/398 (A299). Included in the analysis were also the 16 following biallelic markers from the second of two portions of Region D: 99-25993/367 (A241), 99-16047/115 (A239), 99-15875/165 (A228), 99-16033/244 (A227), 99-16032/292 (A223), 99-25940/182 (A221), 99-15880/162 (A218), 99-16038/118 (A198), 99-15870/400 (A178), 99-24649/186 (A108), 99-2597/143 (A107), 99-24644/194 (A80), 99-5919/215 (A75), 99-5862/167 (A70), 99-16100/147

20

25

(A65), and 99-7652/162 (A62).

A) Single biallelic marker association results in bipolar disorder cases

For each allele of the biallelic markers included in this study, the difference between the allelic frequency in the unaffected population and in the population affected by bipolar disorder was calculated and the absolute value of the difference was determined. The set of biallelic markers and their allelic frequencies included in this study are set forth in Table 15. The more the difference in allelic frequency for a particular biallelic marker or a particular set of biallelic markers, the more probable an association between the genomic region harboring this particular biallelic marker or set of biallelic markers and bipolar disorder. Allelic frequencies were also useful to check that the markers used in the haplotype studies meet the Hardy-Weinberg proportions (under random mating assumptions)

Table 15

REGION	CONTIG	POSITION ON CONTIG	SNPS GENOTYPED	POLYMORPHISM	FREQUENCY IN CONTROLS
D	Region D first Half	168,02	99-26150/276	A/G	62,93
		173,29	99-26156/290	A/C	72,42
		177,01	99-26153/44	A/C	52,66
		186,41	99-25985/194	C/T	28,87
		190,15	99-25974/143	A/G	31,79
		216,43	99-25977/311	A/G	63,82
		224,62	99-25972/317	C/T	72,32
		236,64	99-25965/399	A/G	58,24
		244,82	99-25961/376	A/C	44,35
		254,70	99-25966/241	A/G	66,18
		257,85	99-25967/57	A/G	42,44
		261,23	99-25969/200	G/T	35,76
		263,67	99-25979/93	A/G	67,15
		269,39	99-25989/398	A/G	35,88
		299,02	99-25993/367	A/G	47,38
	Region D second Half	303,04	99-16047/115	C/T	69,01
		335,02	99-15875/165	C/T	61,3
		354,81	99-16033/244	C/T	50,3
		366,51	99-16032/292	A/C	62,87
		367,14	99-25940/182	A/G	54,39
		372,98	99-15880/162	A/G	62,72
		375,28	99-16038/118	A/G	37,29

		383,41	99-15870/400	A/G	29,65
		394,16	99-24649/186	C/T	66,57
		395,27	99-5897/143	A/C	52,6
		409,93	99-24644/194	A/G	38,29
		424,95	99-5919/215	A/G	60,63
		441,62	99-5862/167	C/T	46,53
		444,00	99-16100/147	A/G	48,84
		445,84	99-7652/162	A/G	49,7
TOTAL			30		

(1) : frequency (%) in caucasian controls (N=177) of the first allele (alphabetic order)

Region D was arbitrarily split in two halves (D 1st half and D 2nd half) for purpose of the analysis.

5 The present inventors have previously demonstrated significant association of biallelic markers located on the Region D subregion of the human chromosome 13q31-33 region with disease. Using a set of 30 biallelic markers shown in Table 15, D 1st half contained 14 markers and D 2nd half contained 16 markers.

10 Table 15 also shows the physical order of the biallelic markers on Region D of the human chromosome 13q31-q33 region. The mean intermarker distances of the biallelic markers on the first and the second subjective portions of Region D were as listed below in Table 16.

Table 16

Region	Mean Inter-marker distance (std)
D 1 st half	7.80(6.33)
D 2 nd half	9.79 (8.78)
D 1 st and 2 nd half	9.58 (8.46)

15 The analysis using selected Region D biallelic markers of the invention demonstrated a significant association with bipolar disorder for the second portion of Region D. The analysis was conducted using the sample population described above with 182 caucasian cases and 177 caucasian controls selected from the total case and control group.

20 One biallelic marker in particular, 99-15875/165(A228), located on the second half of Region D, demonstrated a significant association with disease at a significance level of better than 5% (corresponding to an absolute logarithm (p-value) of 1.3).

B) Haplotype association results in bipolar disorder cases

Haplotype analysis for association of chromosome 13q31-q33-related biallelic markers and bipolar disorder was performed by estimating the frequencies of all possible 2, 3 and 4 marker haplotypes in the affected and control populations described above. Haplotype frequencies estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier and Slatkin, 1995), modified by Nicholas Schork.

Significant results were obtained in haplotype studies indicating an association of the nucleotide sequences of the invention with bipolar disorder. The haplotype analysis as shown in the Figures 9A, 9B, 10A, 10B, 11A and 11B was conducted using the sample population described above, using 182 caucasian cases and 177 caucasian controls selected from the total case and control group.

Using the Omnibus LR test which compares the profile of haplotype frequencies, and Haplo-maxM test which is based on haplotype frequencies differences for each haplotype in two groups, Figures 9A, 9B, 10A, 10B, 11A and 11B show the results of a comparison of the first and second portions of Region D which demonstrated an association of the second portion of Region D with bipolar disorder.

a - Omnibus LR tests values

For a given combination of 2, 3 or 4 biallelic markers, one likelihood ratio test (LR test) is obtained based on the haplotype frequencies values calculated using the E-M algorithm.

Figures 9A and 9B show a comparison of the LR test value distributions of haplotype frequencies in the two portions of Region D. This association of the second portion of Region D with bipolar disorder is shown using both 2-marker and 3-marker combinations. A Kruskal Wallis rank test was used to compare LR test values distributions in the two subjective portions of Region D. This test has an asymptotic Chi-square distribution, under the null hypothesis of no difference between the sets compared, with $(r-1)$ degrees of freedom, where r represents the number of sets compared. Here, we compare the 2 portions of region D, so $r=2$, and the asymptotic Chi-square distribution has 1 degree of freedom. As shown, the significance of the association is demonstrated by a chi-square value (one degree of freedom) of 46.62 and a p-value of 8.62×10^{-12} for 2 marker combinations, and a chi-square value (one degree of freedom) of 124.72 and a p-value of 5.86×10^{-29} for 3- marker combinations.

b - Haplo-max tests values

Another association analysis approach based on haplotype frequencies differences, referred to as the Haplo-max test, was conducted using region D biallelic markers. The haplo-

max test selects the difference showing the maximum positive (maxM) or negative (maxS) test value between cases versus controls (rejecting test values based on rare haplotype frequencies, i.e, with an estimated number of haplotypes carriers inferior to 10) ; for one combination of markers there is therefore one Max-M and one Max-S test values.

5 Figures 10A and 10B show the distribution of haplo-maxM test values obtained for both 2-marker and 3-marker combinations in the two portions of Region D, demonstrating an association of the second portion of Region D with bipolar disorder. The comparison of the distribution of Haplo-maxM test values in the two regions was analyzed using a Kruskal-Wallis rank test, a chi-square test with 1 degree of freedom. As shown, the significance of the
10 association is demonstrated by a chi-square value of 29.07 and a p-value 6.98×10^{-8} for 2 marker combinations, and a chi-square value of 98.63 and a p-value of 3.04×10^{-23} for 3- marker combinations.

 Figures 11A and 11B show the distribution of Haplo-maxS test values again obtained for all 2-marker and 3-marker combinations in the two portions of Region D, demonstrating an
15 association of the second portion of Region D with bipolar disorder. The comparison of the distributions of Haplo-maxS test values in the two portions was analyzed using a Kruskal-Wallis rank test with one degree of freedom. As shown, the significance of the association is demonstrated by a chi-square value of 34.6 and a p-value of 4.05×10^{-9} for 2 marker combinations, and a chi-square value of 98.31 and a p-value of 3.58×10^{-23} for 3- marker
20 combinations.

 The results from the haplo-maxM and haplo-maxS tests thus further confirm the association shown using the Omnibus LR test results.

Example 5e

Confirmation of Associations With Schizophrenia and Bipolar Disorder ("SCREENING II")

25 Results obtained above using French Canadian schizophrenia samples and Argentinian bipolar disorder cases were confirmed in larger screening samples and in several different populations using markers spanning Region D of the chromosome 13q31-q33 region.

 In the confirmation studies, French Canadian schizophrenia samples (Algene) described
30 above, additional United States schizophrenia samples and Argentinian bipolar disorder (Labimo) samples were analyzed in sub-regions of Region D referred to as sub-regions D1 to D4. The schizophrenia sample referred to as the Algene (or French Canadian) and the bipolar disorder sample referred to as the Labimo sample (Argentinian) are as described above. The United States schizophrenia samples are described in Table 17 below.

Table 17

United States Schizophrenia Cases and Control Populations (United States Caucasians)			
Sample type		Cases	Random US Controls
Sample size		131	188
Ethnic origin			
	European Causasians (26 female, 66 male)	92	
	Ashkenazi caucasians (7 female, 17 female)	24	
	Other Caucasians (7 female, 8 male)	15	
Familial history of psychosis (FH)			
	positive (FH+)	133	
	none (FH-)	147	198

A set of 32 SNPs covering sub-regions D1 to D4 (mean density of 1 SNP/25kb) was genotyped on the two different schizophrenia samples and one bipolar disorder sample. The 32 biallelic markers genotyped are shown in Table 18.

Table 18

SNPs	Polymorphism	% Frequency in Algene Controls(141)
99-5873/159	C/T	22
99-30329/380	C/T	48
99-15253/382	C/T	37
99-15280/432	C/T	39
99-15256/392	C/T	35
99-15258/337	G/T	24
99-27345/189	G/C	26
99-26150/276	A/G	48
99-25974/143	A/G	23
99-25950/121	G/C	28
99-25972/317	C/T	28
99-25965/399	A/G	50
99-25966/241	A/G	37
99-25989/398	A/G	28

99-16047/115	C/T	25
99-16052/214	A/G	37
99-15875/165	C/T	34
99-16105/152	A/G	46
99-16032/292	A/C	44
99-15880/162	A/G	44
99-15870/400	A/G	30
99-5897/143	A/C	39
99-24644/194	A/G	41
99-24658/410	C/T	39
99-5919/215	A/G	40
99-5862/167	C/T	49
99-24634/108	A/T	50
99-24656/260	A/G	46
99-31960/363	A/G	39
8-128/33	C/T	23
99-27935/193	G/C	21
99-27943/150	G/C	35

For each of the three populations, the number of significant tests in each sub-region of Region D based on single and multiple point biallelic marker analyses were compared among cases and controls. For single point analyses, excess of heterozygotes and deficiency of heterozygotes (Hardy-Weinberg disequilibrium coefficient), allelic and genotypic association analyses and logistic regression analyses were compared. For multipoint analyses, the haplotypic frequency differences between case and controls were examined, reported as MaxM for the maximum positive difference, and MaxS as the maximum negative difference, and the Omnibus LR test. The HaploMax tests giving MaxS and MaxM results and the Omnibus LR test are known and otherwise described herein. As noted in Figures 12 to 17, the tests containing the footnote (1) involved significance thresholds which were assessed from observed distributions, inferred taking into account the D1, D2, D3 and D4 subregions for each sub-population studied relative to the number of tests performed; for tests containing the footnote (2) in Figures 12 to 17, significant tests were defined as those having a significance level of 5% or better.

The present inventors have found that samples from three different populations all show a significant association to the schizophrenia trait with biallelic markers located in region D, thus confirming previous association studies with different samples and markers. Furthermore,

the inventors have found in all three populations that the association is most significant in the sub-region D3. Thus, it is likely that a gene associated with schizophrenia and bipolar disorder resides in the region. The sbg1 and g35030 nucleic acid sequences described herein reside in the region D3.

5 In addition to results using markers in previous analyses, analyses with the 32 biallelic markers listed in Table 18 demonstrated significant results in single point analyses for several newly analyzed biallelic markers. In particular, markers 99-25974-143 (A292), 99-25972-317 (A291), 99-15870-400 (A178), 99-24656-260 (A48) demonstrated a statistically significant excess or deficiency of heterozygotes.

10 *Schizophrenia: Algene (French Canadian)*

The analysis using Algene samples compared (1) the total patients cluster of patients selected for analysis (2) cases of the cluster showing a familial history of psychosis (FH+), and (3) cases of the cluster with an absence of familial history of psychosis (FH-) to Algene control samples. Additionally, for further comparison, the number of significant tests in Region D and each of the sub-regions of Region D were compared among total cases and total controls from the screening sample of example 5b above is listed in Figure 12 under "first screening sample". As previously reported, the original French Canadian (Algene) samples show a significant association to the schizophrenia trait with biallelic markers located in region D, both in single and multi-point analyses. Furthermore, results show that the association is clearly confined to sub-region D3 and does not extend to D2 and D4. In single point analyses, a significant concentration of biallelic markers containing the sbg1 gene presented an excess of heterozygotes for familial cases. Five of 13 (5/13) markers around sbg1 were significant for allelic association analysis.

Figure 12 provides the results from a single and multi-point biallelic marker analysis comparing regions D1, D2, D3, and D4 located in the chromosome 13q31-q33 region.

Figure 13 shows the sum of the results shown in Figure 12 over the larger Region D span tested (ie. D1, D2, D3 and D4).

Figures 12 and 13 thus demonstrate that there is a significant association with Region D and schizophrenia in the Algene sample. Furthermore, these figures show that the number and percentage of significant tests was highest in sub-region D3 consistently across comparisons among controls and FH+, FH- and total cases. In comparing the number of significant tests in sub-region D3 among FH+ and FH- cases, the figures show that the association is more clearly observed in cases having a familial history of psychosis; single point analyses suggested a higher number of significant tests in the FH+ cases than multiple point analyses.

Figures 12 and 13 also show that a larger screening sample confirms the results of the smaller sample from the first screening of Algene samples, both for the larger Region D and for

the sub-region D3.

Schizophrenia: United States Schizophrenia samples

As in the French Canadian samples, the present inventors have found Region D, and more specifically sub-region D3, to be significantly associated with schizophrenia in a first, smaller screening sample of the United States Schizophrenia samples. Further analysis in the United States Schizophrenia population using a set of biallelic markers covering Region D confirms that the association of sub-region D3 with schizophrenia is of high statistical significance.

The United States Schizophrenia samples selected for the analysis consisted of the 92 European caucasians. Two analyses were performed, a first analysis using controls consisting of 188 random US controls, and a second analysis where controls consisted of 241 controls from the French Canadian samples described above.

Figure 14 provides the results from a single and multi-point biallelic marker analysis comparing regions D1, D2, D3, and D4 located in the chromosome 13q31-q33 region. Figure 15 shows the sum of the results shown in Figure 14 over the larger Region D span tested (ie. D1, D2, D3 and D4).

As shown in the figures, the analysis in United States Schizophrenia samples also suggests a significant association of sub-region D2 with schizophrenia, when considering multi-point analyses. However, this association of the D2 region with schizophrenia is of lesser statistical significance than the association of schizophrenia with sub-region D3 because a lower number of tests were carried out in the D2 region. Additionally, one marker (99-5897/143) in particular, localized in the *sbg1* gene showed a significant excess of heterozygotes in schizophrenia familial cases.

In general, the number of significant tests in United States Schizophrenia samples were lower than in French Canadian population. This may be attributed to the higher heterogeneity of the United States Schizophrenia sample in comparison to the French Canadian samples. Analyses using the United States Schizophrenia samples were done using either caucasian controls from the French Canadian samples, or US random controls.

Bipolar disorder: Labimo (Argentinian)

As in the French Canadian and United States Schizophrenia samples, the present inventors have found Region D, and more specifically sub-region D3, to be significantly associated with bipolar disorder in Labimo samples from Argentina. Further analysis using a more extensive set of biallelic markers covering Region D confirms that the association of sub-region D3 with bipolar disorder is of high statistical significance.

Figure 16 provides the results from a single and multi-point biallelic marker analysis

comparing regions D1, D2, D3, and D4 located in the chromosome 13q31-q33 region. Figure 17 shows the sum of the results shown in Figure 16 over the larger Region D span tested (ie. D1, D2, D3 and D4). While results showed the most significant association for D3 in Labimo samples, some background signal was seen for D2. It is possible that this variance in the percentage of significant tests reflects the higher relative heterogeneity of the Labimo samples in comparison to the French Canadian samples.

Figures 16 and 17 thus demonstrate that there is a significant association with Region D and bipolar disorder in the Labimo sample.

Analyses of Labimo samples were also conducted separately in bipolar disorder I and bipolar disorder II cases, as shown in Figure 16. In comparisons of results obtained with bipolar disorder I and II types, the association of sub-region D3 with schizophrenia tended to be more clearly found in bipolar disorder I cases.

Example 6

Preparation of Antibody Compositions to the sbg1 protein

Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the sbg1 protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes in the sbg1 protein or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., Nature. 256:495 (1975) or derivative methods thereof. Also see Harlow, E., and D. Lane. 1988. Antibodies A Laboratory Manual. Cold Spring Harbor Laboratory. pp. 53-242.

Briefly, a mouse is repetitively inoculated with a few micrograms of the sbg1 protein or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody

production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2.

B. Polyclonal Antibody Production by Immunization

5 Polyclonal antiserum containing antibodies to heterogeneous epitopes in the sbg1 protein or a portion thereof can be prepared by immunizing suitable non-human animal with the sbg1 protein or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable non-human animal is preferably a non-human mammal is selected, usually a mouse, rat, rabbit, goat, or horse. Alternatively, a crude preparation which has been enriched for sbg1 concentration can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e.g. 10 aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent which will increase antigenicity, such agents are known in the art and include, for example, methylated bovine serum albumin (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known 15 procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. Also, host animals vary in response to site of inoculations and 20 dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987). An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971).

25 Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M). Affinity of the antisera for the antigen is determined by preparing 30 competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen- 35 bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to

identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

5

Example 7

Study of effect of sbg1 peptides on behavior of mice

Animals: Male C57BL6 adult mice (approximately 6 weeks old)

10

Peptides: sbg1 peptide:
NH₂-QPLERMWTCNYNQQKDQSCNHKEITSTKAE-COOH
Control 1: NH₂-REAHKSETISSKLQKEKQIKKQ-COOH
Control 2: NH₂-MHMKTILGPRLGLGE-COOH

15

Protocol:

1. Inject mice intraperitoneally with 50 µg peptide in 200 µl sterile physiological saline (n = 4 / peptide).
2. Place mice in clean empty cages containing no litter, and only a small test tube rack. The cages are covered with a plastic sheet to enable taking photographs and video-tracking.
3. Observe behavior for one minute from t = 5 min up to t = 45 min, as indicated. Any locomotor or stereotypy movements were recorded as positive over 1 min intervals. Locomotor movements include climbing, and rearing while stereotypy movements include grooming and scratching. At the end of the experiment, the number of movements were added up for each animal.

20

25

Results:

1. Mice injected with the sbg1 peptide exhibited a decrease in the frequency of their movements over the time course of the experiment, shown in Figure 18. This is illustrated in the left top panel of Figure 18, where we compare the average number of movements in 3 separate time points (5, 10, and 15 min) with the average movements per min in the last period of observations (30, 35, 40, and 45 min). The sbg1 peptide also increased

30

35

stereotypy – this effect was most prominent during the last period of observations. However, because the onset of stereotypy was variable, we presented the data as the average of stereotypy for observations over the entire time period.

The disclosures of all issued patents, published PCT applications, scientific references or other publications cited herein are incorporated herein by reference in their entireties.

5 Although this invention has been described in terms of certain preferred embodiments, other embodiments which will be apparent to those of ordinary skill in the art of view of the disclosure herein are also within the scope of this invention. Accordingly, the scope of the invention is intended to be defined only by reference to the appended claims.

Sequence listing free text

The following free text appears in the accompanying Sequence Listing:

	Schizophrenia
5	Associated
	Protein
	Biallelic
	marker
	regulatory
10	region
	gene
	exon
	complement
	polymorphic
15	base
	or
	allele
	deletion
	of
20	basic
	protease
	cleavage
	site
	probe
25	primer
	downstream
	upstream
	amplification
	sequencing
30	oligonucleotide

The disclosures of the following references are incorporated herein by reference in their entireties:

- Abbondanzo S.J. et al. (1993) *Methods in Enzymology*, Academic Press, New York. pp. 803-823.
- 5 Ajioka R.S. et al. (1997) *Am. J. Hum. Genet.* 60:1439-1447.
- Altschul et al., 1990, *J. Mol. Biol.* 215(3):403-410;
- Altschul et al., 1993, *Nature Genetics* 3:266-272
- Altschul et al., 1997, *Nuc. Acids Res.* 25:3389-3402
- Anton M. et al., 1995, *J. Virol.*, 69: 4600-4606.
- 10 Araki K et al. (1995) *Proc. Natl. Acad. Sci. US A.* 92(1):160-4.
- Ausubel et al. (1989) *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Interscience, N.Y.
- Baubonis W. (1993) *Nucleic Acids Res.* 21(9):2025-9.
- Beaucage et al., *Tetrahedron Lett* 1981, 22: 1859-1862
- 15 Bradley A., (1987) Production and analysis of chimaeric mice. In: E.J. Robertson (Ed.), *Teratocarcinomas and embryonic stem cells: A practical approach*. IRL Press, Oxford, pp. 113.
- Brown EL, Belagaje R, Ryan MJ, Khorana HG, *Methods Enzymol* 1979; 68:109-151
- Brutlag et al. *Comp. App. Biosci.* 6:237-245, 1990
- Chai H. et al. (1993) *Biotechnol. Appl. Biochem.* 18:259-273.
- 20 Chee et al. (1996) *Science.* 274:610-614.
- Chen and Kwok *Nucleic Acids Research* 25:347-353 1997
- Chen et al. (1987) *Mol. Cell. Biol.* 7:2745-2752.
- Chen et al., 1987, *Mol. Cell. Biol.*, 7: 2745-2752.
- Chou J.Y. (1989) *Mol. Endocrinol.* 3:1511-1514.
- 25 Clark A.G. (1990) *Mol. Biol. Evol.* 7:111-122.
- Coles et al. *Hum. Mol. Genet.*, 7:791-800, 1998
- Compton J. (1991) *Nature.* 350(6313):91-92.
- Davis et al., *Basic Methods in Molecular Biology*, ed., Elsevier Press, NY, 1986
- Dempster et al., (1977) *J.R. Stat. Soc.*, 39B:1-38.
- 30 Dent D.S. and Latchman D.S. (1993) The DNA mobility shift assay. In: *Transcription Factors: A Practical Approach* (Latchman DS, ed.) Oxford: IRL Press. pp 1-26.
- Eckner R. et al. (1991) *EMBO J.* 10:3513-3522.
- Excoffier L. and Slatkin M. (1995) *Mol. Biol. Evol.*, 12(5): 921-927.
- Feldman and Steg, 1996, *Medecine*
- 35 *Sciences, synthese*, 12:47-55

- Flotte et al. (1992) *Am. J. Respir. Cell Mol. Biol.* 7:349-356.
- Fodor et al. (1991) *Science* 251:767-777.
- Fraley et al. (1979) *Proc. Natl. Acad. Sci. USA.* 76:3348-3352.
- Fried M. and Crothers D.M. (1981) *Nucleic Acids Res.* 9:6505-6525.
- 5 Fuller S. A. et al. (1996) *Immunology in Current Protocols in Molecular Biology*, Ausubel et al. Eds, John Wiley & Sons, Inc., USA.
- Furth P.A. et al. (1994) *Proc. Natl. Acad. Sci. USA.* 91:9302-9306.
- Garner M.M. and Revzin A. (1981) *Nucleic Acids Res.* 9:3047-3060.
- Geysen H. Mario et al. 1984. *Proc. Natl. Acad. Sci. U.S.A.* 81:3998-4002
- 10 Ghosh and Bacchawat (1991) *Targeting of liposomes to hepatocytes*, IN: *Liver Diseases, Targeted diagnosis and therapy using specific receptors and ligands.* Wu et al. Eds., Marcel Dekker, New York, pp. 87-104.
- Gonnet et al., 1992, *Science* 256:1443-1445;
- Gopal (1985) *Mol. Cell. Biol.*, 5:1188-1190.
- 15 Gossen M. et al. (1992) *Proc. Natl. Acad. Sci. USA.* 89:5547-5551.
- Gossen M. et al. (1995) *Science.* 268:1766-1769.
- Graham et al. (1973) *Virology* 52:456-457.
- Green et al. (1986) *Ann. Rev. Biochem.* 55:569-597.
- Griffin et al. (1989) *Science.* 245:967-971.
- 20 Grompe, M. (1993) *Nature Genetics.* 5:111-117.
- Grompe, M. et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86:5855-5892.
- Gu H. et al. (1993) *Cell* 73:1155-1164.
- Guatelli J C et al. *Proc. Natl. Acad. Sci. USA.* 35:273-286.
- Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS, *Nat Genet* 1996;14(4):441-447
- 25 Haff L. A. and Smirnov I. P. (1997) *Genome Research*, 7:378-388.
- Hames B.D. and Higgins S.J. (1985) *Nucleic Acid Hybridization: A Practical Approach.* Hames and Higgins Ed., IRL Press, Oxford.
- Harju L, Weber T, Alexandrova L, Lukin M, Ranki M, Jalanko A, *Clin Chem* 1993;39(11 Pt 1):2282-2287
- 30 Harland et al. (1985) *J. Cell. Biol.* 101:1094-1095.
- Hawley M.E. et al. (1994) *Am. J. Phys. Anthropol.* 18:104.
- Henikoff and Henikoff, 1993, *Proteins* 17:49-61
- Higgins et al., 1996, *Methods Enzymol.* 266:383-402;
- Hillier L. and Green P. *Methods Appl.*, 1991, 1: 124-8. Gu H. et al. (1994) *Science* 265:103-35 106.

- Hoess et al. (1986) *Nucleic Acids Res.* 14:2287-2300.
- Huang L. et al. (1996) *Cancer Res* 56(5):1137-1141.
- Huygen et al. (1996) *Nature Medicine* 2(8):893-898.
- Izant J.G. and Weintraub H. (1984) *Cell* 36(4):1007-1015.
- 5 Julan et al. (1992) *J. Gen. Virol.* 73:3251-3255.
- Kanegae Y. et al., *Nucl. Acids Res.* 23:3816-3821.
- Karlin and Altschul, 1990, *Proc. Natl. Acad. Sci. USA* 87:2267-2268;
- Khoury J. et al. (1993) *Fundamentals of Genetic Epidemiology*, Oxford University Press, NY.
- Kim U-J. et al. (1996) *Genomics* 34:213-218.
- 10 Kleinet al. (1987) *Nature*. 327:70-73.
- Koller et al. (1992) *Annu. Rev. Immunol.* 10:705-730.
- Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR, *Nat Med* 1996;2(7):753-759
- Landegren U. et al. (1998) *Genome Research*, 8:769-776.
- 15 Lander and Schork, *Science*, 265, 2037-2048, 1994
- Lenhard T. et al. (1996) *Gene*. 169:187-190.
- Linton M.F. et al. (1993) *J. Clin. Invest.* 92:3029-3037.
- Liu Z. et al. (1994) *Proc. Natl. Acad. Sci. USA*. 91: 4528-4262.
- Livak et al., *Nature Genetics*, 9:341-342, 1995
- 20 Livak KJ, Hainer JW, *Hum Mutat* 1994;3(4):379-385
- Lockhart et al. (1996) *Nature Biotechnology* 14:1675-1680.
- Mansour S.L. et al. (1988) *Nature*. 336:348-352.
- Marshall R. L. et al. (1994) *PCR Methods and Applications*. 4:80-84.
- McCormick et al. (1994) *Genet. Anal. Tech. Appl.* 11:158-164.
- 25 McLaughlin B.A. et al. (1996) *Am. J. Hum. Genet.* 59:561-569.
- Morton N.E. (1955) *Am. J. Hum. Genet.* 7:277-318.
- Muzyczka et al. (1992) *Curr. Topics in Micro. and Immunol.* 158:97-129.
- Nada S. et al. (1993) *Cell* 73:1125-1135.
- Nagy A. et al. (1993) *Proc. Natl. Acad. Sci. USA*. 90: 8424-8428.
- 30 Narang SA, Hsiung HM, Brousseau R, *Methods Enzymol* 1979;68:90-98
- Neda et al. (1991) *J. Biol. Chem.* 266:14143-14146.
- Newton et al. (1989) *Nucleic Acids Res.* 17:2503-2516.
- Nickerson D.A. et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:8923-8927.
- Nicolau et al. (1982) *Biochim. Biophys. Acta*. 721:185-190.
- 35 Nyren P, Pettersson B, Uhlen M, *Anal Biochem* 1993;208(1):171-175

- O'Reilly et al. (1992) *Baculovirus Expression Vectors: A Laboratory Manual*. W. H. Freeman and Co., New York.
- Ohno et al. (1994) *Science*. 265:781-784.
- Orita et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86: 2776-2770.
- 5 Ott J. (1991) *Analysis of Human Genetic Linkage*. John Hopkins University Press, Baltimore.
- Pastinen et al., *Genome Research* 1997; 7:606-614
- Pearson and Lipman, 1988, *Proc. Natl. Acad. Sci. USA* 85(8):2444-2448;
- Pease S. and William R.S. (1990) *Exp. Cell. Res.* 190:99-211.
- Perlin et al. (1994) *Am. J. Hum. Genet.* 55:777-787.
- 10 Peterson et al. (1993) *Proc. Natl. Acad. Sci. USA*. 90: 7593-7597.
- Pietu et al. (1996) *Genome Research*. 6:492-503.
- Potter et al. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81(22):7161-7165.
- Rayl et al., (1996) *J. Bio. Chem.* 271, 2225-2233.
- Reid L.H. et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:4299-4303.
- 15 Risch, N. and Merikangas, K. (1996) *Science*. 273:1516-1517.
- Robertson E. (1987) "Embryo-Derived Stem Cell Lines." In: E.J. Robertson Ed. *Teratocarcinomas And Embryonic Stem Cells: A Practical Approach*. IRL Press, Oxford, pp. 71.
- Rossiet al. (1991) *Pharmacol. Ther.* 50:245-254.
- 20 Roth J.A. et al. (1996) *Nature Medicine*. 2(9):985-991.
- Roux et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86:9079-9083.
- Ruano et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:6296-6300.
- Sambrook, J., Fritsch, E.F., and T. Maniatis. (1989) *Molecular Cloning: A Laboratory Manual*. 2ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
- 25 Samson M, et al. (1996) *Nature*, 382(6593):722-725.
- Samulski et al. (1989) *J. Virol.* 63:3822-3828.
- Sanchez-Pescador R. (1988) *J. Clin. Microbiol.* 26(10):1934-1938.
- Sarkar, G. and Sommer S.S. (1991) *Biotechniques*.
- Sauer B. et al. (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85:5166-5170.
- 30 Schaid D.J. et al. (1996) *Genet. Epidemiol.* 13:423-450.
- Schedl A. et al. (1993a) *Nature*. 362:258-261.
- Schedl et al. (1993b) *Nucleic Acids Res.* 21:4783-4787.
- Schedl et al. (1993b) *Nucleic Acids Res.* 21:4783-4787.
- Schena et al. (1995) *Science*. 270:467-470.
- 35 Schena et al. (1996) *Proc. Natl. Acad. Sci. U.S.A.* 93(20):10614-10619.

- Schneider et al.(1997) Arlequin: A Software For Population Genetics Data Analysis. University of Geneva.
- Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation
- 5 Sczakiel G. et al. (1995) Trends Microbiol. 3(6):213-217.
- Shay J.W. et al. (1991) Biochem. Biophys. Acta. 1072:1-7.
- Sheffield, V.C. et al. (1991) Proc. Natl. Acad. Sci. U.S.A. 49:699-706.
- Shizuya et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:8794-8797.
- Shoemaker DD, Lashkari DA, Morris D, Mittmann M, Davis RW, Nat Genet 1996;14(4):450-10 456
- Smith (1957) Ann. Hum. Genet. 21:254-276.
- Smith et al. (1983) Mol. Cell. Biol. 3:2156-2165.
- Sosnowski R.G. et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:1119-1123.
- Spielmann S. and Ewens W. J. (1998) Am. J. Hum. Genet. 62:450-458.
- 15 Spielmann S. et al. (1993) Am. J. Hum. Genet. 52:506-516.
- Sternberg N.L. (1992) Trends Genet. 8:1-16.
- Sternberg N.L. (1994) Mamm. Genome. 5:397-404.
- Syvanen AC, Clin Chim Acta 1994;226(2):225-236
- Tacson et al. (1996) Nature Medicine. 2(8):888-892.
- 20 Te Riele et al. (1990) Nature. 348:649-651.
- Terwilliger J.D. and Ott J. (1994) Handbook of Human Genetic Linkage. John Hopkins University Press, London.
- Thomas K.R. et al. (1986) Cell. 44:419-428.
- Thomas K.R. et al. (1987) Cell. 51:503-512.
- 25 Thompson et al., 1994, Nucleic Acids Res. 22(2):4673-4680;
- Tur-Kaspa et al. (1986) Mol. Cell. Biol. 6:716-718.
- Tyagi et al. (1998) Nature Biotechnology. 16:49-53.
- Urdea M.S. (1988) Nucleic Acids Research. 11:4937-4957.
- Urdea M.S. et al. (1991) Nucleic Acids Symp. Ser. 24:197-200.
- 30 Van der Lugt et al. (1991) Gene. 105:263-267.
- Vlasak R. et al. (1983) Eur. J. Biochem. 135:123-126.
- Wabiko et al. (1986) DNA. 5(4):305-314.
- Walker et al. (1996) Clin. Chem. 42:9-13.
- Weir, B.S. (1996) Genetic data Analysis II: Methods for Discrete population genetic Data, 35 Sinauer Assoc., Inc., Sunderland, MA, U.S.A.

- White, M.B. et al. (1992) Genomics. 12:301-306.
- White, M.B. et al. (1997) Genomics. 12:301-306.
- Wong et al. (1980) Gene.10:87-94.
- Wood S.A. et al. (1993) Proc. Natl. Acad. Sci. U.S.A.90:4582-4585.
- 5 Wu and Wu (1987) J. Biol. Chem. 262:4429-4432.
- Wu and Wu (1988) Biochemistry. 27:887-892.
- Wu et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:2757.
- Yagi T. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87:9918-9922.
- Zhao et al. (1998) Am.J. Hum. Genet. 63:225-240.
- 10 Zou Y. R. et al. (1994) Curr. Biol.4:1099-1103

CLAIMS

1. An isolated, purified or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides selected from the group consisting of: nucleotide position range 213818 to 243685 of SEQ ID No. 1, SEQ ID Nos. 2 to 26 and 44 to 111, and the complements thereof.

2. An isolated, purified or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides selected from the group consisting of: SEQ ID Nos 36 to 40, SEQ ID Nos. 112 to 229, and nucleotide position ranges 31 to 292651 and 292844 to 319608 of SEQ ID No. 1, and the complements thereof.

3. An isolated, purified or recombinant polynucleotide according to claim 2, wherein said contiguous span of SEQ ID No 1 or the complements thereof comprises at least 1 of the following nucleotide positions of SEQ ID No 1:

- (a) 292653 to 296047, 292653 to 292841, 295555 to 296047, and 295580 to 296047;
- (b) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;
- (c) 94124 to 94964;
- (d) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and
- (e) 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915

4. An isolated, purified or recombinant polynucleotide according to claims 1 or 2, wherein said span comprises a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489.

5. A recombinant vector comprising a polynucleotide according to any one of claims 1 to 4.

6. A host cell comprising a recombinant vector according to claim 5.

7. A non-human host animal or mammal comprising a recombinant vector according to claim 5.

8. A mammalian host cell comprising an sbg1, g34665, sbg2, g35018 or g35017 gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1 or 3.

9. A non-human host mammal comprising an sbg1, g34665, sbg2, g35018 or g35017 gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1 or 3.

10. Use of a polynucleotide comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of the SEQ ID Nos 1 to 26, 36 to 40 and 112 to 229 or the complementary sequence thereto for determining the identity of the nucleotide at a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489.

11. Use of a polynucleotide according to claim 10 in a microsequencing assay, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of a biallelic marker in said sequence.

12. Use of a polynucleotide according to claim 10 in a hybridization assay, wherein said span includes a biallelic marker.

13. Use of a polynucleotide according to claim 10 in a specific amplification assay, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide.

14. Use of a polynucleotide according to claim 10 in a sequencing assay, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide.

15. A polynucleotide according to claim 11, wherein said polynucleotide consists essentially of a sequence selected from the group consisting of D1 to D69, D71 to D74, D76 to D94, D96 to

D106, D108 to D112, D114 to D177, D179 to D197, D199 to D222, D224 to D246, D250, D251, D253, D255, D259, D266, D268 to D232 and D328 to D360.

5 16. A polynucleotide according to claim 2, consisting essentially of a sequence selected from the following sequences: B1 to B229, C1 to C229, and B1 to B229, C1 to C229, and P1 to P69, P71 to P74, P76 to P94, P96 to P106, P108 to P112, P114 to P177, P179 to P197, P199 to P222, P224 to P246, P250, P251, P253, P255, P259, P266, P268 to P232 and P328 to P360..

10 17. Use of a polynucleotide comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of the SEQ ID Nos 1 to 26, 36 to 40 and 112 to 229 or the complementary sequence thereto for amplifying a segment of nucleotides comprising a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489.

15 18. A polynucleotide according to any one of claims 1 to 4, 15, or 16 attached to a solid support.

19. An array of polynucleotides comprising at least one polynucleotide according to claim 18.

20 20. An array according to claim 19, wherein said array is addressable.

21. A polynucleotide according to any one of claims 1 to 4, 15, 16 or 18 to 20 further comprising a label.

25 22. A method of genotyping comprising determining the identity of a nucleotide at a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489 or the complement thereof in a biological sample.

30 23. A method of genotyping comprising determining the identity of a nucleotide at a Region D-related biallelic marker, or the complement thereof in a biological sample.

35 24. A method according to claim 22, wherein said biological sample is derived from a single subject.

25. A method according to claim 22, wherein said biological sample is derived from multiple subjects.

5 26. A method according to claim 22, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step.

27. A method according to claim 26, wherein said amplifying is performed by PCR.

10 28. A method according to claim 22, wherein said determining is performed by a hybridization assay.

29. A method according to claim 22, wherein said determining is performed by a sequencing assay.

15 30. A method according to claim 22, wherein said determining is performed by a microsequencing assay.

20 31. A method according to claim 22, wherein said determining is performed by an enzyme-based mismatch detection assay.

32. A method of estimating the frequency of an allele of a biallelic marker in a population comprising:

25 a) genotyping individuals from said population for said biallelic marker according to the method of claim 22; and

b) determining the proportional representation of said biallelic marker in said population.

33. A method of detecting an association between a genotype and a trait, comprising the steps of:

30 a) determining the frequency of at least one biallelic marker in trait positive population according to the method of claim 32;

b) determining the frequency of at least one biallelic marker in a control population according to the method of claim 32; and

35 c) determining whether a statistically significant association exists between said genotype and said trait.

34. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:

- a) genotyping at least one biallelic marker according to claim 22 for each individual in said population;
- b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and
- c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

35. A method according to claim 34, wherein said haplotype determination method is selected from the group consisting of asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark method, or an expectation maximization algorithm.

36. A method of detecting an association between a haplotype and a trait, comprising the steps of:

- a) estimating the frequency of at least one haplotype in a trait positive population according to the method of claim 34;
- b) estimating the frequency of said haplotype in a control population according to the method of claim 34; and
- c) determining whether a statistically significant association exists between said haplotype and said trait.

37. A method according to claim 33, wherein said genotyping of step a) is performed on each individual of said population.

38. A method according to claim 33, wherein said genotyping is performed on a single pooled biological sample derived from said population.

39. A method of detecting an association between an allele and a phenotype, comprising the steps of:

- a) determining the frequency of at least one biallelic marker allele in a trait positive population according to the method of claim 32;
- b) determining the frequency of said biallelic marker allele in a control population according to

the method of claim 32; and

c) determining whether a statistically significant association exists between said allele and said phenotype.

5 40. A method according to claim 33 or 36, wherein said trait is schizophrenia or bipolar disorder.

10 41. A method according to claim 33 or 36, wherein said trait is predisposition to schizophrenia or bipolar disorder, an early onset of schizophrenia or bipolar disorder, or a beneficial response to or side effects related to treatment against schizophrenia or bipolar disorder.

42. A method according to claim 39, wherein said phenotype is a symptom of schizophrenia or bipolar disorder.

15 43. A method according to claim 33 or 36, wherein said control population is a trait negative population.

20 44. A method according to claim 33 or 36, wherein said case control population is a random population.

45. A method of determining whether an individual is at risk of schizophrenia or bipolar disorder, comprising:

- a) genotyping at least one biallelic marker according to the method of claim 22; and
b) correlating the result of step a) with a risk of developing schizophrenia or bipolar disorder.

25 46. A method according to any one of claims 22, 32 to 34, 36, 39 and 45 wherein said biallelic marker is selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242, A250 to A251, A259, A269 to A270, A278, A285 to A295, A303 to A307, A330, A334 to A335, A346 to 357 and 361 to 489, and the complements thereof.

30 47. A diagnostic kit comprising a polynucleotide according to any one of claims 1 to 4, 15, 16 or 18 to 20.

35 48. A purified or isolated sbg1 or g35018 polypeptide which is encoded by a nucleic acid

comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 26 and 36 to 40, and fragments or variants thereof.

5 49. A purified or isolated sbg1 or g35018 polypeptide comprising at least 6 contiguous amino acid residues of any of SEQ ID Nos 27 to 25 and 41 to 43.

50. A purified or isolated sbg1 or g35018 polypeptide according to claim 49, comprising at least one amino acid substitution, addition or deletion.

10 51. A purified or isolated sbg1 peptide consisting essentially of an amino acid position range selected from the group consisting of:
1 to 63 and 64 to 102 of SEQ ID No 29; 1 to 64, 65 to 111 and 112 to 119 of SEQ ID No 30;
1 to 64 and 65 to 126 of SEQ ID No 32; 1 to 64, 65 to 123 and 124 to 153 of SEQ ID No 34;
and 1 to 61 and 65 to 106 of SEQ ID No 35.

15 52. A method for producing an sbg1 or g35018 polypeptide, wherein said method comprises the following steps:
a) providing a cell host comprising a recombinant vector according to claim 5 containing a nucleic acid encoding an sbg1 or g35018 polypeptide;
20 b) recovering the sbg1 or g35018 polypeptide produced by said recombinant cell host.

53. The method according to claim 52, wherein the recombinant cell host is a recombinant cell host according to claim 6.

25 54. An isolated or purified antibody composition capable of selectively binding to a polypeptide according to claim 49 to 51.

30 55. A method for specifically detecting the presence of an sbg1 or g35018 polypeptide in a biological sample, said method comprising the following steps :
a) bringing into contact the biological sample with an antibody directed against an sbg1 or g35018 polypeptide according to any one of claims 49 to 51;
b) detecting the antigen-antibody complex formed between said antibody and said polypeptide.

35 56. A diagnostic kit for detecting *in vitro* the presence of an sbg1 or 35018 polypeptide in a biological sample, said kit comprising:

- a) a polyclonal or monoclonal antibody directed against an sbg1 or g35018 polypeptide according to any one of claims 49 to 51 or a fragment thereof, optionally labeled;
- b) a reagent allowing the detection of the antigen-antibody complexes formed between said sbg1 or g35018 polypeptide and an antibody.

5

57. A method for the screening of a candidate substance, wherein said method comprises the following steps:

- a) providing a polypeptide according to anyone of claims 49 to 51;
- b) obtaining a candidate substance;
- 10 c) bringing into contact said polypeptide with said candidate substance;
- d) detecting the complexes formed between said polypeptide and said candidate substance.

58. The method of claim 66, wherein at step d), the complexes formed are incubated in the presence of a polyclonal or a monoclonal antibody according to claim 63 .

15

59. A kit for screening a candidate substance interacting with an sbg1 or g35018 polypeptide, wherein said kit comprises:

- a) a polypeptide according to anyone of claims 49 to 51;
- b) optionally a monoclonal or a polyclonal antibody according to claim 54.

20

60. A method for the screening of a candidate substance, where said method comprises the following steps:

- a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding an sbg1 protein or a variant or a fragment thereof, placed under the control of its own promoter;
- 25 b) bringing into contact the cultivated cell with a molecule to be tested;
- c) quantifying the expression of the sbg1 protein or a variant or a fragment thereof.

30

61. A method for identifying a compound for the treatment of a disease, where said method comprises the following steps comprising:

- (a) exposing an animal to a level of sbg1 activity sufficient to cause a schizophrenia-related or bipolar disorder-related symptom or endpoint, and
- (b) exposing said animal to a test compound.

35

62. A method according to claim 61, wherein said animal is a non-human mammal.

63. A method according to claim 61, wherein said animal is a non-human primate.

5 64. A method according to claim 61, wherein said animal is treated with an sbg1 polypeptide according to any one of claims 49 to 51.

65. A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:

10 a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 31 to 292651 and 292844 to 319608.

15 b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 54 to 229, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID.

c) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 2 to 26, 36 to 40, or the complements thereof.

20 d) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1:

(i) 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047;

25 (ii) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;

(iii) 94124 to 94964;

30 (iv) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and

35 (v) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915;

e) a contiguous span according to a), b), c) or d), wherein said span includes a biallelic marker selected from the group consisting of A1 to A489.

f) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said
5 contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one the ranges of nucleotide positions designated pos1 to pos166 of SEQ ID No. 1 listed in Table 1 above;

g) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 40 and 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic
10 marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018 - related biallelic marker;

h) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos 2 to 26, 36 to 40 and 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic
15 marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018 - related biallelic marker with the alternative allele present at said biallelic marker.

i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A1 to A69,
20 A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and 361 to A489;

j) a nucleotide sequence complementary to any one of the contiguous spans of a), b), c), d), e), f), g), h) and i).

25 66. A computer readable medium having stored thereon a sequence consisting of a polypeptide code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos. 27 to 35 and 41 to 43.

30 67. A computer system comprising a processor and a data storage device wherein said data storage device comprises a computer readable medium according to any one of claims 65 ot 66.

68. A computer system according to claim 67, further comprising a sequence comparer and a data storage device having reference sequences stored thereon.

35 69. A computer system of claim 68 wherein said sequence comparer comprises a computer

program which indicates polymorphisms.

70. A computer system of claim 68 further comprising an identifier which identifies features in said sequence.

71. A method for comparing a first sequence to a reference sequence, comprising the steps of:
a) reading said first sequence and said reference sequence through use of a computer program which compares sequences; and

b) determining differences between said first sequence and said reference sequence with said computer program,

wherein said first sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

(i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 31 to 292651 and 292844 to 319608.

(ii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 54 to 229, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID.

(iii) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 2 to 26, 36 to 40, or the complements thereof.

(iv) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1:

a) 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047;

b) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;

c) 94124 to 94964;

d) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993

and 241686 to 243685; and

e) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915;

(v) a contiguous span according to (i) to (iv), wherein said span includes a biallelic marker
5 selected from the group consisting of A1 to A489.

(vi) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one the ranges of nucleotide positions designated pos1 to pos166 of SEQ ID No. 1 listed in Table 1;

10 (vii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 40, 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018 - related biallelic marker;

15 (viii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos 2 to 26, 36 to 40, 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018 - related biallelic marker with the alternative allele present at said biallelic marker.

20 (ix) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and 361 to A489;

25 (x) a nucleotide sequence complementary to any one of the contiguous spans of (i) to (ix); and

(xi) a polypeptide code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos 27 to 35 and 41 to 43.

30 72. A method according to claim 71, wherein said step of determining differences between the first sequence and the reference sequence comprises identifying at least one polymorphism.

73. A method for identifying a feature in a sequence, comprising the steps of:

a) reading said sequence through the use of a computer program which identifies features in
35 sequences; and

b) identifying features in said sequence with said computer program;
wherein said sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

5 (i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 31 to 292651 and 292844 to 319608.

10 (ii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 54 to 229, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID.

(iii) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 2 to 26, 36 to 40, or the complements thereof.

15 (iv) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1:

a) 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047;

20 b) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854;

c) 94124 to 94964;

25 d) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and

e) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915;

30 (v) a contiguous span according to (i) to (iv), wherein said span includes a biallelic marker selected from the group consisting of A1 to A489.

35 (vi) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one the ranges of nucleotide positions designated pos1 to pos166 of SEQ ID No. 1 listed in Table 1;

(vii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 40, 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018 - related biallelic marker;


(viii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 40, 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018 - related biallelic marker with the alternative allele present at said biallelic marker.

(ix) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and 361 to A489;

(x) a nucleotide sequence complementary to any one of the contiguous spans of (i) to (ix); and

(xi) a polypeptide code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos 27 to 35 and 41 to 43.

Figure 1: exon structure of the SBG1 gene



2/22

SIGNIFICANCE OF SINGLE BIALLELIC MARKER ASSOCIATION STUDY IN THE 13q31-33 REGION




Figure 2

3/22

Detailed haplotype analysis (case/controls: N=215/N=241)

MARKERS	HAPLOTYPE DESCRIPTION									
	Frequency ⁽¹⁾									
	Statistics on a haplotype ⁽²⁾									
	Frequency	OR	p-value	OR	p-value	OR	p-value	OR	p-value	OR
haplotype 1	0.288	0.195	1.67	1.20E-03	***					
haplotype 2	0.238	0.155	1.71	1.70E-03	***					
haplotype 3	0.223	0.144	1.71	2.60E-03	***					
haplotype 4	0.173	0.105	1.79	3.40E-03	**					
haplotype 5	0.231	0.159	1.59	7.70E-03	**					
haplotype 6	0.306	0.228	1.49	8.60E-03	**					
haplotype 7	0.305	0.229	1.48	9.60E-03	**					
haplotype 8	0.4	0.319	1.42	1.00E-02	**					
haplotype 87	0.124	0.043	3.18	1.30E-05	*****					
haplotype 88	0.121	0.042	3.13	2.00E-05	*****					
haplotype 89	0.13	0.048	2.96	2.60E-05	*****					
haplotype 90	0.188	0.091	2.32	2.90E-05	*****					
haplotype 91	0.094	0.026	3.88	3.40E-05	*****					
haplotype 92	0.127	0.047	2.92	3.70E-05	*****					
haplotype 93	0.121	0.044	3.01	3.90E-05	*****					
haplotype 94	0.128	0.049	2.85	4.90E-05	*****					
haplotype 95	0.143	0.062	2.55	5.40E-05	*****					
haplotype 96	0.098	0.033	3.15	1.00E-04	****					
haplotype 287	0.138	0.038	4.01	3.10E-07	*****					
haplotype 288	0.138	0.04	3.84	4.20E-07	*****					
haplotype 289	0.135	0.038	3.94	5.40E-07	*****					
haplotype 290	0.086	0.013	6.93	6.70E-07	*****					
haplotype 291	0.134	0.04	3.75	8.20E-07	*****					

*maxM : Table of haplotypes giving the Maximum positive difference between cases/controls.

1: Frequency of the haplotype leading to the maximum chi square test

2: Test on the frequency of this haplotype in cases vs in controls

3: p-value assuming that the test has a chi-square distribution with 1 degree of freedom

Figure 3

4/22

Figure 4

Markers involved in selected haplotypes

			markers											
# of markers in the haplotype	Threshold of significance	# of haplotypes concerned	99-16082/218	99-5862/167	99-16100/147	99-7652/162	99-5919/215	99-5897/143	99-16032/292	99-15880/162	99-16038/118	99-15875/165	99-16033/244	99-16047/115
2-mks	$\leq 10^{-2}$	7	*	*	*	*	*	*	*	*	*	*	*	*
3-mks	$\leq 10^{-5}$	10	*	*	*	*	*	*	*	*	*	*	*	*
4-mks	$\leq 10^{-6}$	5	*	*	*	*	*	*	*	*	*	*	*	*

6/22

MARKERS		HAPLOTYPE DESCRIPTION										HAPLOTYPE TEST BY PERMUTATION PROCEDURE																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
diff (cases-controls)	p-value	HW-test	controls	Statistics on a haplotype ⁽²⁾										Max.Chiz	# iter/obs																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																													
				cases	Frequency ⁽¹⁾	Controls	OR	p-value(10 ⁴) ⁽³⁾	AV.Chiz																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
140 vs 140	A	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T

Figure 6

SCHIZOPHRENIA STUDY OMNIBUS LR TEST VALUES DISTRIBUTIONS ALL SAMPLE

CASES (N=213) / ALL CONTROLS (N=241)

Combination of 2 markers




Figure 7A

Combination of 3 markers




Figure 7B

SCHIZOPHRENIA STUDY HAPLO_MAXM TEST DISTRIBUTIONS ALL SAMPLE

CASES (N=213) / ALL CONTROLS (N=241)





Figure 8A

Figure 8B

BIPOLAR DISORDERS STUDY
OMNIBUS LR TEST VALUES DISTRIBUTIONS
FIRST HALF AND SECOND HALF D REGION

CAUCASIAN CASES (N=182) / CAUCASIAN CONTROLS (N=177)



10/22

BIPOLAR DISORDERS STUDY
HAPLO_MAXM TEST VALUES DISTRIBUTIONS

CAUCASIAN CASES (N=182) / CAUCASIAN CONTROLS (N=177)




Figure 10A




Figure 10B

11/22

BIPOLAR DISORDERS STUDY **HAPLO_MAXS TEST VALUES DISTRIBUTIONS**

CAUCASIAN CASES (N=182) / CAUCASIAN CONTROLS (N=177)




Figure 11A




Figure 11B

12/22

FIGURE 12: ALGENE SAMPLES: SUMMARY OF SINGLE POINT AND MULTI POINT ANALYSES IN SUB-REGIONS OF D

SUB-POPULATION STUDIED		Algene sample First screening cases vs first screening controls				HC cases (1) (13) vs all controls (241)				HC HF+ cases (1) (60) vs all controls (241)				HC HF- cases (1) (133) vs all controls (241)			
SUB-REGIONS D		Chromosome 1q33				Chromosome 1q33				Chromosome 1q33				Chromosome 1q33			
		D1	D2	D3	D4	D1	D2	D3	D4	D1	D2	D3	D4	D1	D2	D3	D4
MAP	Sub-contig sizes	168 Kb	134 Kb	152 Kb	153 Kb	168 Kb	134 Kb	152 Kb	153 Kb	168 Kb	134 Kb	152 Kb	153 Kb	168 Kb	134 Kb	152 Kb	153 Kb
	NB OF SNPs GENOTYPED	7	7	13	5	7	7	13	5	7	7	13	5	7	7	13	5
	COVERAGE IN KB	129	102	151	99	129	102	151	99	129	102	151	99	129	102	151	99
	Density of genotyped SNP in region covered (kb)	16	13	11	17	16	13	11	17	16	13	11	17	16	13	11	17
	Mean Inter marker distances [Min, Max] in Kb	21 [12,32]	19 [12,33]	11 [7,24]	25 [13,54]	21 [12,32]	19 [12,33]	11 [7,24]	25 [13,54]	21 [12,32]	19 [12,33]	11 [7,24]	25 [13,54]	21 [12,32]	19 [12,33]	11 [7,24]	25 [13,54]
	Mean and Stdv of NORMALIZED GAMETIC LD for first screening Algene controls (nb of LD)	Mean -0.15 Stdv 0.79 (21)	Mean -0.31 Stdv 0.33 (21)	Mean -0.03 Stdv 0.48 (78)	Mean -0.13 Stdv 0.65 (10)	Mean -0.15 Stdv 0.79 (21)	Mean -0.31 Stdv 0.33 (21)	Mean -0.03 Stdv 0.48 (78)	Mean -0.13 Stdv 0.65 (10)	Mean -0.15 Stdv 0.79 (21)	Mean -0.31 Stdv 0.33 (21)	Mean -0.03 Stdv 0.48 (78)	Mean -0.13 Stdv 0.65 (10)	Mean -0.15 Stdv 0.79 (21)	Mean -0.31 Stdv 0.33 (21)	Mean -0.03 Stdv 0.48 (78)	Mean -0.13 Stdv 0.65 (10)
	Mean and Stdv COMPOSITE GENOTYPIC LD for first screening Algene controls (nb of LD)	Mean 9.7 Stdv 4.49 (21)	Mean 5.55 Stdv 4.01 (21)	Mean 6.42 Stdv 6.87 (78)	Mean 10.35 Stdv 4.78 (10)	Mean 9.7 Stdv 4.49 (21)	Mean 5.55 Stdv 4.01 (21)	Mean 6.42 Stdv 6.87 (78)	Mean 10.35 Stdv 4.78 (10)	Mean 9.7 Stdv 4.49 (21)	Mean 5.55 Stdv 4.01 (21)	Mean 6.42 Stdv 6.87 (78)	Mean 10.35 Stdv 4.78 (10)	Mean 9.7 Stdv 4.49 (21)	Mean 5.55 Stdv 4.01 (21)	Mean 6.42 Stdv 6.87 (78)	Mean 10.35 Stdv 4.78 (10)
	cases	0 (0)	0 (3)	1 (11)	0 (1)	0 (1)	0 (2)	0 (11)	0 (2)	0 (1)	0 (2)	0 (11)	0 (2)	0 (1)	0 (2)	0 (11)	0 (2)
	controls	1 (7)	0 (2)	0 (7)	0 (2)	0 (7)	0 (1)	0 (5)	0 (1)	0 (7)	0 (1)	0 (5)	0 (1)	0 (7)	0 (1)	0 (5)	0 (1)
	cases	0 (7)	0 (4)	0 (2)	1 (4)	1 (6)	1 (5)	0 (2)	1 (3)	0 (6)	0 (3)	0 (3)	0 (1)	0 (1)	0 (7)	0 (6)	0 (3)
SINGLE POINT ANALYSIS	ALLELIC ASSOCIATION ANALYSIS	0 (0)	0 (5)	0 (6)	1 (3)	0 (0)	4 (6)	7 (8)	2 (4)	0 (0)	4 (6)	7 (8)	2 (4)	0 (0)	4 (6)	7 (8)	2 (4)
	test pvalue (1)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	4 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)
	allelic Frequency difference (1)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)
	GENOTYPIC ASSOCIATION ANALYSIS	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)
	test pvalue (1)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)
	LOGISTIC REGRESSION ANALYSIS	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)
	Dominant model (1)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)	0 (7)	0 (7)	2 (13)	0 (5)
	2 POINTS	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)
	3 POINTS	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	1 (35)	18 (286)	0 (10)	0 (35)	0 (33)	19 (286)	0 (10)	0 (35)	1 (35)	18 (286)	0 (10)
	Frequency haplotype difference (1)	0 (21)	0 (21)	8 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (20)	7 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)
MULTIPOINT ANALYSIS	HAPLOTYPE FREQUENCY ANALYSIS maxM (in function of haplotype giving the max positive difference between)	0 (35)	0 (35)	20 (286)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	0 (33)	19 (286)	0 (10)	0 (35)	1 (35)	18 (286)	0 (10)
	2 POINTS	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (21)	8 (78)	0 (10)	0 (21)	0 (21)	6 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)
	3 POINTS	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	0 (33)	20 (287)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)
	Frequency haplotype difference (1)	0 (21)	0 (21)	9 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (21)	8 (78)	0 (10)
	3 POINTS	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	0 (33)	17 (267)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)
	Likelihood Ratio test (1)	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)	0 (21)	0 (21)	6 (78)	0 (10)	0 (21)	0 (21)	7 (78)	0 (10)
	2 POINTS	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	0 (33)	19 (286)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)
	3 POINTS	0 (21)	0 (21)	28 (78)	0 (10)	0 (21)	0 (21)	33 (78)	0 (10)	0 (21)	1 (20)	26 (78)	0 (10)	0 (21)	0 (21)	27 (78)	0 (10)
	Significant Omnibus Test (2)	0 (35)	0 (35)	118 (286)	0 (10)	0 (35)	1 (35)	132 (286)	0 (10)	0 (35)	3 (33)	110 (286)	0 (10)	0 (35)	1 (35)	100 (286)	0 (10)
	3 POINTS	0 (35)	0 (35)	118 (286)	0 (10)	0 (35)	1 (35)	132 (286)	0 (10)	0 (35)	3 (33)	110 (286)	0 (10)	0 (35)	1 (35)	100 (286)	0 (10)

Figure 13: Algene samples -summary of analyses in Region D

SINGLE POINT ANALYSIS		First screening cases vs First screening controls		HC cases vs All controls		FH+ cases vs All controls		FH- cases vs All controls	
HARDY WEINBERG Dis-equilibrium coefficient (Da) EXCESS OF HETEROZYGOTES	Cases		2,79 % (15)	2,25 % (32)	7,03 % (32)	2,81 % (32)			
	Controls		3,075 % (18)	2,25 % (32)	2,25 % (32)	2,25 % (32)			
HARDY WEINBERG Dis-equilibrium coefficient (Da) EXCESS OF HOMOZYGOTES	Cases		0,16 % (17)	0,075 % (32)	0,44 % (32)	0,38 % (32)			
	Controls		0,865 % (14)	0 % (32)	0 % (32)	0 % (32)			
ALLELIC ASSOCIATION ANALYSIS & frequency difference			2.8E-02 (32)	1.4E-02 (32)	3.6E-02 (32)	2.4E-02 (32)			
			8,945 % (32)	8,33 % (32)	9,62 % (32)	8,535 % (32)			
GENOTYPIC ASSOCIATION ANALYSIS			3.7E-02 (32)	3.5E-02 (32)	3.2E-02 (32)	3.2E-02 (32)			
LOGISTIC REGRESSION ANALYSIS	Dominant model		1.4E-02 (32)	1.7E-02 (32)	2.2E-02 (32)	2.2E-02 (32)			

MULTIPOINT ANALYSIS		PVALUE FOR HAPLOTYPE (in function of haplotype giving the max positive difference between cases vs controls)		2 POINTS		8.4E-03 (130)		4.9E-03 (130)		6.5E-03 (129)		4.9E-03 (130)	
HAPLOTYPE Frequency difference (%)							1.4E-03 (366)		9.7E-04 (366)		7.0E-04 (364)		1.1E-03 (366)
							10.8 (130)		8.855 (130)		10.48 (129)		9.455 (130)
PVALUE FOR HAPLOTYPE (in function of haplotype giving the max negative difference between cases vs controls)							10 (366)		8.25 (366)		11.785 (364)		9.45 (366)
							1.5E-05 (130)		6.7E-05 (130)		4.3E-05 (120)		1.3E-03 (130)
HAPLOTYPE Frequency difference (%)							6.7E-06 (366)		6.4E-06 (366)		1.2E-05 (352)		3.2E-04 (366)
							12.2 (130)		9.855 (130)		10.395 (120)		9.3 (130)
Likelihood Ratio test							12.375 (366)		9.875 (366)		13.39 (352)		9.175 (366)
							14.313 (130)		16.0015 (130)		13.226 (129)		12.172 (130)
							23.07 (366)		26.215 (366)		23.537 (364)		19.91 (366)

14/22

FIGURE 14: US Schizophrenia Samples: SUMMARY OF SINGLE POINT AND MULTI POINT ANALYSES IN SUB-REGION D

SUB-POPULATION STUDIED			european caucasian cases (92) vs caucasian controls (ALGENE samples) (241)					european caucasian cases (92) vs US random controls (188) Chromosome 13q33									
SUB-REGIONS D			CENTIL(5%) (no. of performed)		Chromosome 13q33			CENTIL(5%) (no. of performed)		Chromosome 13q33							
			D1	D2	D3	D4	D1	D2	D3	D4							
MAP	Sub-contig sizes			168 Kb				168 Kb				153 Kb					
	NB OF SNPs GENOTYPED			7				7				13					
	COVERAGE IN KB			129				102				151					
	Density of genotyped SNP in region covered (kb)			16				13				11					
	Mean inter marker distances [Min, Max] in Kb			21				19				11					
				[12,32]				[12,33]				[7,24]					
	Mean and Stdev of NORMALIZED GAMETIC LD for first screening Algene controls (nb of LD)			Mean -0.15 Stdev 0.79 (21)				Mean 0.31 Stdev 0.33 (21)				Mean -0.13 Stdev 0.65 (10)					
	Mean and Stdev COMPOSITE GENOTYPIC LD for first screening Algene controls (nb of LD)			Mean 9.7 Stdev 4.49 (21)				Mean 5.55 Stdev 4.01 (21)				Mean 6.42 Stdev 6.87 (78)					
SINGLE POINT ANALYSIS			HARDY WEINBERG Disequilibrium coefficient (D _a)		EXCESS OF HETEROZYGOTES (1)		cases	-7,015 % (18)	0 (2)	0 (2)	1 (9)	0 (5)	-7,015 % (18)	0 (2)	0 (2)	1 (9)	0 (5)
					controls		-2,25 % (14)	1 (7)	0 (1)	0 (5)	0 (1)	-3,415 % (20)	1 (7)	0 (2)	2 (9)	1 (2)	
					DEFICIENCY OF HETEROZYGOTES (1)		cases	0,2 % (13)	1 (5)	1 (4)	0 (4)	0 (0)	0,2 % (13)	1 (5)	1 (4)	0 (4)	0 (0)
					controls		0 % (18)	0 (0)	1 (6)	1 (8)	0 (4)	0,055 % (12)	0 (0)	0 (5)	0 (4)	1 (3)	
			ALLELIC ASSOCIATION ANALYSIS		test pvalue (1)		cases vs controls	4.2E-02 (32)	0 (7)	1 (7)	1 (13)	0 (5)	5.6E-02 (32)	0 (7)	0 (7)	0 (13)	0 (5)
					allelic Frequency difference (1)		8,485 % (32)	0 (7)	1 (7)	1 (13)	0 (5)	8,29 % (32)	0 (7)	0 (7)	1 (13)	0 (5)	
			GENOTYPIC ASSOCIATION ANALYSIS		test pvalue (1)		cases vs controls	4.9E-02 (32)	0 (7)	0 (7)	2 (13)	0 (5)	3.8E-02 (32)	1 (7)	0 (7)	1 (13)	1 (5)
					Dominant model (1)		7.5E-02 (32)	0 (7)	1 (7)	1 (13)	0 (5)	3.4E-02 (32)	0 (7)	2 (7)	2 (13)	0 (5)	
			HAPLOTYPE FREQUENCY ANALYSIS maxM <i>(in function of haplotype giving the max positive difference between cases vs controls)</i>		pvalue (1df) (1)		2 POINTS	5.9E-03 (129)	0 (21)	2 (21)	5 (78)	0 (9)	1.7E-02 (129)	1 (21)	2 (20)	7 (78)	0 (10)
					3 POINTS		3.6E-04 (362)	0 (34)	1 (32)	18 (288)	0 (10)	2.6E-03 (365)	1 (34)	0 (35)	18 (286)	0 (10)	
					2 POINTS		9.72 (129)	0 (21)	2 (21)	5 (78)	0 (9)	10.96 (129)	0 (21)	3 (20)	4 (78)	0 (10)	
					3 POINTS		10.6 (362)	0 (34)	5 (32)	16 (286)	0 (10)	10.78 (365)	0 (34)	4 (35)	15 (286)	0 (10)	
			HAPLOTYPE FREQUENCY ANALYSIS maxS <i>(in function of haplotype giving the max negative difference between cases vs controls)</i>		pvalue (1df) (1)		2 POINTS	1.2E-02 (130)	0 (21)	1 (21)	6 (78)	0 (10)	3.1E-02 (129)	0 (21)	0 (21)	7 (77)	0 (10)
					3 POINTS		1.7E-03 (363)	0 (34)	1 (33)	19 (286)	0 (10)	2.9E-03 (365)	0 (35)	1 (34)	19 (286)	0 (10)	
					2 POINTS		10.755 (130)	0 (21)	3 (21)	4 (78)	0 (10)	10.16 (129)	0 (21)	1 (21)	6 (77)	0 (10)	
3 POINTS		11.27 (363)			0 (34)	2 (33)	17 (286)	0 (10)	10.6 (365)	1 (35)	3 (34)	17 (286)	0 (10)				
OMNIBUS LR TEST		Likelihood Ratio test (1)		2 POINTS	10.755 (130)	0 (21)	4 (21)	3 (78)	0 (9)	10.16 (129)	1 (21)	0 (20)	6 (78)	0 (10)			
		3 POINTS		11.27 (363)	0 (34)	6 (32)	13 (286)	0 (10)	10.6 (365)	1 (34)	3 (35)	15 (286)	0 (10)				
		2 POINTS		0.05 (130)	0 (21)	0 (21)	0 (78)	0 (9)	0.05 (129)	4 (21)	4 (20)	13 (78)	0 (10)				
		3 POINTS		0.05(363)	0 (34)	10 (32)	27 (286)	0 (10)	0.05 (365)	3 (34)	4 (35)	8 (286)	0 (10)				

Figure 15
US Schizophrenia Samples: Summary of analyses in Region D

15/22

SINGLE POINT ANALYSIS		European caucasian cases (92) vs All Algine controls (241)	European caucasian cases (92) vs random controls (188)
HARDY WEINBERG Disequilibrium coefficient (Da) EXCESS OF HETEROZYGOTES	Cases	-7,015 % (18)	-7,015 % (18)
	Controls	-2,25 % (14)	-3,415 % (20)
HARDY WEINBERG Disequilibrium coefficient (Da) EXCESS OF HOMOZYGOTES	Cases	0,2 % (13)	0,2 % (13)
	Controls	0 % (18)	0,055 % (12)
ALLELIC ASSOCIATION ANALYSIS & frequency difference		4.2E-02 (32)	5.6E-02 (32)
GENOTYPIC ASSOCIATION ANALYSIS		8,485 % (32)	8,29 % (32)
LOGISTIC REGRESSION ANALYSIS		4.9E-02 (32)	3.8E-02 (32)
Dominant model		7.5E-02 (32)	3.4E-02 (32)

MULTIPOINT ANALYSIS		European caucasian cases (92) vs All Algine controls (241)	European caucasian cases (92) vs random controls (188)
PVALUE FOR HAPLOTYPE (in function of haplotype giving the max positive difference between cases vs controls)	2 POINTS	5.9E-03 (129)	1.7E-02 (129)
	3 POINTS	3.6E-04 (362)	2.6E-03 (365)
HAPLOTYPE Frequency difference (%)	2 POINTS	9.72 (129)	10.96 (129)
	3 POINTS	10.6 (362)	10.78 (365)
PVALUE FOR HAPLOTYPE (in function of haplotype giving the max negative difference between cases vs controls)	2 POINTS	1.2E-02 (130)	3.1E-02 (129)
	3 POINTS	1.7E-03 (363)	2.9E-03 (365)
HAPLOTYPE Frequency difference (%)	2 POINTS	10.755 (130)	10.16 (129)
	3 POINTS	11.27 (363)	10.6 (365)
Likelihood Ratio test	2 POINTS	8.376 (129)	7.6 (129)
	3 POINTS	15.2595 (362)	13.654 (365)

16/22


FIGURE 16: Labimo Samples: SUMMARY OF SINGLE POINT AND MULTI POINT ANALYSES IN SUB-REGION D

SUB-POPULATIONS STUDIED		Bipolar caucasian cases (182) vs caucasian controls (177) Chromosome 1q33				Bipolar type I cases (104) vs caucasian controls (177) Chromosome 1q33				Bipolar type II cases (69) vs caucasian controls (177) Chromosome 1q33			
		D1	D2	D3	D4	D1	D2	D3	D4	D1	D2	D3	D4
		168 Kb	134 Kb	152 Kb	153 Kb	168 Kb	134 Kb	152 Kb	153 Kb	168 Kb	134 Kb	152 Kb	153 Kb
SUB-REGIONS D													
Sub-contig sizes		168 Kb	134 Kb	152 Kb	153 Kb	168 Kb	134 Kb	152 Kb	153 Kb	168 Kb	134 Kb	152 Kb	153 Kb
NB OF SNPs GENOTYPED		7	7	13	5	7	7	13	5	7	7	13	5
COVERAGE IN KB		129	102	151	99	129	102	151	99	129	102	151	99
Density of genotyped SNP in region covered (kb)		16	13	11	17	16	13	11	17	16	13	11	17
Mean Inter marker distances [Min, Max] in Kb		21 [12,32]	19 [12,33]	11 [7,24]	25 [13,54]	21 [12,32]	19 [12,33]	11 [7,24]	25 [13,54]	21 [12,32]	19 [12,33]	11 [7,24]	25 [13,54]
Mean and Std of NORMALIZED GENETIC LD for first screening Aligene controls (nb of LD)		Mean -0.15 Stdv 0.79 (21)	Mean 0.31 Stdv 0.33 (21)	Mean -0.03 Stdv 0.48 (76)	Mean -0.13 Stdv 0.65 (10)	Mean -0.15 Stdv 0.79 (21)	Mean 0.31 Stdv 0.33 (21)	Mean -0.03 Stdv 0.48 (78)	Mean -0.13 Stdv 0.65 (10)	Mean -0.15 Stdv 0.79 (21)	Mean 0.31 Stdv 0.33 (21)	Mean -0.03 Stdv 0.48 (78)	Mean -0.13 Stdv 0.65 (10)
Mean and Stdv COMPOSITE GENOTYPIC LD for first screening Aligene controls (nb of LD)		Mean 9.7 Stdv 4.49 (21)	Mean 5.55 Stdv 4.01 (21)	Mean 6.42 Stdv 6.87 (78)	Mean 10.35 Stdv 4.78 (10)	Mean 9.7 Stdv 4.49 (21)	Mean 5.55 Stdv 4.01 (21)	Mean 6.42 Stdv 6.87 (78)	Mean 10.35 Stdv 4.78 (10)	Mean 9.7 Stdv 4.49 (21)	Mean 5.55 Stdv 4.01 (21)	Mean 6.42 Stdv 6.87 (78)	Mean 10.35 Stdv 4.78 (10)
SINGLE POINT ANALYSIS													
HARDY WEINBERG Disequilibrium coefficient (D _e)	EXCESS OF HETEROZYGOSES (1)	cases controls	1 (4) 0 (0)	0 (7) 0 (6)	0 (5) 1 (5)	1 (4) 0 (5)	0 (3) 0 (0)	0 (6) 0 (8)	1 (3) 1 (5)	0 (2) 0 (5)	3 (4) 0 (0)	6 (9) 0 (8)	1 (3) 1 (5)
	DEFICIENCY OF HETEROZYGOSES (1)	cases controls	0 (5) 0 (3)	1 (6) 0 (5)	0 (0) 0 (0)	0 (3) 0 (2)	0 (4) 1 (7)	2 (7) 0 (5)	0 (2) 0 (0)	0 (5) 0 (2)	0 (3) 1 (7)	0 (4) 0 (5)	0 (2) 0 (0)
ALLELIC ASSOCIATION ANALYSIS	test pvalue (1)	cases vs controls	1 (7)	1 (7)	0 (13)	0 (7)	0 (7)	1 (13)	0 (5)	2 (7)	1 (7)	3 (13)	0 (5)
	allelic Frequency difference (1)	cases vs controls	1 (7)	1 (7)	0 (13)	0 (5)	0 (7)	2 (13)	0 (5)	4 (7)	4 (7)	4 (13)	1 (5)
GENOTYPIC ASSOCIATION ANALYSIS	test pvalue (1)	cases vs controls	1 (7)	0 (7)	1 (13)	0 (5)	0 (7)	1 (13)	0 (5)	3 (7)	3 (7)	1 (13)	0 (5)
	Dominant model (1)	cases vs controls	1 (7)	0 (7)	1 (13)	0 (5)	0 (7)	1 (13)	0 (5)	0 (7)	3 (7)	1 (13)	0 (5)
MULTIPOINT ANALYSIS													
HAPLOTYPE FREQUENCY ANALYSIS max (in function of haplotype giving the max positive difference between cases vs controls)	pvalue (1df) (1)	2 POINTS	0 (21)	0 (21)	7 (78)	0 (21)	0 (21)	7 (76)	0 (10)	0 (21)	2 (21)	5 (77)	0 (10)
	Frequency haplotypic difference (1)	3 POINTS	0 (34)	0 (35)	19 (282)	0 (35)	0 (35)	20 (274)	0 (10)	0 (35)	2 (35)	17 (283)	0 (9)
	pvalue (1df) (1)	2 POINTS	0 (21)	0 (21)	7 (78)	0 (21)	0 (21)	7 (76)	0 (10)	0 (21)	2 (21)	5 (77)	0 (10)
	Frequency haplotypic difference (1)	3 POINTS	0 (34)	0 (35)	21 (282)	0 (35)	0 (35)	19 (274)	0 (10)	0 (35)	2 (35)	17 (283)	0 (9)
HAPLOTYPE FREQUENCY ANALYSIS max (in function of haplotype giving the max negative difference between cases vs controls)	pvalue (1df) (1)	2 POINTS	0 (21)	0 (21)	7 (78)	0 (21)	0 (21)	7 (76)	0 (10)	0 (21)	2 (21)	5 (77)	0 (10)
	Frequency haplotypic difference (1)	3 POINTS	0 (35)	0 (35)	20 (286)	0 (35)	0 (35)	20 (286)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)
	pvalue (1df) (1)	2 POINTS	0 (21)	0 (21)	7 (78)	0 (21)	0 (21)	7 (76)	0 (10)	0 (21)	2 (21)	5 (77)	0 (10)
	Frequency haplotypic difference (1)	3 POINTS	0 (35)	0 (35)	21 (286)	0 (35)	0 (35)	19 (286)	0 (10)	0 (35)	0 (35)	19 (286)	0 (10)
OMNIBUS LR TEST	Likelihood Ratio test (1)	2 POINTS	0 (21)	0 (21)	7 (78)	0 (21)	0 (21)	7 (76)	0 (10)	0 (21)	2 (21)	5 (77)	0 (10)
	Significant Omnibus Test (2)	3 POINTS	1 (34)	1 (35)	18 (282)	2 (10)	0 (35)	18 (274)	0 (10)	1 (35)	1 (35)	18 (283)	0 (9)
	Significant Omnibus Test (2)	2 POINTS	0 (21)	0 (21)	0 (78)	0 (10)	0 (21)	57 (76)	0 (10)	2 (21)	4 (21)	46 (77)	0 (10)
	Significant Omnibus Test (2)	3 POINTS	0 (34)	0 (35)	62 (282)	0 (10)	0 (35)	48 (274)	0 (10)	2 (35)	3 (35)	38 (283)	0 (9)

17/22

Figure 17
Labimo Samples: Summary of analyses in Region D

SINGLE POINT ANALYSIS		All caucasian vs controls	Bipolar I vs controls	Bipolar II vs controls
HARDY WEINBERG Disequilibrium coefficient (D _a) EXCESS OF HETEROZYGOTES	Cases	2,415 % (18)	3,4 % (16)	6,055 % (18)
	Controls	2,775 % (18)	2,775 % (18)	2,775 % (18)
HARDY WEINBERG Disequilibrium coefficient (D _a) EXCESS OF HOMOZYGOTES	Cases	0,065 % (14)	0 % (16)	1,055 % (14)
	Controls	0,265 % (14)	0,265 % (14)	0,265 % (14)
ALLELIC ASSOCIATION ANALYSIS & frequency difference		1.5E-01 (32)	1.9E-01 (32)	6.6E-02 (32)
		5.56 % (32)	5,49 % (32)	9,25 % (32)
GENOTYPIC ASSOCIATION ANALYSIS		1.1E-01 (32)	1.9E-01 (32)	4.9E-02 (32)
LOGISTIC REGRESSION ANALYSIS		Dominant model	1.2E-01 (32)	4.9E-02 (32)
MULTIPOINT ANALYSIS				
PVALUE FOR HAPLOTYPE (in function of haplotype giving the max positive difference between cases vs controls)	2 POINTS	1.01E-02 (130)	3.1E-02 (128)	7.42E-03 (129)
	3 POINTS	4.3E-04 (361)	1.9E-03 (354)	2.33E-03 (362)
HAPLOTYPE Frequency difference (%)	2 POINTS	7.61 (130)	8,255 (128)	10.58 (129)
	3 POINTS	7.7 (361)	9.6 (354)	10.595 (362)
PVALUE FOR HAPLOTYPE (in function of haplotype giving the max negative difference between cases vs controls)	2 POINTS	5.17E-03 (130)	9.9E-03 (130)	2.59E-02 (130)
	3 POINTS	6.3E-04 (366)	1.9E-03 (366)	4.45E-03 (366)
HAPLOTYPE Frequency difference (%)	2 POINTS	9.41 (130)	10,185 (130)	10.7 (130)
	3 POINTS	10.5 (366)	11.45 (366)	11.5 (366)
Likelihood Ratio test	2 POINTS	10,851 (130)	7,4745 (128)	7.896 (129)
	3 POINTS	27.01 (361)	20,0225 (354)	16,6645 (362)






FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22

SEQUENCE LISTING

<110> GENSET

<120> SCHIZOPHRENIA ASSOCIATED GENES, PROTEINS AND BIALLELIC MARKERS

<130> 53.W01

<150> US 60/126,903

<151> 1999-03-30

<150> US 60/131,971

<151> 1999-04-30

<150> US 60/132,065

<151> 1999-04-30

<150> US 60/143,928

<151> 1999-07-14

<150> US 60/145,915

<151> 1999-07-27

<150> US 60/146,453

<151> 1999-07-29

<150> US 60/146,452

<151> 1999-07-29

<150> US 60/162,288

<151> 1999-10-28

<160> 231

<170> Patent.pm

<210> 1

<211> 319608

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> 31..1107

<223> 5'regulatory region g35018 gene

<220>

<221> exon

<222> 1108..1289

<223> exon A g35018 gene

<220>

<221> exon

<222> 14877..14920

<223> exon B g35018 gene

<220>

<221> exon

<222> 18778..18862